temozolomide has been researched along with Local Neoplasm Recurrence in 586 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The optimal dose schedule of vincristine, irinotecan, and temozolomide (VIT) in relapsed or refractory patients with Ewing sarcoma requires clarification." | 9.69 | Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial. ( Cai, Z; Guo, W; Liang, X; Liu, K; Sun, X; Tang, X; Xie, L; Xu, J, 2023) |
| "Irinotecan and temozolomide achieve objective responses in patients with Ewing sarcoma that recurs after initial therapy." | 9.41 | Irinotecan dose schedule for the treatment of Ewing sarcoma. ( Meyers, PA; Slotkin, EK, 2023) |
| "Preclinical studies have suggested promising activity for the combination of disulfiram and copper (DSF/Cu) against glioblastoma (GBM) including re-sensitization to temozolomide (TMZ)." | 9.30 | A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. ( Boockvar, J; Campian, JL; Chaudhary, R; Chinnaiyan, P; Cohen, AL; Fink, K; Goldlust, S; Huang, J; Marcus, S; Wan, L, 2019) |
| " This phase II study examined the safety and efficacy of intermittent veliparib with carboplatin/paclitaxel (VCP) or temozolomide (VT) in patients with BRCA1/2-mutated breast cancer." | 9.27 | Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. ( Bondarenko, I; Campone, M; Chmielowska, E; Citrin, D; Diéras, V; Domchek, SM; Friedlander, M; Garber, JE; Gradishar, W; Han, HS; Isakoff, SJ; Jager, A; Jakobsen, EH; Kaklamani, V; Kaufman, B; Marcom, PK; Nickner, C; Palácová, M; Puhalla, S; Qian, J; Qin, Q; Ratajczak, CK; Robson, M; Shepherd, SP; Shparyk, Y; Telli, ML, 2018) |
| " We sought to study vorinostat (VOR), a histone deacetylase inhibitor, in combination with bevacizumab (BEV) and daily metronomic temozolomide (TMZ) in a Phase I/II trial in recurrent high-grade gliomas (HGGs)." | 9.27 | Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. ( Desjardins, A; Friedman, HS; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Peters, KB; Reardon, DA, 2018) |
| "Mibefradil (MIB), previously approved for treatment of hypertension, is a selective T-type calcium channel blocker with preclinical activity in high-grade gliomas (HGGs)." | 9.24 | Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. ( Desai, AS; Desideri, S; Fisher, JD; Grossman, SA; Holdhoff, M; Leal, J; Lesser, GJ; Lieberman, FS; Lodge, MA; Nabors, LB; Read, WL; Schiff, D; Supko, JG; Wahl, RL; Walbert, T; Ye, X, 2017) |
| "We report a longitudinal assessment of health-related quality of life (HRQOL) in patients with glioblastoma (GBM) treated on a prospective dose escalation trial of 5-fraction stereotactic radiosurgery (25-40 Gy in 5 fractions) with concurrent and adjuvant temozolomide." | 9.24 | Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results. ( Adler, JR; Azoulay, M; Chang, SD; Choi, CYH; Fujimoto, D; Gibbs, IC; Hancock, SL; Harraher, C; Harsh, GR; Jacobs, LR; Li, G; Modlin, LA; Nagpal, S; Pollom, EL; Recht, LD; Seiger, K; Soltys, SG; Thomas, RP; Tupper, L; von Eyben, R; Wynne, J, 2017) |
| "Bevacizumab plus bi-weekly temozolomide was well tolerated and may be a salvage regimen to be considered in a subset of patients with recurrent glioblastoma." | 9.24 | Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma. ( Ahmadi, MM; Badruddoja, MA; Kuzma, K; Mahadevan, D; Norton, T; Pazzi, M; Sanan, A; Schroeder, K; Scully, T, 2017) |
| "In glioblastoma multiforme (GBM), both temozolomide (TMZ) and cisplatin are very active at various toxic levels." | 9.24 | Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients. ( Guo, Y; Kong, X; Ma, W; Wang, R; Wang, Y, 2017) |
| "The primary aim of this Phase I study was to determine the maximum tolerated dose (MTD) of TPI 287 and the safety and tolerability of TPI 287 alone and in combination with temozolomide (TMZ) in pediatric patients with refractory or recurrent neuroblastoma or medulloblastoma." | 9.22 | A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma. ( Ashikaga, T; Bergendahl, G; DeSarno, M; Eslin, D; Ferguson, W; Hanna, GK; Higgins, T; Kaplan, J; Kraveka, J; Mitchell, D; Roberts, W; Sholler, GL; Werff, AV, 2016) |
| "This phase II study was conducted to determine the efficacy and safety of metronomic temozolomide (TMZ) in combination with irinotecan in glioblastoma (GB) at first relapse." | 9.22 | Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma. ( Balañá, C; Benavides, M; Fleitas, T; Gallego, O; Gil-Gil, M; Martínez-Sales, V; Palomero, I; Pérez-Segura, P; Reche, E; Reynés, G; Vaz, MA; Vila, V, 2016) |
| "Adding temozolomide (TMZ) to radiation for patients with newly-diagnosed anaplastic astrocytomas (AAs) is common clinical practice despite the lack of prospective studies demonstrating a survival advantage." | 9.22 | The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. ( Abuali, I; Grossman, SA; Lu, Y; Strowd, RE; Ye, X, 2016) |
| "Rechallenge with temozolomide (TMZ) at first progression of glioblastoma after temozolomide chemoradiotherapy (TMZ/RT→TMZ) has been studied in retrospective and single-arm prospective studies, applying temozolomide continuously or using 7/14 or 21/28 days schedules." | 9.20 | MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. ( Bähr, O; Felsberg, J; Goldbrunner, R; Hau, P; Herrlinger, U; Homicsko, K; Hüsing, J; Kästner, B; Ketter, R; Kollias, S; Marosi, C; Meixensberger, J; Nikkhah, G; Pichler, J; Platten, M; Reifenberger, G; Sabel, MC; Schlegel, U; Schnell, O; Steinbach, JP; Stupp, R; Tabatabai, G; Tonn, JC; Vajkoczy, P; Weller, M; Wick, A; Wick, W; Wirsching, HG, 2015) |
| "The aim of this prospective and multicentric phase II study was to evaluate the efficacy and safety of temozolomide (TMZ) and bevacizumab (BV) in patients (pts) with recurrent glioblastoma (GB), previously treated with chemoradiotherapy and at least three cycles of adjuvant TMZ." | 9.20 | A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma. ( Balañá, C; Belda-Iniesta, C; Berrocal, A; Capellades, J; Gallego, O; Gil-Gil, M; La Orden, B; Ordoñez, JM; Pérez-Segura, P; Reynés, G; Sepúlveda, JM, 2015) |
| "To assess objective response rate (ORR) after two cycles of temozolomide in combination with topotecan (TOTEM) in children with refractory or relapsed neuroblastoma." | 9.19 | Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study. ( Aerts, I; Amoroso, L; Boubaker, A; Casanova, M; Chastagner, P; Courbon, F; Devos, A; Di Giannatale, A; Dias-Gastellier, N; Ducassoul, S; Geoerger, B; Landman-Parker, J; Le Deley, MC; Malekzadeh, K; Mc Hugh, K; Munzer, C; Riccardi, R; Rubie, H; Verschuur, A; Zwaan, CM, 2014) |
| "To determine the maximum tolerated dose of irinotecan administered every 2 weeks, in combination with a fixed and continuous administration of temozolomide, in patients with glioblastoma at first relapse." | 9.19 | A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma. ( Balañá, C; Gallego, O; García, JL; Iglesias, L; Pérez, P; Reynés, G, 2014) |
| "The integrin antagonist cilengitide has been explored as an adjunct with anti-angiogenic properties to standard of care temozolomide chemoradiotherapy (TMZ/RT → TMZ) in newly diagnosed glioblastoma." | 9.19 | Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. ( Clément, PM; Eisele, AC; Eisele, G; Krex, D; Neyns, B; Nikkhah, G; Ochsenbein, A; Picard, M; Schlegel, U; Simon, M; Stupp, R; Tabatabai, G; Tonn, J; Weller, M; Wick, A; Wick, W, 2014) |
| "The aim of this study was to assess the objective response rate (ORR) of children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor (MB/PNET) treated with temozolomide (TMZ)." | 9.19 | Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial. ( Abate, ME; Barone, G; Cefalo, G; Colosimo, C; Garrè, ML; Madon, E; Mascarin, M; Massimino, M; Perilongo, G; Potepan, P; Riccardi, R; Ridola, V; Ruggiero, A; Spreafico, F, 2014) |
| "The objective of this study was to report the patterns of failure in patients with glioblastoma multiforme (GBM) treated on a phase II trial of hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with concurrent and adjuvant temozolomide (TMZ)." | 9.19 | Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme. ( Chen, C; Gaspar, LE; Kavanagh, BD; Reddy, K, 2014) |
| "To determine the safety and efficacy of hypofractionated intensity modulated radiation therapy (Hypo-IMRT) using helical tomotherapy (HT) with concurrent low dose temozolomide (TMZ) followed by adjuvant TMZ in patients with glioblastoma multiforme (GBM)." | 9.17 | Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. ( Abdulkarim, B; Fallone, G; Field, C; Fulton, D; Ghosh, S; Jastaniyah, N; Le, D; Mackenzie, M; Murtha, A; Patel, S; Pervez, N; Roa, W, 2013) |
| "Among patients with glioblastoma (GBM) who progress on standard temozolomide, the optimal therapy is unknown." | 9.17 | Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. ( Batchelor, TT; Beroukhim, R; Doherty, L; Drappatz, J; Fadul, CE; Hammond, SN; Lafrankie, D; Lee, EQ; Lesser, GJ; Ligon, KL; Lis, R; Muzikansky, A; Norden, AD; Plotkin, SR; Reardon, DR; Rosenfeld, MR; Smith, K; Stack, EC; Tafoya, V; Wen, PY; Zhu, JJ, 2013) |
| "To evaluate the efficacy and safety of temozolomide (TMZ) versus semustine (Me-CCNU) in the treatment of recurrent glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA)." | 9.17 | [Multicenter randomized controlled study of temozolomide versus semustine in the treatment of recurrent malignant glioma]. ( Sun, J; Yang, SY; Yang, XJ, 2013) |
| "Patients with mucosal melanoma in stage II/III after surgery were randomized into three groups: observation group (group A, surgery alone), HDI group (group B, treated with 15 × 10(6) U/m(2)/d IFN-α2b, followed by 9 × 10(6) U IFN-α2b), and temozolomide (200 mg/m(2)/d) plus cisplatin (75 mg/m(2)) group (group C)." | 9.17 | Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. ( Chi, Z; Cui, C; Guo, J; Kong, Y; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B, 2013) |
| "The current standard-of-care for glioblastoma (GBM) is represented by concomitant radiotherapy (RT) and temozolomide (TMZ), according to Stupp's protocol." | 9.17 | Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma. ( Caroli, M; Carrabba, G; DI Cristofori, A; Lanfranchi, G; Menghetti, C; Rampini, P, 2013) |
| " Multiple glioma cell lines were analyzed for viability after treatment with radiation, temozolomide, or sorafenib or combinations of them." | 9.17 | A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. ( Andrews, DW; Camphausen, K; Den, RB; Dicker, AP; Dougherty, E; Friedman, DP; Glass, J; Green, MR; Hegarty, S; Hyslop, T; Kamrava, M; Lawrence, YR; Marinucchi, M; Sheng, Z; Werner-Wasik, M, 2013) |
| "We performed a dose-escalation trial to determine the maximum tolerated dose (MTD) of intensity-modulated radiotherapy (IMRT) with standard concurrent and sequential-dose temozolomide (TMZ) in patients with glioblastoma multiforme." | 9.17 | Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1). ( Balducci, M; Cilla, S; Deodato, F; Ferro, M; Macchia, G; Massaccesi, M; Morganti, AG; Valentini, V, 2013) |
| "In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedule in the treatment of recurrent malignant gliomas (MGs)." | 9.17 | Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. ( Abrey, LE; Chan, TA; Deangelis, LM; Gavrilovic, IT; Heguy, A; Hormigo, A; Hottinger, AF; Huse, JT; Kaley, TJ; Kaufman, A; Khasraw, M; Lassman, AB; Mellinghoff, I; Nolan, CP; Omuro, A; Panageas, KS; Reiner, AS; Salvant, C, 2013) |
| "We undertook this phase I study to investigate the feasibility of the combination of temozolomide (TMZ) and lapatinib (LP) and to define the maximum tolerated dose (MTD) of LP in patients with relapsed high-grade gliomas." | 9.17 | A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas. ( Bobos, M; Chrisafi, S; Fountzilas, G; Karavasilis, V; Kotoula, V; Lambaki, S; Pentheroudakis, G; Televantou, D, 2013) |
| "The authors performed a phase 2 trial of combined protracted daily temozolomide and biweekly bevacizumab for patients with recurrent glioblastoma who had previously received radiation therapy and temozolomide." | 9.16 | Bevacizumab and daily temozolomide for recurrent glioblastoma. ( Bailey, L; Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; Marcello, J; Peters, KB; Reardon, DA; Vredenburgh, JJ, 2012) |
| "To report toxicity and overall survival (OS) in patients with newly diagnosed glioblastoma multiforme (GBM) treated with hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with concurrent and adjuvant temozolomide (TMZ)." | 9.16 | Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. ( Chen, C; Damek, D; Gaspar, LE; Kavanagh, BD; Lillehei, K; Ney, D; Reddy, K; Stuhr, K; Waziri, A, 2012) |
| "In the present study we investigated the feasibility and effectiveness of a new biweekly schedule of fotemustine (FTM) in patients with recurrent glioblastoma, after at least one previous treatment." | 9.15 | A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. ( Abbruzzese, A; Addeo, R; Caraglia, M; Carraturo, M; Cennamo, G; De Santi, MS; Del Prete, S; Faiola, V; Genovese, M; Montella, L; Parlato, C; Vincenzi, B, 2011) |
| "To determine the maximal tolerated biologic dose intensification of radiotherapy using fractional dose escalation with temozolomide (TMZ) chemotherapy in patients with newly diagnosed glioblastoma multiforme." | 9.15 | Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. ( Chen, C; Damek, D; Gaspar, LE; Kavanagh, BD; Kleinschmidt-DeMasters, BK; Lillehei, K; Robischon, M; Rusthoven, KE; Stuhr, K; Waziri, A, 2011) |
| "To analyse patterns of failure in patients with glioblastoma multiforme treated with concurrent radiation and temozolomide." | 9.15 | Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. ( Burnett Iii, OL; Dobelbower, MC; Fiveash, JB; Hyatt, MD; Markert, JM; Nabors, LB; Nordal, RA, 2011) |
| "The primary objectives of this phase II study were to evaluate the use of preirradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma (MOA)." | 9.14 | Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. ( Berkey, B; Biggs, C; Blumenthal, DT; Brown, P; Giannini, C; Herman, J; Jenkins, R; Macdonald, D; Mehta, M; Peereboom, D; Schultz, C; Suh, JH; Vogelbaum, MA, 2009) |
| "This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administering O(6)-BG in combination with temozolomide." | 9.14 | Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5-day dosing regimens of temozolomide (TMZ) in combination with O(6)-benzylguanine (O(6)-BG)." | 9.14 | Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "Because of the poor outcomes for patients with recurrent glioblastoma multiforme (GBM), and some laboratory and clinical evidence of efficacy using interferon in GBM, we assessed the toxicity and efficacy of temozolomide (TMZ) combined with either short-acting (IFN) or long-acting (pegylated) interferon alpha2b (PEG) in two single-arm phase II studies, and compared the results to 6-month progression-free survival (PFS-6) data from historical controls." | 9.14 | Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. ( Alfred Yung, WK; Conrad, CA; Gilbert, MR; Groves, MD; Hess, KR; Hunter, K; Levin, VA; Liu, VH; Meyers, C; Puduvalli, VK, 2009) |
| "This alternating weekly, dose-dense temozolomide regimen was well tolerated and clinically active in heavily pretreated patients with brain metastases, particularly in patients with melanoma." | 9.14 | Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. ( Bajetta, E; Cascinu, S; Crinò, L; Danova, M; Del Prete, S; Salvagni, S; Schiavetto, I; Siena, S; Vitali, M, 2010) |
| "The aim of this clinical trial was to investigate safety and efficacy when combining cetuximab with bevacizumab and irinotecan in patients with recurrent primary glioblastoma multiforme (GBM)." | 9.14 | Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. ( Broholm, H; Hansen, S; Hasselbalch, B; Holmberg, M; Kosteljanetz, M; Lassen, U; Poulsen, HS; Stockhausen, MT; Sørensen, M, 2010) |
| "Compared with historical controls, the addition of concomitant and adjuvant cilengitide to standard chemoradiotherapy demonstrated promising activity in patients with glioblastoma with MGMT promoter methylation." | 9.14 | Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. ( Clement, PM; Dietrich, PY; Diserens, AC; Goldbrunner, R; Grabenbauer, GG; Hegi, ME; Hermisson, M; Hicking, C; Krueger, S; Neyns, B; Ochsenbein, AF; Pica, A; Picard, M; Pietsch, T; Schlegel, U; Simon, M; Stupp, R; Tonn, JC; Weller, M, 2010) |
| "To evaluate efficacy and safety of fotemustine chemotherapy in temozolomide (TMZ) pretreated adults with recurrent glioblastoma multiforme (GBM)." | 9.13 | Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. ( Ammannati, F; Biti, G; Bordi, L; Borghesi, S; Detti, B; Iannalfi, A; Leonulli, BG; Martinelli, F; Meattini, I; Sardaro, A; Scoccianti, S, 2008) |
| "The primary objective of this prospective phase 2 study of CPT-11 in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) was to evaluate 6-month progression-free survival (PFS)." | 9.13 | Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma. ( Blumenthal, DT; Chamberlain, MC; Glantz, MJ; Wei-Tsao, DD, 2008) |
| "The aim of the present study was to determine in patients with progressive or recurrent low grade gliomas, the response rate and toxicity incurred by a continued schedule of temozolomide chemotherapy administered before radiation therapy, and to explore correlations between response and survival with 1p/19q deletions and MGMT promoter methylation status." | 9.13 | Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. ( Bertorelle, R; Blatt, V; Bonaldi, L; Brandes, AA; Ermani, M; Franceschi, E; Tosoni, A, 2008) |
| "To evaluate outcome after fractionated stereotactic radiotherapy (FSRT) and concomitant daily temozolomide (TMZ) in patients with recurrent gliomas." | 9.13 | Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. ( Bischof, M; Combs, SE; Debus, J; Hof, H; Oertel, S; Schulz-Ertner, D; Welzel, T, 2008) |
| "A Phase II study of CPT-11 in adults with recurrent, temozolomide (TMZ)-refractory, 1p19q co-deleted, anaplastic oligodendroglioma (AO) with a primary objective of determining 6-month progression free survival (PFS)." | 9.13 | CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. ( Chamberlain, MC; Glantz, MJ, 2008) |
| "In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the treatment of IDH-mutant gliomas." | 9.12 | From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas. ( Sun, X; Turcan, S, 2021) |
| "The objective of the study was to evaluate the efficacy and toxicity of Temozolomide (TMZ) administered for 5 consecutive days in three daily dosing in children with recurrent or refractory high-grade glioma." | 9.12 | Phase II trial of temozolomide in children with recurrent high-grade glioma. ( Abate, ME; Attinà, G; Caldarelli, M; Cefalo, G; Clerico, A; Colosimo, C; Di Rocco, C; Garré, ML; Lazzareschi, I; Madon, E; Massimino, M; Maurizi, P; Mazzarella, G; Riccardi, R; Ridola, V; Ruggiero, A; Sandri, A, 2006) |
| "A prospective Phase II study of cyclophosphamide (CYC) was conducted in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) with a primary objective of evaluating 6-month progression-free survival (PFS)." | 9.12 | Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma. ( Chamberlain, MC; Groshen, S; Tsao-Wei, DD, 2006) |
| "Based on our findings in two paediatric patients, temozolomide may be a useful agent in the management of progressive recurrent low grade spinal cord astrocytomas." | 9.12 | Role of temozolomide in spinal cord low grade astrocytomas: results in two paediatric patients. ( Abboud, MR; Al Kutoubi, AO; Alaraj, AM; Chamoun, RB; Haddad, GF, 2006) |
| "The purpose of this study was to define the maximum tolerated dose of erlotinib and characterize its pharmaco-kinetics and safety profile, alone and with temozolomide, with and without enzyme-inducing antiepileptic drugs (EIAEDs), in patients with malignant gliomas." | 9.12 | Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. ( Burton, E; Butowski, N; Chang, S; Fedoroff, A; Kapadia, A; Kelley, SK; Lamborn, KR; Malec, M; Page, MS; Prados, MD; Rabbitt, J; Xie, D, 2006) |
| "Since anaplastic gliomas (AG) depend on matrix metalloproteinases for tumor cell invasion and angiogenesis, we undertook this phase II study to evaluate the matrix metalloproteinase inhibitor marimastat (MT), combined with the alkylator temozolomide (TMZ) in patients with recurrent AG, looking for improved outcomes." | 9.12 | Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. ( Aldape, KD; Conrad, CA; Gilbert, MR; Groves, MD; Hess, KR; Jaeckle, K; Levin, VA; Liu, V; Puduvalli, VK; Yung, WK, 2006) |
| "To date, no data are available on the relationship between 1p/19q deletions and the response to temozolomide (TMZ) in primary anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) recurrent after surgery and standard radiotherapy." | 9.12 | Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. ( Bertorelle, R; Blatt, V; Bonaldi, L; Brandes, AA; Cavallo, G; Ermani, M; Franceschi, E; Gardiman, M; Ghimenton, C; Iuzzolino, P; Pession, A; Reni, M; Tosoni, A, 2006) |
| " The aim of this pilot study was to evaluate the efficacy and safety of metronomic temozolomide (TMZ) treatment in twelve consecutive patients with recurrent TMZ-refractory glioblastoma." | 9.12 | A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. ( Eoh, W; Kim, JH; Kim, ST; Kim, WS; Kong, DS; Lee, JI; Lim, DH; Nam, DH; Park, K; Son, MJ, 2006) |
| "Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM)." | 9.12 | A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. ( Abrey, LE; Chang, SM; Cloughesy, TF; Conrad, CA; DeAngelis, LM; Gilbert, MR; Greenberg, H; Groves, MD; Hess, KR; Lamborn, KR; Liu, TJ; Peterson, P; Prados, MD; Puduvalli, VK; Schiff, D; Tremont-Lukats, IW; Wen, PY; Yung, WK, 2007) |
| "Temozolomide (TMZ) has demonstrated activity and acceptable toxicity for the treatment of recurrent malignant gliomas in carious prospective phase II studies." | 9.12 | [Temozolomide in the treatment of recurrent malignant glioma]. ( Ishii, N; Iwasaki, Y; Kobayashi, H; Murata, J; Sawamura, Y, 2006) |
| "To evaluate if timing of chemotherapy with Temozolomide (TMZ) was able to modify the outcome of glioblastoma (GBM), we analyzed two comparable series of supratentorial GBM patients, treated with surgery and radiotherapy, in which the administration of TMZ has been performed in the first group at first relapse and in the second group in newly diagnosed cases." | 9.12 | Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol? ( Borsa, S; Campanella, R; Caroli, M; Gaini, SM; Locatelli, M; Martinelli-Boneschi, F; Mora, A; Motta, F; Prada, F; Saladino, A, 2007) |
| "Evaluation of toxicity and efficacy of an alternating weekly regimen of temozolomide administered 1 week on and 1 week off in patients with recurrent glioma." | 9.12 | Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. ( Blaschke, B; Felsberg, J; Herrlinger, U; Meyermann, R; Platten, M; Reifenberger, G; Steinbach, JP; Weller, M; Wick, A; Wick, W, 2007) |
| "To compare results of treatment with temozolomide or dacarbazine, in combination with an anthracycline, in dogs with relapsed or refractory lymphoma." | 9.12 | Efficacy of temozolomide or dacarbazine in combination with an anthracycline for rescue chemotherapy in dogs with lymphoma. ( Cadile, CD; Dervisis, NG; Dominguez, PA; Kitchell, BE; Newman, RG; Sarbu, L; Swanson, CN, 2007) |
| "To determine the tolerability, pharmacokinetics, and mechanisms of temozolomide resistance in children with relapsed or refractory leukemia." | 9.12 | Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. ( Adamson, PC; Berg, SL; Blaney, SM; Delaney, SM; Dolan, ME; Hedge, M; Horton, TM; Ingle, AM; Thompson, PA; Weiss, HL; Wu, MF, 2007) |
| "To determine the maximum tolerated dose of irinotecan when administrated with temozolomide every 28 days, in patients with recurrent malignant glioma who were also receiving CYP450 enzyme-inducing antiepileptic drugs (EIAED), and to characterize the pharmacokinetics of irinotecan and its metabolites." | 9.12 | Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. ( Aldape, KD; Chang, SM; Cloughesy, T; DeAngelis, LM; Fine, H; Fink, KL; Junck, L; Kuhn, J; Lamborn, K; Lieberman, F; Loghin, ME; Metha, M; Prados, MD; Robins, IH; Wen, P; Yung, WK, 2007) |
| "Patients with recurrent malignant glioma at any time during recurrence were treated with oral temozolomide at a dose of 150 mg/m2 per day on a 5-day schedule every 28 days." | 9.11 | Temozolomide in the treatment of recurrent malignant glioma. ( Chang, SM; Lamborn, K; Malec, M; Page, M; Prados, MD; Rabbitt, J; Theodosopoulos, P, 2004) |
| "The purpose of this study was to evaluate the activity, measured in terms of progression-free survival (PFS) and response rates, of 1,3-bis(chloro-ethyl)-1-nitrosourea (BCNU) plus temozolomide in adult patients with recurrent glioblastoma multiforme." | 9.11 | Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. ( Chang, SM; Fine, HA; Fink, KL; Greenberg, HS; Hess, KR; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, MP; Nicholas, MK; Prados, MD; Robins, HI; Schold, SC; Yung, WK, 2004) |
| "Temozolomide has established activity in the treatment of recurrent glioblastoma multiforme (GBM)." | 9.11 | Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. ( Ashley, DM; Cher, LM; Chua, SL; Dowling, A; Rosenthal, MA; Wong, SS; Woods, AM, 2004) |
| "The primary objective of the current prospective Phase II study of cyclophosphamide (CYC) in adult patients with recurrent, temozolomide-refractory glioblastoma multiforme was to evaluate 6-month progression-free survival (PFS)." | 9.11 | Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. ( Chamberlain, MC; Tsao-Wei, DD, 2004) |
| "A prospective Phase II study of temozolomide (TMZ) was conducted in 16 patients with refractory meningioma." | 9.11 | Temozolomide for treatment-resistant recurrent meningioma. ( Chamberlain, MC; Groshen, S; Tsao-Wei, DD, 2004) |
| "Cisplatin and temozolomide (TMZ) are active in glioblastoma multiforme (GBM), with different profiles of toxicity." | 9.11 | First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. ( Basso, U; Brandes, AA; Cavallo, G; Ermani, M; Ferreri, AJ; Monfardini, S; Panucci, MG; Reni, M; Scopece, L; Tosoni, A; Vastola, F, 2004) |
| "Seventy-five consecutive patients with recurrent malignant astrocytomas and glioblastomas had been treated at our institute with per os temozolomide for five days every month." | 9.11 | Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas. ( Afra, D; Sipos, L; Vitanovics, D, 2004) |
| "The authors determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of irinotecan (CPT-11), a topoisomerase I inhibitor, when administered with temozolomide among patients with recurrent malignant glioma (MG)." | 9.11 | Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. ( Badruddoja, M; Burkart, JL; Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, R; Newton, HB; Provenzale, J; Quinn, JA; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, J, 2005) |
| "To determine the anti-tumour efficacy and safety profile of temozolomide in local Chinese patients with recurrent malignant glioma." | 9.11 | Temozolomide in the treatment of recurrent malignant glioma in Chinese patients. ( Chan, DT; Chan, YL; Ng, HK; Poon, WS, 2005) |
| "Although temozolomide is active against recurrent malignant glioma, responses in many patients are modest and short-lived." | 9.10 | Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. ( Benita-Weiss, M; Bushunow, P; Coyle, TE; Evans, B; Friedman, H; Korones, DN; Mechtler, L; Quinn, JA; Reardon, DA, 2003) |
| "Temozolomide (TMZ) and 13-cis-retinoic acid (cRA) have shown activity in prior single-agent trials of recurrent malignant gliomas (MG)." | 9.10 | Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. ( Chang, S; Cloughesy, T; Fine, H; Fink, K; Greenberg, H; Hess, KR; Jaeckle, KA; Kuhn, J; Mehta, M; Nicholas, MK; Pollack, IF; Prados, M; Schiff, D; Yung, WK, 2003) |
| "Temozolomide is an effective agent in the treatment of recurrent malignant gliomas." | 9.10 | A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. ( Abrey, LE; Bazylewicz, KA; Khan, RB; Malkin, MG; Raizer, JJ, 2002) |
| "Temozolomide has shown efficacy in the treatment of metastatic melanoma similar to that of dacarbazine (DTIC), the standard chemotherapy, but with the added benefit of penetration into the central nervous system (CNS)." | 9.10 | Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. ( Brampton, MH; Calvert, AH; Middleton, MR; Paul, MJ; Rustin, G; Summers, Y; Thatcher, N, 2002) |
| "To determine the antitumor efficacy and safety profile of temozolomide in patients with malignant astrocytoma at first relapse." | 9.09 | Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. ( Albright, R; Brada, M; Bruner, J; Chang, SM; Dugan, M; Friedman, AH; Friedman, HS; Levin, VA; O'Neill, AM; Olson, J; Prados, MD; Rosenfeld, SS; Yaya-Tur, R; Yue, N; Yung, WK; Zaknoen, S, 1999) |
| "One of the objectives of this phase II study was to determine whether temozolomide (TMZ) improved the health-related quality of life (HRQL) of patients with recurrent anaplastic astrocytoma (AA)." | 9.09 | Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. ( Brada, M; Osoba, D; Prados, MD; Yung, WK, 2000) |
| "Forty-one patients with high-grade glioma, at second recurrence or progression, of which twenty-two (54%) had glioblastoma multiforme, ten (24%) anaplastic astrocytoma, and nine (22%) anaplastic oligodendroglioma were administered temozolomide, 150 mg/m2/daily for five days every four weeks." | 9.09 | Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. ( Amistà, P; Basso, U; Berti, F; Brandes, AA; Ermani, M; Gardiman, M; Monfardini, S; Pinna, G; Rotilio, A; Scienza, R, 2001) |
| "We report an open-label, uncontrolled, multicenter phase II trial of temozolomide in 138 patients (intent-to-treat [ITT] population) with glioblastoma multiforme at first relapse and a Karnofsky performance status (KPS) > or = 70." | 9.09 | Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. ( Brada, M; Bravo-Marques, JM; Bruner, J; Dietrich, PY; Dirix, LY; Dugan, M; Heimans, JJ; Henriksson, R; Hoang-Xuan, K; Macdonald, D; Rampling, R; Rao, S; Stupp, R; Yue, N; Zaknoen, S; Zonnenberg, BA, 2001) |
| " A novel second-generation alkylating agent, temozolomide, has recently demonstrated efficacy and safety in patients with recurrent glioblastoma multiforme and anaplastic astrocytoma." | 9.09 | Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. ( Barrie, M; Braguer, D; Chinot, OL; Dufour, H; Figarella-Branger, D; Grisoli, F; Honore, S; Martin, PM; Muracciole, X, 2001) |
| "Temozolomide, a new oral cytotoxic agent, was given to 75 patients with malignant gliomas." | 9.08 | The Charing Cross Hospital experience with temozolomide in patients with gliomas. ( Bower, M; Brampton, MH; Brock, C; Colquhoun, I; Evans, H; Glaser, MG; Illingworth, RD; Lewis, P; Newlands, ES; O'Reilly, SM; Rice-Edwards, JM; Richards, PG, 1996) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 8.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| "There is a growing body of evidence that carmustine wafer implantation during surgery is an effective therapeutic adjunct to the standard combined radio-chemotherapy regimen using temozolomide in newly diagnosed and recurrent high-grade glioma patient management with a statistically significant survival benefit demonstrated across several randomized clinical trials, as well as prospective and retrospective studies (grade A recommendation)." | 8.95 | Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery. ( Caire, F; Guyotat, J; Menei, P; Metellus, P; Pallud, J; Roux, A, 2017) |
| "This review article summarizes in vitro, in vivo, and clinical evidence pertaining to temozolomide (TMZ) and bevacizumab (BEV) efficacy and mechanism of action in gliomas." | 8.91 | Current evidence of temozolomide and bevacizumab in treatment of gliomas. ( Chattipakorn, N; Chattipakorn, SC; Nanegrungsunk, D; Onchan, W, 2015) |
| "The goal of this meta-analysis was to identify the temozolomide (TMZ) regimen with optimal efficacy and tolerance for treatment of recurrent high-grade glioma (HGG)." | 8.91 | The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis. ( Chen, X; Guo, Z; Ma, X; Wang, D; Wei, W, 2015) |
| "The standard therapy for newly diagnosed malignant gliomas comprises surgery, radiotherapy, and commonly temozolomide chemotherapy." | 8.87 | An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting. ( Kyritsis, AP; Levin, VA, 2011) |
| "Complete resection of glioblastoma via a supraorbital transciliary approach with 5-Aminolevulinic Acid use was performed without any complications, as demonstrated on postoperative MRI." | 8.31 | Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note. ( Aboukaïs, R; Bourgeois, P; Devalckeneer, A; Lejeune, JP; Reyns, N, 2023) |
| "Temozolomide (TMZ)-based chemotherapy plays a central part in glioma treatment." | 8.31 | SRSF4 Confers Temozolomide Resistance of Glioma via Accelerating Double Strand Break Repair. ( Liu, X; Sun, Y; Wang, X; Wu, Z; Yan, W; You, Y; Zhang, Y, 2023) |
| "Glioblastoma patients commonly develop resistance to temozolomide chemotherapy." | 8.31 | Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion. ( Bindila, L; Geiß, C; Kim, E; Lieberwirth, I; Régnier-Vigouroux, A; Sousa, N, 2023) |
| "Temozolomide (TMZ) is a common alkylating chemotherapeutic agent used to treat brain tumors such as glioblastoma multiforme (GBM) and anaplastic astrocytoma." | 8.31 | LncRNA-associated competing endogenous RNA network analysis uncovered key lncRNAs involved in temozolomide resistance and tumor recurrence of glioblastoma. ( Mallick, B; Nayak, R, 2023) |
| "This retrospective study enrolled 65 patients with IDH wild-type recurrent glioblastoma who received standard therapy and then received either bevacizumab (46 patients) or temozolomide (19 patients) as a secondary treatment." | 8.12 | Contrast enhancing pattern on pre-treatment MRI predicts response to anti-angiogenic treatment in recurrent glioblastoma: comparison of bevacizumab and temozolomide treatment. ( Kim, HS; Kim, JH; Kim, YH; Moon, HH; Park, JE, 2022) |
| "Irinotecan plus temozolomide combination chemotherapy showed antitumor activity and an acceptable safety profile in patients with relapsed Ewing sarcoma." | 8.12 | Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies. ( Lin, GH; Wang, BC; Xiao, BY, 2022) |
| "The aim of this study was to clarify whether PET with 11C-methyl-l-methionine (11C-met PET) can predict consequential outcomes at the time of discontinuing temozolomide (TMZ)-adjuvant chemotherapy in patients with residual isocitrate dehydrogenase gene (IDH)-mutant lower-grade glioma." | 8.12 | PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma. ( Beppu, T; Fujiwara, S; Iwaya, T; Nomura, JI; Ogasawara, K; Sasaki, T; Sato, Y; Sugai, T; Terasaki, K; Yamada, N, 2022) |
| " Temozolomide is the standard of care for gliomas, frequently results in resistance to drug and tumor recurrence." | 8.12 | Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration of Human U251 Glioma Cells. ( Alaverdian, DA; Buntovskaya, AS; Chernov, AN; Fedorov, EV; Filatenkova, TA; Galimova, ES; Glushakov, RI; Kim, AV; Matsko, MV; Shamova, OV; Skliar, SS; Tsapieva, AN, 2022) |
| "A first-line therapeutic for high-grade glioma, notably glioblastoma (GBM), is the DNA methylating drug temozolomide (TMZ)." | 8.12 | Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics. ( Beltzig, L; Christmann, M; Kaina, B, 2022) |
| "A MEX3A/CCR4-NOT/MSH2 axis plays a crucial role in promoting temozolomide resistance, providing new insights into the function of MEX3A and suggesting MEX3A as a potential therapeutic target in therapy-resistant glioblastoma." | 8.12 | MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma. ( Gan, T; Miao, F; Nie, E; Qian, X; Shen, Z; Shi, Q; Wang, P; Wang, Q; Wang, Y; Xie, M; Zhao, S, 2022) |
| "Systemic chemotherapy including monotherapy with temozolomide (TMZ) or bevacizumab (BEV); two-drug combinations, such as irinotecan (IRI) and BEV, TMZ and BEV and a three-drug combination with TMZ, IRI and BEV (TIB) have been used in treating patients with progressive high-grade gliomas including glioblastoma (GBM)." | 8.12 | Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab. ( Ballester, LY; Bhattacharjee, MB; Brown, RE; Buja, LM; Chen, L; Glass, WF; Hergenroeder, GW; Hunter, RL; Linendoll, N; Lu, G; Pilichowska, M; Pillai, AK; Rao, M; Tian, X; Wu, JK; Zhang, R; Zhu, JJ; Zhu, P, 2022) |
| "It was found that radiotherapy combined with temozolomide administration often increased the size of the original lesion or produced a new glioblastoma lesion." | 8.12 | Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report. ( Cheng, P; Han, Q; Ma, H; Yang, H; Zhao, M; Zhao, Y, 2022) |
| "Glioblastomas (GBM) often acquire resistance against temozolomide (TMZ) after continuous treatment and recur as TMZ-resistant GBM (TMZ-R-GBM)." | 8.02 | Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance. ( Fujii, T; Ichimura, K; Kawauchi, D; Kobayashi, T; Kondo, A; Nakano, T; Narita, Y; Sasaki, N; Satomi, K; Takahashi, M; Tomiyama, A; Uchida, E; Wada, K; Yamamuro, S; Yoshino, A, 2021) |
| "Bortezomib and temozolomide effectively destroy cells of a radioresistant recurrent human glioblastoma; proteome mapping of the recurrent GBM cancer cells allows to identify new targets for therapy to improve the treatment results." | 8.02 | Effectiveness of bortezomib and temozolomide for eradication of recurrent human glioblastoma cells, resistant to radiation. ( Bryukhovetskiy, I; Pak, O; Sharma, A; Sharma, HS; Shevchenko, V; Zaitsev, S, 2021) |
| "About 95% of Glioblastoma (GBM) patients experience tumor relapse as a consequence of resistance to the first-line standard chemotherapy using temozolomide (TMZ)." | 8.02 | Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells. ( Bartsch, JW; Culmsee, C; Elsässer, K; Nimsky, C; Pagenstecher, A; Schäfer, A; Zhang, Z; Zhao, K; Zhong, L, 2021) |
| "To assess the efficacy of single-agent temozolomide, a standard agent is used for metastatic melanoma in late adjuvant chemotherapy for cutaneous melanoma." | 8.02 | Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma. ( Erturk, K; Tas, F, 2021) |
| "Irinotecan and temozolomide (IT) is a widely used regimen for relapsed Ewing sarcoma (ES), although studies are largely limited to paediatric populations." | 8.02 | Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma. ( Abuhijla, F; Abuhijlih, R; Alnsour, A; Halalsheh, H; Ismail, T; Khozouz, O; Lewin, J; Salah, S; Shahin, O; Sultan, I; To, YH; Yaser, S, 2021) |
| "The purpose of this study is to clarify the clinical features of temozolomide (TMZ)-related hepatitis B virus (HBV) reactivation and to identify HBV reactivation predictive factors." | 8.02 | Hepatitis B virus reactivation during temozolomide administration for malignant glioma. ( Chonan, M; Inoue, J; Kanamori, M; Masamune, A; Osada, Y; Saito, R; Shimoda, Y; Shoji, T; Tominaga, T; Uenohara, H, 2021) |
| "Chemotherapy improves overall survival after surgery and radiotherapy for newly diagnosed high-risk IDH-mutant low-grade gliomas (LGGs), but a proportion of patients treated with temozolomide (TMZ) will develop recurrent tumors with TMZ-induced hypermutation." | 8.02 | Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. ( Berger, MS; Butowski, N; Chang, SM; Choi, S; Clarke, JL; Costello, JF; Grimmer, MR; Haas-Kogan, D; Hilz, S; Hong, C; Mazor, T; McDermott, M; Molinaro, AM; Oberheim Bush, NA; Phillips, JJ; Shai, A; Solomon, DA; Taylor, JW; Villanueva-Meyer, J; Wahl, M; Wainer, BH; Yu, Y, 2021) |
| "Glioblastoma multiforme (GBM) is the most fatal cancer among brain tumors, and the standard treatment of GBM patients is surgical tumor resection followed by radiotherapy and temozolomide (TMZ) chemotherapy." | 8.02 | 17β-estradiol induces temozolomide resistance through NRF2-mediated redox homeostasis in glioblastoma. ( Chen, GY; Hsu, SP; Hsu, TI; Hung, CY; Ko, CY; Liao, KH; Lin, HY, 2021) |
| "Apatinib and TMZ may represent an alternative treatment option for patients with recurrent high-gradeglioma, especially those with a low Karnofsky performance status." | 8.02 | Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas. ( Feng, M; Gan, W; Huang, Y; Li, X; Liu, J; Shao, Y; Wang, X; Yao, H; Zhang, C; Zhou, Y, 2021) |
| " In this report, we present the case of a 3-year-old girl with glioblastoma who continues to experience an exceptional and durable response (>2 years) to the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib." | 7.96 | Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response. ( Britt, N; Chudnovsky, Y; Duncan, D; Edgerly, C; Elvin, J; Erlich, RL; Gay, L; Gorelyshev, S; Hemmerich, A; Huang, RSP; Konovalov, A; Kram, DE; McCorkle, J; Miller, V; Ramkissoon, SH; Rankin, A; Ross, JS; Savateev, A; Severson, E; Trunin, Y; Valiakhmetova, A, 2020) |
| "Temozolomide (TMZ) is a drug of choice in glioblastoma treatment." | 7.96 | Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions. ( Barciszewska, AM; Barciszewski, J; Belter, A, 2020) |
| "Temozolomide (TMZ) resistance is a major cause of recurrence and poor prognosis in glioblastoma (GBM)." | 7.96 | LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma. ( Chi, Y; Fu, Z; Guo, H; Huang, Q; Lian, C; Liao, C; Liu, B; Wang, C; Wei, Q; Xu, N; Yang, Z; Zeng, H; Zhou, J, 2020) |
| "To assess the patterns of failure and prognostic factors in Brazilian patients with glioblastoma multiforme (GBM) treated with radiotherapy (RT) and concurrent and adjuvant temozolomide (TMZ)." | 7.96 | Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide. ( Faustino, AC; Hamamura, AC; Viani, GA, 2020) |
| "Despite aggressive treatment with temozolomide and radiotherapy and extensive research into alternative therapies there has been little improvement in Glioblastoma patient survival." | 7.96 | Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma. ( Areeb, Z; Gomez, J; Jones, J; Kaye, AH; Luwor, RB; Morokoff, AP; Nguyen, HPT; Paradiso, L; Stuart, SF; West, AJ; Zulkifli, A, 2020) |
| "In the management of patients with newly diagnosed glioblastoma, there is no standard duration for adjuvant temozolomide treatment." | 7.91 | Feasibility study of finalizing the extended adjuvant temozolomide based on methionine positron emission tomography (Met-PET) findings in patients with glioblastoma. ( Hasegawa, Y; Hatano, K; Hirono, S; Iuchi, T; Sakaida, T; Uchino, Y, 2019) |
| "Glioblastoma multiforme (GBM) is the most malignant tumor of the central nervous system, and chemoresistance blunts the effect of temozolomide (TMZ) in the treatment of GBM." | 7.91 | MiR-7-5p suppresses stemness and enhances temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1. ( Gu, J; Guo, Q; Hao, Q; Jia, B; Liu, W; Lv, W; Mu, N; Pang, Z; Wang, J; Zhang, W, 2019) |
| "Crooke's cell adenoma (CCA) is an aggressive subtype of corticotroph adenoma; however, CCA is associated with a high incidence of low expression of methyl guanine methyl transferase (MGMT), suggesting that temozolomide (TMZ) treatment might be effective for this tumor type." | 7.91 | Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide. ( Inoshita, N; Kanazawa, I; Kurosaki, M; Morita, M; Oki, Y; Sugimoto, T; Takeno, A; Tanaka, S; Yamada, S; Yamaguchi, T; Yamamoto, M, 2019) |
| "To retrospectively determine the safety and efficacy of combined chemotherapy with carmustine (BCNU) wafer, bevacizumab, and temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma (GBM)." | 7.88 | Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience. ( Akiyama, Y; Enatsu, R; Kimura, Y; Mikami, T; Mikuni, N; Wanibuchi, M, 2018) |
| "To identify patients with recurrent glioblastoma after temozolomide (TMZ) concurrent with and adjuvant to radiotherapy who could benefit from TMZ rechallenge at the time of disease progression." | 7.88 | Temozolomide rechallenge in recurrent glioblastoma: when is it useful? ( Bartolini, S; Brandes, AA; Cubeddu, A; De Biase, D; Di Battista, M; Franceschi, E; Lamberti, G; Minichillo, S; Mura, A; Paccapelo, A; Pession, A; Tallini, G; Tosoni, A; Visani, M, 2018) |
| "To investigate the clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent glioma." | 7.88 | [Clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent brain glioma]. ( Jiang, C; Li, X; Liu, S; Tang, S; Zhao, H, 2018) |
| "Temozolomide (TMZ) is the first-line chemotherapeutic agent in the treatment of glioblastoma multiforme (GBM)." | 7.88 | Caffeine Sensitizes U87-MG Human Glioblastoma Cells to Temozolomide through Mitotic Catastrophe by Impeding G2 Arrest. ( Cheng, YS; Kiang, KMY; Leung, GKK; Li, N; Zhang, P, 2018) |
| "Discriminating between tumor recurrence and treatment effects in glioblastoma patients undergoing radiation-temozolomide (RT/TMZ) therapy remains a major clinical challenge." | 7.88 | Diagnostic utility of restriction spectrum imaging (RSI) in glioblastoma patients after concurrent radiation-temozolomide treatment: A pilot study. ( Bartsch, H; Chen, CC; Dale, AM; Farid, N; Khan, UA; Rennert, RC; White, NS, 2018) |
| "The efficacy of temozolomide (TMZ) chemotherapy for treating newly diagnosed glioblastoma (GBM), a primary brain tumor with short survival, was demonstrated in a clinical trial in 2005, and since then, the standard-of-care for newly diagnosed GBM has been maximal safe surgery followed by 60 Gray of radiation with concomitant and adjuvant TMZ (standard radiotherapy and TMZ)." | 7.88 | Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice. ( Carter, TC; Lawler, BE; Medina-Flores, R, 2018) |
| "Temozolomide (TMZ) is a promising chemotherapeutic agent to treat Glioblastoma multiforme (GBM)." | 7.85 | MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor. ( Chen, Y; Li, R; Liu, N; Pan, M; Shi, Z; Wang, X; Yan, W; You, Y; Zhang, J, 2017) |
| "Temozolomide (TMZ) is commonly used in glioblastoma (GBM) chemotherapy." | 7.85 | PomGnT1 enhances temozolomide resistance by activating epithelial-mesenchymal transition signaling in glioblastoma. ( Chen, H; Chen, Q; Han, C; Lan, J; Liu, Q; Lou, M; Que, S; Wang, L; Xue, Y; Zhang, X, 2017) |
| "Temozolomide (TMZ), as a kind of alkylating agent, is widely utilized for the treatment of glioblastoma (GBM)." | 7.85 | miR‑146b‑5p suppresses glioblastoma cell resistance to temozolomide through targeting TRAF6. ( Lan, J; Lin, Y; Qian, Z; Qiu, Y; Que, S; Yang, X; Zhou, S; Zhou, Z, 2017) |
| "To assess the efficacy and cost-effectiveness of modulated electrohyperthermia (mEHT) concurrent to dose-dense temozolomide (ddTMZ) 21/28 days regimen versus ddTMZ 21/28 days alone in patients with recurrent glioblastoma (GBM)." | 7.85 | Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison ( Roussakow, SV, 2017) |
| "Temozolomide is an increasingly described treatment option for refractory pituitary adenomas and carcinomas." | 7.83 | Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response. ( Laterra, JJ; Salvatori, R; Strowd, RE, 2016) |
| "Few data are available on temozolomide (TMZ) in ependymomas." | 7.83 | Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. ( Bosa, C; Cassoni, P; Fiano, V; Franchino, F; Magistrello, M; Pellerino, A; Rudà, R; Soffietti, R; Trevisan, M, 2016) |
| "Temozolomide is effective in some patients with progressive pituitary adenoma or carcinoma." | 7.83 | Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. ( Bogazzi, F; Cannavo, S; Ceccato, F; Curtò, L; De Marinis, L; Iacovazzo, D; Lombardi, G; Losa, M; Mantovani, G; Mazza, E; Minniti, G; Nizzoli, M; Reni, M; Scaroni, C, 2016) |
| "Glioblastoma (GB) recurrences are rarely removed, therefore, tissue modifications induced by radiotherapy, and temozolomide chemotherapy are scarcely known." | 7.83 | Cyclin D1 Co-localizes with Beclin-1 in Glioblastoma Recurrences: A Clue to a Therapy-induced, Autophagy-mediated Degradative Mechanism? ( Belmonte, G; Miracco, C; Pirtoli, L; Tini, P; Toscano, M, 2016) |
| "Twenty patients with recurrent glioblastoma were treated with biweekly BEV plus temozolomide." | 7.83 | MRI and 11C-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma. ( Beppu, T; Kato, K; Ogasawara, K; Sasaki, M; Sasaki, T; Sato, Y; Terasaki, K; Tomabechi, M, 2016) |
| "The cellular responses to two new temozolomide (TMZ) analogues, DP68 and DP86, acting against glioblastoma multiforme (GBM) cell lines and primary culture models are reported." | 7.81 | Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth. ( Gynther, M; Mladek, AC; Phillips, RM; Ramirez, YP; Rautio, J; Ross, AH; Sakaria, JN; Wheelhouse, RT, 2015) |
| "We retrospectively investigated the prognostic impact of molecular phenotypes in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide (TMZ)." | 7.81 | Prognostic impact of molecular phenotype in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide. ( Choi, YR; Kim, HR; Kong, DS; Lee, JI; Nam, DH; Seol, HJ, 2015) |
| "Temozolomide (TMZ), used to treat glioblastoma and malignant glioma, induces autophagy, apoptosis and senescence in cancer cells." | 7.80 | Antitumor effect of fibrin glue containing temozolomide against malignant glioma. ( Anai, S; Hide, T; Kuratsu, J; Kuroda, J; Makino, K; Nakamura, H; Shinojima, N; Takezaki, T; Yano, S, 2014) |
| "We present a case of inadvertent high-dose therapy with temozolomide in a child with recurrent diffuse intrinsic pontine glioma followed by a rapid clinical response." | 7.80 | Inadvertent high-dose therapy with temozolomide in a child with recurrent pontine glioma followed by a rapid clinical response but deteriorated after substitution with low-dose therapy. ( Altonok, D; Konski, A; Poulik, J; Sood, S; Wang, ZJ, 2014) |
| "To analyze patterns of failure in patients with glioblastoma multiforme (GBM) treated with limited-margin radiation therapy and concurrent temozolomide." | 7.80 | Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide. ( Bag, AK; Dobelbower, MC; Ennis, WH; Fiveash, JB; Gebhardt, BJ; Markert, JM, 2014) |
| "Standard treatment for glioblastoma comprises surgical resection, chemotherapy with temozolomide, and radiotherapy." | 7.80 | KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis. ( Ham, Y; Jin, J; Joo, KM; Kang, W; Kim, S; Nam, DH; Woo, SR; Yang, H, 2014) |
| "Nine post-temozolomide recurrent or progressive high-grade glioma patients (seven with glioblastoma and two with anaplastic astrocytoma) were treated with BV monotherapy." | 7.80 | Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report. ( Kobayashi, K; Nagane, M; Shimizu, S; Shiokawa, Y; Shishido-Hara, Y; Tanaka, M; Tsuchiya, K, 2014) |
| "We investigated the pattern of failure in glioblastoma multiforma (GBM) patients treated with concurrent radiation, bevacizumab (BEV), and temozolomide (TMZ)." | 7.79 | Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme. ( Kadner, R; Shields, LB; Spalding, AC; Vitaz, TW, 2013) |
| "To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation." | 7.79 | Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. ( Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2013) |
| "Although there is a relationship between DNA repair deficiency and temozolomide (TMZ) resistance in glioblastoma (GBM), it remains unclear which molecule is associated with GBM recurrence." | 7.79 | Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma. ( Arita, K; Furukawa, T; Hirano, H; Ikeda, R; Kawahara, K; Minami, K; Nishizawa, Y; Shinsato, Y; Tokimura, H; Yamamoto, M; Yonezawa, H; Yunoue, S, 2013) |
| "To analyze initial recurrence patterns in patients with newly diagnosed glioblastoma after radiotherapy plus concurrent and adjuvant temozolomide, and to investigate cumulative recurrence patterns after salvage treatment, including surgery, stereotactic radiotherapy, and chemotherapy." | 7.79 | Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution. ( Arakawa, Y; Hiraoka, M; Miyamoto, S; Mizowaki, T; Ogura, K; Ogura, M; Sakanaka, K, 2013) |
| "We report here a rare case of a young male patient presenting with a Multiple Endocrine Neoplasia Type 1 - prolactin-secreting pituitary carcinoma, controlled long-term after temozolomide withdrawal." | 7.78 | Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. ( Barlier, A; Barrie, M; Brue, T; Castinetti, F; Conte-Devolx, B; Dufour, H; Morange, I; Philippon, M; Taieb, D, 2012) |
| "We analyzed 62 consecutive patients with newly diagnosed glioblastoma treated between 2006 and 2008 with standard fractionation to a total dose of 60 Gy with concurrent temozolomide (97%) or arsenic trioxide (3%)." | 7.77 | Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. ( Crocker, IR; Curran, WJ; McDonald, MW; Shu, HK, 2011) |
| "The aim of this paper is to evaluate the efficacy of fractionated stereotactic radiotherapy (FSRT) and concomitant temozolomide (TMZ) as a salvage treatment option in patients with recurrent glioblastoma (GBM)." | 7.77 | Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. ( Armosini, V; Caporello, P; Lanzetta, G; Maurizi, RE; Mei, M; Minniti, G; Osti, MF; Salvati, M, 2011) |
| "Prolonged administration of temozolomide is widely used in patients with glioblastoma; whereas the treatment of anaplastic glioma differs between neurooncological centres." | 7.77 | Prolonged administration of temozolomide in adult patients with anaplastic glioma. ( Freyschlag, CF; Janzen, E; Lohr, F; Schmieder, K; Seiz, M; Smolczyk, DR; Thomé, C; Tuettenberg, J; Weiss, C; Wenz, F, 2011) |
| "To determine recurrence patterns of glioblastoma treated with temozolomide-based chemoradiation." | 7.76 | Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. ( Donatello, RS; Korones, DN; Milano, MT; Mohile, NA; Okunieff, P; Sul, J; Walter, KA, 2010) |
| "To analyze the recurrence patterns in patients with newly diagnosed glioblastoma (GBM) treated with conformal radiotherapy (RT) plus concomitant and adjuvant temozolomide (TMZ), and to compare the patterns of failure according to different target volume delineations." | 7.76 | Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. ( Amelio, D; Amichetti, M; Arcella, A; Bozzao, A; Enrici, RM; Lanzetta, G; Minniti, G; Muni, R; Salvati, M; Scarpino, S, 2010) |
| "Early radionecrosis after the Stupp protocol is not a rare event due to the radiosensitization effect of temozolomide." | 7.75 | Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? ( Del Basso De Caro, ML; Elefante, A; Giamundo, A; Maiuri, F; Mariniello, G; Pacelli, R; Peca, C; Vergara, P, 2009) |
| "The aim of the present study was to evaluate factors predicting the recurrence pattern after the administration of temozolomide (TMZ), initially concurrent with radiotherapy (RT) and subsequently as maintenance therapy, which has become standard treatment for patients with newly diagnosed glioblastoma (GBM)." | 7.75 | Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. ( Amistà, P; Brandes, AA; Ermani, M; Franceschi, E; Frezza, G; Morandi, L; Sotti, G; Spagnolli, F; Tosoni, A, 2009) |
| "Temozolomide (TMZ) is the standard of care for patients with newly diagnosed glioblastoma (GBM) as well as those with recurrent anaplastic glioma (AG) and GBM." | 7.75 | Rechallenge with temozolomide in patients with recurrent gliomas. ( Bogdahn, U; Hau, P; Jauch, T; Pascher, C; Weller, M; Wick, A; Wick, W, 2009) |
| "Temozolomide (TMZ) is an alkylating agent used in the management of gliomas." | 7.75 | Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? ( Bell, D; Khasraw, M; Wheeler, H, 2009) |
| "Case report of a 77-year-old woman with a radiation-induced, high-grade cerebellar glioma that responded durably to temozolomide." | 7.74 | Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide. ( Doherty, LM; Drappatz, J; Kesari, S; Monje, ML; Ramakrishna, NR; Wen, PY; Young, G, 2007) |
| "Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities of survival." | 7.74 | Fatal outcome related to carmustine implants in glioblastoma multiforme. ( Barcia, JA; Barcia-Mariño, C; Gallego, JM, 2007) |
| "Glioblastomas are treated by surgical resection followed by radiotherapy [X-ray therapy (XRT)] and the alkylating chemotherapeutic agent temozolomide." | 7.74 | Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. ( Batchelor, TT; Betensky, RA; Cahill, DP; Codd, PJ; Curry, WT; Futreal, PA; Iafrate, AJ; Levine, KK; Louis, DN; Reavie, LB; Romany, CA; Stratton, MR, 2007) |
| "To evaluate the predictive impact of chromosome 1p/19q deletions on the response and outcome of progressive low-grade gliomas (LGG) treated with up-front temozolomide (TMZ) chemotherapy." | 7.74 | Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. ( Benouaich-Amiel, A; Capelle, L; Carpentier, A; Cornu, P; Delattre, JY; Diakite, F; Duffau, H; Hoang-Xuan, K; Idbaih, A; Iraqi, W; Kaloshi, G; Laigle-Donadey, F; Lejeune, J; Mokhtari, K; Omuro, A; Paris, S; Polivka, M; Renard, MA; Sanson, M; Simon, JM; Taillibert, S, 2007) |
| "Temozolomide (TMZ) is active against newly diagnosed glioblastoma (GBM), and O(6)-methylguanine-DNA methyltransferase (MGMT) is implicated in resistance to TMZ and nitrosoureas." | 7.74 | Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. ( Kobayashi, K; Nagane, M; Ohnishi, A; Shimizu, S; Shiokawa, Y, 2007) |
| "To evaluate the feasibility, safety and efficacy of daily temozolomide concurrent with postoperative radiotherapy in malignant glioma." | 7.73 | Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma. ( Eich, HT; Kocher, M; Kunze, S; Müller, RP; Semrau, R, 2005) |
| "There are new scientific data concerning the treatment of patients with glioblastoma multiforme with concomitant and adjuvant temozolomide following surgery and radiotherapy." | 7.73 | [Temozolomide in patients with a glioblastoma multiforme: new developments]. ( Bromberg, JE; Postma, TJ, 2005) |
| "To describe the results of the treatment of recurrent glioma with temozolomide." | 7.73 | [Favourable result for temozolomide in recurrent high-grade glioma]. ( Enting, RH; Kros, JM; Sillevis Smitt, PA; Taal, W; van den Bent, MJ; van der Rijt, CD; van Heuvel, I, 2005) |
| "Children and young adults with recurrent or treatment-induced malignant gliomas have limited responses to temozolomide or oral VP-16 when either is administered as a single agent." | 7.73 | Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas. ( Bouffet, E; Foreman, N; Korones, DN; Smith, A, 2006) |
| "To re-evaluate the cost effectiveness and median overall survival (OS) achieved in patients with recurrent malignant gliomas treated with temozolomide in British Columbia, as compared to previous lomustine use in the same patient population based on updated outcomes data." | 7.73 | Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia. ( Mabasa, VH; Taylor, SC, 2006) |
| "To report on an irinotecan and temozolomide regimen for neuroblastoma (NB)." | 7.73 | Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. ( Cheung, NK; Kramer, K; Kushner, BH; Modak, S, 2006) |
| "To assess whether the survival of patients with recurrent malignant glioma receiving temozolomide in everyday practice is comparable to that reported in previous studies." | 7.72 | Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study. ( Maltoni, S; Messori, A; Pelagotti, F; Trippoli, S; Vacca, F; Vaiani, M, 2003) |
| "Seven patients who had received rituximab and temozolomide were identified from the database of the brain tumor clinic at the authors' institution: three patients had developed recurrent primary CNS lymphoma (PCNSL), one patient had newly diagnosed PCNSL but had poor renal function, and three other patients with systemic non-Hodgkin lymphoma developed recurrent lymphoma in the brain only." | 7.72 | Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. ( Barron, L; Tishler, R; Wong, ET; Wu, JK, 2004) |
| "Temozolomide, an imidazotetrazine prodrug has shown activity in phase II studies in patients with high-grade glioma at first recurrence." | 7.71 | Temozolomide as second-line chemotherapy for relapsed gliomas. ( Ashley, S; Brada, M; Dowe, A; Hines, F; Kong, A; Short, SC; Traish, D; Trent, S, 2002) |
| "The authors determined the tolerance, response rate, and duration of recurrent anaplastic oligodendroglioma in 30 patients to temozolomide given orally at 150 to 200 mg/m2 on days 1 through 5 in cycles of 28 days." | 7.71 | Temozolomide chemotherapy in recurrent oligodendroglioma. ( Brandes, AA; Carpentier, AF; Eskens, FA; Keime-Guibert, F; Kros, JM; Taphoorn, MJ; van den Bent, MJ, 2001) |
| "Forty patients with recurrent malignant gliomas had been treated with temozolomide (Temodal)." | 7.71 | [Treatment of recidive malignant gliomas with temozolomide]. ( Afra, D; Sipos, L; Vitanovics, D, 2002) |
| "Glioblastoma is the most frequent and malignant primary brain tumor." | 7.11 | Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial. ( Becker, A; Burger, MC; Clusmann, H; Delev, D; Giordano, FA; Glas, M; Goldbrunner, R; Grauer, O; Güresir, E; Hau, P; Heiland, DH; Herrlinger, U; Krex, D; Nemeth, R; Potthoff, AL; Radbruch, A; Sabel, M; Schaub, C; Schilling, J; Schlegel, U; Schmid, M; Schneider, M; Schnell, O; Schuss, P; Seidel, C; Steinbach, JP; Tabatabai, G; Thon, N; Vatter, H; Weller, J; Winkler, F; Zeyen, T, 2022) |
| " Common adverse events (AEs) were blurred vision (63%), fatigue (38%), and photophobia (35%)." | 6.90 | Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. ( Ansell, PJ; Bain, E; Butowski, N; Gan, HK; Gomez, E; Holen, KD; Kumthekar, P; Lassman, AB; Lee, HJ; Lwin, Z; Maag, D; Merrell, R; Mikkelsen, T; Nabors, LB; Papadopoulos, KP; Penas-Prado, M; Reardon, DA; Roberts-Rapp, L; Scott, AM; Simes, J; van den Bent, MJ; Walbert, T; Wheeler, H; Xiong, H, 2019) |
| " Pharmacokinetic testing did not show evidence of drug-drug interaction between irinotecan and alisertib." | 6.82 | Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. ( Bagatell, R; Courtier, J; Czarnecki, S; DuBois, SG; Fox, E; Goodarzian, F; Groshen, S; Hawkins, R; Kudgus, RA; Lai, H; Malvar, J; Marachelian, A; Maris, JM; Matthay, KK; Mosse, YP; Reid, JM; Shimada, H; Tsao-Wei, D; Wagner, L, 2016) |
| " Metronomic dosing of cytotoxic chemotherapy has emerged as a promising option to achieve this objective." | 6.82 | Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas. ( Alsop, DC; Callahan, A; Giarusso, B; O'Loughlin, L; Timmons, J; Wong, ET, 2016) |
| "Retreatment with temozolomide (TMZ) is one treatment option." | 6.80 | Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme. ( Ancelet, LR; Bauer, E; Dzhelali, M; Findlay, MP; Gasser, O; Hamilton, DA; Hermans, IF; Hunn, MK; Mester, B; Sharples, KJ; Wood, CE, 2015) |
| "Patients with newly diagnosed anaplastic astrocytoma (AA) or anaplastic oligo-astrocytoma (AOA) were treated with concurrent radiotherapy (60 Gy over 6 weeks) and temozolomide (75 mg/m(2)), and six adjuvant 28-day cycles of either dose-dense (150 mg/m(2), days 1-7, 15-21) or metronomic (50 mg/m(2), days 1-28) temozolomide." | 6.80 | Radiotherapy and temozolomide for anaplastic astrocytic gliomas. ( Abrey, LE; Braunthal, SG; DeAngelis, LM; Huse, JT; Lassman, AB; Nayak, L; Panageas, KS; Pentsova, E; Reiner, AS, 2015) |
| " In addition, various protracted temozolomide dosing schedules have been evaluated as a strategy to further enhance its anti-tumor activity." | 6.76 | Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2011) |
| " PCB was administered as an oral dosage of 450 mg on days 1-2 and a total dose of 300 mg on day 3." | 6.73 | Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. ( Boiardi, A; Botturi, A; Eoli, M; Falcone, C; Filippini, G; Fiumani, A; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A, 2008) |
| "Perillyl alcohol has shown to have both chemopreventive and chemotherapeutic activities in preclinical studies." | 6.73 | Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. ( da Fonseca, CO; Fischer, J; Futuro, D; Gattass, CR; Nagel, J; Quirico-Santos, T; Schwartsmann, G, 2008) |
| "Temozolomide was in general well tolerated; the most frequent side-effects were hematological." | 6.71 | Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. ( Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ, 2003) |
| "Aggressive pituitary adenomas (APAs) and pituitary carcinomas (PCs) are challenging for their invasive nature, resistance to treatment and recurrences." | 6.66 | Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. ( Barbot, M; Bellu, L; Ceccato, F; Gardiman, MP; Lizzul, L; Lombardi, G; Losa, M; Mazza, E; Regazzo, D; Scaroni, C, 2020) |
| "Myxopapillary ependymomas are intradural tumors which grow from the terminal filum of the spinal cord." | 6.58 | Remarkable efficacy of temozolomide for relapsed spinal myxopapillary ependymoma with multiple recurrence and cerebrospinal dissemination: a case report and literature review. ( Adachi, N; Fujiwara, Y; Izumi, B; Manabe, H; Shima, T, 2018) |
| "Fibrosarcoma is a rare brain tumour with 33 cases reported so far." | 6.53 | Intracranial fibrosarcoma treated with adjuvant radiation and temozolomide: Report of a case and review of all published cases. ( Giridhar, P; Gupta, S; Haresh, KP; Julka, PK; Mallick, S; Rath, GK, 2016) |
| "Irinotecan is a water-soluble derivative of camptothecin, an alkylator originally extracted from the Chinese tree Camptotheca acuminata." | 6.42 | The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. ( Friedman, HS; Houghton, PJ; Keir, ST, 2003) |
| " The drug is well tolerated with dose limiting myelosuppression and thrombocytopenia occurring in less than 10% of patients at current dosage schedules." | 6.41 | The use of temozolomide in recurrent malignant gliomas. ( Gaya, A; Greenstein, A; Rees, J; Stebbing, J, 2002) |
| "New approaches to the treatment of glioblastoma, including immune checkpoint blockade and oncolytic viruses, offer the possibility of improving glioblastoma outcomes and have as such been under intense study." | 5.91 | Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma. ( Craig, M; Fiset, B; Jenner, AL; Karimi, E; Quail, DF; Surendran, A; Walsh, LA, 2023) |
| " The most common adverse events were leukocytopenia (66." | 5.91 | Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma. ( Bu, L; Cai, J; Chen, Q; Huang, K; Meng, X; Weng, Y; Xu, Q; Zhan, R; Zhang, L; Zheng, X, 2023) |
| "Allopregnanolone (allo) is a physiological regulator of neuronal activity that treats multiple neurological disorders." | 5.72 | Allopregnanolone suppresses glioblastoma survival through decreasing DPYSL3 and S100A11 expression. ( Feng, YH; Hsu, SP; Hsu, TI; Kao, TJ; Ko, CY; Lim, SW; Lin, HY; Wang, SA, 2022) |
| "Temozolomide (TMZ) is a DNA alkylating agent that appears to have a radiosensitizing effect when used in combination with RT and may be worthwhile in meningioma treatment." | 5.72 | Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review. ( Belanger, K; Damek, D; Lillehei, KO; Ormond, DR; Ung, TH, 2022) |
| "Glioblastoma multiforme is a malignant neoplasia with a median survival of less than two years and without satisfactory therapeutic options." | 5.72 | The role of Shikonin in improving 5-aminolevulinic acid-based photodynamic therapy and chemotherapy on glioblastoma stem cells. ( Buchner, A; Lyu, C; Pohla, H; Schrader, I; Sroka, R; Stadlbauer, B; Stepp, H; Werner, M, 2022) |
| "The optimal dose schedule of vincristine, irinotecan, and temozolomide (VIT) in relapsed or refractory patients with Ewing sarcoma requires clarification." | 5.69 | Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial. ( Cai, Z; Guo, W; Liang, X; Liu, K; Sun, X; Tang, X; Xie, L; Xu, J, 2023) |
| "Glioblastoma multiforme is a malignant central nervous system (CNS) disease with dismal prognosis." | 5.62 | Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab. ( Fioretzaki, RG; Kosmas, C; Papageorgiou, GI; Tsakatikas, SA, 2021) |
| "GBM (glioblastoma multiforme) is the most common and aggressive brain tumor." | 5.62 | Regorafenib in glioblastoma recurrence: A case report. ( Desideri, I; Detti, B; Ganovelli, M; Greto, D; Livi, L; Lorenzetti, V; Lucidi, S; Maragna, V; Scoccianti, S; Scoccimarro, E; Teriaca, MA, 2021) |
| "Temozolomide was labeled with [11C], and serial PET-MRI scans were performed in patients with recurrent GBM treated with bevacizumab and daily temozolomide." | 5.56 | Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. ( Batchelor, T; Beers, AL; Catana, C; Chang, K; Dietrich, J; Duda, DG; Emblem, KE; Gerstner, ER; Hooker, JM; Jain, RK; Kalpathy-Cramer, J; Plotkin, SR; Rosen, B; Vakulenko-Lagun, B; Yen, YF, 2020) |
| "Temozolomide/etoposide is a feasible candidate as salvage therapy for relapsed osteosarcoma." | 5.56 | Temozolomide and etoposide combination for the treatment of relapsed osteosarcoma. ( Adachi, S; Akazawa, R; Arakawa, Y; Hiramatsu, H; Kato, I; Moritake, H; Okamoto, T; Saida, S; Sakamoto, A; Sumiyoshi, S; Takita, J; Umeda, K, 2020) |
| "Long‑term local treatment of glioblastoma is rarely achieved and the majority of the patients undergo relapse." | 5.51 | Synergistic effect of arsenic trioxide, vismodegib and temozolomide on glioblastoma. ( Bureta, C; Komiya, S; Maeda, S; Nagano, S; Saitoh, Y; Sasaki, H; Setoguchi, T; Taniguchi, N; Tokumoto, H, 2019) |
| " Our results demonstrate benefit of ddTMZ after previous treatment with standard TMZ dosing with no apparent increase in treatment-related toxicities." | 5.48 | Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study. ( Garcia, CR; Gruber, L; Kumar, SS; Lightner, DD; Morgan, RM; Slone, SA; Villano, JL, 2018) |
| "Valproic acid (VPA) is an anti-epileptic drug with properties of a histone deacetylase inhibitor (HDACi)." | 5.43 | Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. ( Dietrich, J; Le, A; McDonnell, E; Nahed, BV; Redjal, N; Reinshagen, C; Walcott, BP, 2016) |
| "Seizures are a common symptom in patients with low-grade glioma (LGG), negatively influencing quality of life, if uncontrolled." | 5.42 | Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide. ( Dirven, L; Heimans, JJ; Koekkoek, JA; Postma, TJ; Reijneveld, JC; Taphoorn, MJ; Vos, MJ, 2015) |
| "Irinotecan and temozolomide achieve objective responses in patients with Ewing sarcoma that recurs after initial therapy." | 5.41 | Irinotecan dose schedule for the treatment of Ewing sarcoma. ( Meyers, PA; Slotkin, EK, 2023) |
| "Temozolomide is an oral alkylating agent that is used as the first line treatment for glioblastoma multiform, and in recurrent anaplastic astrocytoma, as well as having demonstrable activity in patients with metastatic melanoma." | 5.41 | Is Autophagy Inhibition in Combination with Temozolomide a Therapeutically Viable Strategy? ( Elshazly, AM; Gewirtz, DA, 2023) |
| " This preclinical study sought to test the efficacy of the food additive Triacetin (glyceryl triacetate, GTA) as a novel therapy to increase acetate bioavailability in glioma cells." | 5.40 | Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma. ( Davies, MT; Driscoll, HE; Jaworski, DM; Lawler, SE; Long, PM; Penar, PL; Pendlebury, WW; Spees, JL; Teasdale, BA; Tsen, AR; Viapiano, MS, 2014) |
| "Diffuse brainstem glioma is a rare disease in adults." | 5.40 | Temozolomide after radiotherapy in recurrent "low grade" diffuse brainstem glioma in adults. ( Delattre, JY; Laigle-Donadey, F; Martin-Duverneuil, N; Mokhtari, K; Reyes-Botero, G, 2014) |
| " In the present analysis, we retrospectively investigated the feasibility and effectiveness of bevacizumab combined with ICE in patients with glioblastoma at second relapse during ICE treatment." | 5.39 | Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma. ( Arakawa, Y; Fujimoto, K; Kikuchi, T; Kunieda, T; Miyamoto, S; Mizowaki, T; Murata, D; Takagi, Y; Takahashi, JC, 2013) |
| "Temozolomide is an attractive candidate treatment in neuroblastoma with methylated MGMT, especially in central nervous system relapsed cases." | 5.39 | Efficacy of temozolomide in a central nervous system relapse of neuroblastoma with O 6 -methylguanine methyltransferase (MGMT) promoter methylation. ( Marutsuka, K; Moritake, H; Nunoi, H; Shimonodan, H; Takeshima, H; Yamada, A; Yokogami, K, 2013) |
| " The growing body of evidence demonstrating the clinical importance of O6-methylguanine methyltransferase (MGMT) has generated a considerable interest in the exploration of strategies to overcome MGMT-mediated resistance to alkylating agents; for example protracted administration of Temozolomide (TMZ) may result in more extensive and sustained depletion of MGMT; for this reason a variety of dosing schedules that increase the duration of exposure and the cumulative dose of TMZ are being investigated for the treatment of patient with recurrent malignant glioma after standard treatment." | 5.37 | Rechallenge with temozolomide in recurrent glioma. ( Botturi, A; Fariselli, L; Ferrari, D; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A; Simonetti, G, 2011) |
| "A 33-year-old woman presented with rare brain metastases from undifferentiated high-grade sarcoma manifesting as headache and vomiting." | 5.36 | Brain metastasis of undifferentiated sarcoma and response to temozolomide treatment. Case report. ( Arai, A; Itoh, T; Kanomata, N; Kawamura, A; Kohmura, E; Nishihara, M; Sasayama, T; Tanaka, H, 2010) |
| "Paclitaxel is an antineoplastic agent that is used in the treatment of a variety of solid tumors." | 5.35 | Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma. ( Fangusaro, J; Finlay, J; Rook, J; Rosser, T, 2008) |
| "In this open-label, randomized, phase 3 clinical trial, 439 patients with glioblastoma at first recurrence following standard radiation and temozolomide therapy were enrolled, and 369 were randomized." | 5.34 | Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. ( Ahluwalia, MS; Baehring, J; Bähr, O; Brandes, AA; Carleton, M; De Souza, P; Lim, M; Mulholland, P; Omuro, A; Phuphanich, S; Reardon, DA; Roth, P; Sahebjam, S; Sampson, J; Sepulveda, JM; Taitt, C; Tatsuoka, K; Weller, M; Wick, A; Zwirtes, R, 2020) |
| "Treatment with temozolomide resulted in relief of clinical symptoms and stabilization of tumour growth for 8 months." | 5.34 | Metastatic medulloblastoma in an adult; treatment with temozolomide. ( Bernsen, HJ; Poelen, J; Prick, MJ, 2007) |
| "Temozolomide is an oral cytotoxic agent that has demonstrated its interest in high grade glioma tumors." | 5.34 | Temozolomide treatment of an adult with a relapsing medulloblastoma. ( Bay, JO; Durando, X; Gilliot, O; Irthum, B; Thivat, E; Verrelle, P; Vincent, C, 2007) |
| "The time-to-maximum plasma concentration (tmax) of TMZ was about 1 h and the elimination half-life of terminal excretion phase (t 1/2lambda z) was about 2 h." | 5.34 | Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians. ( Adachi, J; Aoki, T; Matsutani, M; Mishima, K; Mizutani, T; Nishikawa, R; Nojima, K, 2007) |
| "Preclinical studies have suggested promising activity for the combination of disulfiram and copper (DSF/Cu) against glioblastoma (GBM) including re-sensitization to temozolomide (TMZ)." | 5.30 | A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. ( Boockvar, J; Campian, JL; Chaudhary, R; Chinnaiyan, P; Cohen, AL; Fink, K; Goldlust, S; Huang, J; Marcus, S; Wan, L, 2019) |
| "Combined PET-MRI with the tracer O-(2-18F-fluoroethyl)-l-tyrosine (18F-FET) prior to re-RT was performed in recurrent glioma patients in a phase I trial." | 5.30 | Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation. ( Albert, NL; Bartenstein, P; Belka, C; Corradini, S; Fleischmann, DF; Förster, S; la Fougère, C; Niyazi, M; Rottler, M; Schwaiger, M; Siepmann, T; Unterrainer, M, 2019) |
| "In this exploratory analysis of AVAglio, a randomized phase III clinical study that investigated the addition of bevacizumab (Bev) to radiotherapy/temozolomide in newly diagnosed glioblastoma, we aim to radiologically characterize glioblastoma on therapy until progression and investigate whether the type of radiologic progression differs between treatment arms and is related to survival and molecular data." | 5.27 | Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio. ( Abrey, LE; Bendszus, M; Chinot, OL; Cloughesy, TF; Ellingson, BM; Garcia, J; Henriksson, R; Kickingereder, P; Mason, WP; Nishikawa, R; Nowosielski, M; Platten, M; Radbruch, A; Revil, C; Sandmann, T; Saran, F; Wick, W, 2018) |
| " This phase II study examined the safety and efficacy of intermittent veliparib with carboplatin/paclitaxel (VCP) or temozolomide (VT) in patients with BRCA1/2-mutated breast cancer." | 5.27 | Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. ( Bondarenko, I; Campone, M; Chmielowska, E; Citrin, D; Diéras, V; Domchek, SM; Friedlander, M; Garber, JE; Gradishar, W; Han, HS; Isakoff, SJ; Jager, A; Jakobsen, EH; Kaklamani, V; Kaufman, B; Marcom, PK; Nickner, C; Palácová, M; Puhalla, S; Qian, J; Qin, Q; Ratajczak, CK; Robson, M; Shepherd, SP; Shparyk, Y; Telli, ML, 2018) |
| "To determine the impact on overall survival with different salvage therapies, including no treatment, reirradiation, systemic therapy, or radiation and systemic therapy, in participants of a phase 3 clinical trial evaluating dose-dense versus standard-dose temozolomide for patients with newly diagnosed glioblastoma." | 5.27 | Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. ( Andrews, DW; Blumenthal, DT; Brown, PD; Dignam, JJ; Gilbert, MR; Hopkins, K; Howard, SP; Lessard, N; Mehta, MP; Scannell Bryan, M; Shi, W; Souhami, L; Tzuk-Shina, T; Valeinis, E; Werner-Wasik, M; Youssef, EF, 2018) |
| " We sought to study vorinostat (VOR), a histone deacetylase inhibitor, in combination with bevacizumab (BEV) and daily metronomic temozolomide (TMZ) in a Phase I/II trial in recurrent high-grade gliomas (HGGs)." | 5.27 | Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. ( Desjardins, A; Friedman, HS; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Peters, KB; Reardon, DA, 2018) |
| "We evaluated patterns of tumor growth in patients with newly diagnosed MGMT-non-methylated glioblastoma who were assigned to undergo radiotherapy in conjunction with bevacizumab/irinotecan (BEV/IRI) or standard temozolomide (TMZ) within the randomized phase II GLARIUS trial." | 5.27 | Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. ( Bähr, O; Belka, C; Braun, C; Gerlach, R; Glas, M; Goldbrunner, R; Hänel, M; Hattingen, E; Hau, P; Herrlinger, U; Junold, N; Kebir, S; Kortmann, RD; Krex, D; Mack, F; Niessen, M; Proescholdt, M; Rohde, V; Sabel, M; Schäfer, N; Schaub, C; Schlegel, U; Schmidt-Graf, F; Steinbach, JP; Stuplich, M; Tzaridis, T; Vatter, H; Weyerbrock, A, 2018) |
| "Mibefradil (MIB), previously approved for treatment of hypertension, is a selective T-type calcium channel blocker with preclinical activity in high-grade gliomas (HGGs)." | 5.24 | Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. ( Desai, AS; Desideri, S; Fisher, JD; Grossman, SA; Holdhoff, M; Leal, J; Lesser, GJ; Lieberman, FS; Lodge, MA; Nabors, LB; Read, WL; Schiff, D; Supko, JG; Wahl, RL; Walbert, T; Ye, X, 2017) |
| "This post hoc analysis of the EF-14 trial (NCT00916409) of tumor-treating fields (TTFields) plus temozolomide versus temozolomide alone in newly diagnosed glioblastoma compared the efficacy of TTFields plus chemotherapy (physician's choice) versus chemotherapy alone after first recurrence." | 5.24 | Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial. ( Kesari, S; Ram, Z, 2017) |
| "We report a longitudinal assessment of health-related quality of life (HRQOL) in patients with glioblastoma (GBM) treated on a prospective dose escalation trial of 5-fraction stereotactic radiosurgery (25-40 Gy in 5 fractions) with concurrent and adjuvant temozolomide." | 5.24 | Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results. ( Adler, JR; Azoulay, M; Chang, SD; Choi, CYH; Fujimoto, D; Gibbs, IC; Hancock, SL; Harraher, C; Harsh, GR; Jacobs, LR; Li, G; Modlin, LA; Nagpal, S; Pollom, EL; Recht, LD; Seiger, K; Soltys, SG; Thomas, RP; Tupper, L; von Eyben, R; Wynne, J, 2017) |
| "Bevacizumab plus bi-weekly temozolomide was well tolerated and may be a salvage regimen to be considered in a subset of patients with recurrent glioblastoma." | 5.24 | Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma. ( Ahmadi, MM; Badruddoja, MA; Kuzma, K; Mahadevan, D; Norton, T; Pazzi, M; Sanan, A; Schroeder, K; Scully, T, 2017) |
| "In glioblastoma multiforme (GBM), both temozolomide (TMZ) and cisplatin are very active at various toxic levels." | 5.24 | Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients. ( Guo, Y; Kong, X; Ma, W; Wang, R; Wang, Y, 2017) |
| "The primary aim of this Phase I study was to determine the maximum tolerated dose (MTD) of TPI 287 and the safety and tolerability of TPI 287 alone and in combination with temozolomide (TMZ) in pediatric patients with refractory or recurrent neuroblastoma or medulloblastoma." | 5.22 | A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma. ( Ashikaga, T; Bergendahl, G; DeSarno, M; Eslin, D; Ferguson, W; Hanna, GK; Higgins, T; Kaplan, J; Kraveka, J; Mitchell, D; Roberts, W; Sholler, GL; Werff, AV, 2016) |
| "This phase II study was conducted to determine the efficacy and safety of metronomic temozolomide (TMZ) in combination with irinotecan in glioblastoma (GB) at first relapse." | 5.22 | Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma. ( Balañá, C; Benavides, M; Fleitas, T; Gallego, O; Gil-Gil, M; Martínez-Sales, V; Palomero, I; Pérez-Segura, P; Reche, E; Reynés, G; Vaz, MA; Vila, V, 2016) |
| "Adding temozolomide (TMZ) to radiation for patients with newly-diagnosed anaplastic astrocytomas (AAs) is common clinical practice despite the lack of prospective studies demonstrating a survival advantage." | 5.22 | The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. ( Abuali, I; Grossman, SA; Lu, Y; Strowd, RE; Ye, X, 2016) |
| "Rechallenge with temozolomide (TMZ) at first progression of glioblastoma after temozolomide chemoradiotherapy (TMZ/RT→TMZ) has been studied in retrospective and single-arm prospective studies, applying temozolomide continuously or using 7/14 or 21/28 days schedules." | 5.20 | MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. ( Bähr, O; Felsberg, J; Goldbrunner, R; Hau, P; Herrlinger, U; Homicsko, K; Hüsing, J; Kästner, B; Ketter, R; Kollias, S; Marosi, C; Meixensberger, J; Nikkhah, G; Pichler, J; Platten, M; Reifenberger, G; Sabel, MC; Schlegel, U; Schnell, O; Steinbach, JP; Stupp, R; Tabatabai, G; Tonn, JC; Vajkoczy, P; Weller, M; Wick, A; Wick, W; Wirsching, HG, 2015) |
| "The aim of this prospective and multicentric phase II study was to evaluate the efficacy and safety of temozolomide (TMZ) and bevacizumab (BV) in patients (pts) with recurrent glioblastoma (GB), previously treated with chemoradiotherapy and at least three cycles of adjuvant TMZ." | 5.20 | A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma. ( Balañá, C; Belda-Iniesta, C; Berrocal, A; Capellades, J; Gallego, O; Gil-Gil, M; La Orden, B; Ordoñez, JM; Pérez-Segura, P; Reynés, G; Sepúlveda, JM, 2015) |
| "In a phase II study for patients with relapsed small cell lung cancer (SCLC), the administration of Temozolomide, an alkylating agent used in gliomas and anaplastic astrocytoma, showed a effective activity when O(6) -methylguanine-DNA methyltransferase (MGMT) gene promoter was methylated." | 5.20 | Frequency of O⁶-methylguanine-DNA methyltransferase promoter methylation in cytological samples from small cell lung cancer. ( Boldorini, R; Buosi, R; Gaudino, E; Mancuso, G; Mercalli, F; Mezzapelle, R; Miglio, U; Paganotti, A; Rena, O; Veggiani, C, 2015) |
| "To assess objective response rate (ORR) after two cycles of temozolomide in combination with topotecan (TOTEM) in children with refractory or relapsed neuroblastoma." | 5.19 | Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study. ( Aerts, I; Amoroso, L; Boubaker, A; Casanova, M; Chastagner, P; Courbon, F; Devos, A; Di Giannatale, A; Dias-Gastellier, N; Ducassoul, S; Geoerger, B; Landman-Parker, J; Le Deley, MC; Malekzadeh, K; Mc Hugh, K; Munzer, C; Riccardi, R; Rubie, H; Verschuur, A; Zwaan, CM, 2014) |
| "To determine the maximum tolerated dose of irinotecan administered every 2 weeks, in combination with a fixed and continuous administration of temozolomide, in patients with glioblastoma at first relapse." | 5.19 | A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma. ( Balañá, C; Gallego, O; García, JL; Iglesias, L; Pérez, P; Reynés, G, 2014) |
| "The integrin antagonist cilengitide has been explored as an adjunct with anti-angiogenic properties to standard of care temozolomide chemoradiotherapy (TMZ/RT → TMZ) in newly diagnosed glioblastoma." | 5.19 | Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. ( Clément, PM; Eisele, AC; Eisele, G; Krex, D; Neyns, B; Nikkhah, G; Ochsenbein, A; Picard, M; Schlegel, U; Simon, M; Stupp, R; Tabatabai, G; Tonn, J; Weller, M; Wick, A; Wick, W, 2014) |
| "The aim of this study was to assess the objective response rate (ORR) of children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor (MB/PNET) treated with temozolomide (TMZ)." | 5.19 | Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial. ( Abate, ME; Barone, G; Cefalo, G; Colosimo, C; Garrè, ML; Madon, E; Mascarin, M; Massimino, M; Perilongo, G; Potepan, P; Riccardi, R; Ridola, V; Ruggiero, A; Spreafico, F, 2014) |
| "The objective of this study was to report the patterns of failure in patients with glioblastoma multiforme (GBM) treated on a phase II trial of hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with concurrent and adjuvant temozolomide (TMZ)." | 5.19 | Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme. ( Chen, C; Gaspar, LE; Kavanagh, BD; Reddy, K, 2014) |
| "To determine the safety and efficacy of hypofractionated intensity modulated radiation therapy (Hypo-IMRT) using helical tomotherapy (HT) with concurrent low dose temozolomide (TMZ) followed by adjuvant TMZ in patients with glioblastoma multiforme (GBM)." | 5.17 | Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. ( Abdulkarim, B; Fallone, G; Field, C; Fulton, D; Ghosh, S; Jastaniyah, N; Le, D; Mackenzie, M; Murtha, A; Patel, S; Pervez, N; Roa, W, 2013) |
| "Among patients with glioblastoma (GBM) who progress on standard temozolomide, the optimal therapy is unknown." | 5.17 | Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. ( Batchelor, TT; Beroukhim, R; Doherty, L; Drappatz, J; Fadul, CE; Hammond, SN; Lafrankie, D; Lee, EQ; Lesser, GJ; Ligon, KL; Lis, R; Muzikansky, A; Norden, AD; Plotkin, SR; Reardon, DR; Rosenfeld, MR; Smith, K; Stack, EC; Tafoya, V; Wen, PY; Zhu, JJ, 2013) |
| "To evaluate the efficacy and safety of temozolomide (TMZ) versus semustine (Me-CCNU) in the treatment of recurrent glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA)." | 5.17 | [Multicenter randomized controlled study of temozolomide versus semustine in the treatment of recurrent malignant glioma]. ( Sun, J; Yang, SY; Yang, XJ, 2013) |
| "Thirteen patients with recurrent glioblastoma were enrolled in RTOG 0625/ACRIN 6677, a prospective multicenter trial in which bevacizumab was used in combination with either temozolomide or irinotecan." | 5.17 | Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. ( Barboriak, DP; Bokstein, F; Boxerman, JL; Gilbert, MR; McKinstry, RC; Ratai, EM; Safriel, Y; Snyder, BS; Sorensen, AG; Zhang, Z, 2013) |
| "RTOG 0625/ACRIN 6677 is a multicenter, randomized, phase II trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma (GBM)." | 5.17 | Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. ( Barboriak, DP; Boxerman, JL; Chi, TL; Gilbert, MR; Jain, R; Larvie, M; Safriel, Y; Snyder, BS; Sorensen, AG; Zhang, Z, 2013) |
| "Patients with mucosal melanoma in stage II/III after surgery were randomized into three groups: observation group (group A, surgery alone), HDI group (group B, treated with 15 × 10(6) U/m(2)/d IFN-α2b, followed by 9 × 10(6) U IFN-α2b), and temozolomide (200 mg/m(2)/d) plus cisplatin (75 mg/m(2)) group (group C)." | 5.17 | Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. ( Chi, Z; Cui, C; Guo, J; Kong, Y; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B, 2013) |
| "The current standard-of-care for glioblastoma (GBM) is represented by concomitant radiotherapy (RT) and temozolomide (TMZ), according to Stupp's protocol." | 5.17 | Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma. ( Caroli, M; Carrabba, G; DI Cristofori, A; Lanfranchi, G; Menghetti, C; Rampini, P, 2013) |
| " Multiple glioma cell lines were analyzed for viability after treatment with radiation, temozolomide, or sorafenib or combinations of them." | 5.17 | A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. ( Andrews, DW; Camphausen, K; Den, RB; Dicker, AP; Dougherty, E; Friedman, DP; Glass, J; Green, MR; Hegarty, S; Hyslop, T; Kamrava, M; Lawrence, YR; Marinucchi, M; Sheng, Z; Werner-Wasik, M, 2013) |
| "We performed a dose-escalation trial to determine the maximum tolerated dose (MTD) of intensity-modulated radiotherapy (IMRT) with standard concurrent and sequential-dose temozolomide (TMZ) in patients with glioblastoma multiforme." | 5.17 | Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1). ( Balducci, M; Cilla, S; Deodato, F; Ferro, M; Macchia, G; Massaccesi, M; Morganti, AG; Valentini, V, 2013) |
| "In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedule in the treatment of recurrent malignant gliomas (MGs)." | 5.17 | Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. ( Abrey, LE; Chan, TA; Deangelis, LM; Gavrilovic, IT; Heguy, A; Hormigo, A; Hottinger, AF; Huse, JT; Kaley, TJ; Kaufman, A; Khasraw, M; Lassman, AB; Mellinghoff, I; Nolan, CP; Omuro, A; Panageas, KS; Reiner, AS; Salvant, C, 2013) |
| "We undertook this phase I study to investigate the feasibility of the combination of temozolomide (TMZ) and lapatinib (LP) and to define the maximum tolerated dose (MTD) of LP in patients with relapsed high-grade gliomas." | 5.17 | A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas. ( Bobos, M; Chrisafi, S; Fountzilas, G; Karavasilis, V; Kotoula, V; Lambaki, S; Pentheroudakis, G; Televantou, D, 2013) |
| "To evaluate in a single center retrospectively the efficacy and tolerability of a weekly regimen, which alternates temozolomide (TMZ) in patients with recurrent or progressive high-grade glioma (HGG)." | 5.17 | "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center. ( Berhorn, T; Blau, T; Dunkl, V; Fink, GR; Galldiks, N; Schroeter, M, 2013) |
| "The authors performed a phase 2 trial of combined protracted daily temozolomide and biweekly bevacizumab for patients with recurrent glioblastoma who had previously received radiation therapy and temozolomide." | 5.16 | Bevacizumab and daily temozolomide for recurrent glioblastoma. ( Bailey, L; Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; Marcello, J; Peters, KB; Reardon, DA; Vredenburgh, JJ, 2012) |
| "To report toxicity and overall survival (OS) in patients with newly diagnosed glioblastoma multiforme (GBM) treated with hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with concurrent and adjuvant temozolomide (TMZ)." | 5.16 | Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. ( Chen, C; Damek, D; Gaspar, LE; Kavanagh, BD; Lillehei, K; Ney, D; Reddy, K; Stuhr, K; Waziri, A, 2012) |
| "In the present study we investigated the feasibility and effectiveness of a new biweekly schedule of fotemustine (FTM) in patients with recurrent glioblastoma, after at least one previous treatment." | 5.15 | A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. ( Abbruzzese, A; Addeo, R; Caraglia, M; Carraturo, M; Cennamo, G; De Santi, MS; Del Prete, S; Faiola, V; Genovese, M; Montella, L; Parlato, C; Vincenzi, B, 2011) |
| "We evaluated the efficacy of metronomic etoposide or temozolomide administered with bevacizumab among recurrent glioblastoma (GBM) patients who progressed on prior bevacizumab therapy in a phase 2, open-label, two-arm trial." | 5.15 | Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. ( Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Marcello, J; McLendon, R; Peters, K; Reardon, DA; Rich, JN; Sampson, J; Threatt, S; Vredenburgh, JJ, 2011) |
| "To determine the maximal tolerated biologic dose intensification of radiotherapy using fractional dose escalation with temozolomide (TMZ) chemotherapy in patients with newly diagnosed glioblastoma multiforme." | 5.15 | Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. ( Chen, C; Damek, D; Gaspar, LE; Kavanagh, BD; Kleinschmidt-DeMasters, BK; Lillehei, K; Robischon, M; Rusthoven, KE; Stuhr, K; Waziri, A, 2011) |
| "To analyse patterns of failure in patients with glioblastoma multiforme treated with concurrent radiation and temozolomide." | 5.15 | Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. ( Burnett Iii, OL; Dobelbower, MC; Fiveash, JB; Hyatt, MD; Markert, JM; Nabors, LB; Nordal, RA, 2011) |
| "The primary objectives of this phase II study were to evaluate the use of preirradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma (MOA)." | 5.14 | Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. ( Berkey, B; Biggs, C; Blumenthal, DT; Brown, P; Giannini, C; Herman, J; Jenkins, R; Macdonald, D; Mehta, M; Peereboom, D; Schultz, C; Suh, JH; Vogelbaum, MA, 2009) |
| "This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administering O(6)-BG in combination with temozolomide." | 5.14 | Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5-day dosing regimens of temozolomide (TMZ) in combination with O(6)-benzylguanine (O(6)-BG)." | 5.14 | Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "Because of the poor outcomes for patients with recurrent glioblastoma multiforme (GBM), and some laboratory and clinical evidence of efficacy using interferon in GBM, we assessed the toxicity and efficacy of temozolomide (TMZ) combined with either short-acting (IFN) or long-acting (pegylated) interferon alpha2b (PEG) in two single-arm phase II studies, and compared the results to 6-month progression-free survival (PFS-6) data from historical controls." | 5.14 | Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. ( Alfred Yung, WK; Conrad, CA; Gilbert, MR; Groves, MD; Hess, KR; Hunter, K; Levin, VA; Liu, VH; Meyers, C; Puduvalli, VK, 2009) |
| "This alternating weekly, dose-dense temozolomide regimen was well tolerated and clinically active in heavily pretreated patients with brain metastases, particularly in patients with melanoma." | 5.14 | Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. ( Bajetta, E; Cascinu, S; Crinò, L; Danova, M; Del Prete, S; Salvagni, S; Schiavetto, I; Siena, S; Vitali, M, 2010) |
| "The aim of this clinical trial was to investigate safety and efficacy when combining cetuximab with bevacizumab and irinotecan in patients with recurrent primary glioblastoma multiforme (GBM)." | 5.14 | Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. ( Broholm, H; Hansen, S; Hasselbalch, B; Holmberg, M; Kosteljanetz, M; Lassen, U; Poulsen, HS; Stockhausen, MT; Sørensen, M, 2010) |
| "Compared with historical controls, the addition of concomitant and adjuvant cilengitide to standard chemoradiotherapy demonstrated promising activity in patients with glioblastoma with MGMT promoter methylation." | 5.14 | Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. ( Clement, PM; Dietrich, PY; Diserens, AC; Goldbrunner, R; Grabenbauer, GG; Hegi, ME; Hermisson, M; Hicking, C; Krueger, S; Neyns, B; Ochsenbein, AF; Pica, A; Picard, M; Pietsch, T; Schlegel, U; Simon, M; Stupp, R; Tonn, JC; Weller, M, 2010) |
| "To evaluate efficacy and safety of fotemustine chemotherapy in temozolomide (TMZ) pretreated adults with recurrent glioblastoma multiforme (GBM)." | 5.13 | Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. ( Ammannati, F; Biti, G; Bordi, L; Borghesi, S; Detti, B; Iannalfi, A; Leonulli, BG; Martinelli, F; Meattini, I; Sardaro, A; Scoccianti, S, 2008) |
| "The primary objective of this prospective phase 2 study of CPT-11 in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) was to evaluate 6-month progression-free survival (PFS)." | 5.13 | Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma. ( Blumenthal, DT; Chamberlain, MC; Glantz, MJ; Wei-Tsao, DD, 2008) |
| "The aim of the present study was to determine in patients with progressive or recurrent low grade gliomas, the response rate and toxicity incurred by a continued schedule of temozolomide chemotherapy administered before radiation therapy, and to explore correlations between response and survival with 1p/19q deletions and MGMT promoter methylation status." | 5.13 | Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. ( Bertorelle, R; Blatt, V; Bonaldi, L; Brandes, AA; Ermani, M; Franceschi, E; Tosoni, A, 2008) |
| "To evaluate outcome after fractionated stereotactic radiotherapy (FSRT) and concomitant daily temozolomide (TMZ) in patients with recurrent gliomas." | 5.13 | Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. ( Bischof, M; Combs, SE; Debus, J; Hof, H; Oertel, S; Schulz-Ertner, D; Welzel, T, 2008) |
| "A Phase II study of CPT-11 in adults with recurrent, temozolomide (TMZ)-refractory, 1p19q co-deleted, anaplastic oligodendroglioma (AO) with a primary objective of determining 6-month progression free survival (PFS)." | 5.13 | CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. ( Chamberlain, MC; Glantz, MJ, 2008) |
| "In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the treatment of IDH-mutant gliomas." | 5.12 | From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas. ( Sun, X; Turcan, S, 2021) |
| "The objective of the study was to evaluate the efficacy and toxicity of Temozolomide (TMZ) administered for 5 consecutive days in three daily dosing in children with recurrent or refractory high-grade glioma." | 5.12 | Phase II trial of temozolomide in children with recurrent high-grade glioma. ( Abate, ME; Attinà, G; Caldarelli, M; Cefalo, G; Clerico, A; Colosimo, C; Di Rocco, C; Garré, ML; Lazzareschi, I; Madon, E; Massimino, M; Maurizi, P; Mazzarella, G; Riccardi, R; Ridola, V; Ruggiero, A; Sandri, A, 2006) |
| "A prospective Phase II study of cyclophosphamide (CYC) was conducted in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) with a primary objective of evaluating 6-month progression-free survival (PFS)." | 5.12 | Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma. ( Chamberlain, MC; Groshen, S; Tsao-Wei, DD, 2006) |
| "Based on our findings in two paediatric patients, temozolomide may be a useful agent in the management of progressive recurrent low grade spinal cord astrocytomas." | 5.12 | Role of temozolomide in spinal cord low grade astrocytomas: results in two paediatric patients. ( Abboud, MR; Al Kutoubi, AO; Alaraj, AM; Chamoun, RB; Haddad, GF, 2006) |
| "The purpose of this study was to define the maximum tolerated dose of erlotinib and characterize its pharmaco-kinetics and safety profile, alone and with temozolomide, with and without enzyme-inducing antiepileptic drugs (EIAEDs), in patients with malignant gliomas." | 5.12 | Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. ( Burton, E; Butowski, N; Chang, S; Fedoroff, A; Kapadia, A; Kelley, SK; Lamborn, KR; Malec, M; Page, MS; Prados, MD; Rabbitt, J; Xie, D, 2006) |
| "Since anaplastic gliomas (AG) depend on matrix metalloproteinases for tumor cell invasion and angiogenesis, we undertook this phase II study to evaluate the matrix metalloproteinase inhibitor marimastat (MT), combined with the alkylator temozolomide (TMZ) in patients with recurrent AG, looking for improved outcomes." | 5.12 | Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. ( Aldape, KD; Conrad, CA; Gilbert, MR; Groves, MD; Hess, KR; Jaeckle, K; Levin, VA; Liu, V; Puduvalli, VK; Yung, WK, 2006) |
| "To date, no data are available on the relationship between 1p/19q deletions and the response to temozolomide (TMZ) in primary anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) recurrent after surgery and standard radiotherapy." | 5.12 | Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. ( Bertorelle, R; Blatt, V; Bonaldi, L; Brandes, AA; Cavallo, G; Ermani, M; Franceschi, E; Gardiman, M; Ghimenton, C; Iuzzolino, P; Pession, A; Reni, M; Tosoni, A, 2006) |
| " The aim of this pilot study was to evaluate the efficacy and safety of metronomic temozolomide (TMZ) treatment in twelve consecutive patients with recurrent TMZ-refractory glioblastoma." | 5.12 | A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. ( Eoh, W; Kim, JH; Kim, ST; Kim, WS; Kong, DS; Lee, JI; Lim, DH; Nam, DH; Park, K; Son, MJ, 2006) |
| "Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM)." | 5.12 | A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. ( Abrey, LE; Chang, SM; Cloughesy, TF; Conrad, CA; DeAngelis, LM; Gilbert, MR; Greenberg, H; Groves, MD; Hess, KR; Lamborn, KR; Liu, TJ; Peterson, P; Prados, MD; Puduvalli, VK; Schiff, D; Tremont-Lukats, IW; Wen, PY; Yung, WK, 2007) |
| "Temozolomide (TMZ) has demonstrated activity and acceptable toxicity for the treatment of recurrent malignant gliomas in carious prospective phase II studies." | 5.12 | [Temozolomide in the treatment of recurrent malignant glioma]. ( Ishii, N; Iwasaki, Y; Kobayashi, H; Murata, J; Sawamura, Y, 2006) |
| "To evaluate if timing of chemotherapy with Temozolomide (TMZ) was able to modify the outcome of glioblastoma (GBM), we analyzed two comparable series of supratentorial GBM patients, treated with surgery and radiotherapy, in which the administration of TMZ has been performed in the first group at first relapse and in the second group in newly diagnosed cases." | 5.12 | Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol? ( Borsa, S; Campanella, R; Caroli, M; Gaini, SM; Locatelli, M; Martinelli-Boneschi, F; Mora, A; Motta, F; Prada, F; Saladino, A, 2007) |
| "Evaluation of toxicity and efficacy of an alternating weekly regimen of temozolomide administered 1 week on and 1 week off in patients with recurrent glioma." | 5.12 | Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. ( Blaschke, B; Felsberg, J; Herrlinger, U; Meyermann, R; Platten, M; Reifenberger, G; Steinbach, JP; Weller, M; Wick, A; Wick, W, 2007) |
| "To compare results of treatment with temozolomide or dacarbazine, in combination with an anthracycline, in dogs with relapsed or refractory lymphoma." | 5.12 | Efficacy of temozolomide or dacarbazine in combination with an anthracycline for rescue chemotherapy in dogs with lymphoma. ( Cadile, CD; Dervisis, NG; Dominguez, PA; Kitchell, BE; Newman, RG; Sarbu, L; Swanson, CN, 2007) |
| "Although overall objective responses were limited, further exploration of temozolomide may be warranted in children with medulloblastoma and other PNETs, or in patients with low-grade astrocytoma, perhaps in a setting of less pretreatment than the patients in the current study, or in the context of multiagent therapy." | 5.12 | Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. ( Bernstein, M; Fort, D; Friedman, H; Harris, MB; Kadota, R; Krailo, M; Kretschmar, CS; Mazewski, C; Nicholson, HS; Reaman, GH; Sato, J; Tedeschi-Blok, N, 2007) |
| "To determine the tolerability, pharmacokinetics, and mechanisms of temozolomide resistance in children with relapsed or refractory leukemia." | 5.12 | Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. ( Adamson, PC; Berg, SL; Blaney, SM; Delaney, SM; Dolan, ME; Hedge, M; Horton, TM; Ingle, AM; Thompson, PA; Weiss, HL; Wu, MF, 2007) |
| "To determine the maximum tolerated dose of irinotecan when administrated with temozolomide every 28 days, in patients with recurrent malignant glioma who were also receiving CYP450 enzyme-inducing antiepileptic drugs (EIAED), and to characterize the pharmacokinetics of irinotecan and its metabolites." | 5.12 | Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. ( Aldape, KD; Chang, SM; Cloughesy, T; DeAngelis, LM; Fine, H; Fink, KL; Junck, L; Kuhn, J; Lamborn, K; Lieberman, F; Loghin, ME; Metha, M; Prados, MD; Robins, IH; Wen, P; Yung, WK, 2007) |
| "A phase II trial was initiated to analyze the activity of continuously administered pioglitazone and rofecoxib combined with low-dose chemotherapy (capecitabine or temozolomide) in patients with high-grade gliomas (glioblastoma or anaplastic glioma)." | 5.12 | Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. ( Baumgart, U; Bogdahn, U; Hau, P; Hirschmann, B; Kunz-Schughart, L; Muhleisen, H; Reichle, A; Ruemmele, P; Steinbrecher, A; Weimann, E, 2007) |
| "Patients with recurrent malignant glioma at any time during recurrence were treated with oral temozolomide at a dose of 150 mg/m2 per day on a 5-day schedule every 28 days." | 5.11 | Temozolomide in the treatment of recurrent malignant glioma. ( Chang, SM; Lamborn, K; Malec, M; Page, M; Prados, MD; Rabbitt, J; Theodosopoulos, P, 2004) |
| "The purpose of this study was to evaluate the activity, measured in terms of progression-free survival (PFS) and response rates, of 1,3-bis(chloro-ethyl)-1-nitrosourea (BCNU) plus temozolomide in adult patients with recurrent glioblastoma multiforme." | 5.11 | Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. ( Chang, SM; Fine, HA; Fink, KL; Greenberg, HS; Hess, KR; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, MP; Nicholas, MK; Prados, MD; Robins, HI; Schold, SC; Yung, WK, 2004) |
| "Temozolomide has established activity in the treatment of recurrent glioblastoma multiforme (GBM)." | 5.11 | Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. ( Ashley, DM; Cher, LM; Chua, SL; Dowling, A; Rosenthal, MA; Wong, SS; Woods, AM, 2004) |
| "The primary objective of the current prospective Phase II study of cyclophosphamide (CYC) in adult patients with recurrent, temozolomide-refractory glioblastoma multiforme was to evaluate 6-month progression-free survival (PFS)." | 5.11 | Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. ( Chamberlain, MC; Tsao-Wei, DD, 2004) |
| "A prospective Phase II study of temozolomide (TMZ) was conducted in 16 patients with refractory meningioma." | 5.11 | Temozolomide for treatment-resistant recurrent meningioma. ( Chamberlain, MC; Groshen, S; Tsao-Wei, DD, 2004) |
| "Cisplatin and temozolomide (TMZ) are active in glioblastoma multiforme (GBM), with different profiles of toxicity." | 5.11 | First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. ( Basso, U; Brandes, AA; Cavallo, G; Ermani, M; Ferreri, AJ; Monfardini, S; Panucci, MG; Reni, M; Scopece, L; Tosoni, A; Vastola, F, 2004) |
| "Seventy-five consecutive patients with recurrent malignant astrocytomas and glioblastomas had been treated at our institute with per os temozolomide for five days every month." | 5.11 | Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas. ( Afra, D; Sipos, L; Vitanovics, D, 2004) |
| "The authors determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of irinotecan (CPT-11), a topoisomerase I inhibitor, when administered with temozolomide among patients with recurrent malignant glioma (MG)." | 5.11 | Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. ( Badruddoja, M; Burkart, JL; Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, R; Newton, HB; Provenzale, J; Quinn, JA; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, J, 2005) |
| "To determine the anti-tumour efficacy and safety profile of temozolomide in local Chinese patients with recurrent malignant glioma." | 5.11 | Temozolomide in the treatment of recurrent malignant glioma in Chinese patients. ( Chan, DT; Chan, YL; Ng, HK; Poon, WS, 2005) |
| "Although temozolomide is active against recurrent malignant glioma, responses in many patients are modest and short-lived." | 5.10 | Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. ( Benita-Weiss, M; Bushunow, P; Coyle, TE; Evans, B; Friedman, H; Korones, DN; Mechtler, L; Quinn, JA; Reardon, DA, 2003) |
| "Temozolomide (TMZ) and 13-cis-retinoic acid (cRA) have shown activity in prior single-agent trials of recurrent malignant gliomas (MG)." | 5.10 | Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. ( Chang, S; Cloughesy, T; Fine, H; Fink, K; Greenberg, H; Hess, KR; Jaeckle, KA; Kuhn, J; Mehta, M; Nicholas, MK; Pollack, IF; Prados, M; Schiff, D; Yung, WK, 2003) |
| "Temozolomide is an effective agent in the treatment of recurrent malignant gliomas." | 5.10 | A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. ( Abrey, LE; Bazylewicz, KA; Khan, RB; Malkin, MG; Raizer, JJ, 2002) |
| "Temozolomide has shown efficacy in the treatment of metastatic melanoma similar to that of dacarbazine (DTIC), the standard chemotherapy, but with the added benefit of penetration into the central nervous system (CNS)." | 5.10 | Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. ( Brampton, MH; Calvert, AH; Middleton, MR; Paul, MJ; Rustin, G; Summers, Y; Thatcher, N, 2002) |
| "To determine the antitumor efficacy and safety profile of temozolomide in patients with malignant astrocytoma at first relapse." | 5.09 | Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. ( Albright, R; Brada, M; Bruner, J; Chang, SM; Dugan, M; Friedman, AH; Friedman, HS; Levin, VA; O'Neill, AM; Olson, J; Prados, MD; Rosenfeld, SS; Yaya-Tur, R; Yue, N; Yung, WK; Zaknoen, S, 1999) |
| "One of the objectives of this phase II study was to determine whether temozolomide (TMZ) improved the health-related quality of life (HRQL) of patients with recurrent anaplastic astrocytoma (AA)." | 5.09 | Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. ( Brada, M; Osoba, D; Prados, MD; Yung, WK, 2000) |
| "Forty-one patients with high-grade glioma, at second recurrence or progression, of which twenty-two (54%) had glioblastoma multiforme, ten (24%) anaplastic astrocytoma, and nine (22%) anaplastic oligodendroglioma were administered temozolomide, 150 mg/m2/daily for five days every four weeks." | 5.09 | Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. ( Amistà, P; Basso, U; Berti, F; Brandes, AA; Ermani, M; Gardiman, M; Monfardini, S; Pinna, G; Rotilio, A; Scienza, R, 2001) |
| "We report an open-label, uncontrolled, multicenter phase II trial of temozolomide in 138 patients (intent-to-treat [ITT] population) with glioblastoma multiforme at first relapse and a Karnofsky performance status (KPS) > or = 70." | 5.09 | Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. ( Brada, M; Bravo-Marques, JM; Bruner, J; Dietrich, PY; Dirix, LY; Dugan, M; Heimans, JJ; Henriksson, R; Hoang-Xuan, K; Macdonald, D; Rampling, R; Rao, S; Stupp, R; Yue, N; Zaknoen, S; Zonnenberg, BA, 2001) |
| " A novel second-generation alkylating agent, temozolomide, has recently demonstrated efficacy and safety in patients with recurrent glioblastoma multiforme and anaplastic astrocytoma." | 5.09 | Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. ( Barrie, M; Braguer, D; Chinot, OL; Dufour, H; Figarella-Branger, D; Grisoli, F; Honore, S; Martin, PM; Muracciole, X, 2001) |
| "Temozolomide, a new oral cytotoxic agent, was given to 75 patients with malignant gliomas." | 5.08 | The Charing Cross Hospital experience with temozolomide in patients with gliomas. ( Bower, M; Brampton, MH; Brock, C; Colquhoun, I; Evans, H; Glaser, MG; Illingworth, RD; Lewis, P; Newlands, ES; O'Reilly, SM; Rice-Edwards, JM; Richards, PG, 1996) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 4.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| "There is a growing body of evidence that carmustine wafer implantation during surgery is an effective therapeutic adjunct to the standard combined radio-chemotherapy regimen using temozolomide in newly diagnosed and recurrent high-grade glioma patient management with a statistically significant survival benefit demonstrated across several randomized clinical trials, as well as prospective and retrospective studies (grade A recommendation)." | 4.95 | Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery. ( Caire, F; Guyotat, J; Menei, P; Metellus, P; Pallud, J; Roux, A, 2017) |
| "A meta-analysis of three phase II studies of children with relapsed/refractory neuroblastoma conducted in Europe (temozolomide, topotecan-vincristine-doxorubicin and topotecan-temozolomide) was performed." | 4.95 | Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials. ( Amoroso, L; Bautista, F; Chevance, A; Gambart, M; Garaventa, A; Geoerger, B; Le Deley, MC; Moreno, L; Paoletti, X; Pearson, AD; Rubie, H; Valteau-Couanet, D; Varo, A; Vassal, G, 2017) |
| "This review article summarizes in vitro, in vivo, and clinical evidence pertaining to temozolomide (TMZ) and bevacizumab (BEV) efficacy and mechanism of action in gliomas." | 4.91 | Current evidence of temozolomide and bevacizumab in treatment of gliomas. ( Chattipakorn, N; Chattipakorn, SC; Nanegrungsunk, D; Onchan, W, 2015) |
| " More recently, temozolomide, a second generation oral alkylating agent, has shown therapeutic promise for aggressive pituitary adenomas and carcinomas with favorable clinical and radiographic responses." | 4.91 | The role of temozolomide in the treatment of aggressive pituitary tumors. ( Eloy, JA; Liu, JK; Patel, J, 2015) |
| "The goal of this meta-analysis was to identify the temozolomide (TMZ) regimen with optimal efficacy and tolerance for treatment of recurrent high-grade glioma (HGG)." | 4.91 | The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis. ( Chen, X; Guo, Z; Ma, X; Wang, D; Wei, W, 2015) |
| "For primary therapy three RCTs were identified, enrolling a total of 745 patients, that investigated temozolomide in combination with radiotherapy versus radiotherapy alone for glioblastoma multiforme (GBM)." | 4.89 | Temozolomide for high grade glioma. ( Garside, R; Grant, R; Hart, MG; Rogers, G; Stein, K, 2013) |
| "The standard therapy for newly diagnosed malignant gliomas comprises surgery, radiotherapy, and commonly temozolomide chemotherapy." | 4.87 | An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting. ( Kyritsis, AP; Levin, VA, 2011) |
| "In primary disease two RCTs were identified, enrolling a total of 703 patients, that investigated concomitant and adjuvant temozolomide in Glioblastoma Multiforme (GBM)." | 4.84 | Temozolomide for high grade glioma. ( Garside, R; Grant, R; Hart, MG; Rogers, G; Somerville, M; Stein, K, 2008) |
| " The place of chemotherapy is growing not only for anaplastic oligodendrogliomas, more chemosensitive (particularly when they harbor 1p19q codeletions), but also for glioblastomas patients, which have been shown to benefit from radiotherapy plus concomitant and adjuvant temozolomide." | 4.83 | [Pattern of care of high-grade gliomas]. ( Laigle-Donadey, F; Sanson, M, 2006) |
| " We report a 44-year-old woman with t-MDS (refractory anemia with excess blasts) following treatment of recurrent anaplastic astrocytoma with temozolomide (TMZ)." | 4.82 | Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. ( Chang, MC; Chiang, MF; Hsieh, RK; Su, YW, 2005) |
| " Temozolomide, an alkylating agent that can be administered orally, has been approved for the treatment of recurrent malignant glioma on a daily schedule for 5-day cycles." | 4.81 | Current and future developments in the use of temozolomide for the treatment of brain tumours. ( Gander, M; Leyvraz, S; Newlands, E; Stupp, R, 2001) |
| "Complete resection of glioblastoma via a supraorbital transciliary approach with 5-Aminolevulinic Acid use was performed without any complications, as demonstrated on postoperative MRI." | 4.31 | Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note. ( Aboukaïs, R; Bourgeois, P; Devalckeneer, A; Lejeune, JP; Reyns, N, 2023) |
| "Temozolomide (TMZ)-based chemotherapy plays a central part in glioma treatment." | 4.31 | SRSF4 Confers Temozolomide Resistance of Glioma via Accelerating Double Strand Break Repair. ( Liu, X; Sun, Y; Wang, X; Wu, Z; Yan, W; You, Y; Zhang, Y, 2023) |
| "In our study, we included 169 glioblastoma patients who were admitted to our clinic between 2009 and 2019 and received concurrent radiotherapy (RT) + temozolomide (TMZ) after surgery." | 4.31 | The Assessment of Clinical Outcomes and Prognostic Factors in Glioblastoma Patients. ( Bora, H; Demircan, NV; Erpolat, OP; Guzel, C; Karahacioglu, E; Senturk, E, 2023) |
| "Glioblastoma patients commonly develop resistance to temozolomide chemotherapy." | 4.31 | Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion. ( Bindila, L; Geiß, C; Kim, E; Lieberwirth, I; Régnier-Vigouroux, A; Sousa, N, 2023) |
| "Temozolomide (TMZ) is a common alkylating chemotherapeutic agent used to treat brain tumors such as glioblastoma multiforme (GBM) and anaplastic astrocytoma." | 4.31 | LncRNA-associated competing endogenous RNA network analysis uncovered key lncRNAs involved in temozolomide resistance and tumor recurrence of glioblastoma. ( Mallick, B; Nayak, R, 2023) |
| "Temozolomide (TMZ) is standard treatment for glioblastoma (GBM); nonetheless, resistance and tumor recurrence are still major problems." | 4.31 | Enhanced Sensitivity to ALDH1A3-Dependent Ferroptosis in TMZ-Resistant Glioblastoma Cells. ( Franzmeier, S; Liesche-Starnecker, F; Schlegel, J; Wu, Y, 2023) |
| "We report a case of oligodendroglioma that had consistent histopathological features as well as a distinct change in 1p/19q status in the second recurrence, after temozolomide chemotherapy and radiotherapy." | 4.12 | Recurrent oligodendroglioma with changed 1p/19q status. ( Barresi, V; Calicchia, M; Ghimenton, C; Mafficini, A; Musumeci, A; Piredda, ML; Scarpa, A, 2022) |
| "This retrospective study enrolled 65 patients with IDH wild-type recurrent glioblastoma who received standard therapy and then received either bevacizumab (46 patients) or temozolomide (19 patients) as a secondary treatment." | 4.12 | Contrast enhancing pattern on pre-treatment MRI predicts response to anti-angiogenic treatment in recurrent glioblastoma: comparison of bevacizumab and temozolomide treatment. ( Kim, HS; Kim, JH; Kim, YH; Moon, HH; Park, JE, 2022) |
| "Irinotecan plus temozolomide combination chemotherapy showed antitumor activity and an acceptable safety profile in patients with relapsed Ewing sarcoma." | 4.12 | Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies. ( Lin, GH; Wang, BC; Xiao, BY, 2022) |
| "The aim of this study was to clarify whether PET with 11C-methyl-l-methionine (11C-met PET) can predict consequential outcomes at the time of discontinuing temozolomide (TMZ)-adjuvant chemotherapy in patients with residual isocitrate dehydrogenase gene (IDH)-mutant lower-grade glioma." | 4.12 | PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma. ( Beppu, T; Fujiwara, S; Iwaya, T; Nomura, JI; Ogasawara, K; Sasaki, T; Sato, Y; Sugai, T; Terasaki, K; Yamada, N, 2022) |
| " Temozolomide is the standard of care for gliomas, frequently results in resistance to drug and tumor recurrence." | 4.12 | Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration of Human U251 Glioma Cells. ( Alaverdian, DA; Buntovskaya, AS; Chernov, AN; Fedorov, EV; Filatenkova, TA; Galimova, ES; Glushakov, RI; Kim, AV; Matsko, MV; Shamova, OV; Skliar, SS; Tsapieva, AN, 2022) |
| "A first-line therapeutic for high-grade glioma, notably glioblastoma (GBM), is the DNA methylating drug temozolomide (TMZ)." | 4.12 | Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics. ( Beltzig, L; Christmann, M; Kaina, B, 2022) |
| "A MEX3A/CCR4-NOT/MSH2 axis plays a crucial role in promoting temozolomide resistance, providing new insights into the function of MEX3A and suggesting MEX3A as a potential therapeutic target in therapy-resistant glioblastoma." | 4.12 | MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma. ( Gan, T; Miao, F; Nie, E; Qian, X; Shen, Z; Shi, Q; Wang, P; Wang, Q; Wang, Y; Xie, M; Zhao, S, 2022) |
| "Systemic chemotherapy including monotherapy with temozolomide (TMZ) or bevacizumab (BEV); two-drug combinations, such as irinotecan (IRI) and BEV, TMZ and BEV and a three-drug combination with TMZ, IRI and BEV (TIB) have been used in treating patients with progressive high-grade gliomas including glioblastoma (GBM)." | 4.12 | Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab. ( Ballester, LY; Bhattacharjee, MB; Brown, RE; Buja, LM; Chen, L; Glass, WF; Hergenroeder, GW; Hunter, RL; Linendoll, N; Lu, G; Pilichowska, M; Pillai, AK; Rao, M; Tian, X; Wu, JK; Zhang, R; Zhu, JJ; Zhu, P, 2022) |
| "It was found that radiotherapy combined with temozolomide administration often increased the size of the original lesion or produced a new glioblastoma lesion." | 4.12 | Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report. ( Cheng, P; Han, Q; Ma, H; Yang, H; Zhao, M; Zhao, Y, 2022) |
| "Glioblastomas (GBM) often acquire resistance against temozolomide (TMZ) after continuous treatment and recur as TMZ-resistant GBM (TMZ-R-GBM)." | 4.02 | Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance. ( Fujii, T; Ichimura, K; Kawauchi, D; Kobayashi, T; Kondo, A; Nakano, T; Narita, Y; Sasaki, N; Satomi, K; Takahashi, M; Tomiyama, A; Uchida, E; Wada, K; Yamamuro, S; Yoshino, A, 2021) |
| "Bortezomib and temozolomide effectively destroy cells of a radioresistant recurrent human glioblastoma; proteome mapping of the recurrent GBM cancer cells allows to identify new targets for therapy to improve the treatment results." | 4.02 | Effectiveness of bortezomib and temozolomide for eradication of recurrent human glioblastoma cells, resistant to radiation. ( Bryukhovetskiy, I; Pak, O; Sharma, A; Sharma, HS; Shevchenko, V; Zaitsev, S, 2021) |
| "About 95% of Glioblastoma (GBM) patients experience tumor relapse as a consequence of resistance to the first-line standard chemotherapy using temozolomide (TMZ)." | 4.02 | Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells. ( Bartsch, JW; Culmsee, C; Elsässer, K; Nimsky, C; Pagenstecher, A; Schäfer, A; Zhang, Z; Zhao, K; Zhong, L, 2021) |
| "To assess the efficacy of single-agent temozolomide, a standard agent is used for metastatic melanoma in late adjuvant chemotherapy for cutaneous melanoma." | 4.02 | Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma. ( Erturk, K; Tas, F, 2021) |
| "Irinotecan and temozolomide (IT) is a widely used regimen for relapsed Ewing sarcoma (ES), although studies are largely limited to paediatric populations." | 4.02 | Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma. ( Abuhijla, F; Abuhijlih, R; Alnsour, A; Halalsheh, H; Ismail, T; Khozouz, O; Lewin, J; Salah, S; Shahin, O; Sultan, I; To, YH; Yaser, S, 2021) |
| "The purpose of this study is to clarify the clinical features of temozolomide (TMZ)-related hepatitis B virus (HBV) reactivation and to identify HBV reactivation predictive factors." | 4.02 | Hepatitis B virus reactivation during temozolomide administration for malignant glioma. ( Chonan, M; Inoue, J; Kanamori, M; Masamune, A; Osada, Y; Saito, R; Shimoda, Y; Shoji, T; Tominaga, T; Uenohara, H, 2021) |
| "Using data from the German multi-center E-HIT-REZ-2005 study, we examined the role of local therapy and the efficacy of chemotherapy with blockwise temozolomide (TMZ) in children and adolescents with recurrent ependymomas." | 4.02 | Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study. ( Adolph, JE; Bison, B; Bode, U; Faldum, A; Fleischhack, G; Frühwald, MC; Kortmann, RD; Krauß, J; Kwiecien, R; Mikasch, R; Mynarek, M; Obrecht, D; Pajtler, KW; Pfister, SM; Pietsch, T; Rutkowski, S; Schüller, U; Timmermann, B; Tippelt, S; von Hoff, K; Warmuth-Metz, M; Witt, H; Witt, O; Zeller, J, 2021) |
| "Glioblastoma is the most common malignant brain tumor, currently treated by surgery followed by concomitant radiotherapy and temozolomide-based chemotherapy." | 4.02 | Adjuvant therapeutic potential of moderate hypothermia for glioblastoma. ( Chabardès, S; Fulbert, C; Ratel, D, 2021) |
| "Chemotherapy improves overall survival after surgery and radiotherapy for newly diagnosed high-risk IDH-mutant low-grade gliomas (LGGs), but a proportion of patients treated with temozolomide (TMZ) will develop recurrent tumors with TMZ-induced hypermutation." | 4.02 | Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. ( Berger, MS; Butowski, N; Chang, SM; Choi, S; Clarke, JL; Costello, JF; Grimmer, MR; Haas-Kogan, D; Hilz, S; Hong, C; Mazor, T; McDermott, M; Molinaro, AM; Oberheim Bush, NA; Phillips, JJ; Shai, A; Solomon, DA; Taylor, JW; Villanueva-Meyer, J; Wahl, M; Wainer, BH; Yu, Y, 2021) |
| "Glioma stem cells (GSCs) are tumour initiating cells which contribute to treatment resistance, temozolomide (TMZ) chemotherapy and radiotherapy, in glioblastoma (GBM), the most aggressive adult brain tumour." | 4.02 | Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM. ( Düssmann, H; Juric, V; Lamfers, MLM; Murphy, BM; Prehn, JHM; Rehm, M, 2021) |
| "Glioblastoma multiforme (GBM) is the most fatal cancer among brain tumors, and the standard treatment of GBM patients is surgical tumor resection followed by radiotherapy and temozolomide (TMZ) chemotherapy." | 4.02 | 17β-estradiol induces temozolomide resistance through NRF2-mediated redox homeostasis in glioblastoma. ( Chen, GY; Hsu, SP; Hsu, TI; Hung, CY; Ko, CY; Liao, KH; Lin, HY, 2021) |
| "Apatinib and TMZ may represent an alternative treatment option for patients with recurrent high-gradeglioma, especially those with a low Karnofsky performance status." | 4.02 | Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas. ( Feng, M; Gan, W; Huang, Y; Li, X; Liu, J; Shao, Y; Wang, X; Yao, H; Zhang, C; Zhou, Y, 2021) |
| " In this report, we present the case of a 3-year-old girl with glioblastoma who continues to experience an exceptional and durable response (>2 years) to the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib." | 3.96 | Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response. ( Britt, N; Chudnovsky, Y; Duncan, D; Edgerly, C; Elvin, J; Erlich, RL; Gay, L; Gorelyshev, S; Hemmerich, A; Huang, RSP; Konovalov, A; Kram, DE; McCorkle, J; Miller, V; Ramkissoon, SH; Rankin, A; Ross, JS; Savateev, A; Severson, E; Trunin, Y; Valiakhmetova, A, 2020) |
| "Temozolomide (TMZ) is a drug of choice in glioblastoma treatment." | 3.96 | Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions. ( Barciszewska, AM; Barciszewski, J; Belter, A, 2020) |
| "Emerging data suggest that a subset of patients with diffuse isocitrate dehydrogenase (IDH)-mutant low-grade glioma (LGG) who receive adjuvant temozolomide (TMZ) recur with hypermutation in association with malignant progression to higher-grade tumors." | 3.96 | MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. ( Berger, MS; Bollam, S; Chang, SM; Clarke, J; Costello, JF; Grimmer, MR; Hong, C; Mathur, R; Molinaro, AM; Oberheim-Bush, NA; Petrecca, K; Phillips, JJ; Zhang, M; Zhang, Y, 2020) |
| "Temozolomide (TMZ) resistance is a major cause of recurrence and poor prognosis in glioblastoma (GBM)." | 3.96 | LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma. ( Chi, Y; Fu, Z; Guo, H; Huang, Q; Lian, C; Liao, C; Liu, B; Wang, C; Wei, Q; Xu, N; Yang, Z; Zeng, H; Zhou, J, 2020) |
| "Temozolomide (TMZ) is an oral alkylating agent used for the treatment of glioblastoma and is now becoming a chemotherapeutic option in patients diagnosed with high-risk low-grade gliomas." | 3.96 | MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas. ( Bao, Z; Galán-Ganga, M; Jiang, T; Kim, H; Kroon, P; Liu, H; Mu, Q; Nam, DH; Oldrini, B; Rabadan, R; Rodriguez-Perales, S; Sa, JK; Squatrito, M; Vaquero-Siguero, N; Verhaak, RGW; Wang, J; Wang, Z; Zhang, Y; Zhao, J, 2020) |
| "To assess the patterns of failure and prognostic factors in Brazilian patients with glioblastoma multiforme (GBM) treated with radiotherapy (RT) and concurrent and adjuvant temozolomide (TMZ)." | 3.96 | Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide. ( Faustino, AC; Hamamura, AC; Viani, GA, 2020) |
| "Despite aggressive treatment with temozolomide and radiotherapy and extensive research into alternative therapies there has been little improvement in Glioblastoma patient survival." | 3.96 | Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma. ( Areeb, Z; Gomez, J; Jones, J; Kaye, AH; Luwor, RB; Morokoff, AP; Nguyen, HPT; Paradiso, L; Stuart, SF; West, AJ; Zulkifli, A, 2020) |
| "In the management of patients with newly diagnosed glioblastoma, there is no standard duration for adjuvant temozolomide treatment." | 3.91 | Feasibility study of finalizing the extended adjuvant temozolomide based on methionine positron emission tomography (Met-PET) findings in patients with glioblastoma. ( Hasegawa, Y; Hatano, K; Hirono, S; Iuchi, T; Sakaida, T; Uchino, Y, 2019) |
| " Cases from June 2006 through October 2016 were identified for patients receiving bevacizumab and temozolomide for locally advanced, recurrent or metastatic solitary fibrous tumour or hemangiopericytoma, which is sometimes used to describe tumours arising from the meninges." | 3.91 | Efficacy of bevacizumab and temozolomide therapy in locally advanced, recurrent, and metastatic malignant solitary fibrous tumour: A population-based analysis. ( de Lemos, ML; Kang, I; Schaff, K, 2019) |
| "In heavily pretreated patients with refractory/relapsed solid tumors, the vincristine, irinotecan, and temozolomide regimen seemed promising in Ewing sarcoma patients and was well tolerated." | 3.91 | Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience. ( Büyükkapu Bay, S; Çakır, FB; Darendeliler, E; Görgün, O; Kebudi, R; Zülfikar, B, 2019) |
| "Glioblastoma multiforme (GBM) is the most malignant tumor of the central nervous system, and chemoresistance blunts the effect of temozolomide (TMZ) in the treatment of GBM." | 3.91 | MiR-7-5p suppresses stemness and enhances temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1. ( Gu, J; Guo, Q; Hao, Q; Jia, B; Liu, W; Lv, W; Mu, N; Pang, Z; Wang, J; Zhang, W, 2019) |
| "At present, there is no uniform consensus on the treatment of recurrent glioblastoma, especially the re-irradiation dose and temozolomide (TMZ) dose." | 3.91 | Conventionally fractionated stereotactic radiotherapy (CFRT) in combination with dose-dense temozolomide (TMZ) in relapsed malignant glioma: A case report. ( Li, Y; Qie, S; Shi, HY; Yuan, L; Zhang, X, 2019) |
| "Tumor recurrence in glioblastoma multiforme (GBM) is often attributed to acquired resistance to the standard chemotherapeutic agent, temozolomide (TMZ)." | 3.91 | Glioblastoma Recurrence and the Role of O ( Ahmed, AU; Foo, J; Hawkins-Daarud, A; Leder, K; Rockne, RC; Storey, K; Swanson, K, 2019) |
| "Crooke's cell adenoma (CCA) is an aggressive subtype of corticotroph adenoma; however, CCA is associated with a high incidence of low expression of methyl guanine methyl transferase (MGMT), suggesting that temozolomide (TMZ) treatment might be effective for this tumor type." | 3.91 | Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide. ( Inoshita, N; Kanazawa, I; Kurosaki, M; Morita, M; Oki, Y; Sugimoto, T; Takeno, A; Tanaka, S; Yamada, S; Yamaguchi, T; Yamamoto, M, 2019) |
| " Localized FRT to total dose of 60 Gy with concurrent and adjuvant temozolomide (TMZ) resulted in a statistically significant survival improvement of patients with newly diagnosed glioblastoma compared to those treated with FRT alone, and has emerged as the cornerstone of therapy." | 3.88 | Role of Radiosensitizers in Radiation Treatment of Gliomas. ( Cohen, RJ; Mehta, MP, 2018) |
| "To retrospectively determine the safety and efficacy of combined chemotherapy with carmustine (BCNU) wafer, bevacizumab, and temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma (GBM)." | 3.88 | Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience. ( Akiyama, Y; Enatsu, R; Kimura, Y; Mikami, T; Mikuni, N; Wanibuchi, M, 2018) |
| "To identify patients with recurrent glioblastoma after temozolomide (TMZ) concurrent with and adjuvant to radiotherapy who could benefit from TMZ rechallenge at the time of disease progression." | 3.88 | Temozolomide rechallenge in recurrent glioblastoma: when is it useful? ( Bartolini, S; Brandes, AA; Cubeddu, A; De Biase, D; Di Battista, M; Franceschi, E; Lamberti, G; Minichillo, S; Mura, A; Paccapelo, A; Pession, A; Tallini, G; Tosoni, A; Visani, M, 2018) |
| "To investigate the clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent glioma." | 3.88 | [Clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent brain glioma]. ( Jiang, C; Li, X; Liu, S; Tang, S; Zhao, H, 2018) |
| "Temozolomide (TMZ) is the first-line chemotherapeutic agent in the treatment of glioblastoma multiforme (GBM)." | 3.88 | Caffeine Sensitizes U87-MG Human Glioblastoma Cells to Temozolomide through Mitotic Catastrophe by Impeding G2 Arrest. ( Cheng, YS; Kiang, KMY; Leung, GKK; Li, N; Zhang, P, 2018) |
| "Discriminating between tumor recurrence and treatment effects in glioblastoma patients undergoing radiation-temozolomide (RT/TMZ) therapy remains a major clinical challenge." | 3.88 | Diagnostic utility of restriction spectrum imaging (RSI) in glioblastoma patients after concurrent radiation-temozolomide treatment: A pilot study. ( Bartsch, H; Chen, CC; Dale, AM; Farid, N; Khan, UA; Rennert, RC; White, NS, 2018) |
| "The efficacy of temozolomide (TMZ) chemotherapy for treating newly diagnosed glioblastoma (GBM), a primary brain tumor with short survival, was demonstrated in a clinical trial in 2005, and since then, the standard-of-care for newly diagnosed GBM has been maximal safe surgery followed by 60 Gray of radiation with concomitant and adjuvant TMZ (standard radiotherapy and TMZ)." | 3.88 | Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice. ( Carter, TC; Lawler, BE; Medina-Flores, R, 2018) |
| "Temozolomide (TMZ) is a promising chemotherapeutic agent to treat Glioblastoma multiforme (GBM)." | 3.85 | MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor. ( Chen, Y; Li, R; Liu, N; Pan, M; Shi, Z; Wang, X; Yan, W; You, Y; Zhang, J, 2017) |
| "Temozolomide (TMZ) chemotherapy, in combination with maximal safe resection and radiotherapy, is the current standard of care for patients with glioblastoma (GBM)." | 3.85 | Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus. ( Jahan, N; Lee, JM; Shah, K; Wakimoto, H, 2017) |
| "Temozolomide (TMZ) is commonly used in glioblastoma (GBM) chemotherapy." | 3.85 | PomGnT1 enhances temozolomide resistance by activating epithelial-mesenchymal transition signaling in glioblastoma. ( Chen, H; Chen, Q; Han, C; Lan, J; Liu, Q; Lou, M; Que, S; Wang, L; Xue, Y; Zhang, X, 2017) |
| "Temozolomide (TMZ), as a kind of alkylating agent, is widely utilized for the treatment of glioblastoma (GBM)." | 3.85 | miR‑146b‑5p suppresses glioblastoma cell resistance to temozolomide through targeting TRAF6. ( Lan, J; Lin, Y; Qian, Z; Qiu, Y; Que, S; Yang, X; Zhou, S; Zhou, Z, 2017) |
| "To assess the efficacy and cost-effectiveness of modulated electrohyperthermia (mEHT) concurrent to dose-dense temozolomide (ddTMZ) 21/28 days regimen versus ddTMZ 21/28 days alone in patients with recurrent glioblastoma (GBM)." | 3.85 | Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison ( Roussakow, SV, 2017) |
| "Temozolomide is an increasingly described treatment option for refractory pituitary adenomas and carcinomas." | 3.83 | Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response. ( Laterra, JJ; Salvatori, R; Strowd, RE, 2016) |
| "Few data are available on temozolomide (TMZ) in ependymomas." | 3.83 | Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. ( Bosa, C; Cassoni, P; Fiano, V; Franchino, F; Magistrello, M; Pellerino, A; Rudà, R; Soffietti, R; Trevisan, M, 2016) |
| "Temozolomide is effective in some patients with progressive pituitary adenoma or carcinoma." | 3.83 | Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. ( Bogazzi, F; Cannavo, S; Ceccato, F; Curtò, L; De Marinis, L; Iacovazzo, D; Lombardi, G; Losa, M; Mantovani, G; Mazza, E; Minniti, G; Nizzoli, M; Reni, M; Scaroni, C, 2016) |
| "Twenty patients with high grade glioma relapse received a stereotactic radiation; among them two patients received temozolomide and eight patients received bevacizumab; among the latter, four received also irinotecan." | 3.83 | Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse. ( Ahle, G; Antoni, D; Atlani, D; Chaussemy, D; Clavier, JB; Couchot, J; Gaultier, C; Haoming, QC; Jastaniah, Z; Noël, G; Schott, R; Srour, R, 2016) |
| "Glioblastoma (GB) recurrences are rarely removed, therefore, tissue modifications induced by radiotherapy, and temozolomide chemotherapy are scarcely known." | 3.83 | Cyclin D1 Co-localizes with Beclin-1 in Glioblastoma Recurrences: A Clue to a Therapy-induced, Autophagy-mediated Degradative Mechanism? ( Belmonte, G; Miracco, C; Pirtoli, L; Tini, P; Toscano, M, 2016) |
| "Twenty patients with recurrent glioblastoma were treated with biweekly BEV plus temozolomide." | 3.83 | MRI and 11C-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma. ( Beppu, T; Kato, K; Ogasawara, K; Sasaki, M; Sasaki, T; Sato, Y; Terasaki, K; Tomabechi, M, 2016) |
| "The cellular responses to two new temozolomide (TMZ) analogues, DP68 and DP86, acting against glioblastoma multiforme (GBM) cell lines and primary culture models are reported." | 3.81 | Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth. ( Gynther, M; Mladek, AC; Phillips, RM; Ramirez, YP; Rautio, J; Ross, AH; Sakaria, JN; Wheelhouse, RT, 2015) |
| "We retrospectively identified 68 consecutive patients with high-grade gliomas treated by surgical resection followed by radiation therapy and temozolomide, who then developed increasing enhancing mass lesions indeterminate for treatment-related changes versus recurrent tumor." | 3.81 | Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence. ( Beal, K; Martinez, N; Omuro, A; Prager, AJ; Young, RJ; Zhang, Z, 2015) |
| "We retrospectively investigated the prognostic impact of molecular phenotypes in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide (TMZ)." | 3.81 | Prognostic impact of molecular phenotype in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide. ( Choi, YR; Kim, HR; Kong, DS; Lee, JI; Nam, DH; Seol, HJ, 2015) |
| " In addition, in contrast to IDH1-mutated gliomas, IDH1-wild-type primary GBMs rarely developed hypermutation following temozolomide (TMZ) treatment, indicating low risk for TMZ-induced hypermutation for these tumors under the standard regimen." | 3.81 | Spatiotemporal Evolution of the Primary Glioblastoma Genome. ( Cho, HJ; Johnson, MD; Joo, KM; Jung, YS; Kim, BS; Kim, J; Kim, Y; Kong, DS; Lee, IH; Lee, J; Lee, JI; Nam, DH; Nam, SH; Park, CK; Park, PJ; Park, WY; Seol, HJ; Yoon, Y, 2015) |
| "Our purpose was to analyze the pattern of failure in glioblastoma (GBM) patients at first recurrence after radiotherapy and temozolomide and its relationship with different factors." | 3.80 | Factors associated with a higher rate of distant failure after primary treatment for glioblastoma. ( Aldave, G; de Gallego, J; Díez-Valle, R; Domínguez, PD; Gállego Pérez-Larraya, J; Marigil, M; Tejada, S, 2014) |
| "Patients with glioblastoma treated with BCNU wafer implantation for recurrence frequently receive frontline chemoradiotherapy with temozolomide as part of the Stupp protocol." | 3.80 | Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma. ( Ewelt, C; Hänggi, D; Isik, G; Sabel, M; Samis Zella, MA; Schroeteler, J; Slotty, PJ; Steiger, HJ; Wallocha, M, 2014) |
| "Temozolomide (TMZ), used to treat glioblastoma and malignant glioma, induces autophagy, apoptosis and senescence in cancer cells." | 3.80 | Antitumor effect of fibrin glue containing temozolomide against malignant glioma. ( Anai, S; Hide, T; Kuratsu, J; Kuroda, J; Makino, K; Nakamura, H; Shinojima, N; Takezaki, T; Yano, S, 2014) |
| "We present a case of inadvertent high-dose therapy with temozolomide in a child with recurrent diffuse intrinsic pontine glioma followed by a rapid clinical response." | 3.80 | Inadvertent high-dose therapy with temozolomide in a child with recurrent pontine glioma followed by a rapid clinical response but deteriorated after substitution with low-dose therapy. ( Altonok, D; Konski, A; Poulik, J; Sood, S; Wang, ZJ, 2014) |
| "Temozolomide (TMZ)-resistance in glioblastoma multiforme (GBM) has been linked to upregulation of O(6)-methylguanine-DNA methyltransferase (MGMT)." | 3.80 | A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival. ( Chang, EH; Dagata, JA; Farkas, N; Kim, E; Kim, SS; Nishida, M; Pirollo, KF; Rait, A, 2014) |
| "To analyze patterns of failure in patients with glioblastoma multiforme (GBM) treated with limited-margin radiation therapy and concurrent temozolomide." | 3.80 | Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide. ( Bag, AK; Dobelbower, MC; Ennis, WH; Fiveash, JB; Gebhardt, BJ; Markert, JM, 2014) |
| "Eighteen patients with newly diagnosed, histologically confirmed glioblastoma had 3D-MR proton spectroscopic imaging (MRSI) along with T2 and T1 gadolinium-enhanced MR images at simulation and at boost treatment planning after 17 to 20 fractions of radiation therapy." | 3.80 | 3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy. ( Anderson, CM; Bayouth, JE; Buatti, JM; Capizzano, AA; Clerkin, PP; Magnotta, V; McGuire, SM; Morris, A; Muruganandham, M; Smith, BJ; Smith, MC, 2014) |
| "Therapeutic options for the management of glioblastoma (GBM) have greatly evolved over the last decade with the emergence of new regimens combining radiotherapy plus temozolomide and the use of bevacizumab at recurrence." | 3.80 | Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital. ( Armoiry, X; Aulagner, G; Breant, V; Cartalat-Carel, S; Diebold, G; Ducray, F; Fouquet, A; Frappaz, D; Guyotat, J; Henaine, AM; Honnorat, J, 2014) |
| "Standard treatment for glioblastoma comprises surgical resection, chemotherapy with temozolomide, and radiotherapy." | 3.80 | KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis. ( Ham, Y; Jin, J; Joo, KM; Kang, W; Kim, S; Nam, DH; Woo, SR; Yang, H, 2014) |
| "Nine post-temozolomide recurrent or progressive high-grade glioma patients (seven with glioblastoma and two with anaplastic astrocytoma) were treated with BV monotherapy." | 3.80 | Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report. ( Kobayashi, K; Nagane, M; Shimizu, S; Shiokawa, Y; Shishido-Hara, Y; Tanaka, M; Tsuchiya, K, 2014) |
| "We investigated the pattern of failure in glioblastoma multiforma (GBM) patients treated with concurrent radiation, bevacizumab (BEV), and temozolomide (TMZ)." | 3.79 | Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme. ( Kadner, R; Shields, LB; Spalding, AC; Vitaz, TW, 2013) |
| "To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation." | 3.79 | Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. ( Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2013) |
| "Standard treatment for glioblastoma (GBM) is surgery followed by radiation (RT) and temozolomide (TMZ)." | 3.79 | Chemoirradiation for glioblastoma multiforme: the national cancer institute experience. ( Camphausen, K; Fine, HA; Ho, J; Iwamoto, F; Kim, L; Krauze, A; Kreisl, T; McNeil, K; Ning, H; Ondos, J; Shankavaram, U; Smith, S; Sul, J, 2013) |
| "Although there is a relationship between DNA repair deficiency and temozolomide (TMZ) resistance in glioblastoma (GBM), it remains unclear which molecule is associated with GBM recurrence." | 3.79 | Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma. ( Arita, K; Furukawa, T; Hirano, H; Ikeda, R; Kawahara, K; Minami, K; Nishizawa, Y; Shinsato, Y; Tokimura, H; Yamamoto, M; Yonezawa, H; Yunoue, S, 2013) |
| "To analyze initial recurrence patterns in patients with newly diagnosed glioblastoma after radiotherapy plus concurrent and adjuvant temozolomide, and to investigate cumulative recurrence patterns after salvage treatment, including surgery, stereotactic radiotherapy, and chemotherapy." | 3.79 | Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution. ( Arakawa, Y; Hiraoka, M; Miyamoto, S; Mizowaki, T; Ogura, K; Ogura, M; Sakanaka, K, 2013) |
| " Temozolomide is an alkylating agent approved for treating malignant gliomas." | 3.79 | Impact of temozolomide on gonadal function in patients with primary malignant brain tumors. ( Blackwood, R; Brown, M; Harmon, M; Lesser, G; Lovato, J; Strowd, RE; Yalcinkaya, T, 2013) |
| "After previous treatment with standard radiotherapy (with or without temozolomide) patients with recurrent malignant glioma received bevacizumab (10 mg/kg intravenous) on Day 1 and Day 15 during radiotherapy." | 3.78 | Irradiation and bevacizumab in high-grade glioma retreatment settings. ( Belka, C; Ertl, L; Ganswindt, U; Geisler, J; Kreth, FW; la Fougère, C; Linn, J; Niyazi, M; Schwarz, SB; Siefert, A; Tonn, JC, 2012) |
| "We report here a rare case of a young male patient presenting with a Multiple Endocrine Neoplasia Type 1 - prolactin-secreting pituitary carcinoma, controlled long-term after temozolomide withdrawal." | 3.78 | Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. ( Barlier, A; Barrie, M; Brue, T; Castinetti, F; Conte-Devolx, B; Dufour, H; Morange, I; Philippon, M; Taieb, D, 2012) |
| "We analyzed 62 consecutive patients with newly diagnosed glioblastoma treated between 2006 and 2008 with standard fractionation to a total dose of 60 Gy with concurrent temozolomide (97%) or arsenic trioxide (3%)." | 3.77 | Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. ( Crocker, IR; Curran, WJ; McDonald, MW; Shu, HK, 2011) |
| "The identification and consideration of these factors associated with prolonged functional outcome (preoperative KPS score ≥ 90, seizures, primary glioblastoma, gross-total resection, temozolomide) and decreased functional outcome (older age, coronary artery disease, new postoperative motor deficit) may help guide treatment strategies aimed at improving QOL for patients with glioblastoma." | 3.77 | Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. Clinical article. ( Brem, H; Chaichana, KL; Halthore, AN; Olivi, A; Parker, SL; Quinones-Hinojosa, A; Weingart, JD, 2011) |
| "Temozolomide (TMZ) is an oral alkylating agent with proven antitumoral activity in preclinical and clinical studies in adults with high-grade glioma (HGG)." | 3.77 | Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors. ( Barone, G; Lazzareschi, I; Riccardi, R; Ridola, V; Rizzo, D; Ruggiero, A, 2011) |
| "The aim of this paper is to evaluate the efficacy of fractionated stereotactic radiotherapy (FSRT) and concomitant temozolomide (TMZ) as a salvage treatment option in patients with recurrent glioblastoma (GBM)." | 3.77 | Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. ( Armosini, V; Caporello, P; Lanzetta, G; Maurizi, RE; Mei, M; Minniti, G; Osti, MF; Salvati, M, 2011) |
| "Epigenetic silencing of the O(6) -methylguanine-DNA methyltransferase (MGMT) gene promoter is associated with prolonged survival in glioblastoma patients treated with temozolomide (TMZ)." | 3.77 | Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. ( Eigenbrod, S; Felsberg, J; Hentschel, B; Kreth, FW; Löffler, M; Pietsch, T; Reifenberger, G; Sabel, MC; Schackert, G; Thon, N; Tonn, JC; Weller, M; Westphal, M, 2011) |
| "It is controversial if distant recurrence of glioblastoma is more common after temozolomide (TMZ) concurrent with radiotherapy (RT)." | 3.77 | Glioblastoma: patterns of recurrence and efficacy of salvage treatments. ( Aviv, R; Davey, P; Lam, K; Oh, J; Perry, JR; Sahgal, A; Sanghera, P; Symons, S; Tsao, MN, 2011) |
| "Prolonged administration of temozolomide is widely used in patients with glioblastoma; whereas the treatment of anaplastic glioma differs between neurooncological centres." | 3.77 | Prolonged administration of temozolomide in adult patients with anaplastic glioma. ( Freyschlag, CF; Janzen, E; Lohr, F; Schmieder, K; Seiz, M; Smolczyk, DR; Thomé, C; Tuettenberg, J; Weiss, C; Wenz, F, 2011) |
| "To determine recurrence patterns of glioblastoma treated with temozolomide-based chemoradiation." | 3.76 | Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. ( Donatello, RS; Korones, DN; Milano, MT; Mohile, NA; Okunieff, P; Sul, J; Walter, KA, 2010) |
| "Glioblastoma patients have a poor prognosis, even after surgery, radiotherapy, and chemotherapy with temozolomide or 1,3-bis(2-chloroethy)-1-nitrosourea." | 3.76 | Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres. ( Cochran, BH; Daou, MC; Gilbert, CA; Li, L; Mihaliak, AM; Moser, RP; Reeves, A; Ross, AH, 2010) |
| "To analyze the recurrence patterns in patients with newly diagnosed glioblastoma (GBM) treated with conformal radiotherapy (RT) plus concomitant and adjuvant temozolomide (TMZ), and to compare the patterns of failure according to different target volume delineations." | 3.76 | Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. ( Amelio, D; Amichetti, M; Arcella, A; Bozzao, A; Enrici, RM; Lanzetta, G; Minniti, G; Muni, R; Salvati, M; Scarpino, S, 2010) |
| "Early radionecrosis after the Stupp protocol is not a rare event due to the radiosensitization effect of temozolomide." | 3.75 | Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? ( Del Basso De Caro, ML; Elefante, A; Giamundo, A; Maiuri, F; Mariniello, G; Pacelli, R; Peca, C; Vergara, P, 2009) |
| "The aim of the present study was to evaluate factors predicting the recurrence pattern after the administration of temozolomide (TMZ), initially concurrent with radiotherapy (RT) and subsequently as maintenance therapy, which has become standard treatment for patients with newly diagnosed glioblastoma (GBM)." | 3.75 | Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. ( Amistà, P; Brandes, AA; Ermani, M; Franceschi, E; Frezza, G; Morandi, L; Sotti, G; Spagnolli, F; Tosoni, A, 2009) |
| "Temozolomide (TMZ) is the standard of care for patients with newly diagnosed glioblastoma (GBM) as well as those with recurrent anaplastic glioma (AG) and GBM." | 3.75 | Rechallenge with temozolomide in patients with recurrent gliomas. ( Bogdahn, U; Hau, P; Jauch, T; Pascher, C; Weller, M; Wick, A; Wick, W, 2009) |
| "Temozolomide (TMZ) is an alkylating agent used in the management of gliomas." | 3.75 | Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? ( Bell, D; Khasraw, M; Wheeler, H, 2009) |
| "Case report of a 77-year-old woman with a radiation-induced, high-grade cerebellar glioma that responded durably to temozolomide." | 3.74 | Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide. ( Doherty, LM; Drappatz, J; Kesari, S; Monje, ML; Ramakrishna, NR; Wen, PY; Young, G, 2007) |
| "Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities of survival." | 3.74 | Fatal outcome related to carmustine implants in glioblastoma multiforme. ( Barcia, JA; Barcia-Mariño, C; Gallego, JM, 2007) |
| "Glioblastomas are treated by surgical resection followed by radiotherapy [X-ray therapy (XRT)] and the alkylating chemotherapeutic agent temozolomide." | 3.74 | Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. ( Batchelor, TT; Betensky, RA; Cahill, DP; Codd, PJ; Curry, WT; Futreal, PA; Iafrate, AJ; Levine, KK; Louis, DN; Reavie, LB; Romany, CA; Stratton, MR, 2007) |
| "To evaluate the predictive impact of chromosome 1p/19q deletions on the response and outcome of progressive low-grade gliomas (LGG) treated with up-front temozolomide (TMZ) chemotherapy." | 3.74 | Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. ( Benouaich-Amiel, A; Capelle, L; Carpentier, A; Cornu, P; Delattre, JY; Diakite, F; Duffau, H; Hoang-Xuan, K; Idbaih, A; Iraqi, W; Kaloshi, G; Laigle-Donadey, F; Lejeune, J; Mokhtari, K; Omuro, A; Paris, S; Polivka, M; Renard, MA; Sanson, M; Simon, JM; Taillibert, S, 2007) |
| "Temozolomide (TMZ) is active against newly diagnosed glioblastoma (GBM), and O(6)-methylguanine-DNA methyltransferase (MGMT) is implicated in resistance to TMZ and nitrosoureas." | 3.74 | Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. ( Kobayashi, K; Nagane, M; Ohnishi, A; Shimizu, S; Shiokawa, Y, 2007) |
| "To evaluate the feasibility, safety and efficacy of daily temozolomide concurrent with postoperative radiotherapy in malignant glioma." | 3.73 | Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma. ( Eich, HT; Kocher, M; Kunze, S; Müller, RP; Semrau, R, 2005) |
| "There are new scientific data concerning the treatment of patients with glioblastoma multiforme with concomitant and adjuvant temozolomide following surgery and radiotherapy." | 3.73 | [Temozolomide in patients with a glioblastoma multiforme: new developments]. ( Bromberg, JE; Postma, TJ, 2005) |
| "To describe the results of the treatment of recurrent glioma with temozolomide." | 3.73 | [Favourable result for temozolomide in recurrent high-grade glioma]. ( Enting, RH; Kros, JM; Sillevis Smitt, PA; Taal, W; van den Bent, MJ; van der Rijt, CD; van Heuvel, I, 2005) |
| "Children and young adults with recurrent or treatment-induced malignant gliomas have limited responses to temozolomide or oral VP-16 when either is administered as a single agent." | 3.73 | Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas. ( Bouffet, E; Foreman, N; Korones, DN; Smith, A, 2006) |
| "To develop a valid treatment strategy for recurrent high-grade gliomas using stereotactic hypofractionated reirradiation based on biologic imaging and temozolomide." | 3.73 | Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. ( Franz, M; Grosu, AL; Gumprecht, H; Molls, M; Nieder, C; Piert, M; Schwaiger, M; Stärk, S; Thamm, R; Weber, WA, 2005) |
| "To re-evaluate the cost effectiveness and median overall survival (OS) achieved in patients with recurrent malignant gliomas treated with temozolomide in British Columbia, as compared to previous lomustine use in the same patient population based on updated outcomes data." | 3.73 | Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia. ( Mabasa, VH; Taylor, SC, 2006) |
| "To report on an irinotecan and temozolomide regimen for neuroblastoma (NB)." | 3.73 | Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. ( Cheung, NK; Kramer, K; Kushner, BH; Modak, S, 2006) |
| "To assess whether the survival of patients with recurrent malignant glioma receiving temozolomide in everyday practice is comparable to that reported in previous studies." | 3.72 | Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study. ( Maltoni, S; Messori, A; Pelagotti, F; Trippoli, S; Vacca, F; Vaiani, M, 2003) |
| "Seven patients who had received rituximab and temozolomide were identified from the database of the brain tumor clinic at the authors' institution: three patients had developed recurrent primary CNS lymphoma (PCNSL), one patient had newly diagnosed PCNSL but had poor renal function, and three other patients with systemic non-Hodgkin lymphoma developed recurrent lymphoma in the brain only." | 3.72 | Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. ( Barron, L; Tishler, R; Wong, ET; Wu, JK, 2004) |
| "Temozolomide, an imidazotetrazine prodrug has shown activity in phase II studies in patients with high-grade glioma at first recurrence." | 3.71 | Temozolomide as second-line chemotherapy for relapsed gliomas. ( Ashley, S; Brada, M; Dowe, A; Hines, F; Kong, A; Short, SC; Traish, D; Trent, S, 2002) |
| "The authors determined the tolerance, response rate, and duration of recurrent anaplastic oligodendroglioma in 30 patients to temozolomide given orally at 150 to 200 mg/m2 on days 1 through 5 in cycles of 28 days." | 3.71 | Temozolomide chemotherapy in recurrent oligodendroglioma. ( Brandes, AA; Carpentier, AF; Eskens, FA; Keime-Guibert, F; Kros, JM; Taphoorn, MJ; van den Bent, MJ, 2001) |
| "Forty patients with recurrent malignant gliomas had been treated with temozolomide (Temodal)." | 3.71 | [Treatment of recidive malignant gliomas with temozolomide]. ( Afra, D; Sipos, L; Vitanovics, D, 2002) |
| "Metformin shows preclinical anti-cancer activity through multiple pathways." | 3.30 | A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation. ( Badgett, T; Crimella, J; Fridley, BL; Gill, J; Gorlick, R; Llosa, N; Metts, JL; Reed, D; Sandler, E; Sansil, S; Smith, T; Thapa, R; Thompson, P; Trucco, M; Weiser, DA, 2023) |
| "Glioblastoma is the most frequent and malignant primary brain tumor." | 3.11 | Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial. ( Becker, A; Burger, MC; Clusmann, H; Delev, D; Giordano, FA; Glas, M; Goldbrunner, R; Grauer, O; Güresir, E; Hau, P; Heiland, DH; Herrlinger, U; Krex, D; Nemeth, R; Potthoff, AL; Radbruch, A; Sabel, M; Schaub, C; Schilling, J; Schlegel, U; Schmid, M; Schneider, M; Schnell, O; Schuss, P; Seidel, C; Steinbach, JP; Tabatabai, G; Thon, N; Vatter, H; Weller, J; Winkler, F; Zeyen, T, 2022) |
| " Glioblastoma is the most aggressive and diffusely infiltrative primary brain tumor." | 3.01 | Updates in the Management of Recurrent Glioblastoma Multiforme. ( Ansari, A; Prajapati, HP, 2023) |
| " Common adverse events (AEs) were blurred vision (63%), fatigue (38%), and photophobia (35%)." | 2.90 | Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. ( Ansell, PJ; Bain, E; Butowski, N; Gan, HK; Gomez, E; Holen, KD; Kumthekar, P; Lassman, AB; Lee, HJ; Lwin, Z; Maag, D; Merrell, R; Mikkelsen, T; Nabors, LB; Papadopoulos, KP; Penas-Prado, M; Reardon, DA; Roberts-Rapp, L; Scott, AM; Simes, J; van den Bent, MJ; Walbert, T; Wheeler, H; Xiong, H, 2019) |
| " In addition, OS, PFS and adverse event (AE) data on ndGBM and recurrent GBM (rGBM) were assessed." | 2.82 | Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis. ( Li, H; Ma, W; Qu, T; Wang, Y; Wu, J; Xia, Y; Xing, H; Zhao, B, 2022) |
| "Glioblastoma, the most common malignant primary brain tumor, remains a lethal disease with few therapeutic options." | 2.82 | Immune-checkpoint inhibitors for glioblastoma: what have we learned? ( Omuro, A, 2022) |
| "Therefore, brain cancer research models need to aim to recapitulate glioblastoma stem cell function, whilst remaining amenable for analysis." | 2.82 | Utility of the Cerebral Organoid Glioma 'GLICO' Model for Screening Applications. ( Gray, C; Paterson, E; Peng, L; Tan, ST; Weth, FR, 2022) |
| " Pharmacokinetic testing did not show evidence of drug-drug interaction between irinotecan and alisertib." | 2.82 | Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. ( Bagatell, R; Courtier, J; Czarnecki, S; DuBois, SG; Fox, E; Goodarzian, F; Groshen, S; Hawkins, R; Kudgus, RA; Lai, H; Malvar, J; Marachelian, A; Maris, JM; Matthay, KK; Mosse, YP; Reid, JM; Shimada, H; Tsao-Wei, D; Wagner, L, 2016) |
| "Treatment was bortezomib 1." | 2.82 | A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas. ( Bredel, M; Chandler, JP; Ferrarese, R; Grimm, SA; Helenowski, I; Levy, RM; Muro, K; Paton, M; Rademaker, A; Raizer, JJ; Rosenow, J, 2016) |
| " Metronomic dosing of cytotoxic chemotherapy has emerged as a promising option to achieve this objective." | 2.82 | Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas. ( Alsop, DC; Callahan, A; Giarusso, B; O'Loughlin, L; Timmons, J; Wong, ET, 2016) |
| "Retreatment with temozolomide (TMZ) is one treatment option." | 2.80 | Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme. ( Ancelet, LR; Bauer, E; Dzhelali, M; Findlay, MP; Gasser, O; Hamilton, DA; Hermans, IF; Hunn, MK; Mester, B; Sharples, KJ; Wood, CE, 2015) |
| "Patients with newly diagnosed anaplastic astrocytoma (AA) or anaplastic oligo-astrocytoma (AOA) were treated with concurrent radiotherapy (60 Gy over 6 weeks) and temozolomide (75 mg/m(2)), and six adjuvant 28-day cycles of either dose-dense (150 mg/m(2), days 1-7, 15-21) or metronomic (50 mg/m(2), days 1-28) temozolomide." | 2.80 | Radiotherapy and temozolomide for anaplastic astrocytic gliomas. ( Abrey, LE; Braunthal, SG; DeAngelis, LM; Huse, JT; Lassman, AB; Nayak, L; Panageas, KS; Pentsova, E; Reiner, AS, 2015) |
| "Cefixime prophylaxis was used to reduce irinotecan-associated diarrhea." | 2.78 | Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors. ( Cripe, T; Geller, J; Nagarajan, R; Turpin, B; Wagner, L; Weiss, B, 2013) |
| "The results suggest that Cyberknife re-treatments are relatively safe using selected dose/fraction schemes." | 2.77 | Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas. ( Arpa, D; Cardali, S; Conti, A; De Renzis, C; Granata, F; Pontoriero, A; Romanelli, P; Siragusa, C; Tomasello, C; Tomasello, F, 2012) |
| "The median number of brain metastases was 1." | 2.77 | Chemosensitized radiosurgery for recurrent brain metastases. ( Fortin, MA; Pouliot, JF; Roberge, D; Souhami, L, 2012) |
| " In addition, various protracted temozolomide dosing schedules have been evaluated as a strategy to further enhance its anti-tumor activity." | 2.76 | Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2011) |
| "Temozolomide was given on days 1-5, with vincristine 1." | 2.75 | Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. ( Adamson, PC; Ames, MM; Blaney, SM; Ingle, AM; Nelson, MD; Perentesis, JP; Reid, JM; Safgren, SL; Wagner, LM, 2010) |
| "To evaluate maximum tolerated dose and recommended dose (RD) for phase II studies of topotecan (TPT) combined with temozolomide (TMZ) (TOTEM) in children and adolescents with relapsed or refractory solid malignancies." | 2.75 | Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours. ( Aerts, I; Chastagner, P; Chatelut, E; Corradini, N; Dias, N; Djafari, L; Frappaz, D; Gentet, JC; Geoerger, B; Landman-Parker, J; Le Deley, MC; Leblond, P; Ndiaye, A; Paci, A; Pasquet, M; Rubie, H; Schmitt, A; Vassal, G, 2010) |
| "We conducted a phase I and pharmacokinetic study of the epidermal growth factor receptor (EGFR) inhibitor erlotinib as a single agent and in combination with temozolomide in children with refractory solid tumors." | 2.73 | Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. ( Adamson, PC; Blaney, SM; Dancey, JE; Gilbertson, RJ; Hamilton, M; Ingle, AM; Jakacki, RI; Krailo, MD; Tersak, J; Voss, SD, 2008) |
| " PCB was administered as an oral dosage of 450 mg on days 1-2 and a total dose of 300 mg on day 3." | 2.73 | Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. ( Boiardi, A; Botturi, A; Eoli, M; Falcone, C; Filippini, G; Fiumani, A; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A, 2008) |
| "Perillyl alcohol has shown to have both chemopreventive and chemotherapeutic activities in preclinical studies." | 2.73 | Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. ( da Fonseca, CO; Fischer, J; Futuro, D; Gattass, CR; Nagel, J; Quirico-Santos, T; Schwartsmann, G, 2008) |
| "Temozolomide was in general well tolerated; the most frequent side-effects were hematological." | 2.71 | Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. ( Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ, 2003) |
| "Oral ondansetron (8 mg) was given 1 h prior to temozolomide administration." | 2.71 | Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. ( Abdulkarim, B; Armand, JP; Cioloca, C; Djafari, L; Djazouli, K; Faivre, S; Guillamo, JS; Osorio, M; Parker, F; Raymond, E; Vera, K, 2004) |
| "Temozolomide was administered orally at an initial dose of 150 mg/m(2) daily for 5 days, every 4 weeks." | 2.71 | A phase II evaluation of Temozolomide in patients with recurrent epithelial ovarian cancer. ( Argenta, PA; Blair Harkness, C; Boente, MP; Carson, LF; Downs, LS; Judson, PL, 2004) |
| " Cisplatin-temozolomide combinations are well tolerated without additional toxicity to single-agent treatments; the recommended phase II dosage is 80 mg m(-2) cisplatin and 150 mg m(-2) x 5 temozolomide in heavily treated, and 200 mg m(-2) x 5 temozolomide in less-heavily pretreated children." | 2.71 | Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies. ( Chastagner, P; Couanet, D; Djafari, L; Doz, F; Frappaz, D; Gentet, JC; Geoerger, B; Geoffray, A; Margison, GP; O'Quigley, J; Pein, F; Raquin, MA; Rubie, H; Vassal, G; Wartelle, M; Watson, AJ, 2005) |
| "Temozolomide was administered orally daily for 5 days, with subsequent courses administered every 21 to 28 days after full hematologic recovery." | 2.69 | Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group. ( Ames, MM; Ettinger, AG; Krailo, M; Liu-Mares, W; Nicholson, HS; Reaman, GH; Reid, JM; Seibel, NL; Vezina, LG, 1998) |
| "Aggressive pituitary adenomas (APAs) and pituitary carcinomas (PCs) are challenging for their invasive nature, resistance to treatment and recurrences." | 2.66 | Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. ( Barbot, M; Bellu, L; Ceccato, F; Gardiman, MP; Lizzul, L; Lombardi, G; Losa, M; Mazza, E; Regazzo, D; Scaroni, C, 2020) |
| "Glioblastoma is the most common malignant primary brain tumor." | 2.66 | Management of glioblastoma: State of the art and future directions. ( Ashley, DM; Friedman, HS; Khasraw, M; López, GY; Malinzak, M; Tan, AC, 2020) |
| "Brain tissue necrosis (treatment necrosis [TN]) as a consequence of brain directed cancer therapy remains an insufficiently characterized condition with diagnostic and therapeutic difficulties and is frequently associated with significant patient morbidity." | 2.61 | Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology. ( Batchelor, TT; Dietrich, J; Loebel, F; Loeffler, J; Martinez-Lage, M; Vajkoczy, P; Winter, SF, 2019) |
| "Temozolomide is an oral chemotherapy used to treat aggressive pituitary tumours since 2006." | 2.61 | How and when to use temozolomide to treat aggressive pituitary tumours. ( Whitelaw, BC, 2019) |
| "Myxopapillary ependymomas are intradural tumors which grow from the terminal filum of the spinal cord." | 2.58 | Remarkable efficacy of temozolomide for relapsed spinal myxopapillary ependymoma with multiple recurrence and cerebrospinal dissemination: a case report and literature review. ( Adachi, N; Fujiwara, Y; Izumi, B; Manabe, H; Shima, T, 2018) |
| "Temozolomide (TMZ) has been reported to be useful as an adjunctive treatment for some patients." | 2.58 | Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission. ( Barkhoudarian, G; Eisenberg, A; Kelly, DF; Ogunbameru, R; Palejwala, SK; Wei, H, 2018) |
| "Glioblastomas are rich in blood vessels (i." | 2.58 | Anti-angiogenic therapy for high-grade glioma. ( Ameratunga, M; Grant, R; Khasraw, M; Pavlakis, N; Simes, J; Wheeler, H, 2018) |
| "The tumor, a grade 3 anaplastic oligodendroglioma, was excised, and chemoradiotherapy was administered." | 2.55 | Regression of Recurrent High-Grade Glioma with Temozolomide, Dexamethasone, and Levetiracetam: Case Report and Review of the Literature. ( Abraham Koshy, A; Kumar A, A, 2017) |
| "Glioblastoma is the most common and most aggressive form of primary brain tumor in adults and contributes to high social and medical burden as a result of its incurable nature and significant neurologic morbidity." | 2.55 | Treatment of Glioblastoma. ( de Groot, JF; Nam, JY, 2017) |
| "Fibrosarcoma is a rare brain tumour with 33 cases reported so far." | 2.53 | Intracranial fibrosarcoma treated with adjuvant radiation and temozolomide: Report of a case and review of all published cases. ( Giridhar, P; Gupta, S; Haresh, KP; Julka, PK; Mallick, S; Rath, GK, 2016) |
| "Atypical pituitary adenomas (APAs) are aggressive tumors, harboring a Ki-67 (MIB-1) staining index of 3% or more, and positive immunohistochemical staining for p53 protein, according to the World Health Organization (WHO) classification in 2004." | 2.50 | Treatment of pituitary carcinomas and atypical pituitary adenomas: a review. ( Hirohata, T; Ishii, Y; Matsuno, A, 2014) |
| "Angiocentric gliomas have recently been reclassified as a separate central nervous system tumor." | 2.48 | Imaging characteristics of an unusual, high-grade angiocentric glioma: a case report and review of the literature. ( Aguilar, HN; Hung, RW; Kotylak, T; Mehta, V, 2012) |
| "Anaplastic astrocytoma is an uncommon disease in the adult population." | 2.44 | Anaplastic astrocytoma in adults. ( Gatta, G; Mazza, E; Reni, M; Stupp, R; Vecht, C, 2007) |
| "High-grade glioma is a devastating disease that leaves the majority of its victims dead within 2 years." | 2.44 | Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. ( Kleinberg, LR; Lin, SH, 2008) |
| "Additionally, there is evidence that treatment-related necrosis occurs more frequently and earlier after temozolomide chemotherapy than after radiotherapy alone." | 2.44 | Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. ( Brandsma, D; Sminia, P; Stalpers, L; Taal, W; van den Bent, MJ, 2008) |
| "Irinotecan is a water-soluble derivative of camptothecin, an alkylator originally extracted from the Chinese tree Camptotheca acuminata." | 2.42 | The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. ( Friedman, HS; Houghton, PJ; Keir, ST, 2003) |
| " The drug is well tolerated with dose limiting myelosuppression and thrombocytopenia occurring in less than 10% of patients at current dosage schedules." | 2.41 | The use of temozolomide in recurrent malignant gliomas. ( Gaya, A; Greenstein, A; Rees, J; Stebbing, J, 2002) |
| "Temozolomide appears to produce few serious adverse effects and may also have a positive impact on health-related quality of life." | 2.41 | A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. ( Cave, C; Dinnes, J; Huang, S; Milne, R, 2002) |
| "Gliosarcoma is a histopathological variant of glioblastoma, which is characterized by a biphasic growth pattern consisting of glial and sarcoma components." | 1.91 | Prognostic Factors of Gliosarcoma in the Real World: A Retrospective Cohort Study. ( Shen, J; Song, K; Wei, L; Xu, H; Xu, M; Yu, Z; Zhou, Z; Zhu, W, 2023) |
| "New approaches to the treatment of glioblastoma, including immune checkpoint blockade and oncolytic viruses, offer the possibility of improving glioblastoma outcomes and have as such been under intense study." | 1.91 | Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma. ( Craig, M; Fiset, B; Jenner, AL; Karimi, E; Quail, DF; Surendran, A; Walsh, LA, 2023) |
| " The most common adverse events were leukocytopenia (66." | 1.91 | Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma. ( Bu, L; Cai, J; Chen, Q; Huang, K; Meng, X; Weng, Y; Xu, Q; Zhan, R; Zhang, L; Zheng, X, 2023) |
| "Pituitary carcinomas are thus clinically defined by the presence of craniospinal or distant metastases, typically developing several years after the first presentation." | 1.91 | [Aggressive pituitary adenoma and pituitary carcinoma]. ( Tóth, M, 2023) |
| "A critical challenge in the treatment of glioblastoma (GBM) is its highly invasive nature which promotes cell migration throughout the brain and hinders surgical resection and effective drug delivery." | 1.91 | Invadopodia associated Thrombospondin-1 contributes to a post-therapy pro-invasive response in glioblastoma cells. ( Drummond, KJ; Kaye, AH; Mantamadiotis, T; Morokoff, AP; Stylli, SS; Whitehead, CA, 2023) |
| "Diffuse gliomas are a heterogeneous category of primary central nervous system tumors." | 1.91 | Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences. ( Baird, L; Beadling, C; Corless, C; Harrington, CA; Moore, S; Neff, T; Wood, MD, 2023) |
| "Temozolomide (TMZ) was given to 24 patients and 11 patients received TMZ plus other chemotherapies." | 1.91 | The effect of chemotherapies on the crosstalk interaction between CD8 cytotoxic T-cells and MHC-I peptides in the microenvironment of WHO grade 4 astrocytoma. ( Alkhayyat, S; Alkhotani, A; Almansouri, M; Alshanqiti, M; Alsinani, T; Baeesa, S; Bamaga, AK; Butt, N; Enani, M; Fadul, MM; Faizo, E; Hassan, A; Karami, MM; Kurdi, M, 2023) |
| "Allopregnanolone (allo) is a physiological regulator of neuronal activity that treats multiple neurological disorders." | 1.72 | Allopregnanolone suppresses glioblastoma survival through decreasing DPYSL3 and S100A11 expression. ( Feng, YH; Hsu, SP; Hsu, TI; Kao, TJ; Ko, CY; Lim, SW; Lin, HY; Wang, SA, 2022) |
| "Since high grade gliomas are aggressive brain tumors, intensive search for new treatment options is ongoing." | 1.72 | Tumor treating fields therapy is feasible and safe in a 3-year-old patient with diffuse midline glioma H3K27M - a case report. ( Dohmen, H; Gött, H; Kiez, S; Kolodziej, M; Stein, M, 2022) |
| "Temozolomide (TMZ) is a DNA alkylating agent that appears to have a radiosensitizing effect when used in combination with RT and may be worthwhile in meningioma treatment." | 1.72 | Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review. ( Belanger, K; Damek, D; Lillehei, KO; Ormond, DR; Ung, TH, 2022) |
| "Glioblastoma multiforme is a malignant neoplasia with a median survival of less than two years and without satisfactory therapeutic options." | 1.72 | The role of Shikonin in improving 5-aminolevulinic acid-based photodynamic therapy and chemotherapy on glioblastoma stem cells. ( Buchner, A; Lyu, C; Pohla, H; Schrader, I; Sroka, R; Stadlbauer, B; Stepp, H; Werner, M, 2022) |
| "Glioblastoma is a malignant primary brain tumor that affects approximately 250,000 new patients per year worldwide." | 1.72 | Current therapeutic options for glioblastoma and future perspectives. ( Aquilanti, E; Wen, PY, 2022) |
| "Glioblastoma multiforme is a malignant central nervous system (CNS) disease with dismal prognosis." | 1.62 | Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab. ( Fioretzaki, RG; Kosmas, C; Papageorgiou, GI; Tsakatikas, SA, 2021) |
| "GBM (glioblastoma multiforme) is the most common and aggressive brain tumor." | 1.62 | Regorafenib in glioblastoma recurrence: A case report. ( Desideri, I; Detti, B; Ganovelli, M; Greto, D; Livi, L; Lorenzetti, V; Lucidi, S; Maragna, V; Scoccianti, S; Scoccimarro, E; Teriaca, MA, 2021) |
| "Differentiating treatment necrosis from tumor recurrence poses a diagnostic conundrum for many clinicians in neuro-oncology." | 1.62 | Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas. ( Cui, Y; Gao, F; Jiang, H; Li, M; Lin, S; Ren, X; Zhao, W, 2021) |
| "Temozolomide was labeled with [11C], and serial PET-MRI scans were performed in patients with recurrent GBM treated with bevacizumab and daily temozolomide." | 1.56 | Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. ( Batchelor, T; Beers, AL; Catana, C; Chang, K; Dietrich, J; Duda, DG; Emblem, KE; Gerstner, ER; Hooker, JM; Jain, RK; Kalpathy-Cramer, J; Plotkin, SR; Rosen, B; Vakulenko-Lagun, B; Yen, YF, 2020) |
| "Temozolomide/etoposide is a feasible candidate as salvage therapy for relapsed osteosarcoma." | 1.56 | Temozolomide and etoposide combination for the treatment of relapsed osteosarcoma. ( Adachi, S; Akazawa, R; Arakawa, Y; Hiramatsu, H; Kato, I; Moritake, H; Okamoto, T; Saida, S; Sakamoto, A; Sumiyoshi, S; Takita, J; Umeda, K, 2020) |
| "Gliomas are intrinsic brain tumours, which are classified by the World Health Organization (WHO) into different grades of malignancy, with glioblastoma being the most frequent and most malignant subtype (WHO grade IV)." | 1.56 | A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults. ( Hofer, S; Hottinger, AF; Hundsberger, T; Läubli, H; Mamot, C; Pesce, G; Reinert, M; Roelcke, U; Roth, P; Schucht, P; Weller, M, 2020) |
| "Oligodendroglioma is defined by IDH mutation and 1p/19q codeletion." | 1.56 | Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report. ( Kamataki, A; Nanjo, H; Ono, T; Reinhardt, A; Shimizu, H; Takahashi, M; von Deimling, A, 2020) |
| "our data underline re-RT as a safe and feasible treatment with limited rate of toxicity, and a combined ones as a better option for selected patients." | 1.51 | Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO). ( Alongi, F; Amelio, D; Borzillo, V; Ciammella, P; Clerici, E; di Monale, MB; Draghini, L; Fariselli, L; Ferrarese, F; Fiorentino, A; Galaverni, M; Krengli, M; Livi, L; Magrini, S; Maranzano, E; Masini, L; Minniti, G; Muto, P; Navarria, P; Pasqualetti, F; Pinzi, V; Scartoni, D; Scoccianti, S; Scorsetti, M; Tomatis, S, 2019) |
| "Long‑term local treatment of glioblastoma is rarely achieved and the majority of the patients undergo relapse." | 1.51 | Synergistic effect of arsenic trioxide, vismodegib and temozolomide on glioblastoma. ( Bureta, C; Komiya, S; Maeda, S; Nagano, S; Saitoh, Y; Sasaki, H; Setoguchi, T; Taniguchi, N; Tokumoto, H, 2019) |
| " Our results demonstrate benefit of ddTMZ after previous treatment with standard TMZ dosing with no apparent increase in treatment-related toxicities." | 1.48 | Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study. ( Garcia, CR; Gruber, L; Kumar, SS; Lightner, DD; Morgan, RM; Slone, SA; Villano, JL, 2018) |
| "The current treatment of glioblastoma multiforme (GBM) is limited by the restricted arsenal of agents which effectively cross the blood brain barrier (BBB)." | 1.46 | The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts. ( Adhikari, B; Akers, J; Brandel, MG; Carter, BS; Chen, CC; Deming, T; Futalan, D; Li, J, 2017) |
| "6 μg/day) with negligible leakage into the peripheral blood (<100 ng) rendering ~1000 fold differential drug dosage in tumor versus peripheral blood." | 1.46 | Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma. ( Ashokan, A; Gowd, GS; Junnuthula, VR; Koyakutty, M; Nair, SV; Panikar, D; Peethambaran, R; Ramachandran, R; Thomas, A; Thomas, J; Unni, AK, 2017) |
| "Valproic acid (VPA) is an anti-epileptic drug with properties of a histone deacetylase inhibitor (HDACi)." | 1.43 | Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. ( Dietrich, J; Le, A; McDonnell, E; Nahed, BV; Redjal, N; Reinshagen, C; Walcott, BP, 2016) |
| "Fotemustine (FTM) is a third-generation nitrosourea showing efficacy in gliomas and it has been used with different schedules in adult patients." | 1.43 | Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study. ( Bellu, L; D'Avella, D; Della Puppa, A; Farina, M; Fiduccia, P; Lombardi, G; Pambuku, A; Zagonel, V, 2016) |
| "Only pituitary tumors with cerebrospinal and/or systemic metastasis are considered malignant carcinomas." | 1.43 | Refractory pituitary adenoma: a novel classification for pituitary tumors. ( Bao, X; Dai, C; Deng, K; Feng, M; Lian, W; Liu, X; Ma, S; Ma, W; Sun, B; Wang, R; Wang, Y; Xing, B; Yao, Y; Zhong, D, 2016) |
| "Seizures are a common symptom in patients with low-grade glioma (LGG), negatively influencing quality of life, if uncontrolled." | 1.42 | Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide. ( Dirven, L; Heimans, JJ; Koekkoek, JA; Postma, TJ; Reijneveld, JC; Taphoorn, MJ; Vos, MJ, 2015) |
| "Temozolomide treatment significantly induced mRNA expression of nearly all investigated EMT markers in T98G glioma cells." | 1.42 | Epithelial-to-mesenchymal transition in paired human primary and recurrent glioblastomas. ( Hattermann, K; Held-Feindt, J; Kubelt, C; Mehdorn, HM; Sebens, S, 2015) |
| "Patients diagnosed with primary brain tumors were treated with PDT." | 1.42 | Photodynamic therapy in the treatment of brain tumours. A feasibility study. ( Azinovic, I; Brugarolas, A; Cañón, R; Cases, FG; Rebollo, J; Sapena, NS; Sureda, M; Vanaclocha, V, 2015) |
| " This preclinical study sought to test the efficacy of the food additive Triacetin (glyceryl triacetate, GTA) as a novel therapy to increase acetate bioavailability in glioma cells." | 1.40 | Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma. ( Davies, MT; Driscoll, HE; Jaworski, DM; Lawler, SE; Long, PM; Penar, PL; Pendlebury, WW; Spees, JL; Teasdale, BA; Tsen, AR; Viapiano, MS, 2014) |
| "Diffuse brainstem glioma is a rare disease in adults." | 1.40 | Temozolomide after radiotherapy in recurrent "low grade" diffuse brainstem glioma in adults. ( Delattre, JY; Laigle-Donadey, F; Martin-Duverneuil, N; Mokhtari, K; Reyes-Botero, G, 2014) |
| " We therefore evaluated a 5-day dosing schedule of temozolomide and examined MGMT as a predictive biomarker for temozolomide treatment in SCLC." | 1.40 | Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. ( Bergagnini, I; Drilon, A; Ginsberg, MS; Heguy, A; Holodny, AI; Huberman, K; Kadota, K; Kris, MG; Krug, LM; Pietanza, MC; Riely, GJ; Sima, CS; Sumner, DK; Travis, WD; Zauderer, MG, 2014) |
| " In the present analysis, we retrospectively investigated the feasibility and effectiveness of bevacizumab combined with ICE in patients with glioblastoma at second relapse during ICE treatment." | 1.39 | Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma. ( Arakawa, Y; Fujimoto, K; Kikuchi, T; Kunieda, T; Miyamoto, S; Mizowaki, T; Murata, D; Takagi, Y; Takahashi, JC, 2013) |
| "Temozolomide is an attractive candidate treatment in neuroblastoma with methylated MGMT, especially in central nervous system relapsed cases." | 1.39 | Efficacy of temozolomide in a central nervous system relapse of neuroblastoma with O 6 -methylguanine methyltransferase (MGMT) promoter methylation. ( Marutsuka, K; Moritake, H; Nunoi, H; Shimonodan, H; Takeshima, H; Yamada, A; Yokogami, K, 2013) |
| "Angiocentric glioma is a recently recognized benign brain tumor with unknown histogenesis." | 1.39 | Malignant glioma with angiocentric features. ( Lu, JQ; Mehta, V; Patel, S; Pugh, J; Wilson, BA, 2013) |
| "Temozolomide is an active drug against gliomas in adults." | 1.38 | Temozolomide in relapsed pediatric brain tumors: 14 cases from a single center. ( Akyüz, C; Büyükpamukçu, M; Demir, HA; Kutluk, T; Varan, A; Yalçin, B, 2012) |
| "Combining Gliadel wafers and radiochemotherapy with TMZ may carry the risk of increased adverse events (AE)." | 1.38 | Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma. ( Anile, C; Balducci, M; Chiesa, S; De Bonis, P; Fiorentino, A; Maira, G; Mangiola, A; Pompucci, A, 2012) |
| "Extracranial metastasis of primary brain tumors is rarely observed." | 1.38 | Breast metastasis of anaplastic oligodendroglioma: a case report. ( Alacacioglu, A; Canpolat, S; Coskun, A; Karatas, A; Oztekin, O; Postaci, H; Sop, G; Unal, S; Yurt, A, 2012) |
| "Temozolomide was prescribed, and a disease-free period of 2 years followed." | 1.37 | Case of atypical teratoid/rhabdoid tumor in an adult, with long survival. ( Ikeda, J; Kanno, H; Katoh, M; Kimura, T; Mahabir, R; Nagashima, K; Nishihara, H; Sawamura, Y; Takahashi, K; Tanaka, S; Tanino, M; Yoshinaga, T, 2011) |
| "Communicating hydrocephalus is an uncommon complication in patients treated for glioblastoma multiforme (GBM)." | 1.37 | Communicating hydrocephalus following surgery and adjuvant radiochemotherapy for glioblastoma. ( Bianchi, F; D'Alessandris, QG; Doglietto, F; Fernandez, E; Lauretti, L; Maira, G; Montano, N; Pallini, R, 2011) |
| " The growing body of evidence demonstrating the clinical importance of O6-methylguanine methyltransferase (MGMT) has generated a considerable interest in the exploration of strategies to overcome MGMT-mediated resistance to alkylating agents; for example protracted administration of Temozolomide (TMZ) may result in more extensive and sustained depletion of MGMT; for this reason a variety of dosing schedules that increase the duration of exposure and the cumulative dose of TMZ are being investigated for the treatment of patient with recurrent malignant glioma after standard treatment." | 1.37 | Rechallenge with temozolomide in recurrent glioma. ( Botturi, A; Fariselli, L; Ferrari, D; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A; Simonetti, G, 2011) |
| "The case of a patient with recurrent esthesioneuroblastoma complicated by ectopic adrenocorticotropic hormone production is presented, including the workup and management of this uncommon complication of an uncommon disease." | 1.36 | Esthesioneuroblastoma (Olfactory Neuroblastoma) with Ectopic ACTH Syndrome: a multidisciplinary case presentation from the Joan Karnell cancer center of Pennsylvania Hospital. ( Benito, M; Mintzer, DM; Nagamine, M; Newman, J; Zheng, S, 2010) |
| "Glioblastoma is the most common primary malignant brain tumor; however, glioblastoma in children is less common than in adults, and little is known about its clinical outcome in children." | 1.36 | Long-term outcomes in children with glioblastoma. ( Ahn, HS; Cho, BK; Kim, DG; Kim, IH; Kim, SK; Lee, JY; Park, SH; Phi, JH; Song, KS; Wang, KC, 2010) |
| "A 33-year-old woman presented with rare brain metastases from undifferentiated high-grade sarcoma manifesting as headache and vomiting." | 1.36 | Brain metastasis of undifferentiated sarcoma and response to temozolomide treatment. Case report. ( Arai, A; Itoh, T; Kanomata, N; Kawamura, A; Kohmura, E; Nishihara, M; Sasayama, T; Tanaka, H, 2010) |
| "Meningiomas are usually cured by surgical resection." | 1.35 | Methylation status of MGMT gene promoter in meningiomas. ( Cairncross, G; de Robles, P; Easaw, J; Forsyth, P; Hamilton, M; Kalra, S; Magliocco, T; McIntyre, J; Roldán, G, 2008) |
| "Paclitaxel is an antineoplastic agent that is used in the treatment of a variety of solid tumors." | 1.35 | Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma. ( Fangusaro, J; Finlay, J; Rook, J; Rosser, T, 2008) |
| "Astroblastoma is a historically traded microscopic diagnosis to denote a rare neuroepithelial tumor of uncertain nosology, involving a distinctive pattern of pseudorosette arrangement of neoplastic cells." | 1.35 | Astroblastoma with rhabdoid features and favorable long-term outcome: report of a case with a 12-year follow-up. ( El-Koussy, M; Fathi, AR; Kappeler, A; Mariani, L; Novoa, E; Vajtai, I, 2008) |
| "The anterior temporal lesion was a ganglioglioma and did not recur." | 1.34 | Ganglioglioma occurring with glioblastoma multiforme: separate lesions or the same lesion? ( Dickerman, RD; Howes, G; Lee, JM; Nardone, EM; Stevens, QE, 2007) |
| "Glioblastoma multiforme is characterised by invasive growth and frequent recurrence." | 1.34 | Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma. ( Berger, W; Buchroithner, J; Fischer, J; Marosi, C; Micksche, M; Pichler, J; Pirker, C; Silye, R; Spiegl-Kreinecker, S, 2007) |
| "Treatment with temozolomide resulted in relief of clinical symptoms and stabilization of tumour growth for 8 months." | 1.34 | Metastatic medulloblastoma in an adult; treatment with temozolomide. ( Bernsen, HJ; Poelen, J; Prick, MJ, 2007) |
| "Temozolomide is an oral cytotoxic agent that has demonstrated its interest in high grade glioma tumors." | 1.34 | Temozolomide treatment of an adult with a relapsing medulloblastoma. ( Bay, JO; Durando, X; Gilliot, O; Irthum, B; Thivat, E; Verrelle, P; Vincent, C, 2007) |
| "The time-to-maximum plasma concentration (tmax) of TMZ was about 1 h and the elimination half-life of terminal excretion phase (t 1/2lambda z) was about 2 h." | 1.34 | Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians. ( Adachi, J; Aoki, T; Matsutani, M; Mishima, K; Mizutani, T; Nishikawa, R; Nojima, K, 2007) |
| "The patient remained free from disease progression for a total of 15 months when she was treated for dehydration and a computed tomography (CT) scan showed new small bilateral pleural effusions and enlarging subcarinal, right hilar, and left infrahilar lymph nodes." | 1.33 | Response to temozolomide in second-line treatment of recurrent nonsmall cell lung carcinoma: case report. ( Langer, CJ; Somer, RA, 2005) |
| "Malignant gliomas have a very poor prognosis." | 1.33 | A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. ( Avis, T; Barthorpe, S; Batchelor, TT; Bignell, G; Brackenbury, L; Buck, G; Butler, A; Cahill, DP; Clements, J; Cole, J; Davies, H; Dicks, E; Easton, DF; Edkins, S; Forbes, S; Futreal, PA; Gorton, M; Gray, K; Greenman, C; Halliday, K; Harrison, R; Hills, K; Hinton, J; Hunter, C; Jenkinson, A; Jones, D; Kosmidou, V; Laman, R; Levine, KK; Louis, DN; Lugg, R; Menzies, A; Mueller, W; O'Meara, S; Parker, A; Perry, J; Petty, R; Raine, K; Richardson, D; Riggins, G; Roy, JE; Shepherd, R; Small, A; Smith, R; Solomon, H; Stephens, P; Stevens, C; Stratton, MR; Teague, J; Tofts, C; Varian, J; West, S; Widaa, S; Wooster, R; Yates, A, 2006) |
| "Temozolomide (TMZ) has demonstrated activity and acceptable toxicity for the treatment of recurrent high-grade gliomas in prospective phase II studies." | 1.32 | Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium. ( Branle, F; Everaert, E; Joosens, E; Menten, J; Neyns, B; Strauven, T, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (0.51) | 18.2507 |
| 2000's | 156 (26.62) | 29.6817 |
| 2010's | 293 (50.00) | 24.3611 |
| 2020's | 134 (22.87) | 2.80 |
| Authors | Studies |
|---|---|
| Yamamuro, S | 1 |
| Takahashi, M | 2 |
| Satomi, K | 1 |
| Sasaki, N | 1 |
| Kobayashi, T | 1 |
| Uchida, E | 1 |
| Kawauchi, D | 1 |
| Nakano, T | 1 |
| Fujii, T | 1 |
| Narita, Y | 1 |
| Kondo, A | 1 |
| Wada, K | 1 |
| Yoshino, A | 1 |
| Ichimura, K | 1 |
| Tomiyama, A | 1 |
| Urbantat, RM | 1 |
| Jelgersma, C | 1 |
| Brandenburg, S | 1 |
| Nieminen-Kelhä, M | 1 |
| Kremenetskaia, I | 1 |
| Zollfrank, J | 1 |
| Mueller, S | 1 |
| Rubarth, K | 1 |
| Koch, A | 1 |
| Vajkoczy, P | 3 |
| Acker, G | 1 |
| Pak, O | 1 |
| Zaitsev, S | 1 |
| Shevchenko, V | 1 |
| Sharma, A | 1 |
| Sharma, HS | 1 |
| Bryukhovetskiy, I | 1 |
| Cui, P | 1 |
| Chen, F | 2 |
| Ma, G | 1 |
| Liu, W | 3 |
| Chen, L | 6 |
| Wang, S | 3 |
| Li, W | 3 |
| Li, Z | 3 |
| Huang, G | 3 |
| Fazzari, FGT | 1 |
| Rose, F | 1 |
| Pauls, M | 1 |
| Guay, E | 1 |
| Ibrahim, MFK | 1 |
| Basulaiman, B | 1 |
| Tu, M | 1 |
| Hutton, B | 1 |
| Nicholas, G | 1 |
| Ng, TL | 1 |
| Stelmachowska-Banaś, M | 1 |
| Maksymowicz, M | 1 |
| Kolasińska-Ćwikła, A | 1 |
| Zieliński, G | 1 |
| Korbonits, M | 1 |
| Zgliczyński, W | 1 |
| Zhao, K | 2 |
| Schäfer, A | 1 |
| Zhang, Z | 5 |
| Elsässer, K | 1 |
| Culmsee, C | 1 |
| Zhong, L | 1 |
| Pagenstecher, A | 2 |
| Nimsky, C | 1 |
| Bartsch, JW | 1 |
| Ma, Z | 1 |
| Cai, S | 1 |
| Xiong, Q | 1 |
| Xia, H | 1 |
| Zhu, Z | 2 |
| Huang, Z | 2 |
| Yan, X | 1 |
| Wang, Q | 5 |
| Zeyen, T | 1 |
| Potthoff, AL | 1 |
| Nemeth, R | 1 |
| Heiland, DH | 1 |
| Burger, MC | 1 |
| Steinbach, JP | 6 |
| Hau, P | 6 |
| Tabatabai, G | 3 |
| Glas, M | 4 |
| Schlegel, U | 5 |
| Grauer, O | 1 |
| Krex, D | 5 |
| Schnell, O | 2 |
| Goldbrunner, R | 5 |
| Sabel, M | 5 |
| Thon, N | 2 |
| Delev, D | 1 |
| Clusmann, H | 1 |
| Seidel, C | 1 |
| Güresir, E | 1 |
| Schmid, M | 1 |
| Schuss, P | 1 |
| Giordano, FA | 1 |
| Radbruch, A | 2 |
| Becker, A | 1 |
| Weller, J | 1 |
| Schaub, C | 2 |
| Vatter, H | 2 |
| Schilling, J | 1 |
| Winkler, F | 1 |
| Herrlinger, U | 5 |
| Schneider, M | 1 |
| Umeda, K | 3 |
| Taura, K | 1 |
| Kato, I | 3 |
| Saida, S | 3 |
| Hiramatsu, H | 3 |
| Shimizu, H | 2 |
| Nakamoto, Y | 1 |
| Uto, M | 1 |
| Mizowaki, T | 3 |
| Sakamoto, A | 2 |
| Adachi, S | 2 |
| Okamoto, T | 2 |
| Takita, J | 3 |
| Feng, YH | 1 |
| Lim, SW | 1 |
| Lin, HY | 2 |
| Wang, SA | 1 |
| Hsu, SP | 2 |
| Kao, TJ | 1 |
| Ko, CY | 3 |
| Hsu, TI | 3 |
| Barresi, V | 1 |
| Mafficini, A | 1 |
| Calicchia, M | 1 |
| Piredda, ML | 1 |
| Musumeci, A | 1 |
| Ghimenton, C | 3 |
| Scarpa, A | 1 |
| Zhang, X | 8 |
| Li, T | 2 |
| Yang, M | 1 |
| Du, Q | 1 |
| Wang, R | 3 |
| Fu, B | 1 |
| Tan, Y | 2 |
| Cao, M | 1 |
| Chen, Y | 6 |
| Hu, R | 1 |
| Mehraein-Ghomi, F | 1 |
| Forbes, ME | 1 |
| Namjoshi, SV | 1 |
| Ballard, EA | 1 |
| Song, Q | 1 |
| Chou, PC | 1 |
| Wang, X | 10 |
| Parker Kerrigan, BC | 1 |
| Lang, FF | 1 |
| Lesser, G | 2 |
| Debinski, W | 1 |
| Yang, X | 4 |
| Zhang, W | 5 |
| Gött, H | 1 |
| Kiez, S | 1 |
| Dohmen, H | 1 |
| Kolodziej, M | 1 |
| Stein, M | 1 |
| Essien, EI | 1 |
| Hofer, TP | 1 |
| Atkinson, MJ | 1 |
| Anastasov, N | 1 |
| Moon, HH | 1 |
| Park, JE | 2 |
| Kim, YH | 3 |
| Kim, JH | 5 |
| Kim, HS | 3 |
| Alanazi, R | 1 |
| Nakatogawa, H | 1 |
| Wang, H | 5 |
| Ji, D | 1 |
| Luo, Z | 2 |
| Golbourn, B | 1 |
| Feng, ZP | 1 |
| Rutka, JT | 1 |
| Sun, HS | 1 |
| Wang, BC | 1 |
| Xiao, BY | 1 |
| Lin, GH | 1 |
| Zhou, L | 3 |
| Huang, X | 1 |
| Zhang, Y | 11 |
| Wang, J | 12 |
| Li, H | 7 |
| Huang, H | 3 |
| Belanger, K | 1 |
| Ung, TH | 1 |
| Damek, D | 4 |
| Lillehei, KO | 1 |
| Ormond, DR | 1 |
| Beppu, T | 2 |
| Iwaya, T | 1 |
| Sato, Y | 3 |
| Nomura, JI | 1 |
| Terasaki, K | 2 |
| Sasaki, T | 2 |
| Yamada, N | 1 |
| Fujiwara, S | 1 |
| Sugai, T | 1 |
| Ogasawara, K | 2 |
| Borhan, MK | 1 |
| Tan, FHS | 1 |
| Feldheim, J | 1 |
| Kessler, AF | 1 |
| Feldheim, JJ | 1 |
| Schulz, E | 1 |
| Wend, D | 1 |
| Lazaridis, L | 1 |
| Kleinschnitz, C | 1 |
| Ernestus, RI | 1 |
| Brandner, S | 1 |
| Monoranu, CM | 1 |
| Löhr, M | 1 |
| Hagemann, C | 1 |
| Lan, XY | 1 |
| Li, D | 5 |
| Li, S | 5 |
| Zhong, LZ | 1 |
| Zhao, H | 4 |
| Xi, YL | 1 |
| Sun, ZW | 1 |
| Zhao, B | 1 |
| Wu, J | 3 |
| Xia, Y | 1 |
| Wang, Y | 7 |
| Qu, T | 1 |
| Xing, H | 1 |
| Ma, W | 3 |
| Werner, M | 1 |
| Lyu, C | 1 |
| Stadlbauer, B | 1 |
| Schrader, I | 1 |
| Buchner, A | 1 |
| Stepp, H | 1 |
| Sroka, R | 1 |
| Pohla, H | 1 |
| Prajapati, HP | 1 |
| Ansari, A | 1 |
| Chen, S | 4 |
| Qiu, Q | 1 |
| Wang, D | 3 |
| She, D | 1 |
| Yin, B | 1 |
| Gu, G | 1 |
| Chai, M | 1 |
| Heo, DN | 1 |
| He, H | 1 |
| Chernov, AN | 1 |
| Filatenkova, TA | 1 |
| Glushakov, RI | 1 |
| Buntovskaya, AS | 1 |
| Alaverdian, DA | 1 |
| Tsapieva, AN | 1 |
| Kim, AV | 1 |
| Fedorov, EV | 1 |
| Skliar, SS | 1 |
| Matsko, MV | 1 |
| Galimova, ES | 1 |
| Shamova, OV | 1 |
| Omuro, A | 5 |
| Beltzig, L | 1 |
| Christmann, M | 2 |
| Kaina, B | 3 |
| Shidoh, S | 1 |
| Savjani, RR | 1 |
| Cho, NS | 1 |
| Ullman, HE | 1 |
| Hagiwara, A | 1 |
| Raymond, C | 1 |
| Lai, A | 1 |
| Nghiemphu, PL | 1 |
| Liau, LM | 1 |
| Pope, WB | 1 |
| Cloughesy, TF | 4 |
| Kaprealian, TB | 1 |
| Salamon, N | 1 |
| Ellingson, BM | 3 |
| Aquilanti, E | 1 |
| Wen, PY | 6 |
| Gan, T | 1 |
| Xie, M | 1 |
| Zhao, S | 2 |
| Wang, P | 1 |
| Shi, Q | 1 |
| Qian, X | 1 |
| Miao, F | 1 |
| Shen, Z | 1 |
| Nie, E | 1 |
| Metts, JL | 1 |
| Trucco, M | 1 |
| Weiser, DA | 1 |
| Thompson, P | 1 |
| Sandler, E | 1 |
| Smith, T | 1 |
| Crimella, J | 1 |
| Sansil, S | 1 |
| Thapa, R | 1 |
| Fridley, BL | 1 |
| Llosa, N | 1 |
| Badgett, T | 1 |
| Gorlick, R | 1 |
| Reed, D | 1 |
| Gill, J | 1 |
| Slotkin, EK | 2 |
| Meyers, PA | 1 |
| Lu, G | 1 |
| Zhu, P | 1 |
| Rao, M | 1 |
| Linendoll, N | 1 |
| Buja, LM | 1 |
| Bhattacharjee, MB | 1 |
| Brown, RE | 1 |
| Ballester, LY | 1 |
| Tian, X | 1 |
| Pilichowska, M | 1 |
| Wu, JK | 2 |
| Hergenroeder, GW | 1 |
| Glass, WF | 1 |
| Zhang, R | 1 |
| Pillai, AK | 1 |
| Hunter, RL | 1 |
| Zhu, JJ | 2 |
| Devalckeneer, A | 2 |
| Aboukaïs, R | 2 |
| Bourgeois, P | 2 |
| Reyns, N | 2 |
| Lejeune, JP | 2 |
| Weth, FR | 1 |
| Peng, L | 1 |
| Paterson, E | 1 |
| Tan, ST | 1 |
| Gray, C | 1 |
| Chang, SM | 11 |
| van den Bent, M | 2 |
| Vogelbaum, MA | 2 |
| Li, G | 4 |
| Kim, J | 2 |
| Youssef, G | 1 |
| Wick, W | 9 |
| Lassman, AB | 5 |
| Gilbert, MR | 8 |
| de Groot, JF | 2 |
| Weller, M | 17 |
| Galanis, E | 1 |
| Al-Holou, WN | 1 |
| Ravikumar, V | 1 |
| Shankar, S | 1 |
| Oneka, M | 1 |
| Fehmi, Z | 1 |
| Verhaak, RG | 1 |
| Kim, H | 5 |
| Pratt, D | 1 |
| Camelo-Piragua, S | 1 |
| Speers, C | 1 |
| Wahl, DR | 1 |
| Hollon, T | 1 |
| Sagher, O | 1 |
| Heth, JA | 1 |
| Muraszko, KM | 1 |
| Lawrence, TS | 1 |
| de Carvalho, AC | 1 |
| Mikkelsen, T | 2 |
| Rao, A | 1 |
| Rehemtulla, A | 1 |
| Xu, J | 1 |
| Xie, L | 1 |
| Sun, X | 4 |
| Liu, K | 1 |
| Liang, X | 1 |
| Cai, Z | 1 |
| Tang, X | 2 |
| Guo, W | 1 |
| Zhao, M | 2 |
| Ma, H | 2 |
| Cheng, P | 1 |
| Yang, H | 3 |
| Zhao, Y | 4 |
| Han, Q | 1 |
| Liu, H | 4 |
| Zhang, L | 4 |
| Jiang, Y | 2 |
| Lu, H | 2 |
| Blakstad, H | 1 |
| Brekke, J | 1 |
| Rahman, MA | 1 |
| Arnesen, VS | 1 |
| Miletic, H | 2 |
| Brandal, P | 1 |
| Lie, SA | 1 |
| Chekenya, M | 1 |
| Goplen, D | 1 |
| Yu, Z | 1 |
| Zhou, Z | 2 |
| Xu, M | 1 |
| Song, K | 1 |
| Shen, J | 4 |
| Zhu, W | 1 |
| Wei, L | 2 |
| Xu, H | 1 |
| Anderson, P | 1 |
| Ghisoli, M | 1 |
| Crompton, BD | 1 |
| Klega, KS | 1 |
| Wexler, LH | 1 |
| Stanbery, L | 1 |
| Manning, L | 1 |
| Wallraven, G | 1 |
| Manley, M | 1 |
| Horvath, S | 1 |
| Bognar, E | 1 |
| Nemunaitis, J | 1 |
| Glavatskyi, OY | 1 |
| Griazov, AB | 1 |
| Chuvashova, OY | 1 |
| Kruchok, IV | 1 |
| Griazov, AA | 1 |
| Khmelnytskyi, HV | 1 |
| Shuba, IM | 1 |
| Stuley, VA | 1 |
| Zemskova, OV | 1 |
| Elshazly, AM | 1 |
| Gewirtz, DA | 1 |
| Bosio, A | 1 |
| Cerretti, G | 1 |
| Padovan, M | 1 |
| Caccese, M | 1 |
| Denaro, L | 1 |
| Chioffi, F | 1 |
| Della Puppa, A | 2 |
| Aldegheri, V | 1 |
| Guarneri, V | 1 |
| Zagonel, V | 2 |
| Lombardi, G | 5 |
| Zhou, P | 2 |
| Peng, X | 1 |
| Tang, S | 3 |
| Zhang, K | 1 |
| Tan, Z | 1 |
| Shen, L | 1 |
| Peng, J | 1 |
| Yang, L | 1 |
| Gherardini, L | 1 |
| Vetri Buratti, V | 1 |
| Maturi, M | 1 |
| Inzalaco, G | 1 |
| Locatelli, E | 1 |
| Sambri, L | 1 |
| Gargiulo, S | 1 |
| Barone, V | 1 |
| Bonente, D | 1 |
| Bertelli, E | 1 |
| Tortorella, S | 1 |
| Franci, L | 1 |
| Fioravanti, A | 2 |
| Comes Franchini, M | 1 |
| Chiariello, M | 1 |
| Zha, B | 1 |
| Yang, J | 1 |
| Dang, Q | 1 |
| Li, P | 3 |
| Shi, S | 1 |
| Cui, H | 1 |
| Huangfu, L | 1 |
| Li, Y | 7 |
| Yang, D | 2 |
| Zheng, Y | 2 |
| Erthal, LCS | 1 |
| Shi, Y | 2 |
| Sweeney, KJ | 1 |
| Gobbo, OL | 1 |
| Ruiz-Hernandez, E | 1 |
| Sun, Y | 3 |
| Liu, X | 4 |
| Wu, Z | 2 |
| Yan, W | 3 |
| You, Y | 2 |
| Kobushi, H | 1 |
| Iwai, A | 1 |
| Kozuki, K | 1 |
| Kubota, H | 1 |
| Tanaka, K | 1 |
| Obu, S | 1 |
| Uchihara, Y | 1 |
| Tasaka, K | 1 |
| Graen, P | 1 |
| Christiansen, H | 1 |
| Polemikos, M | 1 |
| Heetfeld, C | 1 |
| Feuerhake, F | 1 |
| Wiese, B | 1 |
| Merten, R | 1 |
| Chu, W | 1 |
| Houston, ZH | 1 |
| Fletcher, NL | 1 |
| Huda, P | 1 |
| Ahamed, M | 1 |
| Lim, TX | 1 |
| Day, BW | 1 |
| Pinkham, M | 1 |
| Thurecht, KJ | 1 |
| Hellmold, D | 1 |
| Kubelt, C | 2 |
| Daunke, T | 1 |
| Beckinger, S | 1 |
| Janssen, O | 1 |
| Hauck, M | 1 |
| Schütt, F | 1 |
| Adelung, R | 1 |
| Lucius, R | 1 |
| Haag, J | 1 |
| Sebens, S | 2 |
| Synowitz, M | 3 |
| Held-Feindt, J | 3 |
| Sato, D | 1 |
| Takami, H | 1 |
| Takayanagi, S | 1 |
| Taoka, K | 1 |
| Tanaka, M | 2 |
| Matsuura, R | 1 |
| Tanaka, S | 4 |
| Saito, N | 2 |
| Paradossi, G | 1 |
| Grossman, R | 1 |
| Riccitelli, F | 1 |
| Todaro, F | 1 |
| Ram, Z | 2 |
| Schioppa, S | 1 |
| Domenici, F | 1 |
| Surendran, A | 1 |
| Jenner, AL | 1 |
| Karimi, E | 1 |
| Fiset, B | 1 |
| Quail, DF | 1 |
| Walsh, LA | 1 |
| Craig, M | 1 |
| Ingham, M | 1 |
| Allred, JB | 1 |
| Das, B | 1 |
| Kochupurakkal, B | 1 |
| Gano, K | 1 |
| George, S | 1 |
| Attia, S | 1 |
| Burgess, MA | 1 |
| Seetharam, M | 1 |
| Boikos, SA | 1 |
| Bui, N | 1 |
| Chen, JL | 1 |
| Close, JL | 1 |
| Cote, GM | 1 |
| Thaker, PH | 1 |
| Ivy, SP | 1 |
| Bose, S | 1 |
| D'Andrea, A | 1 |
| Marino-Enriquez, A | 1 |
| Shapiro, GI | 1 |
| Schwartz, GK | 1 |
| Xu, Q | 1 |
| Huang, K | 1 |
| Meng, X | 1 |
| Weng, Y | 1 |
| Bu, L | 1 |
| Zheng, X | 1 |
| Cai, J | 1 |
| Zhan, R | 1 |
| Chen, Q | 3 |
| Tóth, M | 1 |
| Demircan, NV | 1 |
| Erpolat, OP | 1 |
| Guzel, C | 1 |
| Senturk, E | 1 |
| Bora, H | 1 |
| Karahacioglu, E | 1 |
| Sousa, N | 1 |
| Geiß, C | 1 |
| Bindila, L | 1 |
| Lieberwirth, I | 1 |
| Kim, E | 2 |
| Régnier-Vigouroux, A | 1 |
| Whitehead, CA | 1 |
| Morokoff, AP | 2 |
| Kaye, AH | 3 |
| Drummond, KJ | 1 |
| Mantamadiotis, T | 2 |
| Stylli, SS | 2 |
| Wood, MD | 2 |
| Beadling, C | 1 |
| Neff, T | 2 |
| Moore, S | 1 |
| Harrington, CA | 1 |
| Baird, L | 1 |
| Corless, C | 1 |
| Nayak, R | 1 |
| Mallick, B | 1 |
| Mu, Q | 3 |
| Chai, R | 1 |
| Pang, B | 1 |
| Yang, Y | 2 |
| Zhao, Z | 2 |
| Bao, Z | 2 |
| Song, D | 1 |
| Yan, M | 1 |
| Jiang, B | 1 |
| Mo, Z | 1 |
| Tang, J | 1 |
| Sa, JK | 2 |
| Cho, HJ | 2 |
| Chang, Y | 2 |
| Chan, KHY | 1 |
| Loi, DSC | 1 |
| Tam, SST | 1 |
| Chan, AKY | 1 |
| Wu, AR | 1 |
| Liu, Z | 5 |
| Poon, WS | 2 |
| Ng, HK | 2 |
| Chan, DTM | 1 |
| Iavarone, A | 2 |
| Nam, DH | 9 |
| Jiang, T | 3 |
| Butt, N | 1 |
| Enani, M | 1 |
| Alshanqiti, M | 1 |
| Alkhotani, A | 1 |
| Alsinani, T | 1 |
| Karami, MM | 1 |
| Fadul, MM | 1 |
| Almansouri, M | 1 |
| Hassan, A | 2 |
| Baeesa, S | 1 |
| Bamaga, AK | 1 |
| Alkhayyat, S | 1 |
| Faizo, E | 1 |
| Kurdi, M | 1 |
| Tan, IL | 1 |
| Perez, AR | 1 |
| Lew, RJ | 1 |
| Baldwin, A | 1 |
| Zhu, YK | 1 |
| Shah, MM | 1 |
| Berger, MS | 5 |
| Doudna, JA | 1 |
| Fellmann, C | 1 |
| Wu, Y | 2 |
| Franzmeier, S | 1 |
| Liesche-Starnecker, F | 1 |
| Schlegel, J | 1 |
| Schwendeman, SP | 1 |
| Petrova, L | 1 |
| Korfiatis, P | 1 |
| Petr, O | 1 |
| LaChance, DH | 1 |
| Parney, I | 1 |
| Buckner, JC | 1 |
| Erickson, BJ | 1 |
| Gerstner, ER | 1 |
| Emblem, KE | 1 |
| Chang, K | 1 |
| Vakulenko-Lagun, B | 1 |
| Yen, YF | 1 |
| Beers, AL | 1 |
| Dietrich, J | 3 |
| Plotkin, SR | 2 |
| Catana, C | 1 |
| Hooker, JM | 1 |
| Duda, DG | 1 |
| Rosen, B | 1 |
| Kalpathy-Cramer, J | 1 |
| Jain, RK | 1 |
| Batchelor, T | 1 |
| Bouchart, C | 1 |
| Trépant, AL | 1 |
| Hein, M | 1 |
| Van Gestel, D | 1 |
| Demetter, P | 1 |
| Pacheco, JM | 1 |
| Byers, LA | 1 |
| Sachdeva, R | 1 |
| Wu, M | 4 |
| Johnson, K | 1 |
| Celebre, A | 1 |
| Shahzad, U | 1 |
| Graham, MS | 1 |
| Kessler, JA | 1 |
| Chuang, JH | 1 |
| Karamchandani, J | 1 |
| Bredel, M | 2 |
| Verhaak, R | 1 |
| Das, S | 2 |
| Mukherjee, S | 2 |
| Wood, J | 1 |
| Liaquat, I | 1 |
| Stapleton, SR | 1 |
| Martin, AJ | 1 |
| Draaisma, K | 1 |
| Chatzipli, A | 1 |
| Taphoorn, M | 1 |
| Kerkhof, M | 2 |
| Weyerbrock, A | 2 |
| Sanson, M | 3 |
| Hoeben, A | 2 |
| Lukacova, S | 1 |
| Leenstra, S | 2 |
| Hanse, M | 1 |
| Fleischeuer, R | 1 |
| Watts, C | 1 |
| McAbee, J | 1 |
| Angelopoulos, N | 1 |
| Gorlia, T | 4 |
| Golfinopoulos, V | 2 |
| Kros, JM | 9 |
| Verhaak, RGW | 2 |
| Bours, V | 1 |
| van den Bent, MJ | 11 |
| McDermott, U | 1 |
| Robe, PA | 1 |
| French, PJ | 3 |
| Hirono, S | 2 |
| Hasegawa, Y | 1 |
| Sakaida, T | 1 |
| Uchino, Y | 1 |
| Hatano, K | 1 |
| Iuchi, T | 1 |
| Panje, CM | 1 |
| Putora, PM | 1 |
| Hundsberger, T | 3 |
| Hottinger, AF | 3 |
| Roelcke, U | 2 |
| Pesce, G | 2 |
| Herrmann, E | 1 |
| Matter-Walstra, K | 1 |
| Umphlett, M | 1 |
| Shea, S | 1 |
| Tome-Garcia, J | 1 |
| Hormigo, A | 3 |
| Fowkes, M | 1 |
| Tsankova, NM | 1 |
| Yong, RL | 1 |
| Valiakhmetova, A | 1 |
| Gorelyshev, S | 1 |
| Konovalov, A | 1 |
| Trunin, Y | 1 |
| Savateev, A | 1 |
| Kram, DE | 1 |
| Severson, E | 1 |
| Hemmerich, A | 1 |
| Edgerly, C | 1 |
| Duncan, D | 1 |
| Britt, N | 1 |
| Huang, RSP | 1 |
| Elvin, J | 1 |
| Miller, V | 1 |
| Ross, JS | 1 |
| Gay, L | 1 |
| McCorkle, J | 1 |
| Rankin, A | 1 |
| Erlich, RL | 1 |
| Chudnovsky, Y | 1 |
| Ramkissoon, SH | 1 |
| Belter, A | 1 |
| Barciszewski, J | 1 |
| Barciszewska, AM | 1 |
| Mathur, R | 1 |
| Grimmer, MR | 3 |
| Hong, C | 3 |
| Zhang, M | 5 |
| Bollam, S | 1 |
| Petrecca, K | 2 |
| Clarke, J | 2 |
| Phillips, JJ | 2 |
| Oberheim-Bush, NA | 1 |
| Molinaro, AM | 2 |
| Costello, JF | 4 |
| Marques, B | 1 |
| Monteiro, AR | 1 |
| Martins, RG | 1 |
| Couto, J | 1 |
| Rodrigues, F | 1 |
| Ribeiro, J | 1 |
| Tas, F | 1 |
| Erturk, K | 1 |
| Ma, JP | 1 |
| Weng, JC | 1 |
| Wang, L | 4 |
| Zhang, JT | 1 |
| Lizzul, L | 1 |
| Barbot, M | 1 |
| Ceccato, F | 2 |
| Gardiman, MP | 1 |
| Regazzo, D | 1 |
| Bellu, L | 2 |
| Mazza, E | 4 |
| Losa, M | 2 |
| Scaroni, C | 2 |
| Hsu, BH | 1 |
| Lee, WH | 1 |
| Yang, ST | 1 |
| Han, CT | 1 |
| Tseng, YY | 1 |
| Reardon, DA | 14 |
| Brandes, AA | 15 |
| Mulholland, P | 1 |
| Lim, M | 1 |
| Wick, A | 7 |
| Baehring, J | 1 |
| Ahluwalia, MS | 1 |
| Roth, P | 3 |
| Bähr, O | 3 |
| Phuphanich, S | 1 |
| Sepulveda, JM | 2 |
| De Souza, P | 1 |
| Sahebjam, S | 1 |
| Carleton, M | 1 |
| Tatsuoka, K | 1 |
| Taitt, C | 1 |
| Zwirtes, R | 1 |
| Sampson, J | 2 |
| Liu, B | 2 |
| Zhou, J | 1 |
| Wang, C | 5 |
| Chi, Y | 1 |
| Wei, Q | 2 |
| Fu, Z | 1 |
| Lian, C | 1 |
| Huang, Q | 1 |
| Liao, C | 1 |
| Yang, Z | 1 |
| Zeng, H | 1 |
| Xu, N | 1 |
| Guo, H | 1 |
| Akazawa, R | 1 |
| Arakawa, Y | 3 |
| Sumiyoshi, S | 1 |
| Moritake, H | 2 |
| Tan, AC | 1 |
| Ashley, DM | 2 |
| López, GY | 1 |
| Malinzak, M | 1 |
| Friedman, HS | 13 |
| Khasraw, M | 6 |
| Läubli, H | 1 |
| Schucht, P | 1 |
| Reinert, M | 1 |
| Mamot, C | 1 |
| Hofer, S | 1 |
| Comas, S | 1 |
| Luguera, E | 1 |
| Molero, J | 1 |
| Balaña, C | 5 |
| Estival, A | 1 |
| Castañer, S | 1 |
| Carrato, C | 1 |
| Hostalot, C | 1 |
| Teixidor, P | 1 |
| Villà, S | 1 |
| Oldrini, B | 1 |
| Vaquero-Siguero, N | 1 |
| Kroon, P | 1 |
| Galán-Ganga, M | 1 |
| Wang, Z | 3 |
| Zhao, J | 2 |
| Rodriguez-Perales, S | 1 |
| Rabadan, R | 2 |
| Squatrito, M | 1 |
| Salah, S | 1 |
| To, YH | 1 |
| Khozouz, O | 1 |
| Ismail, T | 1 |
| Yaser, S | 1 |
| Alnsour, A | 1 |
| Shahin, O | 1 |
| Sultan, I | 1 |
| Abuhijlih, R | 1 |
| Halalsheh, H | 1 |
| Abuhijla, F | 1 |
| Lewin, J | 1 |
| Ono, T | 1 |
| Reinhardt, A | 1 |
| Nanjo, H | 1 |
| Kamataki, A | 1 |
| von Deimling, A | 1 |
| Chen, WJ | 1 |
| Han, H | 1 |
| Lv, JN | 1 |
| Kang, EM | 1 |
| Zhang, YL | 1 |
| Liu, WP | 1 |
| He, XS | 1 |
| Wang, GH | 1 |
| Yu, YB | 1 |
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Yu, D | 1 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 1 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Shi, X | 1 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 1 |
| Maeda, K | 1 |
| Punn, R | 1 |
| Noguchi, S | 1 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Kim, Y | 5 |
| Song, J | 3 |
| Bascuñán, J | 2 |
| Chu, Y | 1 |
| Tomita, M | 1 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Li, X | 12 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Qiu, J | 1 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 1 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Liu, ZM | 1 |
| Xue, XD | 1 |
| Zhou, B | 1 |
| Zhang, S | 2 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Zhang, D | 2 |
| Huang, W | 1 |
| Cui, Y | 2 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 1 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 2 |
| Du, H | 1 |
| Lin, D | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Xu, C | 2 |
| Xiang, Y | 1 |
| Xu, X | 1 |
| Dong, X | 2 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Cai, Q | 1 |
| He, Y | 1 |
| Tong, F | 1 |
| Dong, JH | 1 |
| Wu, G | 1 |
| Dong, XR | 1 |
| Tao, F | 1 |
| Xiang, W | 1 |
| Jin, L | 1 |
| Tao, H | 1 |
| Lei, Y | 1 |
| Gan, H | 1 |
| Huang, Y | 2 |
| Shan, A | 1 |
| Ma, Q | 1 |
| Zhang, E | 1 |
| Zhang, J | 4 |
| Xue, F | 1 |
| Deng, L | 1 |
| Liu, L | 3 |
| Yan, Z | 2 |
| Meng, J | 1 |
| Chen, G | 2 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 1 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Du, L | 1 |
| Ren, Y | 1 |
| Li, J | 8 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, F | 2 |
| Wang, YS | 1 |
| Zhou, X | 2 |
| Wang, W | 2 |
| Hou, J | 1 |
| Zhang, A | 1 |
| Lv, B | 1 |
| Gao, C | 1 |
| Pang, D | 1 |
| Lu, K | 2 |
| Ahmad, NH | 1 |
| Zhu, J | 2 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Qu, Y | 2 |
| Yao, H | 2 |
| Lee, DF | 1 |
| Wen, L | 1 |
| Xie, X | 1 |
| Zhao, Q | 2 |
| Hu, W | 1 |
| Wu, X | 1 |
| Lu, J | 2 |
| Li, M | 2 |
| Wu, W | 1 |
| Du, F | 1 |
| Ji, H | 1 |
| Xu, Z | 1 |
| Wan, L | 2 |
| Wen, Q | 1 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Xiao, Z | 1 |
| Liao, J | 1 |
| Su, X | 1 |
| Bi, Z | 1 |
| Su, Q | 1 |
| Wei, Y | 2 |
| Gao, Y | 2 |
| Na, KJ | 1 |
| Choi, H | 2 |
| Oh, HR | 1 |
| Lee, SB | 1 |
| Jung, YJ | 1 |
| Koh, J | 1 |
| Park, S | 1 |
| Lee, HJ | 2 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Cheon, GJ | 1 |
| Kang, KW | 1 |
| Lee, DS | 1 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 1 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 1 |
| Richter, C | 1 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 1 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Liao, Y | 1 |
| Cheng, J | 1 |
| Kong, X | 2 |
| Zhang, H | 1 |
| Yang, T | 2 |
| Dong, Y | 1 |
| Xu, Y | 1 |
| Yuan, Z | 1 |
| Cao, J | 1 |
| Mei, Z | 1 |
| Yao, Y | 2 |
| Liang, C | 1 |
| Song, Y | 1 |
| Yu, K | 1 |
| Zhu, C | 1 |
| Qian, J | 2 |
| Ge, J | 1 |
| Hu, J | 2 |
| Liu, Y | 5 |
| Mi, Y | 1 |
| Kong, H | 1 |
| Xi, D | 1 |
| Luo, X | 1 |
| Ning, Q | 1 |
| Chang, X | 2 |
| Zhang, T | 2 |
| Rathore, MG | 1 |
| Reddy, K | 3 |
| Chen, H | 2 |
| Shin, SH | 1 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Dong, Z | 1 |
| Mu, W | 1 |
| Liu, C | 3 |
| Gao, F | 2 |
| Qi, Y | 1 |
| Cai, X | 1 |
| Ji, RY | 1 |
| Hou, Y | 3 |
| Tian, J | 2 |
| Ying, S | 1 |
| Tan, M | 1 |
| Feng, G | 1 |
| Kuang, Y | 1 |
| Chen, D | 1 |
| Wu, D | 3 |
| Zhu, ZQ | 1 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Kang, J | 1 |
| Liu, Q | 2 |
| Qi, J | 2 |
| Mu, J | 1 |
| Cong, Z | 1 |
| Fu, D | 1 |
| Celestrin, CP | 1 |
| Rocha, GZ | 1 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 1 |
| Sahebkar, A | 1 |
| Mannarino, MR | 1 |
| Pirro, M | 1 |
| Patsourakos, NG | 1 |
| Kouvari, M | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 1 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Lu, Y | 2 |
| Xi, J | 1 |
| Li, C | 1 |
| Chen, W | 2 |
| Hu, X | 1 |
| Zhang, F | 1 |
| Wei, H | 2 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Yamada, H | 1 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 1 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Zhang, Q | 2 |
| Lyu, Y | 1 |
| Huang, J | 2 |
| Yu, N | 1 |
| Wen, Z | 1 |
| Hou, H | 1 |
| Zhao, T | 1 |
| Gupta, A | 1 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Saini, A | 1 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Brown, D | 2 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 2 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Weber, P | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Singh, M | 2 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 1 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Inoue, T | 1 |
| Soshi, S | 1 |
| Kubota, M | 1 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| Johnson, ML | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 1 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 1 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 2 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 1 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Singh, A | 1 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fang, J | 1 |
| Fan, Y | 1 |
| Luo, T | 2 |
| Su, H | 1 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Sacan, O | 1 |
| Turkyilmaz, IB | 1 |
| Bayrak, BB | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Yanardag, R | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Zheng, J | 2 |
| Guan, H | 1 |
| Tan, H | 1 |
| Maji, TK | 1 |
| J R, A | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Dasgupta, K | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Ray, SK | 1 |
| Karmakar, D | 1 |
| Ma, Y | 2 |
| Gao, W | 2 |
| Ma, S | 2 |
| Lin, W | 1 |
| Zhou, T | 1 |
| Wu, T | 1 |
| Wu, Q | 1 |
| Ye, C | 1 |
| He, X | 1 |
| Jiang, F | 1 |
| Yuan, D | 1 |
| Hong, M | 1 |
| Chen, K | 1 |
| Hussain, M | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jiang, J | 1 |
| Jamil, MI | 1 |
| Zhan, X | 1 |
| Cheng, D | 1 |
| Wu, CT | 1 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 1 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 1 |
| Lang, CC | 1 |
| Wang, XW | 1 |
| Yuan, LJ | 1 |
| Chen, WF | 1 |
| Luo, R | 1 |
| Yang, K | 1 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 1 |
| Pellegrini, M | 1 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 1 |
| Begum, R | 1 |
| Song, H | 2 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 1 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Cui, M | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Gu, L | 1 |
| Cao, X | 1 |
| Mukhtar, A | 1 |
| Wu, K | 1 |
| Zhang, YY | 1 |
| Zhu, Y | 1 |
| Lu, DZ | 1 |
| Dong, W | 1 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Sun, H | 1 |
| Qi, MC | 1 |
| Chang, CC | 1 |
| Dinh, TK | 1 |
| Lee, YA | 1 |
| Wang, FN | 1 |
| Sung, YC | 1 |
| Yu, PL | 1 |
| Chiu, SC | 1 |
| Shih, YC | 1 |
| Wu, CY | 1 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Jiang, X | 2 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Yang, R | 1 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| He, Z | 1 |
| Chen, B | 2 |
| Du, X | 1 |
| Moore, J | 2 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Huang, T | 1 |
| Chen, X | 4 |
| Duong, F | 1 |
| Kong, W | 1 |
| Chang, JH | 2 |
| Sun, J | 2 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Sun, D | 1 |
| Fei, P | 1 |
| Xie, Q | 1 |
| Feng, H | 1 |
| Kang, H | 1 |
| Xing, M | 1 |
| Chen, J | 2 |
| Shao, Z | 1 |
| Yuan, C | 1 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 1 |
| Singh, D | 1 |
| Ward, J | 1 |
| Cooper, A | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Lin, YL | 1 |
| Kuo, YF | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| Li, B | 3 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Xiao, M | 1 |
| Feng, X | 1 |
| Gao, R | 1 |
| Du, B | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 1 |
| Marzo, I | 1 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 1 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Fu, Q | 1 |
| Sarapulova, A | 1 |
| Pang, Q | 1 |
| Meng, Y | 1 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Jeong, SH | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Ning, J | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Gao, Z | 1 |
| Wang, T | 1 |
| Li, Q | 1 |
| Cao, T | 1 |
| Guo, L | 1 |
| Fu, Y | 1 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Chu, CH | 1 |
| Roberts, W | 2 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Luo, L | 1 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Gong, Q | 1 |
| Song, W | 1 |
| Sun, B | 2 |
| Cao, P | 1 |
| Gu, S | 1 |
| Zhou, G | 1 |
| Toma, C | 1 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Cho, J | 2 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Xie, S | 1 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Hao, Y | 1 |
| Chapovetsky, A | 1 |
| Liu, JJ | 1 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Eekers, DBP | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Wesseling, P | 1 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Yang, S | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 2 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 1 |
| Hou, G | 1 |
| Cui, J | 1 |
| Xie, H | 1 |
| Sun, Z | 1 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Kim, MJ | 1 |
| Han, C | 2 |
| White, K | 1 |
| Park, HJ | 2 |
| Ding, D | 1 |
| Boyd, K | 1 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Feng, J | 2 |
| Qian, Y | 1 |
| Cheng, Q | 1 |
| Ren, X | 2 |
| Pan, W | 1 |
| Guo, J | 3 |
| Situ, B | 1 |
| An, T | 1 |
| Zheng, L | 1 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 1 |
| Teixeira, JP | 1 |
| Costa, C | 1 |
| Syed, A | 1 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Ye, J | 1 |
| Liao, W | 1 |
| Zhang, P | 2 |
| Nabi, M | 1 |
| Cai, Y | 1 |
| Li, F | 1 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Beuvon, F | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Volpin, F | 1 |
| Woo, YC | 1 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Chen, C | 6 |
| Zuo, W | 1 |
| Yang, P | 1 |
| Faustino, AC | 1 |
| Viani, GA | 1 |
| Hamamura, AC | 1 |
| Golebiewska, A | 1 |
| Hau, AC | 1 |
| Oudin, A | 1 |
| Stieber, D | 1 |
| Yabo, YA | 1 |
| Baus, V | 1 |
| Barthelemy, V | 1 |
| Klein, E | 1 |
| Bougnaud, S | 1 |
| Keunen, O | 1 |
| Wantz, M | 1 |
| Michelucci, A | 1 |
| Neirinckx, V | 1 |
| Muller, A | 1 |
| Kaoma, T | 1 |
| Nazarov, PV | 1 |
| Azuaje, F | 1 |
| De Falco, A | 1 |
| Flies, B | 1 |
| Richart, L | 1 |
| Poovathingal, S | 1 |
| Arns, T | 1 |
| Grzyb, K | 1 |
| Mock, A | 1 |
| Herold-Mende, C | 1 |
| Steino, A | 1 |
| May, P | 1 |
| Malta, TM | 1 |
| Noushmehr, H | 1 |
| Kwon, YJ | 1 |
| Jahn, W | 1 |
| Klink, B | 1 |
| Tanner, G | 1 |
| Stead, LF | 1 |
| Mittelbronn, M | 1 |
| Skupin, A | 1 |
| Hertel, F | 1 |
| Bjerkvig, R | 1 |
| Niclou, SP | 1 |
| Liang, P | 1 |
| Wang, G | 1 |
| Anselmo, P | 1 |
| Maranzano, E | 2 |
| Selimi, A | 1 |
| Lupattelli, M | 1 |
| Palumbo, I | 1 |
| Bini, V | 1 |
| Casale, M | 1 |
| Trippa, F | 1 |
| Bufi, A | 1 |
| Arcidiacono, F | 1 |
| Aristei, C | 1 |
| Areeb, Z | 1 |
| Stuart, SF | 1 |
| West, AJ | 1 |
| Gomez, J | 1 |
| Nguyen, HPT | 1 |
| Paradiso, L | 1 |
| Zulkifli, A | 1 |
| Jones, J | 1 |
| Luwor, RB | 2 |
| Rauschenbach, L | 1 |
| Wieland, A | 1 |
| Reinartz, R | 1 |
| Kebir, S | 2 |
| Till, A | 1 |
| Darkwah Oppong, M | 1 |
| Dobersalske, C | 1 |
| Ullrich, V | 1 |
| Ahmad, A | 1 |
| Jabbarli, R | 1 |
| Pierscianek, D | 1 |
| Fröhlich, H | 1 |
| Simon, M | 3 |
| Brüstle, O | 1 |
| Sure, U | 1 |
| Scheffler, B | 1 |
| Shoji, T | 1 |
| Kanamori, M | 1 |
| Inoue, J | 1 |
| Saito, R | 1 |
| Osada, Y | 1 |
| Shimoda, Y | 1 |
| Chonan, M | 1 |
| Uenohara, H | 1 |
| Masamune, A | 1 |
| Tominaga, T | 1 |
| Papageorgiou, GI | 1 |
| Tsakatikas, SA | 1 |
| Fioretzaki, RG | 1 |
| Kosmas, C | 1 |
| Biswas, A | 2 |
| Kashyap, L | 1 |
| Bakhshi, S | 1 |
| Nickerson, JP | 1 |
| Sayama, C | 1 |
| Raslan, AM | 1 |
| Ambady, P | 1 |
| Corless, CL | 1 |
| Nazemi, KJ | 1 |
| Adolph, JE | 1 |
| Fleischhack, G | 1 |
| Mikasch, R | 1 |
| Zeller, J | 1 |
| Warmuth-Metz, M | 1 |
| Bison, B | 1 |
| Mynarek, M | 1 |
| Rutkowski, S | 1 |
| Schüller, U | 1 |
| von Hoff, K | 1 |
| Obrecht, D | 1 |
| Pietsch, T | 3 |
| Pfister, SM | 1 |
| Pajtler, KW | 1 |
| Witt, O | 1 |
| Witt, H | 1 |
| Kortmann, RD | 2 |
| Timmermann, B | 1 |
| Krauß, J | 1 |
| Frühwald, MC | 1 |
| Faldum, A | 1 |
| Kwiecien, R | 1 |
| Bode, U | 1 |
| Tippelt, S | 1 |
| Detti, B | 3 |
| Scoccianti, S | 4 |
| Lucidi, S | 1 |
| Maragna, V | 1 |
| Teriaca, MA | 1 |
| Ganovelli, M | 1 |
| Desideri, I | 1 |
| Lorenzetti, V | 1 |
| Scoccimarro, E | 1 |
| Greto, D | 1 |
| Livi, L | 2 |
| Seidlitz, A | 1 |
| Beuthien-Baumann, B | 1 |
| Löck, S | 1 |
| Jentsch, C | 1 |
| Platzek, I | 1 |
| Zöphel, K | 1 |
| Linge, A | 1 |
| Kotzerke, J | 1 |
| Petr, J | 1 |
| van den Hoff, J | 1 |
| Steinbach, J | 1 |
| Schmitz-Schackert, G | 1 |
| Falk, M | 1 |
| Baumann, M | 1 |
| Krause, M | 1 |
| Toor, H | 1 |
| Savla, P | 1 |
| Podkovik, S | 1 |
| Patchana, T | 1 |
| Ghanchi, H | 1 |
| Kashyap, S | 1 |
| Tashjian, V | 1 |
| Miulli, D | 1 |
| Park, YW | 1 |
| Choi, D | 1 |
| Ahn, SS | 1 |
| Kim, SH | 1 |
| Lee, SK | 1 |
| Lambden, JP | 1 |
| Kelsten, MF | 1 |
| Schulte, BC | 1 |
| Abbinanti, S | 1 |
| Hayes, JP | 1 |
| Villaflor, V | 1 |
| Agulnik, M | 1 |
| Twelves, C | 1 |
| Checketts, D | 1 |
| Miller, S | 1 |
| Tayo, B | 1 |
| Jove, M | 1 |
| Brazil, L | 1 |
| Short, SC | 2 |
| Fulbert, C | 1 |
| Chabardès, S | 1 |
| Ratel, D | 1 |
| Yu, Y | 2 |
| Villanueva-Meyer, J | 1 |
| Hilz, S | 1 |
| Solomon, DA | 1 |
| Choi, S | 2 |
| Wahl, M | 2 |
| Mazor, T | 2 |
| Shai, A | 1 |
| Wainer, BH | 1 |
| McDermott, M | 1 |
| Haas-Kogan, D | 1 |
| Taylor, JW | 2 |
| Butowski, N | 3 |
| Clarke, JL | 1 |
| Oberheim Bush, NA | 1 |
| Zhao, W | 1 |
| Jiang, H | 2 |
| Lin, S | 1 |
| Renaud, L | 1 |
| Bossard, JB | 1 |
| Carpentier, B | 1 |
| Terriou, L | 1 |
| Cambier, N | 1 |
| Chanteau, G | 1 |
| Escure, G | 1 |
| Tilmont, R | 1 |
| Barbieux, S | 1 |
| Wemeau, M | 1 |
| Hieulle, J | 1 |
| Boyle, EM | 1 |
| Morschhauser, F | 1 |
| Schou Nørøxe, D | 1 |
| Flynn, A | 1 |
| Westmose Yde, C | 1 |
| Østrup, O | 1 |
| Cilius Nielsen, F | 1 |
| Skjøth-Rasmussen, J | 1 |
| Brennum, J | 1 |
| Hamerlik, P | 1 |
| Weischenfeldt, J | 1 |
| Skovgaard Poulsen, H | 1 |
| Lassen, U | 2 |
| Juric, V | 1 |
| Düssmann, H | 1 |
| Lamfers, MLM | 1 |
| Prehn, JHM | 1 |
| Rehm, M | 1 |
| Murphy, BM | 1 |
| Turcan, S | 1 |
| Ju, HY | 1 |
| Park, M | 1 |
| Lee, JA | 1 |
| Park, SY | 1 |
| Kang, HG | 1 |
| Yang, HC | 1 |
| Park, BK | 1 |
| Liao, KH | 1 |
| Chen, GY | 1 |
| Hung, CY | 1 |
| Liu, S | 2 |
| Shi, W | 3 |
| Zheng, Z | 1 |
| Meng, L | 1 |
| Dong, L | 1 |
| Ozaki, K | 1 |
| Hara, A | 1 |
| Yamaki, T | 1 |
| Matsutani, T | 1 |
| Iwadate, Y | 1 |
| Liu, J | 2 |
| Zhang, C | 1 |
| Shao, Y | 1 |
| Feng, M | 2 |
| Gan, W | 1 |
| Zhou, Y | 1 |
| Lania, A | 1 |
| Ferraù, F | 1 |
| Rubino, M | 1 |
| Modica, R | 1 |
| Colao, A | 1 |
| Faggiano, A | 1 |
| Shi, J | 1 |
| Han, W | 1 |
| Jiang, Q | 1 |
| Cheng, S | 1 |
| Yuan, J | 1 |
| Qian, Z | 2 |
| Dong, J | 1 |
| Holdhoff, M | 1 |
| Ye, X | 4 |
| Supko, JG | 1 |
| Nabors, LB | 3 |
| Desai, AS | 1 |
| Walbert, T | 3 |
| Lesser, GJ | 2 |
| Read, WL | 1 |
| Lieberman, FS | 1 |
| Lodge, MA | 1 |
| Leal, J | 1 |
| Fisher, JD | 1 |
| Desideri, S | 1 |
| Grossman, SA | 4 |
| Wahl, RL | 1 |
| Schiff, D | 4 |
| Kesari, S | 2 |
| Lasolle, H | 1 |
| Cortet, C | 1 |
| Castinetti, F | 2 |
| Cloix, L | 1 |
| Caron, P | 1 |
| Delemer, B | 1 |
| Desailloud, R | 1 |
| Jublanc, C | 1 |
| Lebrun-Frenay, C | 1 |
| Sadoul, JL | 1 |
| Taillandier, L | 2 |
| Batisse-Lignier, M | 1 |
| Bonnet, F | 1 |
| Bourcigaux, N | 1 |
| Bresson, D | 1 |
| Chabre, O | 1 |
| Chanson, P | 1 |
| Garcia, C | 2 |
| Haissaguerre, M | 1 |
| Reznik, Y | 1 |
| Borot, S | 1 |
| Villa, C | 1 |
| Vasiljevic, A | 1 |
| Gaillard, S | 1 |
| Jouanneau, E | 2 |
| Assié, G | 1 |
| Raverot, G | 1 |
| Rapp, M | 1 |
| Baernreuther, J | 1 |
| Turowski, B | 1 |
| Steiger, HJ | 2 |
| Kamp, MA | 1 |
| Alter, RA | 1 |
| White, TG | 1 |
| Fanous, AA | 1 |
| Chakraborty, S | 1 |
| Filippi, CG | 1 |
| Pisapia, DJ | 1 |
| Tsiouris, AJ | 1 |
| Boockvar, JA | 3 |
| Lin, CH | 1 |
| Chuang, JY | 1 |
| Chang, WC | 1 |
| Li, R | 1 |
| Pan, M | 1 |
| Shi, Z | 1 |
| Liu, N | 1 |
| Jahan, N | 1 |
| Lee, JM | 2 |
| Shah, K | 1 |
| Wakimoto, H | 1 |
| Pollom, EL | 1 |
| Fujimoto, D | 1 |
| Wynne, J | 1 |
| Seiger, K | 1 |
| Modlin, LA | 1 |
| Jacobs, LR | 1 |
| Azoulay, M | 1 |
| von Eyben, R | 1 |
| Tupper, L | 1 |
| Gibbs, IC | 1 |
| Hancock, SL | 1 |
| Chang, SD | 1 |
| Adler, JR | 1 |
| Harsh, GR | 1 |
| Harraher, C | 1 |
| Nagpal, S | 1 |
| Thomas, RP | 1 |
| Recht, LD | 1 |
| Choi, CYH | 1 |
| Soltys, SG | 1 |
| Parasramka, S | 1 |
| Talari, G | 1 |
| Rosenfeld, M | 1 |
| Villano, JL | 3 |
| Setty, BA | 1 |
| Stanek, JR | 1 |
| Mascarenhas, L | 2 |
| Miller, A | 1 |
| Bagatell, R | 3 |
| Okcu, F | 1 |
| Nicholls, L | 1 |
| Lysecki, D | 1 |
| Gupta, AA | 1 |
| Magrath, JW | 1 |
| Badruddoja, MA | 1 |
| Pazzi, M | 1 |
| Sanan, A | 1 |
| Schroeder, K | 1 |
| Kuzma, K | 1 |
| Norton, T | 1 |
| Scully, T | 1 |
| Mahadevan, D | 1 |
| Ahmadi, MM | 1 |
| Burri, SH | 1 |
| Gondi, V | 1 |
| Brown, PD | 2 |
| Mehta, MP | 5 |
| Kumar A, A | 1 |
| Abraham Koshy, A | 1 |
| Adhikari, B | 1 |
| Brandel, MG | 1 |
| Futalan, D | 1 |
| Akers, J | 1 |
| Deming, T | 1 |
| Chen, CC | 2 |
| Carter, BS | 1 |
| Micko, ASG | 1 |
| Wöhrer, A | 1 |
| Höftberger, R | 1 |
| Vila, G | 1 |
| Marosi, C | 7 |
| Knosp, E | 1 |
| Wolfsberger, S | 1 |
| Nowosielski, M | 1 |
| Chinot, OL | 3 |
| Garcia, J | 1 |
| Revil, C | 1 |
| Nishikawa, R | 3 |
| Mason, WP | 3 |
| Henriksson, R | 2 |
| Saran, F | 1 |
| Kickingereder, P | 2 |
| Platten, M | 4 |
| Sandmann, T | 1 |
| Abrey, LE | 9 |
| Bendszus, M | 1 |
| Nam, JY | 1 |
| Han, HS | 1 |
| Diéras, V | 1 |
| Robson, M | 1 |
| Palácová, M | 1 |
| Marcom, PK | 1 |
| Jager, A | 1 |
| Bondarenko, I | 1 |
| Citrin, D | 1 |
| Campone, M | 2 |
| Telli, ML | 1 |
| Domchek, SM | 1 |
| Friedlander, M | 1 |
| Kaufman, B | 1 |
| Garber, JE | 1 |
| Shparyk, Y | 1 |
| Chmielowska, E | 1 |
| Jakobsen, EH | 1 |
| Kaklamani, V | 1 |
| Gradishar, W | 1 |
| Ratajczak, CK | 1 |
| Nickner, C | 1 |
| Qin, Q | 1 |
| Shepherd, SP | 1 |
| Isakoff, SJ | 1 |
| Puhalla, S | 1 |
| Xue, Y | 1 |
| Que, S | 2 |
| Lou, M | 2 |
| Lan, J | 2 |
| Zhou, S | 1 |
| Qiu, Y | 1 |
| Lin, Y | 2 |
| Tini, P | 2 |
| Nardone, V | 1 |
| Pastina, P | 1 |
| Battaglia, G | 1 |
| Miracco, C | 2 |
| Carbone, SF | 1 |
| Sebaste, L | 1 |
| Rubino, G | 1 |
| Cerase, A | 1 |
| Pirtoli, L | 2 |
| Scannell Bryan, M | 1 |
| Blumenthal, DT | 3 |
| Valeinis, E | 1 |
| Hopkins, K | 1 |
| Souhami, L | 3 |
| Andrews, DW | 2 |
| Tzuk-Shina, T | 1 |
| Howard, SP | 1 |
| Youssef, EF | 1 |
| Lessard, N | 1 |
| Dignam, JJ | 1 |
| Werner-Wasik, M | 2 |
| Roussakow, SV | 1 |
| Roux, A | 1 |
| Caire, F | 1 |
| Guyotat, J | 5 |
| Menei, P | 1 |
| Metellus, P | 2 |
| Pallud, J | 2 |
| Bilbao, I | 1 |
| Egaña, N | 1 |
| Olaizola, I | 1 |
| Peters, KB | 4 |
| Lipp, ES | 2 |
| Miller, E | 1 |
| Herndon, JE | 9 |
| McSherry, F | 1 |
| Desjardins, A | 11 |
| Fujiwara, Y | 1 |
| Manabe, H | 1 |
| Izumi, B | 1 |
| Shima, T | 1 |
| Adachi, N | 1 |
| Tutt, A | 1 |
| Jackson, S | 1 |
| Weingart, J | 1 |
| Nduom, EK | 1 |
| Harfi, TT | 1 |
| George, RT | 1 |
| McAreavey, D | 1 |
| Anders, NM | 1 |
| Peer, C | 1 |
| Figg, WD | 1 |
| Gilbert, M | 1 |
| Rudek, MA | 1 |
| Cohen, RJ | 1 |
| Akiyama, Y | 1 |
| Kimura, Y | 1 |
| Enatsu, R | 1 |
| Mikami, T | 1 |
| Wanibuchi, M | 1 |
| Mikuni, N | 1 |
| Feng, F | 1 |
| Ji, P | 1 |
| Ge, S | 1 |
| Yang, C | 1 |
| Gao, G | 1 |
| Franceschi, E | 8 |
| Lamberti, G | 2 |
| Visani, M | 1 |
| Paccapelo, A | 3 |
| Mura, A | 1 |
| Tallini, G | 2 |
| Pession, A | 3 |
| De Biase, D | 2 |
| Minichillo, S | 1 |
| Tosoni, A | 9 |
| Di Battista, M | 1 |
| Cubeddu, A | 1 |
| Bartolini, S | 2 |
| Jiang, C | 1 |
| Junold, N | 1 |
| Hattingen, E | 1 |
| Schäfer, N | 1 |
| Niessen, M | 1 |
| Mack, F | 1 |
| Stuplich, M | 1 |
| Tzaridis, T | 1 |
| Schmidt-Graf, F | 1 |
| Rohde, V | 2 |
| Braun, C | 1 |
| Hänel, M | 1 |
| Gerlach, R | 1 |
| Belka, C | 3 |
| Proescholdt, M | 1 |
| Lukács, G | 1 |
| Tóth, Z | 1 |
| Sipos, D | 1 |
| Csima, M | 1 |
| Hadjiev, J | 1 |
| Bajzik, G | 1 |
| Cselik, Z | 1 |
| Semjén, D | 1 |
| Repa, I | 1 |
| Kovács, Á | 1 |
| Hersh, DS | 1 |
| Harder, BG | 1 |
| Roos, A | 1 |
| Peng, S | 1 |
| Heath, JE | 1 |
| Legesse, T | 1 |
| Kim, AJ | 1 |
| Woodworth, GF | 1 |
| Tran, NL | 1 |
| Winkles, JA | 1 |
| Mardaleishvili, K | 1 |
| Orkodashvili, G | 1 |
| de Lemos, ML | 1 |
| Kang, I | 1 |
| Schaff, K | 1 |
| Liu, F | 1 |
| Marinelli, A | 1 |
| Cerbone, L | 1 |
| Cordua, N | 1 |
| Buonerba, C | 1 |
| Peluso, G | 1 |
| Di Lorenzo, G | 1 |
| De Placido, S | 1 |
| Gan, HK | 2 |
| Kumthekar, P | 1 |
| Lwin, Z | 2 |
| Papadopoulos, KP | 1 |
| Penas-Prado, M | 1 |
| Simes, J | 2 |
| Wheeler, H | 5 |
| Scott, AM | 1 |
| Gomez, E | 1 |
| Roberts-Rapp, L | 1 |
| Xiong, H | 1 |
| Ansell, PJ | 1 |
| Bain, E | 1 |
| Holen, KD | 1 |
| Maag, D | 1 |
| Merrell, R | 1 |
| Wong, ET | 5 |
| Lok, E | 2 |
| Swanson, KD | 2 |
| Barkhoudarian, G | 1 |
| Palejwala, SK | 1 |
| Ogunbameru, R | 1 |
| Eisenberg, A | 1 |
| Kelly, DF | 1 |
| Li, N | 1 |
| Kiang, KMY | 1 |
| Cheng, YS | 1 |
| Leung, GKK | 1 |
| Büyükkapu Bay, S | 1 |
| Kebudi, R | 1 |
| Görgün, O | 1 |
| Zülfikar, B | 1 |
| Darendeliler, E | 1 |
| Çakır, FB | 1 |
| Gempt, J | 1 |
| Meyer, B | 1 |
| Klein, M | 2 |
| Smits, M | 1 |
| Reijneveld, JC | 3 |
| Clement, P | 1 |
| de Vos, FYF | 1 |
| Mulholland, PJ | 1 |
| Taphoorn, MJB | 1 |
| Lewis, J | 1 |
| de Heer, I | 1 |
| Verschuere, T | 1 |
| Coens, C | 1 |
| Idbaih, A | 2 |
| Garcia, CR | 1 |
| Slone, SA | 1 |
| Morgan, RM | 1 |
| Gruber, L | 1 |
| Kumar, SS | 1 |
| Lightner, DD | 1 |
| Khan, UA | 1 |
| Rennert, RC | 1 |
| White, NS | 1 |
| Bartsch, H | 1 |
| Farid, N | 1 |
| Dale, AM | 1 |
| Debus, C | 1 |
| Afshar-Oromieh, A | 1 |
| Floca, R | 1 |
| Ingrisch, M | 1 |
| Knoll, M | 1 |
| Debus, J | 3 |
| Haberkorn, U | 1 |
| Abdollahi, A | 1 |
| Ameratunga, M | 1 |
| Pavlakis, N | 2 |
| Grant, R | 4 |
| Navarria, P | 1 |
| Minniti, G | 4 |
| Clerici, E | 1 |
| Tomatis, S | 1 |
| Pinzi, V | 1 |
| Ciammella, P | 1 |
| Galaverni, M | 1 |
| Amelio, D | 2 |
| Scartoni, D | 1 |
| Krengli, M | 1 |
| Masini, L | 1 |
| Draghini, L | 1 |
| Borzillo, V | 1 |
| Muto, P | 1 |
| Ferrarese, F | 1 |
| Fariselli, L | 2 |
| Pasqualetti, F | 2 |
| Fiorentino, A | 2 |
| Alongi, F | 1 |
| di Monale, MB | 1 |
| Magrini, S | 1 |
| Scorsetti, M | 1 |
| Nazha, B | 1 |
| Owonikoko, TK | 1 |
| Atkins, RJ | 1 |
| Kurganovs, N | 1 |
| Mangiola, S | 1 |
| Nowell, CJ | 1 |
| Ware, TM | 1 |
| Corcoran, NM | 1 |
| Brown, DV | 1 |
| Morokoff, A | 1 |
| Hovens, CM | 1 |
| Schwartz, S | 1 |
| Szeto, C | 1 |
| Tian, Y | 1 |
| Cecchi, F | 1 |
| Corallo, S | 1 |
| Calegari, MA | 1 |
| Di Bartolomeo, M | 1 |
| Morano, F | 1 |
| Raimondi, A | 1 |
| Fucà, G | 1 |
| Martinetti, A | 1 |
| De Pascalis, I | 1 |
| Martini, M | 1 |
| Belfiore, A | 1 |
| Milione, M | 1 |
| Orlandi, A | 1 |
| Barault, L | 1 |
| Barone, C | 1 |
| de Braud, F | 1 |
| Di Nicolantonio, F | 1 |
| Benz, S | 1 |
| Hembrough, T | 1 |
| Pietrantonio, F | 1 |
| Jia, B | 1 |
| Gu, J | 1 |
| Lv, W | 1 |
| Hao, Q | 1 |
| Pang, Z | 1 |
| Mu, N | 1 |
| Guo, Q | 1 |
| Sachkova, A | 1 |
| Sperling, S | 1 |
| Mielke, D | 1 |
| Schatlo, B | 1 |
| Ninkovic, M | 1 |
| Qie, S | 1 |
| Yuan, L | 1 |
| Shi, HY | 1 |
| Wen, X | 1 |
| Carter, TC | 1 |
| Medina-Flores, R | 1 |
| Lawler, BE | 1 |
| Storey, K | 1 |
| Leder, K | 1 |
| Hawkins-Daarud, A | 1 |
| Swanson, K | 1 |
| Ahmed, AU | 2 |
| Rockne, RC | 1 |
| Foo, J | 1 |
| Chaudhary, R | 1 |
| Cohen, AL | 1 |
| Fink, K | 2 |
| Goldlust, S | 1 |
| Boockvar, J | 1 |
| Chinnaiyan, P | 1 |
| Marcus, S | 1 |
| Campian, JL | 1 |
| Laprie, A | 1 |
| Ken, S | 1 |
| Filleron, T | 1 |
| Lubrano, V | 1 |
| Vieillevigne, L | 1 |
| Tensaouti, F | 1 |
| Catalaa, I | 1 |
| Boetto, S | 1 |
| Khalifa, J | 1 |
| Attal, J | 1 |
| Peyraga, G | 1 |
| Gomez-Roca, C | 1 |
| Uro-Coste, E | 1 |
| Noel, G | 2 |
| Truc, G | 1 |
| Sunyach, MP | 2 |
| Magné, N | 2 |
| Charissoux, M | 1 |
| Supiot, S | 1 |
| Bernier, V | 2 |
| Mounier, M | 1 |
| Poublanc, M | 1 |
| Fabre, A | 1 |
| Delord, JP | 1 |
| Cohen-Jonathan Moyal, E | 1 |
| Winter, SF | 1 |
| Loebel, F | 1 |
| Loeffler, J | 1 |
| Batchelor, TT | 5 |
| Martinez-Lage, M | 1 |
| Hasan, T | 1 |
| Caragher, SP | 1 |
| Shireman, JM | 1 |
| Park, CH | 1 |
| Atashi, F | 1 |
| Baisiwala, S | 1 |
| Lee, G | 1 |
| Guo, D | 1 |
| Wang, JY | 1 |
| Dey, M | 1 |
| Lesniak, MS | 1 |
| Horbinski, CM | 1 |
| James, CD | 1 |
| Bureta, C | 1 |
| Saitoh, Y | 1 |
| Tokumoto, H | 1 |
| Sasaki, H | 2 |
| Maeda, S | 1 |
| Nagano, S | 1 |
| Komiya, S | 1 |
| Taniguchi, N | 1 |
| Setoguchi, T | 1 |
| Back, M | 1 |
| Jayamanne, D | 1 |
| Brazier, D | 1 |
| Newey, A | 1 |
| Bailey, D | 1 |
| Schembri, G | 1 |
| Hsiao, E | 1 |
| Wong, M | 1 |
| Kastelan, M | 1 |
| Brown, C | 1 |
| Carabenciov, ID | 1 |
| Bhargav, AG | 1 |
| Uhm, JH | 1 |
| Ruff, MW | 1 |
| Yamamoto, M | 2 |
| Morita, M | 1 |
| Takeno, A | 1 |
| Kanazawa, I | 1 |
| Yamaguchi, T | 1 |
| Yamada, S | 1 |
| Inoshita, N | 1 |
| Oki, Y | 1 |
| Kurosaki, M | 1 |
| Sugimoto, T | 1 |
| Jablonska, PA | 1 |
| Diez-Valle, R | 2 |
| Pérez-Larraya, JG | 1 |
| Moreno-Jiménez, M | 1 |
| Idoate, MÁ | 1 |
| Arbea, L | 1 |
| Tejada, S | 2 |
| Garcia de Eulate, MR | 1 |
| Ramos, L | 1 |
| Arbizu, J | 1 |
| Domínguez, P | 1 |
| Aristu, JJ | 1 |
| Bozzato, E | 1 |
| Joudiou, N | 1 |
| Ghiassinejad, S | 1 |
| Danhier, F | 1 |
| Gallez, B | 1 |
| Préat, V | 1 |
| Whitelaw, BC | 1 |
| Fleischmann, DF | 1 |
| Unterrainer, M | 1 |
| Corradini, S | 1 |
| Rottler, M | 1 |
| Förster, S | 1 |
| la Fougère, C | 2 |
| Siepmann, T | 1 |
| Schwaiger, M | 2 |
| Bartenstein, P | 1 |
| Albert, NL | 1 |
| Niyazi, M | 2 |
| Jastaniyah, N | 1 |
| Murtha, A | 1 |
| Pervez, N | 1 |
| Le, D | 1 |
| Roa, W | 1 |
| Patel, S | 2 |
| Mackenzie, M | 1 |
| Fulton, D | 1 |
| Field, C | 1 |
| Ghosh, S | 1 |
| Fallone, G | 1 |
| Abdulkarim, B | 2 |
| Sun, S | 1 |
| Lee, D | 1 |
| Ho, AS | 1 |
| Pu, JK | 1 |
| Zhang, XQ | 1 |
| Lee, NP | 1 |
| Day, PJ | 1 |
| Lui, WM | 1 |
| Fung, CF | 1 |
| Leung, GK | 1 |
| Furuta, T | 1 |
| Nakada, M | 1 |
| Misaki, K | 1 |
| Hayashi, Y | 1 |
| Nakanuma, Y | 1 |
| Hamada, J | 1 |
| Yeo, KK | 1 |
| Puscasiu, E | 1 |
| Keating, RF | 1 |
| Rood, BR | 1 |
| Kruser, TJ | 1 |
| Robins, HI | 2 |
| Norden, AD | 1 |
| Drappatz, J | 2 |
| Ligon, KL | 2 |
| Hammond, SN | 1 |
| Lee, EQ | 1 |
| Reardon, DR | 1 |
| Fadul, CE | 1 |
| Beroukhim, R | 1 |
| Muzikansky, A | 1 |
| Doherty, L | 1 |
| Lafrankie, D | 1 |
| Smith, K | 1 |
| Tafoya, V | 1 |
| Lis, R | 1 |
| Stack, EC | 1 |
| Rosenfeld, MR | 1 |
| Yang, XJ | 1 |
| Yang, SY | 1 |
| Kast, RE | 2 |
| Brüning, A | 1 |
| Cappello, F | 1 |
| Chang, WW | 1 |
| Cvek, B | 1 |
| Dou, QP | 1 |
| Duenas-Gonzalez, A | 1 |
| Efferth, T | 1 |
| Focosi, D | 1 |
| Ghaffari, SH | 1 |
| Karpel-Massler, G | 2 |
| Ketola, K | 1 |
| Khoshnevisan, A | 1 |
| Keizman, D | 1 |
| McDonald, K | 1 |
| Muñoz, M | 1 |
| Paranjpe, A | 1 |
| Pourgholami, MH | 1 |
| Sardi, I | 2 |
| Sella, A | 1 |
| Srivenugopal, KS | 1 |
| Tuccori, M | 1 |
| Wirtz, CR | 2 |
| Halatsch, ME | 2 |
| Massimino, M | 4 |
| Casanova, M | 2 |
| Polastri, D | 1 |
| Biassoni, V | 1 |
| Modena, P | 1 |
| Pecori, E | 1 |
| Schiavello, E | 1 |
| De Pava, MV | 1 |
| Indini, A | 1 |
| Rampini, P | 2 |
| Bauer, D | 1 |
| Catania, S | 1 |
| Podda, M | 1 |
| Gandola, L | 1 |
| Alexander, BM | 1 |
| Shields, LB | 1 |
| Kadner, R | 1 |
| Vitaz, TW | 1 |
| Spalding, AC | 1 |
| Wagner, L | 2 |
| Turpin, B | 1 |
| Nagarajan, R | 1 |
| Weiss, B | 1 |
| Cripe, T | 1 |
| Geller, J | 1 |
| Hart, MG | 2 |
| Garside, R | 2 |
| Rogers, G | 2 |
| Stein, K | 2 |
| Ratai, EM | 1 |
| Snyder, BS | 2 |
| Boxerman, JL | 2 |
| Safriel, Y | 2 |
| McKinstry, RC | 1 |
| Bokstein, F | 1 |
| Sorensen, AG | 2 |
| Barboriak, DP | 2 |
| Ruggiero, A | 5 |
| Rizzo, D | 3 |
| Attinà, G | 3 |
| Lazzareschi, I | 4 |
| Maurizi, P | 3 |
| Ridola, V | 4 |
| Mastrangelo, S | 2 |
| Migliorati, R | 2 |
| Bertolini, P | 2 |
| Colosimo, C | 4 |
| Riccardi, R | 6 |
| Dielemans, JC | 1 |
| van Breemen, MS | 1 |
| Zwinkels, H | 1 |
| Walchenbach, R | 1 |
| Taphoorn, MJ | 7 |
| Vecht, CJ | 2 |
| Larvie, M | 2 |
| Jain, R | 1 |
| Chi, TL | 1 |
| Lolli, I | 2 |
| Morra, I | 1 |
| Cimmino, A | 1 |
| Trevisan, E | 1 |
| Rudà, R | 3 |
| Piombino, M | 1 |
| Campanella, G | 1 |
| Gillio Tos, A | 1 |
| De Marco, L | 1 |
| Trevisan, M | 2 |
| Fiano, V | 2 |
| Soffietti, R | 3 |
| Penas, C | 1 |
| Pastori, C | 1 |
| Komotar, RJ | 1 |
| Bregy, A | 1 |
| Shah, AH | 1 |
| Wahlestedt, C | 1 |
| Ayad, NG | 1 |
| Lian, B | 1 |
| Si, L | 1 |
| Cui, C | 1 |
| Chi, Z | 1 |
| Sheng, X | 1 |
| Mao, L | 1 |
| Kong, Y | 1 |
| Tang, B | 1 |
| Blume, C | 1 |
| von Lehe, M | 1 |
| van Landeghem, F | 1 |
| Greschus, S | 1 |
| Boström, J | 1 |
| DI Cristofori, A | 1 |
| Carrabba, G | 1 |
| Lanfranchi, G | 1 |
| Menghetti, C | 1 |
| Caroli, M | 2 |
| Ho, J | 1 |
| Ondos, J | 1 |
| Ning, H | 1 |
| Smith, S | 1 |
| Kreisl, T | 1 |
| Iwamoto, F | 1 |
| Sul, J | 2 |
| Kim, L | 1 |
| McNeil, K | 1 |
| Krauze, A | 1 |
| Shankavaram, U | 1 |
| Fine, HA | 2 |
| Camphausen, K | 2 |
| Tsen, AR | 1 |
| Long, PM | 1 |
| Driscoll, HE | 1 |
| Davies, MT | 1 |
| Teasdale, BA | 1 |
| Penar, PL | 1 |
| Pendlebury, WW | 1 |
| Spees, JL | 1 |
| Lawler, SE | 1 |
| Viapiano, MS | 1 |
| Jaworski, DM | 1 |
| Di Giannatale, A | 1 |
| Dias-Gastellier, N | 1 |
| Devos, A | 1 |
| Mc Hugh, K | 1 |
| Boubaker, A | 1 |
| Courbon, F | 1 |
| Verschuur, A | 1 |
| Ducassoul, S | 1 |
| Malekzadeh, K | 1 |
| Amoroso, L | 2 |
| Chastagner, P | 3 |
| Zwaan, CM | 1 |
| Munzer, C | 1 |
| Aerts, I | 2 |
| Landman-Parker, J | 2 |
| Le Deley, MC | 3 |
| Geoerger, B | 4 |
| Rubie, H | 4 |
| Venkatramani, R | 1 |
| Malogolowkin, MH | 1 |
| Bazan, F | 1 |
| Vollmer, I | 1 |
| Gayete, A | 1 |
| Aldave, G | 1 |
| Marigil, M | 1 |
| Gállego Pérez-Larraya, J | 1 |
| de Gallego, J | 1 |
| Domínguez, PD | 1 |
| Murata, D | 1 |
| Fujimoto, K | 1 |
| Kikuchi, T | 1 |
| Kunieda, T | 1 |
| Takahashi, JC | 1 |
| Takagi, Y | 1 |
| Miyamoto, S | 2 |
| Norris, R | 1 |
| Ingle, AM | 4 |
| Ahern, C | 1 |
| Voss, S | 1 |
| Fox, E | 2 |
| Little, AR | 1 |
| Weigel, BJ | 1 |
| Adamson, PC | 4 |
| Blaney, S | 1 |
| Shinsato, Y | 1 |
| Furukawa, T | 1 |
| Yunoue, S | 1 |
| Yonezawa, H | 1 |
| Minami, K | 1 |
| Nishizawa, Y | 1 |
| Ikeda, R | 1 |
| Kawahara, K | 1 |
| Hirano, H | 1 |
| Tokimura, H | 1 |
| Arita, K | 1 |
| Samis Zella, MA | 1 |
| Wallocha, M | 1 |
| Slotty, PJ | 1 |
| Isik, G | 1 |
| Hänggi, D | 1 |
| Schroeteler, J | 1 |
| Ewelt, C | 1 |
| Reynés, G | 4 |
| Gallego, O | 4 |
| Iglesias, L | 1 |
| Pérez, P | 1 |
| García, JL | 1 |
| Johnson, BE | 1 |
| Barnes, M | 1 |
| Aihara, K | 1 |
| McLean, CY | 1 |
| Fouse, SD | 1 |
| Yamamoto, S | 1 |
| Ueda, H | 1 |
| Tatsuno, K | 1 |
| Asthana, S | 1 |
| Jalbert, LE | 1 |
| Nelson, SJ | 1 |
| Bollen, AW | 1 |
| Gustafson, WC | 1 |
| Charron, E | 1 |
| Weiss, WA | 1 |
| Smirnov, IV | 1 |
| Song, JS | 1 |
| Olshen, AB | 1 |
| Cha, S | 1 |
| Moore, RA | 1 |
| Mungall, AJ | 1 |
| Jones, SJM | 1 |
| Hirst, M | 1 |
| Marra, MA | 1 |
| Aburatani, H | 1 |
| Mukasa, A | 1 |
| Taylor, BS | 1 |
| Sha, SJ | 1 |
| Wu, HP | 1 |
| Chen, HJ | 1 |
| Huang, PH | 1 |
| Huang, SH | 1 |
| Hsu, CT | 1 |
| Eisele, G | 2 |
| Eisele, AC | 1 |
| Clément, PM | 3 |
| Tonn, J | 1 |
| Ochsenbein, A | 1 |
| Neyns, B | 6 |
| Nikkhah, G | 2 |
| Picard, M | 2 |
| Stupp, R | 12 |
| Donovan, P | 1 |
| Cato, K | 1 |
| Legaie, R | 1 |
| Jayalath, R | 1 |
| Olsson, G | 1 |
| Hall, B | 1 |
| Olson, S | 1 |
| Boros, S | 1 |
| Reynolds, BA | 1 |
| Harding, A | 1 |
| Magnuson, W | 1 |
| Ian Robins, H | 1 |
| Mohindra, P | 1 |
| Howard, S | 1 |
| McNamara, MG | 1 |
| Templeton, AJ | 1 |
| Zadeh, G | 1 |
| Bernstein, M | 2 |
| Chung, C | 1 |
| Millar, BA | 1 |
| Laperriere, N | 1 |
| Cefalo, G | 2 |
| Barone, G | 2 |
| Spreafico, F | 1 |
| Potepan, P | 1 |
| Abate, ME | 2 |
| Mascarin, M | 1 |
| Garrè, ML | 2 |
| Perilongo, G | 1 |
| Madon, E | 2 |
| Ogura, K | 1 |
| Ogura, M | 1 |
| Sakanaka, K | 1 |
| Hiraoka, M | 1 |
| Badaoui, N | 1 |
| Meyronet, D | 1 |
| Cartalat-Carel, S | 4 |
| d'Hombres, A | 1 |
| Jouvet, A | 1 |
| Louis-Tisserand, G | 1 |
| Archinet, A | 1 |
| Frappaz, D | 5 |
| Bauchet, L | 2 |
| Honnorat, J | 4 |
| Ducray, F | 4 |
| Anai, S | 1 |
| Hide, T | 1 |
| Takezaki, T | 1 |
| Kuroda, J | 1 |
| Shinojima, N | 1 |
| Makino, K | 2 |
| Nakamura, H | 2 |
| Yano, S | 1 |
| Kuratsu, J | 2 |
| Wang, ZJ | 1 |
| Altonok, D | 1 |
| Sood, S | 1 |
| Konski, A | 1 |
| Poulik, J | 1 |
| Kim, SS | 1 |
| Rait, A | 1 |
| Pirollo, KF | 1 |
| Nishida, M | 1 |
| Farkas, N | 1 |
| Dagata, JA | 1 |
| Chang, EH | 1 |
| Turner, SG | 1 |
| Gergel, T | 1 |
| Wu, H | 1 |
| Lacroix, M | 1 |
| Toms, SA | 1 |
| Gebhardt, BJ | 1 |
| Dobelbower, MC | 2 |
| Ennis, WH | 1 |
| Bag, AK | 1 |
| Markert, JM | 2 |
| Fiveash, JB | 2 |
| Gaspar, LE | 5 |
| Kavanagh, BD | 5 |
| Muruganandham, M | 1 |
| Clerkin, PP | 1 |
| Smith, BJ | 1 |
| Anderson, CM | 1 |
| Morris, A | 1 |
| Capizzano, AA | 1 |
| Magnotta, V | 1 |
| McGuire, SM | 1 |
| Smith, MC | 1 |
| Bayouth, JE | 1 |
| Buatti, JM | 1 |
| Nanegrungsunk, D | 1 |
| Onchan, W | 1 |
| Chattipakorn, N | 1 |
| Chattipakorn, SC | 1 |
| Koekkoek, JA | 1 |
| Dirven, L | 1 |
| Heimans, JJ | 4 |
| Postma, TJ | 4 |
| Vos, MJ | 3 |
| Reyes-Botero, G | 1 |
| Laigle-Donadey, F | 3 |
| Mokhtari, K | 2 |
| Martin-Duverneuil, N | 1 |
| Delattre, JY | 3 |
| Hamisch, C | 1 |
| Suchorska, B | 1 |
| Galldiks, N | 2 |
| Visser-Vandewalle, V | 1 |
| Kocher, M | 2 |
| Treuer, H | 1 |
| Voges, J | 1 |
| Ruge, MI | 1 |
| Diebold, G | 2 |
| Henaine, AM | 2 |
| Breant, V | 1 |
| Fouquet, A | 1 |
| Aulagner, G | 2 |
| Armoiry, X | 2 |
| Zauderer, MG | 1 |
| Drilon, A | 1 |
| Kadota, K | 1 |
| Huberman, K | 1 |
| Sima, CS | 1 |
| Bergagnini, I | 1 |
| Sumner, DK | 1 |
| Travis, WD | 1 |
| Heguy, A | 2 |
| Ginsberg, MS | 1 |
| Holodny, AI | 1 |
| Riely, GJ | 1 |
| Kris, MG | 1 |
| Krug, LM | 1 |
| Pietanza, MC | 1 |
| Adeberg, S | 1 |
| König, L | 1 |
| Bostel, T | 1 |
| Harrabi, S | 1 |
| Welzel, T | 2 |
| Combs, SE | 2 |
| Ameratunga, MS | 1 |
| Woo, SR | 1 |
| Ham, Y | 1 |
| Kang, W | 1 |
| Kim, S | 1 |
| Jin, J | 1 |
| Joo, KM | 2 |
| Ramirez, YP | 1 |
| Mladek, AC | 1 |
| Phillips, RM | 1 |
| Gynther, M | 1 |
| Rautio, J | 1 |
| Ross, AH | 3 |
| Wheelhouse, RT | 1 |
| Sakaria, JN | 1 |
| Hunn, MK | 1 |
| Bauer, E | 1 |
| Wood, CE | 1 |
| Gasser, O | 1 |
| Dzhelali, M | 1 |
| Ancelet, LR | 1 |
| Mester, B | 1 |
| Sharples, KJ | 1 |
| Findlay, MP | 1 |
| Hamilton, DA | 1 |
| Hermans, IF | 1 |
| Zhang, RR | 1 |
| Pointer, KB | 1 |
| Kuo, JS | 1 |
| Dempsey, RJ | 1 |
| Hirohata, T | 1 |
| Ishii, Y | 1 |
| Matsuno, A | 2 |
| Roos, WP | 1 |
| Quiros, S | 1 |
| Krumm, A | 1 |
| Merz, S | 1 |
| Switzeny, OJ | 1 |
| Loquai, C | 1 |
| Chamberlain, MC | 10 |
| Prager, AJ | 1 |
| Martinez, N | 1 |
| Beal, K | 1 |
| Young, RJ | 2 |
| Kim, HR | 2 |
| Kim, KH | 1 |
| Kong, DS | 5 |
| Seol, HJ | 3 |
| Lim, DH | 2 |
| Lee, JI | 5 |
| Strowd, RE | 3 |
| Salvatori, R | 1 |
| Laterra, JJ | 1 |
| Kästner, B | 1 |
| Felsberg, J | 3 |
| Sabel, MC | 2 |
| Wirsching, HG | 1 |
| Ketter, R | 1 |
| Tonn, JC | 4 |
| Homicsko, K | 1 |
| Pichler, J | 4 |
| Meixensberger, J | 1 |
| Kollias, S | 1 |
| Hüsing, J | 1 |
| Reifenberger, G | 3 |
| Favero, F | 1 |
| McGranahan, N | 1 |
| Salm, M | 1 |
| Birkbak, NJ | 1 |
| Sanborn, JZ | 1 |
| Benz, SC | 1 |
| Becq, J | 1 |
| Peden, JF | 1 |
| Kingsbury, Z | 1 |
| Grocok, RJ | 1 |
| Humphray, S | 1 |
| Bentley, D | 1 |
| Spencer-Dene, B | 1 |
| Gutteridge, A | 1 |
| Brada, M | 5 |
| Roger, S | 1 |
| Dietrich, PY | 3 |
| Forshew, T | 1 |
| Gerlinger, M | 1 |
| Rowan, A | 1 |
| Stamp, G | 1 |
| Eklund, AC | 1 |
| Szallasi, Z | 1 |
| Swanton, C | 1 |
| Ampie, L | 1 |
| Kusne, Y | 1 |
| Sanai, N | 1 |
| Liu, JK | 1 |
| Patel, J | 1 |
| Eloy, JA | 1 |
| Kazda, T | 2 |
| Pospisil, P | 1 |
| Vrzal, M | 1 |
| Sevela, O | 1 |
| Prochazka, T | 1 |
| Jancalek, R | 2 |
| Slampa, P | 2 |
| Laack, NN | 1 |
| Hattermann, K | 2 |
| Mehdorn, HM | 2 |
| Tabouret, E | 2 |
| Tchoghandjian, A | 1 |
| Denicolai, E | 2 |
| Delfino, C | 2 |
| Graillon, T | 2 |
| Boucard, C | 2 |
| Nanni, I | 2 |
| Padovani, L | 2 |
| Ouafik, L | 1 |
| Figarella-Branger, D | 3 |
| Chinot, O | 4 |
| Nayak, L | 1 |
| Panageas, KS | 2 |
| Reiner, AS | 2 |
| Huse, JT | 2 |
| Pentsova, E | 1 |
| Braunthal, SG | 1 |
| DeAngelis, LM | 5 |
| Belda-Iniesta, C | 1 |
| Gil-Gil, M | 2 |
| Pérez-Segura, P | 3 |
| Berrocal, A | 1 |
| Capellades, J | 1 |
| Ordoñez, JM | 1 |
| La Orden, B | 1 |
| Vanaclocha, V | 1 |
| Sureda, M | 1 |
| Azinovic, I | 1 |
| Rebollo, J | 1 |
| Cañón, R | 1 |
| Sapena, NS | 1 |
| Cases, FG | 1 |
| Brugarolas, A | 1 |
| Choi, YR | 1 |
| Miglio, U | 1 |
| Mezzapelle, R | 1 |
| Paganotti, A | 1 |
| Veggiani, C | 1 |
| Mercalli, F | 1 |
| Mancuso, G | 1 |
| Gaudino, E | 1 |
| Rena, O | 1 |
| Buosi, R | 1 |
| Boldorini, R | 1 |
| Mitchell, D | 1 |
| Bergendahl, G | 1 |
| Ferguson, W | 1 |
| Higgins, T | 1 |
| Ashikaga, T | 1 |
| DeSarno, M | 1 |
| Kaplan, J | 1 |
| Kraveka, J | 1 |
| Eslin, D | 1 |
| Werff, AV | 1 |
| Hanna, GK | 1 |
| Sholler, GL | 1 |
| Giridhar, P | 1 |
| Mallick, S | 1 |
| Haresh, KP | 1 |
| Gupta, S | 1 |
| Julka, PK | 1 |
| Rath, GK | 1 |
| Thomas, AA | 1 |
| Arevalo-Perez, J | 1 |
| Kaley, T | 1 |
| Lyo, J | 1 |
| Peck, KK | 1 |
| Bosa, C | 1 |
| Magistrello, M | 1 |
| Franchino, F | 1 |
| Pellerino, A | 2 |
| Cassoni, P | 1 |
| Wei, W | 1 |
| Ma, X | 1 |
| Guo, Z | 1 |
| Lee, IH | 2 |
| Park, CK | 3 |
| Jung, YS | 1 |
| Nam, SH | 1 |
| Kim, BS | 1 |
| Johnson, MD | 1 |
| Yoon, Y | 1 |
| Park, WY | 2 |
| Lee, J | 1 |
| Park, PJ | 1 |
| Duerinck, J | 1 |
| Du Four, S | 1 |
| Sander, W | 1 |
| Van Binst, AM | 1 |
| Everaert, H | 2 |
| Michotte, A | 3 |
| Alshami, J | 1 |
| Guiot, MC | 2 |
| Owen, S | 1 |
| Kavan, P | 1 |
| Gibson, N | 1 |
| Solca, F | 1 |
| Cseh, A | 1 |
| Muanza, T | 1 |
| Bulik, M | 1 |
| Ellsworth, S | 1 |
| Martínez-Sales, V | 1 |
| Vila, V | 1 |
| Vaz, MA | 1 |
| Benavides, M | 2 |
| Palomero, I | 1 |
| Fleitas, T | 1 |
| Reche, E | 1 |
| Bogazzi, F | 1 |
| Cannavo, S | 1 |
| Curtò, L | 1 |
| De Marinis, L | 1 |
| Iacovazzo, D | 1 |
| Mantovani, G | 1 |
| Nizzoli, M | 1 |
| Reni, M | 6 |
| Ortega, A | 1 |
| Sarmiento, JM | 1 |
| Ly, D | 1 |
| Nuño, M | 1 |
| Mukherjee, D | 1 |
| Black, KL | 1 |
| Patil, CG | 1 |
| Abuali, I | 1 |
| Paubel, N | 1 |
| Hartmann, D | 1 |
| Redjal, N | 1 |
| Reinshagen, C | 1 |
| Le, A | 1 |
| Walcott, BP | 1 |
| McDonnell, E | 1 |
| Nahed, BV | 1 |
| DuBois, SG | 1 |
| Marachelian, A | 1 |
| Kudgus, RA | 1 |
| Reid, JM | 3 |
| Groshen, S | 3 |
| Malvar, J | 1 |
| Maris, JM | 1 |
| Hawkins, R | 1 |
| Courtier, J | 1 |
| Lai, H | 1 |
| Goodarzian, F | 1 |
| Shimada, H | 1 |
| Czarnecki, S | 1 |
| Tsao-Wei, D | 1 |
| Matthay, KK | 1 |
| Mosse, YP | 1 |
| Berglund, A | 1 |
| Kenchappa, RS | 1 |
| Forsyth, PA | 1 |
| Mulé, JJ | 1 |
| Etame, AB | 1 |
| Yu, F | 1 |
| Gao, J | 1 |
| Liu, P | 1 |
| Gao, H | 1 |
| Lei, T | 1 |
| Cheng, Y | 1 |
| Zhai, X | 1 |
| Sayari, AJ | 1 |
| Drachsler, M | 1 |
| Kleber, S | 1 |
| Mateos, A | 1 |
| Volk, K | 1 |
| Mohr, N | 1 |
| Cirovic, B | 1 |
| Tüttenberg, J | 1 |
| Gieffers, C | 1 |
| Sykora, J | 1 |
| Mueller, W | 2 |
| Martin-Villalba, A | 1 |
| Pambuku, A | 1 |
| Fiduccia, P | 1 |
| Farina, M | 1 |
| D'Avella, D | 1 |
| Cazzato, E | 1 |
| Ladewig, E | 1 |
| Frattini, V | 1 |
| Rosenbloom, DI | 1 |
| Zairis, S | 1 |
| Abate, F | 1 |
| Elliott, O | 1 |
| Shin, YJ | 1 |
| Lee, JK | 1 |
| Eoli, M | 5 |
| Blumberg, AJ | 1 |
| Lasorella, A | 1 |
| Finocchiaro, G | 2 |
| Raizer, JJ | 4 |
| Chandler, JP | 1 |
| Ferrarese, R | 1 |
| Grimm, SA | 1 |
| Levy, RM | 1 |
| Muro, K | 1 |
| Rosenow, J | 1 |
| Helenowski, I | 1 |
| Rademaker, A | 1 |
| Paton, M | 1 |
| Antoni, D | 1 |
| Jastaniah, Z | 1 |
| Haoming, QC | 1 |
| Gaultier, C | 1 |
| Ahle, G | 1 |
| Couchot, J | 1 |
| Atlani, D | 1 |
| Schott, R | 1 |
| Clavier, JB | 1 |
| Srour, R | 1 |
| Chaussemy, D | 1 |
| Holla, FK | 1 |
| Blankenstein, MA | 1 |
| van Mierlo, TJM | 1 |
| Sizoo, EM | 1 |
| de Groot, M | 1 |
| Uitdehaag, BMJ | 1 |
| Buter, J | 1 |
| Kim, C | 1 |
| Shim, WH | 1 |
| Choi, CG | 1 |
| Kim, SJ | 1 |
| Belmonte, G | 1 |
| Toscano, M | 1 |
| Kamamoto, D | 1 |
| Ohara, K | 1 |
| Mizutani, K | 1 |
| Yoshida, K | 1 |
| Moreno, L | 1 |
| Varo, A | 1 |
| Chevance, A | 1 |
| Garaventa, A | 1 |
| Gambart, M | 1 |
| Bautista, F | 1 |
| Valteau-Couanet, D | 1 |
| Vassal, G | 3 |
| Paoletti, X | 1 |
| Pearson, AD | 1 |
| Gao, YT | 1 |
| Chen, XB | 1 |
| Liu, HL | 1 |
| Flüh, C | 1 |
| Engel, D | 1 |
| Mentlein, R | 1 |
| Tomabechi, M | 1 |
| Kato, K | 1 |
| Sasaki, M | 1 |
| Dai, C | 1 |
| Bao, X | 1 |
| Deng, K | 1 |
| Xing, B | 1 |
| Lian, W | 1 |
| Zhong, D | 1 |
| Timmons, J | 1 |
| Callahan, A | 1 |
| O'Loughlin, L | 1 |
| Giarusso, B | 1 |
| Alsop, DC | 1 |
| Chi, AS | 1 |
| Cahill, DP | 4 |
| Louis, DN | 4 |
| Colman, H | 2 |
| Kim, BT | 1 |
| Raizer, J | 1 |
| Ramachandran, R | 1 |
| Junnuthula, VR | 1 |
| Gowd, GS | 1 |
| Ashokan, A | 1 |
| Thomas, J | 1 |
| Peethambaran, R | 1 |
| Thomas, A | 1 |
| Unni, AK | 1 |
| Panikar, D | 1 |
| Nair, SV | 1 |
| Koyakutty, M | 1 |
| Guo, Y | 1 |
| Danieli, D | 1 |
| Zunarelli, E | 1 |
| Lanza, G | 1 |
| Silini, EM | 1 |
| Sturiale, C | 1 |
| Volpin, L | 1 |
| Servadei, F | 1 |
| Talacchi, A | 1 |
| Pia Foschini, M | 1 |
| Ermani, M | 8 |
| Sardaro, A | 1 |
| Iannalfi, A | 1 |
| Meattini, I | 1 |
| Leonulli, BG | 1 |
| Borghesi, S | 1 |
| Martinelli, F | 1 |
| Bordi, L | 1 |
| Ammannati, F | 1 |
| Biti, G | 1 |
| Beule, AC | 1 |
| Bromberg, J | 1 |
| Ernemann, U | 1 |
| Rorden, C | 1 |
| Karnath, HO | 1 |
| Perry, JR | 2 |
| Rizek, P | 1 |
| Cashman, R | 1 |
| Morrison, M | 1 |
| Morrison, T | 1 |
| Berkey, B | 1 |
| Peereboom, D | 1 |
| Macdonald, D | 2 |
| Giannini, C | 1 |
| Suh, JH | 1 |
| Jenkins, R | 1 |
| Herman, J | 1 |
| Brown, P | 1 |
| Biggs, C | 1 |
| Schultz, C | 1 |
| Mehta, M | 2 |
| Baumert, BG | 1 |
| Jakacki, RI | 1 |
| Hamilton, M | 2 |
| Gilbertson, RJ | 1 |
| Blaney, SM | 3 |
| Tersak, J | 1 |
| Krailo, MD | 1 |
| Voss, SD | 1 |
| Dancey, JE | 1 |
| Somerville, M | 1 |
| Sadones, J | 1 |
| Veld, P | 1 |
| Chaskis, C | 2 |
| Sciot, R | 1 |
| Menten, J | 3 |
| Joossens, EJ | 1 |
| Strauven, T | 2 |
| D'Hondt, LA | 1 |
| Sartenaer, D | 1 |
| Califice, SF | 1 |
| Bierau, K | 1 |
| Svensson, C | 1 |
| De Grève, J | 1 |
| Happold, C | 1 |
| Linnebank, M | 1 |
| de Robles, P | 1 |
| McIntyre, J | 1 |
| Kalra, S | 1 |
| Roldán, G | 1 |
| Cairncross, G | 1 |
| Forsyth, P | 1 |
| Magliocco, T | 1 |
| Easaw, J | 1 |
| Peca, C | 1 |
| Pacelli, R | 1 |
| Elefante, A | 1 |
| Del Basso De Caro, ML | 1 |
| Vergara, P | 1 |
| Mariniello, G | 1 |
| Giamundo, A | 1 |
| Maiuri, F | 1 |
| De Ridder, M | 1 |
| Sotti, G | 2 |
| Frezza, G | 1 |
| Amistà, P | 3 |
| Morandi, L | 1 |
| Spagnolli, F | 1 |
| Quinn, JA | 5 |
| Jiang, SX | 3 |
| Vredenburgh, JJ | 8 |
| Rich, JN | 5 |
| Gururangan, S | 7 |
| Friedman, AH | 6 |
| Bigner, DD | 3 |
| Sampson, JH | 6 |
| McLendon, RE | 4 |
| Walker, A | 2 |
| Rampling, R | 2 |
| Kouwenhoven, MC | 2 |
| Carpentier, AF | 2 |
| Frenay, M | 2 |
| Baurain, JF | 1 |
| Armand, JP | 2 |
| Kletzl, H | 1 |
| Klughammer, B | 1 |
| Lacombe, D | 1 |
| Pascher, C | 1 |
| Jauch, T | 1 |
| Bogdahn, U | 3 |
| Codd, PJ | 2 |
| Curry, WT | 2 |
| Bell, D | 1 |
| Johnston, SK | 1 |
| Fabrini, MG | 2 |
| Perrone, F | 2 |
| De Franco, L | 1 |
| Grespi, S | 1 |
| Vannozzi, R | 1 |
| Cionini, L | 1 |
| Groves, MD | 5 |
| Puduvalli, VK | 5 |
| Levin, VA | 6 |
| Conrad, CA | 5 |
| Liu, VH | 1 |
| Hunter, K | 1 |
| Meyers, C | 1 |
| Hess, KR | 6 |
| Alfred Yung, WK | 1 |
| Dresemann, G | 1 |
| Rosenthal, MA | 3 |
| Wedding, U | 1 |
| Wagner, W | 1 |
| Engel, E | 1 |
| Heinrich, B | 1 |
| Mayer-Steinacker, R | 1 |
| Karup-Hansen, A | 1 |
| Fluge, O | 1 |
| Nowak, A | 1 |
| Mehdorn, M | 1 |
| Schleyer, E | 1 |
| Olver, IN | 1 |
| Hosius, C | 1 |
| Sieder, C | 1 |
| Sorenson, G | 1 |
| Parker, R | 1 |
| Nikolova, Z | 1 |
| Cetica, V | 1 |
| Buccoliero, AM | 1 |
| Giunti, L | 1 |
| Genitori, L | 1 |
| Aricò, M | 1 |
| Siena, S | 1 |
| Crinò, L | 2 |
| Danova, M | 1 |
| Del Prete, S | 2 |
| Cascinu, S | 1 |
| Salvagni, S | 1 |
| Schiavetto, I | 1 |
| Vitali, M | 1 |
| Bajetta, E | 1 |
| Yang, I | 1 |
| Aghi, MK | 1 |
| Song, SW | 1 |
| Mandonnet, E | 1 |
| Fontaine, D | 1 |
| Peruzzi, P | 1 |
| Baron, MH | 1 |
| Duffau, H | 2 |
| Capelle, L | 2 |
| Yamanaka, R | 1 |
| Wagner, LM | 1 |
| Perentesis, JP | 1 |
| Ames, MM | 2 |
| Safgren, SL | 1 |
| Nelson, MD | 1 |
| Mintzer, DM | 1 |
| Zheng, S | 1 |
| Nagamine, M | 1 |
| Newman, J | 1 |
| Benito, M | 1 |
| Kim, ST | 2 |
| Kim, WS | 2 |
| Suh, YL | 1 |
| Dong, SM | 1 |
| Milano, MT | 1 |
| Okunieff, P | 1 |
| Donatello, RS | 1 |
| Mohile, NA | 1 |
| Walter, KA | 1 |
| Korones, DN | 3 |
| Agha, CA | 1 |
| Ibrahim, S | 1 |
| Elias, DA | 1 |
| Fathallah-Shaykh, HM | 1 |
| Jung, TY | 1 |
| Jung, S | 1 |
| Moon, KS | 1 |
| Kim, IY | 1 |
| Kang, SS | 1 |
| Park, CS | 1 |
| Lee, KH | 1 |
| McDonald, MW | 1 |
| Shu, HK | 1 |
| Curran, WJ | 1 |
| Crocker, IR | 1 |
| Hasselbalch, B | 1 |
| Hansen, S | 1 |
| Holmberg, M | 1 |
| Sørensen, M | 1 |
| Kosteljanetz, M | 1 |
| Broholm, H | 1 |
| Stockhausen, MT | 1 |
| Poulsen, HS | 1 |
| Mihaliak, AM | 1 |
| Gilbert, CA | 2 |
| Li, L | 1 |
| Daou, MC | 2 |
| Moser, RP | 2 |
| Reeves, A | 1 |
| Cochran, BH | 1 |
| Hegi, ME | 2 |
| Grabenbauer, GG | 1 |
| Ochsenbein, AF | 1 |
| Hicking, C | 1 |
| Diserens, AC | 1 |
| Pica, A | 3 |
| Hermisson, M | 1 |
| Krueger, S | 1 |
| Peters, K | 2 |
| Marcello, J | 3 |
| Janney, D | 2 |
| Rizzieri, D | 1 |
| LoRusso, S | 1 |
| Tse, W | 1 |
| Khan, K | 1 |
| Advani, A | 1 |
| Karsten, V | 1 |
| Cahill, A | 1 |
| Gerson, SL | 1 |
| Chaichana, KL | 1 |
| Halthore, AN | 1 |
| Parker, SL | 1 |
| Olivi, A | 1 |
| Weingart, JD | 1 |
| Brem, H | 1 |
| Quinones-Hinojosa, A | 1 |
| Pastore, M | 1 |
| Schmitt, A | 1 |
| Leblond, P | 1 |
| Ndiaye, A | 1 |
| Gentet, JC | 2 |
| Paci, A | 1 |
| Dias, N | 1 |
| Djafari, L | 3 |
| Pasquet, M | 1 |
| Chatelut, E | 1 |
| Corradini, N | 1 |
| Yung, WK | 9 |
| Bobustuc, GC | 1 |
| Hsu, SH | 1 |
| Bekele, BN | 1 |
| Qiao, W | 1 |
| Song, KS | 1 |
| Phi, JH | 1 |
| Cho, BK | 1 |
| Wang, KC | 1 |
| Lee, JY | 1 |
| Kim, DG | 1 |
| Kim, IH | 2 |
| Ahn, HS | 1 |
| Park, SH | 2 |
| Kim, SK | 1 |
| Addeo, R | 1 |
| Caraglia, M | 1 |
| De Santi, MS | 1 |
| Montella, L | 1 |
| Abbruzzese, A | 1 |
| Parlato, C | 1 |
| Vincenzi, B | 1 |
| Carraturo, M | 1 |
| Faiola, V | 1 |
| Genovese, M | 1 |
| Cennamo, G | 1 |
| Rusthoven, KE | 2 |
| Olsen, C | 1 |
| Franklin, W | 1 |
| Kleinschmidt-DeMasters, BK | 2 |
| Lillehei, K | 4 |
| Waziri, A | 4 |
| Damek, DM | 1 |
| Tanaka, H | 1 |
| Sasayama, T | 1 |
| Nishihara, M | 1 |
| Arai, A | 1 |
| Kawamura, A | 1 |
| Kanomata, N | 1 |
| Itoh, T | 1 |
| Kohmura, E | 1 |
| McLendon, R | 3 |
| Threatt, S | 1 |
| Amichetti, M | 1 |
| Salvati, M | 3 |
| Muni, R | 1 |
| Bozzao, A | 1 |
| Lanzetta, G | 2 |
| Scarpino, S | 1 |
| Arcella, A | 1 |
| Enrici, RM | 1 |
| Robischon, M | 1 |
| Stuhr, K | 2 |
| Ganswindt, U | 1 |
| Schwarz, SB | 1 |
| Kreth, FW | 2 |
| Geisler, J | 1 |
| Ertl, L | 1 |
| Linn, J | 1 |
| Siefert, A | 1 |
| Fields, EC | 1 |
| Liu, AK | 1 |
| Armosini, V | 1 |
| Caporello, P | 1 |
| Mei, M | 1 |
| Osti, MF | 1 |
| Maurizi, RE | 1 |
| Aguilera, DG | 1 |
| Goldman, S | 1 |
| Fangusaro, J | 2 |
| Takahashi, K | 1 |
| Nishihara, H | 1 |
| Katoh, M | 1 |
| Yoshinaga, T | 1 |
| Mahabir, R | 1 |
| Kanno, H | 1 |
| Kimura, T | 1 |
| Tanino, M | 1 |
| Ikeda, J | 1 |
| Sawamura, Y | 2 |
| Nagashima, K | 1 |
| Matuschek, C | 1 |
| Bölke, E | 1 |
| Nawatny, J | 1 |
| Hoffmann, TK | 1 |
| Peiper, M | 1 |
| Orth, K | 1 |
| Gerber, PA | 1 |
| Rusnak, E | 1 |
| Lammering, G | 1 |
| Budach, W | 1 |
| Burnett Iii, OL | 1 |
| Nordal, RA | 1 |
| Hyatt, MD | 1 |
| Eigenbrod, S | 1 |
| Hentschel, B | 1 |
| Westphal, M | 1 |
| Schackert, G | 1 |
| Löffler, M | 1 |
| Takano, M | 1 |
| Kikuchi, Y | 1 |
| Susumu, N | 1 |
| Kudoh, K | 1 |
| Kita, T | 1 |
| Kouta, H | 1 |
| Goto, T | 1 |
| Furuya, K | 1 |
| Kyritsis, AP | 1 |
| Park, MS | 1 |
| Patel, SR | 1 |
| Ludwig, JA | 1 |
| Trent, JC | 1 |
| Lazar, AJ | 1 |
| Wang, WL | 1 |
| Boonsirikamchai, P | 1 |
| Benjamin, RS | 1 |
| Araujo, DM | 1 |
| Cuneo, KC | 1 |
| Willett, CG | 1 |
| Kirkpatrick, JP | 1 |
| Kumar, N | 1 |
| Vasishta, RK | 1 |
| Gupta, K | 1 |
| Sharma, SC | 1 |
| Patel, F | 1 |
| Mathuriya, SN | 1 |
| Davis, ME | 1 |
| Stoiber, AM | 1 |
| Oh, J | 1 |
| Sahgal, A | 1 |
| Sanghera, P | 2 |
| Tsao, MN | 1 |
| Davey, P | 1 |
| Lam, K | 1 |
| Symons, S | 1 |
| Aviv, R | 1 |
| Coan, A | 2 |
| Bailey, L | 1 |
| Rogers, S | 1 |
| Merlo, A | 1 |
| Berberat, J | 1 |
| Bodis, S | 1 |
| Akyüz, C | 1 |
| Demir, HA | 1 |
| Varan, A | 1 |
| Yalçin, B | 1 |
| Kutluk, T | 1 |
| Büyükpamukçu, M | 1 |
| Montano, N | 1 |
| D'Alessandris, QG | 1 |
| Bianchi, F | 1 |
| Lauretti, L | 1 |
| Doglietto, F | 1 |
| Fernandez, E | 1 |
| Maira, G | 2 |
| Pallini, R | 1 |
| Adachi, J | 2 |
| Mishima, K | 2 |
| Wakiya, K | 1 |
| Suzuki, T | 1 |
| Fukuoka, K | 1 |
| Yanagisawa, T | 1 |
| Matsutani, M | 2 |
| Sasaki, A | 1 |
| Conti, A | 1 |
| Pontoriero, A | 1 |
| Arpa, D | 1 |
| Siragusa, C | 1 |
| Tomasello, C | 1 |
| Romanelli, P | 1 |
| Cardali, S | 1 |
| Granata, F | 1 |
| De Renzis, C | 1 |
| Tomasello, F | 1 |
| Gaviani, P | 3 |
| Silvani, A | 5 |
| Lamperti, E | 5 |
| Botturi, A | 5 |
| Simonetti, G | 1 |
| Ferrari, D | 1 |
| Salmaggi, A | 5 |
| Murakami, M | 1 |
| Fujimaki, T | 1 |
| Asano, S | 1 |
| Nakaguchi, H | 1 |
| Yamada, SM | 1 |
| Hoya, K | 1 |
| Yamazaki, K | 1 |
| Ishida, Y | 1 |
| Freyschlag, CF | 1 |
| Smolczyk, DR | 1 |
| Janzen, E | 1 |
| Schmieder, K | 1 |
| Thomé, C | 1 |
| Lohr, F | 1 |
| Wenz, F | 1 |
| Weiss, C | 1 |
| Tuettenberg, J | 1 |
| Seiz, M | 1 |
| Kilickap, S | 2 |
| Oztoprak, I | 1 |
| Yucel, B | 1 |
| Vauleon, E | 1 |
| Mesbah, H | 1 |
| Gedouin, D | 1 |
| Lecouillard, I | 1 |
| Louvel, G | 1 |
| Hamlat, A | 1 |
| Riffaud, L | 1 |
| Carsin, B | 1 |
| Quillien, V | 1 |
| Audrain, O | 1 |
| Lesimple, T | 1 |
| Sathornsumetee, S | 2 |
| Taal, W | 3 |
| Segers-van Rijn, JM | 1 |
| van Heuvel, I | 2 |
| van der Rijt, CC | 3 |
| Bromberg, JE | 2 |
| Sillevis Smitt, PA | 2 |
| Shin, BJ | 1 |
| Burkhardt, JK | 1 |
| Riina, HA | 1 |
| Ney, D | 1 |
| Philippon, M | 1 |
| Morange, I | 1 |
| Barrie, M | 2 |
| Barlier, A | 1 |
| Taieb, D | 1 |
| Dufour, H | 2 |
| Conte-Devolx, B | 1 |
| Brue, T | 1 |
| Silvano, G | 1 |
| Savio, G | 1 |
| Santoni, M | 1 |
| Bonizzoni, E | 1 |
| Perrone, T | 1 |
| Gil, MJ | 1 |
| de Las Peñas, R | 1 |
| García-Velasco, A | 1 |
| Mesia, C | 1 |
| Fernández-Chacón, C | 1 |
| Martínez-García, M | 1 |
| Herrero, A | 1 |
| Andrés, R | 1 |
| Quintanar, T | 1 |
| Pérez-Martin, X | 1 |
| Den, RB | 1 |
| Kamrava, M | 1 |
| Sheng, Z | 1 |
| Dougherty, E | 1 |
| Marinucchi, M | 1 |
| Lawrence, YR | 1 |
| Hegarty, S | 1 |
| Hyslop, T | 1 |
| Glass, J | 1 |
| Friedman, DP | 1 |
| Green, MR | 1 |
| Dicker, AP | 1 |
| De Bonis, P | 1 |
| Anile, C | 1 |
| Pompucci, A | 1 |
| Balducci, M | 2 |
| Chiesa, S | 1 |
| Mangiola, A | 1 |
| Massaccesi, M | 1 |
| Ferro, M | 1 |
| Cilla, S | 1 |
| Deodato, F | 1 |
| Macchia, G | 1 |
| Valentini, V | 1 |
| Morganti, AG | 1 |
| Roberge, D | 1 |
| Fortin, MA | 1 |
| Pouliot, JF | 1 |
| Wong, SF | 1 |
| Cher, L | 2 |
| Yamada, A | 1 |
| Shimonodan, H | 1 |
| Yokogami, K | 1 |
| Takeshima, H | 2 |
| Marutsuka, K | 1 |
| Nunoi, H | 1 |
| Panet-Raymond, V | 1 |
| Vajtai, I | 2 |
| Vassella, E | 1 |
| Hewer, E | 1 |
| Kappeler, A | 2 |
| Reinert, MM | 1 |
| Lu, JQ | 1 |
| Wilson, BA | 1 |
| Pugh, J | 1 |
| Mehta, V | 2 |
| Chan, TA | 1 |
| Kaley, TJ | 1 |
| Nolan, CP | 2 |
| Gavrilovic, IT | 2 |
| Salvant, C | 1 |
| Kaufman, A | 1 |
| Mellinghoff, I | 1 |
| Melguizo, C | 1 |
| Prados, J | 1 |
| González, B | 1 |
| Ortiz, R | 1 |
| Concha, A | 1 |
| Alvarez, PJ | 1 |
| Madeddu, R | 1 |
| Perazzoli, G | 1 |
| Oliver, JA | 1 |
| López, R | 1 |
| Rodríguez-Serrano, F | 1 |
| Aránega, A | 1 |
| Xu, T | 1 |
| Karavasilis, V | 1 |
| Kotoula, V | 1 |
| Pentheroudakis, G | 1 |
| Televantou, D | 1 |
| Lambaki, S | 1 |
| Chrisafi, S | 1 |
| Bobos, M | 1 |
| Fountzilas, G | 1 |
| Blackwood, R | 1 |
| Brown, M | 1 |
| Harmon, M | 1 |
| Lovato, J | 1 |
| Yalcinkaya, T | 1 |
| Berhorn, T | 1 |
| Blau, T | 1 |
| Dunkl, V | 1 |
| Fink, GR | 1 |
| Schroeter, M | 1 |
| Hernández-Marqués, C | 1 |
| Lassaletta-Atienza, A | 1 |
| Ruiz Hernández, A | 1 |
| Blumenfeld Olivares, JA | 1 |
| Arce Abaitua, B | 1 |
| Cormenzana Carpio, M | 1 |
| Madero Lopez, L | 1 |
| Nagane, M | 2 |
| Kobayashi, K | 2 |
| Tsuchiya, K | 1 |
| Shishido-Hara, Y | 1 |
| Shimizu, S | 2 |
| Shiokawa, Y | 2 |
| Lee, SH | 1 |
| Kim, TM | 1 |
| Choi, SH | 1 |
| Heo, DS | 1 |
| Jung, HW | 1 |
| Aguilar, HN | 1 |
| Hung, RW | 1 |
| Kotylak, T | 1 |
| Sherriff, J | 1 |
| Tamangani, J | 1 |
| Senthil, L | 1 |
| Cruickshank, G | 1 |
| Spooner, D | 1 |
| Jones, B | 1 |
| Brookes, C | 1 |
| Alacacioglu, A | 1 |
| Unal, S | 1 |
| Canpolat, S | 1 |
| Yurt, A | 1 |
| Oztekin, O | 1 |
| Coskun, A | 1 |
| Karatas, A | 1 |
| Postaci, H | 1 |
| Sop, G | 1 |
| Trent, S | 1 |
| Kong, A | 1 |
| Traish, D | 1 |
| Ashley, S | 1 |
| Dowe, A | 1 |
| Hines, F | 1 |
| Gaya, A | 1 |
| Rees, J | 1 |
| Greenstein, A | 1 |
| Stebbing, J | 1 |
| Zheludkova, OG | 1 |
| Tarasova, IS | 1 |
| Gorbatykh, SV | 1 |
| Belogurova, MB | 1 |
| Kumirova, EV | 1 |
| Borodina, ID | 1 |
| Prityko, AG | 1 |
| Melikian, AG | 1 |
| Shcherbenko, OI | 1 |
| Uitdehaag, BM | 1 |
| Barkhof, F | 1 |
| Baayen, HC | 1 |
| Boogerd, W | 2 |
| Castelijns, JA | 1 |
| Elkhuizen, PH | 1 |
| Bravo Marques, J | 1 |
| De Beule, N | 1 |
| Baron, B | 1 |
| Benita-Weiss, M | 1 |
| Coyle, TE | 1 |
| Mechtler, L | 1 |
| Bushunow, P | 1 |
| Evans, B | 1 |
| Friedman, H | 2 |
| Keir, ST | 1 |
| Houghton, PJ | 1 |
| Jaeckle, KA | 3 |
| Greenberg, H | 2 |
| Fine, H | 2 |
| Pollack, IF | 1 |
| Kuhn, J | 3 |
| Cloughesy, T | 2 |
| Nicholas, MK | 2 |
| Chang, S | 2 |
| Prados, M | 1 |
| Vecht, ChJ | 1 |
| Allgeier, A | 1 |
| Trippoli, S | 1 |
| Pelagotti, F | 1 |
| Messori, A | 1 |
| Vacca, F | 1 |
| Vaiani, M | 1 |
| Maltoni, S | 1 |
| Rojas-Marcos, I | 1 |
| Calvet, D | 1 |
| Janoray, P | 1 |
| Piccirilli, M | 1 |
| Caroli, E | 1 |
| Brogna, C | 1 |
| Artizzu, S | 1 |
| Frati, A | 1 |
| Aoki, T | 2 |
| Mizutani, T | 2 |
| Ishikawa, M | 1 |
| Sugiyama, K | 1 |
| Hashimoto, N | 1 |
| Vera, K | 1 |
| Faivre, S | 1 |
| Guillamo, JS | 1 |
| Djazouli, K | 1 |
| Osorio, M | 1 |
| Parker, F | 1 |
| Cioloca, C | 1 |
| Raymond, E | 1 |
| Keles, GE | 1 |
| Lamborn, KR | 3 |
| Prados, MD | 8 |
| Theodosopoulos, P | 1 |
| Lamborn, K | 2 |
| Malec, M | 2 |
| Rabbitt, J | 2 |
| Page, M | 1 |
| Gruber, ML | 1 |
| Buster, WP | 1 |
| Greenberg, HS | 1 |
| Junck, L | 2 |
| Fink, KL | 2 |
| Schold, SC | 1 |
| Chua, SL | 1 |
| Wong, SS | 1 |
| Woods, AM | 1 |
| Dowling, A | 1 |
| Cher, LM | 1 |
| Tsao-Wei, DD | 3 |
| Ashley, DL | 1 |
| Basso, U | 3 |
| Vastola, F | 1 |
| Cavallo, G | 3 |
| Scopece, L | 1 |
| Ferreri, AJ | 2 |
| Panucci, MG | 1 |
| Monfardini, S | 3 |
| Donfrancesco, A | 2 |
| Jenkner, A | 2 |
| Castellano, A | 2 |
| Ilari, I | 1 |
| Milano, GM | 2 |
| De Sio, L | 2 |
| Cozza, R | 1 |
| Fidani, P | 2 |
| Deb, G | 1 |
| De Laurentis, C | 1 |
| Inserra, A | 1 |
| Dominici, C | 2 |
| Judson, PL | 1 |
| Blair Harkness, C | 1 |
| Boente, MP | 1 |
| Downs, LS | 1 |
| Argenta, PA | 1 |
| Carson, LF | 1 |
| Tishler, R | 1 |
| Barron, L | 1 |
| Enting, RH | 2 |
| Demopoulos, A | 1 |
| Wasserfallen, JB | 2 |
| Ostermann, S | 2 |
| Mirimanoff, RO | 1 |
| Leyvraz, S | 3 |
| Villemure, JG | 1 |
| Everaert, E | 1 |
| Joosens, E | 1 |
| Branle, F | 1 |
| Spence, AM | 1 |
| Peterson, RA | 1 |
| Scharnhorst, JD | 1 |
| Silbergeld, DL | 1 |
| Rostomily, RC | 1 |
| Valduga, F | 1 |
| Nicolardi, L | 1 |
| Sipos, L | 2 |
| Vitanovics, D | 2 |
| Afra, D | 2 |
| Su, YW | 1 |
| Chang, MC | 1 |
| Chiang, MF | 1 |
| Hsieh, RK | 1 |
| Aksoy, S | 1 |
| Abali, H | 1 |
| Güler, N | 1 |
| Kunze, S | 1 |
| Eich, HT | 1 |
| Semrau, R | 1 |
| Müller, RP | 1 |
| Somer, RA | 1 |
| Langer, CJ | 1 |
| Hebart, H | 1 |
| Kanz, L | 1 |
| Dichgans, J | 1 |
| van der Rijt, CD | 1 |
| Smith, A | 1 |
| Foreman, N | 1 |
| Bouffet, E | 3 |
| Vredenburgh, J | 1 |
| Badruddoja, M | 1 |
| Provenzale, J | 1 |
| Dowell, JM | 1 |
| Burkart, JL | 1 |
| Newton, HB | 1 |
| Doz, F | 1 |
| O'Quigley, J | 1 |
| Wartelle, M | 1 |
| Watson, AJ | 1 |
| Raquin, MA | 1 |
| Couanet, D | 1 |
| Geoffray, A | 1 |
| Margison, GP | 1 |
| Pein, F | 1 |
| Koch, HJ | 1 |
| Roeber, S | 1 |
| Zimmermann, UW | 1 |
| Schäfer, C | 1 |
| Villarrubia, V | 1 |
| Kuchelmeister, K | 1 |
| Schachenmayr, W | 1 |
| Steinbrecher, A | 2 |
| Grosu, AL | 1 |
| Weber, WA | 1 |
| Franz, M | 1 |
| Stärk, S | 1 |
| Piert, M | 1 |
| Thamm, R | 1 |
| Gumprecht, H | 1 |
| Molls, M | 1 |
| Nieder, C | 1 |
| Boiardi, A | 4 |
| Broggi, G | 3 |
| Bissola, L | 1 |
| Mazzarella, G | 1 |
| Caldarelli, M | 1 |
| Di Rocco, C | 1 |
| Clerico, A | 1 |
| Sandri, A | 1 |
| Chan, DT | 1 |
| Chan, YL | 1 |
| Chamoun, RB | 1 |
| Alaraj, AM | 1 |
| Al Kutoubi, AO | 1 |
| Abboud, MR | 1 |
| Haddad, GF | 1 |
| Burton, E | 1 |
| Kapadia, A | 1 |
| Page, MS | 1 |
| Fedoroff, A | 1 |
| Xie, D | 1 |
| Kelley, SK | 1 |
| Rehman, S | 1 |
| Brock, C | 3 |
| Newlands, ES | 4 |
| Colin, P | 1 |
| Pelissou-Guyotat, I | 1 |
| Mahla, K | 1 |
| Audra, P | 1 |
| Gaucherand, P | 1 |
| Trouillas, P | 1 |
| Hunter, C | 1 |
| Smith, R | 1 |
| Stephens, P | 1 |
| Stevens, C | 1 |
| Teague, J | 1 |
| Greenman, C | 1 |
| Edkins, S | 1 |
| Bignell, G | 1 |
| Davies, H | 1 |
| O'Meara, S | 1 |
| Parker, A | 1 |
| Avis, T | 1 |
| Barthorpe, S | 1 |
| Brackenbury, L | 1 |
| Buck, G | 1 |
| Butler, A | 1 |
| Clements, J | 1 |
| Cole, J | 1 |
| Dicks, E | 1 |
| Forbes, S | 1 |
| Gorton, M | 1 |
| Gray, K | 1 |
| Halliday, K | 1 |
| Harrison, R | 1 |
| Hills, K | 1 |
| Hinton, J | 1 |
| Jenkinson, A | 1 |
| Jones, D | 1 |
| Kosmidou, V | 1 |
| Laman, R | 1 |
| Lugg, R | 1 |
| Menzies, A | 1 |
| Perry, J | 2 |
| Petty, R | 1 |
| Raine, K | 1 |
| Richardson, D | 1 |
| Shepherd, R | 1 |
| Small, A | 1 |
| Solomon, H | 1 |
| Tofts, C | 1 |
| Varian, J | 1 |
| West, S | 1 |
| Widaa, S | 1 |
| Yates, A | 1 |
| Easton, DF | 1 |
| Riggins, G | 1 |
| Roy, JE | 1 |
| Levine, KK | 2 |
| Stratton, MR | 2 |
| Futreal, PA | 2 |
| Wooster, R | 1 |
| Jaeckle, K | 1 |
| Liu, V | 1 |
| Aldape, KD | 2 |
| Dehdashti, AR | 1 |
| Regli, L | 1 |
| Bartolomei, M | 1 |
| Hassler, M | 1 |
| Micksche, M | 2 |
| Stockhammer, G | 1 |
| Payer, F | 1 |
| Abuja, B | 1 |
| Deinsberger, R | 1 |
| Charnley, N | 1 |
| West, CM | 1 |
| Barnett, CM | 1 |
| Bydder, GM | 1 |
| Glaser, M | 1 |
| Swindell, R | 1 |
| Matthews, J | 2 |
| Price, P | 1 |
| Schwarzmaier, HJ | 1 |
| Eickmeyer, F | 1 |
| von Tempelhoff, W | 1 |
| Fiedler, VU | 1 |
| Niehoff, H | 1 |
| Ulrich, SD | 1 |
| Yang, Q | 1 |
| Ulrich, F | 1 |
| Sterba, J | 1 |
| Valik, D | 1 |
| Mudry, P | 1 |
| Kepak, T | 1 |
| Pavelka, Z | 1 |
| Bajciova, V | 1 |
| Zitterbart, K | 1 |
| Kadlecova, V | 1 |
| Mazanek, P | 1 |
| Yang, SH | 1 |
| Kim, MK | 1 |
| Lee, TK | 1 |
| Lee, KS | 1 |
| Jeun, SS | 1 |
| Kang, JK | 1 |
| Kim, MC | 1 |
| Hong, YK | 1 |
| Baruchel, S | 1 |
| Diezi, M | 1 |
| Hargrave, D | 1 |
| Stempak, D | 1 |
| Gammon, J | 1 |
| Moghrabi, A | 1 |
| Coppes, MJ | 1 |
| Fernandez, CV | 1 |
| Biemond-ter Stege, EM | 1 |
| Graveland, WJ | 1 |
| Bonaldi, L | 2 |
| Bertorelle, R | 3 |
| Gardiman, M | 2 |
| Iuzzolino, P | 1 |
| Blatt, V | 3 |
| Terheggen, F | 1 |
| Troost, D | 1 |
| Majoie, CB | 1 |
| Richel, DJ | 1 |
| Mabasa, VH | 1 |
| Taylor, SC | 1 |
| Rook, J | 1 |
| Rosser, T | 1 |
| Finlay, J | 1 |
| Son, MJ | 1 |
| Park, K | 1 |
| Eoh, W | 1 |
| Gioia, V | 1 |
| Biscuola, M | 1 |
| Koch, D | 2 |
| Boor, S | 1 |
| Tremont-Lukats, IW | 1 |
| Liu, TJ | 1 |
| Peterson, P | 2 |
| Stevens, QE | 1 |
| Howes, G | 1 |
| Dickerman, RD | 1 |
| Nardone, EM | 1 |
| Kushner, BH | 1 |
| Kramer, K | 1 |
| Modak, S | 1 |
| Cheung, NK | 1 |
| Kobayashi, H | 1 |
| Ishii, N | 1 |
| Murata, J | 1 |
| Iwasaki, Y | 1 |
| Pitini, V | 1 |
| Baldari, S | 1 |
| Altavilla, G | 1 |
| Arrigo, C | 1 |
| Naro, C | 1 |
| Perniciaro, F | 1 |
| Zaja, F | 1 |
| Mason, W | 1 |
| Spina, M | 1 |
| Bordonaro, R | 1 |
| Ilariucci, F | 1 |
| Faedi, M | 1 |
| Corazzelli, G | 1 |
| Manno, P | 1 |
| Pace, A | 1 |
| Candela, M | 1 |
| Abbadessa, A | 1 |
| Stelitano, C | 1 |
| Latte, G | 1 |
| Monje, ML | 1 |
| Ramakrishna, NR | 1 |
| Young, G | 1 |
| Doherty, LM | 1 |
| Gallego, JM | 1 |
| Barcia, JA | 1 |
| Barcia-Mariño, C | 1 |
| Spiegl-Kreinecker, S | 1 |
| Pirker, C | 1 |
| Buchroithner, J | 1 |
| Silye, R | 1 |
| Fischer, J | 2 |
| Berger, W | 1 |
| Locatelli, M | 1 |
| Campanella, R | 1 |
| Motta, F | 1 |
| Mora, A | 1 |
| Prada, F | 1 |
| Borsa, S | 1 |
| Martinelli-Boneschi, F | 1 |
| Saladino, A | 1 |
| Gaini, SM | 1 |
| Betensky, RA | 1 |
| Romany, CA | 1 |
| Reavie, LB | 1 |
| Iafrate, AJ | 1 |
| Choong, NW | 1 |
| Mauer, AM | 1 |
| Hoffman, PC | 1 |
| Rudin, CM | 1 |
| Winegarden, JD | 1 |
| Kozloff, M | 1 |
| Wade, JL | 1 |
| Sciortino, DF | 1 |
| Szeto, L | 1 |
| Vokes, EE | 1 |
| Gatta, G | 1 |
| Vecht, C | 1 |
| Kaloshi, G | 1 |
| Benouaich-Amiel, A | 1 |
| Diakite, F | 1 |
| Taillibert, S | 1 |
| Lejeune, J | 1 |
| Renard, MA | 1 |
| Iraqi, W | 1 |
| Paris, S | 1 |
| Cornu, P | 1 |
| Simon, JM | 1 |
| Polivka, M | 1 |
| Carpentier, A | 1 |
| Hoang-Xuan, K | 2 |
| Kudo, M | 1 |
| Fiumani, A | 2 |
| Falcone, C | 2 |
| Filippini, G | 2 |
| Blaschke, B | 1 |
| Meyermann, R | 1 |
| Dervisis, NG | 1 |
| Dominguez, PA | 1 |
| Sarbu, L | 1 |
| Newman, RG | 1 |
| Cadile, CD | 1 |
| Swanson, CN | 1 |
| Kitchell, BE | 1 |
| Nicholson, HS | 2 |
| Kretschmar, CS | 1 |
| Krailo, M | 2 |
| Kadota, R | 1 |
| Harris, MB | 1 |
| Tedeschi-Blok, N | 1 |
| Mazewski, C | 1 |
| Sato, J | 1 |
| Reaman, GH | 2 |
| Poelen, J | 1 |
| Bernsen, HJ | 1 |
| Prick, MJ | 1 |
| Durando, X | 1 |
| Thivat, E | 1 |
| Gilliot, O | 1 |
| Irthum, B | 1 |
| Verrelle, P | 1 |
| Vincent, C | 1 |
| Bay, JO | 1 |
| Nojima, K | 1 |
| Horton, TM | 1 |
| Thompson, PA | 1 |
| Berg, SL | 1 |
| Dolan, ME | 1 |
| Delaney, SM | 1 |
| Hedge, M | 1 |
| Weiss, HL | 1 |
| Wu, MF | 1 |
| Iwamoto, FM | 1 |
| Omuro, AM | 1 |
| Terasaki, M | 1 |
| Katsuki, H | 1 |
| Fukushima, S | 1 |
| Shigemori, M | 1 |
| Loghin, ME | 1 |
| Wen, P | 1 |
| Lieberman, F | 1 |
| Metha, M | 1 |
| Robins, IH | 1 |
| Ohnishi, A | 1 |
| Fathi, AR | 1 |
| Novoa, E | 1 |
| El-Koussy, M | 1 |
| Mariani, L | 1 |
| Solari, A | 1 |
| Di Meco, F | 1 |
| da Fonseca, CO | 1 |
| Schwartsmann, G | 1 |
| Nagel, J | 1 |
| Futuro, D | 1 |
| Quirico-Santos, T | 1 |
| Gattass, CR | 1 |
| Kunz-Schughart, L | 1 |
| Baumgart, U | 1 |
| Hirschmann, B | 1 |
| Weimann, E | 1 |
| Muhleisen, H | 1 |
| Ruemmele, P | 1 |
| Reichle, A | 1 |
| Wei-Tsao, DD | 1 |
| Glantz, MJ | 2 |
| Lin, SH | 1 |
| Kleinberg, LR | 1 |
| Dehart, WK | 1 |
| Gilliam, AC | 1 |
| Lu, KQ | 1 |
| Brell, J | 1 |
| Brandsma, D | 1 |
| Stalpers, L | 1 |
| Sminia, P | 1 |
| Bischof, M | 1 |
| Hof, H | 1 |
| Oertel, S | 1 |
| Schulz-Ertner, D | 1 |
| O'Reilly, SM | 2 |
| Glaser, MG | 1 |
| Bower, M | 1 |
| Evans, H | 2 |
| Brampton, MH | 2 |
| Colquhoun, I | 1 |
| Lewis, P | 1 |
| Rice-Edwards, JM | 1 |
| Illingworth, RD | 1 |
| Richards, PG | 1 |
| Seibel, NL | 1 |
| Liu-Mares, W | 1 |
| Vezina, LG | 1 |
| Ettinger, AG | 1 |
| Yaya-Tur, R | 1 |
| Rosenfeld, SS | 1 |
| Albright, R | 1 |
| Olson, J | 1 |
| O'Neill, AM | 1 |
| Bruner, J | 2 |
| Yue, N | 2 |
| Dugan, M | 2 |
| Zaknoen, S | 2 |
| Brock, CS | 1 |
| Young, H | 1 |
| Osman, S | 1 |
| Price, PM | 1 |
| Osoba, D | 1 |
| Berti, F | 1 |
| Scienza, R | 1 |
| Rotilio, A | 1 |
| Pinna, G | 1 |
| Dirix, LY | 1 |
| Zonnenberg, BA | 1 |
| Bravo-Marques, JM | 1 |
| Rao, S | 1 |
| Honore, S | 1 |
| Muracciole, X | 1 |
| Braguer, D | 1 |
| Martin, PM | 1 |
| Grisoli, F | 1 |
| Lutterbach, J | 1 |
| Liegibel, J | 1 |
| Madlinger, A | 1 |
| Frommhold, H | 1 |
| Keime-Guibert, F | 1 |
| Eskens, FA | 1 |
| Christodoulou, C | 1 |
| Olson, JD | 1 |
| Mack, M | 1 |
| Rodavitch, A | 1 |
| Boutros, DY | 1 |
| Malkin, MG | 2 |
| Khan, RB | 1 |
| Bazylewicz, KA | 1 |
| Dinnes, J | 1 |
| Cave, C | 1 |
| Huang, S | 1 |
| Milne, R | 1 |
| Gander, M | 1 |
| Newlands, E | 1 |
| Paul, MJ | 1 |
| Summers, Y | 1 |
| Calvert, AH | 1 |
| Rustin, G | 1 |
| Thatcher, N | 1 |
| Middleton, MR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A First-line Multi-center, Single-arm Exploratory Study Using Low-dose Radiotherapy (LDRT) Combined With Durvalumab (MEDI4736), Etoposide, and Cisplatin/Carboplatin for Patients With Extensive-stage Small Cell Lung Cancer[NCT05092412] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-03-02 | Recruiting | ||
| A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination With Ipilimumab Across Different Lines of Glioblastoma[NCT02017717] | Phase 3 | 529 participants (Actual) | Interventional | 2014-02-07 | Active, not recruiting | ||
| Research on Precise Immune Prevention and Treatment of Glioma Based on Multi-omics Sequencing Data[NCT04792437] | 120 participants (Anticipated) | Observational | 2021-03-10 | Recruiting | |||
| A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma[NCT01812603] | Phase 1/Phase 2 | 6 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma[NCT01812616] | Phase 1/Phase 2 | 21 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects With Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment[NCT01480050] | Phase 1 | 28 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| The Use of TTFields for Newly Diagnosed GBM Patients in Germany in Routine Clinical Care - TIGER Study[NCT03258021] | 710 participants (Actual) | Observational | 2017-08-31 | Active, not recruiting | |||
| A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM.[NCT00916409] | Phase 3 | 700 participants (Anticipated) | Interventional | 2009-06-30 | Completed | ||
| A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation [NCT01506609] | Phase 2 | 294 participants (Actual) | Interventional | 2012-01-23 | Completed | ||
| A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)[NCT02573324] | Phase 3 | 691 participants (Actual) | Interventional | 2015-01-04 | Completed | ||
| INTELLANCE-2: ABT-414 Alone or ABT-414 Plus Temozolomide Versus Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase 2 Study of the EORTC Brain Tumor Group[NCT02343406] | Phase 2 | 266 participants (Actual) | Interventional | 2015-02-17 | Completed | ||
| A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme[NCT01800695] | Phase 1 | 202 participants (Actual) | Interventional | 2013-04-02 | Completed | ||
| Randomized Trial Assessing the Significance of Bevacizumab in Recurrent Grade II and Grade III Gliomas - The TAVAREC Trial[NCT01164189] | Phase 2 | 155 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| Safety of Intensity-modulated Radiotherapy Treatment With Inhomogeneous Dose Distribution in Patients With Relapsed High-grade Gliomas.[NCT04610229] | 12 participants (Actual) | Interventional | 2016-02-01 | Completed | |||
| Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial[NCT05136326] | Phase 2 | 21 participants (Anticipated) | Interventional | 2021-12-01 | Recruiting | ||
| Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study[NCT05031975] | Phase 2 | 35 participants (Anticipated) | Interventional | 2022-05-02 | Recruiting | ||
| A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of DIsulfiram and Copper Gluconate in Recurrent Glioblastoma[NCT03034135] | Phase 2 | 23 participants (Actual) | Interventional | 2017-03-09 | Completed | ||
| Phase III Randomized Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma : Standard 3D Conformational Radiotherapy Versus Intensity-modulated Radiotherapy With Simultaneous-integrated Boost[NCT01507506] | Phase 3 | 180 participants (Actual) | Interventional | 2011-03-15 | Terminated | ||
| Ependymomics: Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents[NCT05151718] | 370 participants (Anticipated) | Observational | 2021-09-30 | Recruiting | |||
| The Prospective Trial for Validation of the Role of Levetiracetam as a Sensitizer of Temozolomide in the Treatment of Newly Diagnosed Glioblastoma Patients[NCT02815410] | Phase 2 | 73 participants (Anticipated) | Interventional | 2016-07-31 | Not yet recruiting | ||
| A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma[NCT02023710] | Phase 2 | 182 participants (Anticipated) | Interventional | 2013-12-31 | Recruiting | ||
| Phase I Study of Subventricular Zone Tumor Stem Cell Stereotactic Radiosurgery With Standard of Care Chemoradiation Therapy in Newly Diagnosed Malignant Gliomas (WHO III and WHO IV Astrocytomas)[NCT03956706] | 0 participants (Actual) | Interventional | 2018-12-24 | Withdrawn (stopped due to no partipants enrolled and investigator left the institution) | |||
| An Italian Multicenter Phase II Trial of Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study[NCT05554003] | Phase 2 | 46 participants (Anticipated) | Interventional | 2022-01-14 | Recruiting | ||
| The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial[NCT01847235] | Phase 2 | 23 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| A Phase II Trial Of Pre-Irradiation And Concurrent Temozolomide In Patients With Newly Diagnosed Anaplastic Oligodendrogliomas And Mixed Anaplastic Oligoastrocytomas[NCT00033280] | Phase 2 | 42 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Randomized Phase II of TARCEVA™ (Erlotinib) Versus Temozolomide Or BCNU in Patients With Recurrent Glioblastoma Multiforme[NCT00086879] | Phase 2 | 110 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Phase I Trial of Temodar Plus O6-Benzylguanine (O6-BG) (NSC 637037) in the Treatment of Patients With Newly Diagnosed (Part 1) or Recurrent/Progressive (Parts 1 and 2) Cerebral Anaplastic Gliomas[NCT00006474] | Phase 1 | 0 participants | Interventional | 2001-03-31 | Completed | ||
| Multicenter Phase 2 Evaluation of Temozolomide for Treatment of Brain Metastases of Either Malignant Melanoma, Breast and Non-small Cell Lung Cancer.[NCT00831545] | Phase 2 | 162 participants (Actual) | Interventional | 2000-12-01 | Completed | ||
| A Phase I Study of Temozolomide, Oral Irinotecan, and Vincristine for Children With Refractory Solid Tumors[NCT00138216] | Phase 1 | 42 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Phase II Study of Neoadjuvant Chemoradiation for Resectable Glioblastoma (NeoGlio)[NCT04209790] | Phase 2 | 30 participants (Anticipated) | Interventional | 2020-04-01 | Recruiting | ||
| Phase 2 Study of Sorafenib Plus Protracted Temozolomide in Recurrent Glioblastoma Multiforme[NCT00597493] | Phase 2 | 32 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| A Phase I Study Of Cloretazine™ (VNP40101M) And Temozolomide In Patients With Hematologic Malignancies[NCT00098436] | Phase 1 | 25 participants (Anticipated) | Interventional | 2004-09-30 | Completed | ||
| A Phase I Dose Escalation Study of Vandetanib (ZACTIMA, ZD6474) With Hypofractionated Stereotactic Radiotherapy in Patients With Recurrent Malignant Gliomas[NCT00822887] | Phase 1 | 13 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Hypofractionated Stereotactic Radiation Treatments (SBRT) on Children, Teenagers and Young Adults Malignant Tumors[NCT02013297] | 61 participants (Actual) | Interventional | 2013-12-03 | Completed | |||
| Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients[NCT03023124] | Phase 2 | 50 participants (Anticipated) | Interventional | 2018-03-04 | Recruiting | ||
| A Phase II Study of Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma[NCT00501891] | Phase 2 | 32 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Hypofractionated IMRT (VMAT-RA) With Temozolomide for Patients With Newly Diagnosed High Grade Glioma (HGG)[NCT02082119] | 82 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| A Phase I Dose Per Fraction Escalation Study of Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining With Temozolomide (TMZ) Chemotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)[NCT00792012] | Phase 1 | 37 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma[NCT00498927] | Phase 2 | 47 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Second Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors After PCV-Chemotherapy[NCT00003304] | Phase 2 | 29 participants (Anticipated) | Interventional | 1998-04-30 | Completed | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| First Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors, a Phase II Trial[NCT00003731] | Phase 2 | 39 participants (Actual) | Interventional | 1998-12-31 | Completed | ||
| A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas[NCT02209428] | Phase 2 | 54 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas[NCT00003176] | Phase 2 | 82 participants | Interventional | 1998-03-25 | Completed | ||
| Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma[NCT05532397] | 10 participants (Anticipated) | Interventional | 2023-02-17 | Recruiting | |||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| Amino-acid PET Versus MRI Guided Re-irradiation in Patients With Recurrent Glioblastoma Multiforme - a Randomised Phase II Trial[NCT01252459] | Phase 2 | 200 participants (Anticipated) | Interventional | 2011-07-31 | Not yet recruiting | ||
| Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies[NCT00770263] | Phase 1 | 46 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Phase II Evaluation of Temozolomide (SCH52365) and Thalidomide for the Treatment of Recurrent and Progressive Glioblastoma Multiforme[NCT00006358] | Phase 2 | 44 participants (Actual) | Interventional | 2000-06-13 | Completed | ||
| Monoinstitutional Phase II Trial Addressing Tolerability and Activity of RCHOP Chemoimmunotherapy Preceded by BBB Permeabilization by t-NGR Necrosis Factor in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma[NCT03536039] | Phase 2 | 28 participants (Actual) | Interventional | 2016-01-27 | Completed | ||
| Clinical Efficacy and Safety of IBER Salvage Treatment Followed by Ibrutinib Maintenance for Transplant-ineligible Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL): a Multicenter, Single-arm, Prospective Phase II Study[NCT04066920] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-10-01 | Not yet recruiting | ||
| Phase Ⅱ Trial of Temozolomide Plus Concurrent Whole-Brain Radiation Followed by TNV Regimen as Adjuvant Therapy for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (PCNSL)[NCT01735747] | Phase 2 | 16 participants (Anticipated) | Interventional | 2008-06-30 | Active, not recruiting | ||
| Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating Agents[NCT03557359] | Phase 2 | 20 participants (Actual) | Interventional | 2018-06-12 | Active, not recruiting | ||
| A Phase II Study of Temozolomide in the Treatment of Children With High Grade Glioma[NCT00028795] | Phase 2 | 170 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway[NCT01601184] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2012-06-30 | Terminated (stopped due to The number of successes is not reached at the end of first stage of the phase II. The study is stopped.) | ||
| A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas[NCT01837862] | Phase 1/Phase 2 | 36 participants (Anticipated) | Interventional | 2013-10-22 | Recruiting | ||
| A Phase I Trial Of Temozolomide In Pediatric Patients With Refractory/Recurrent Leukemias[NCT00083070] | Phase 1 | 16 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| A Phase I/II Trial Of Temozolomide And Vinorelbine For Patients With Recurrent Brain Metastases[NCT00026494] | Phase 1/Phase 2 | 49 participants (Actual) | Interventional | 2001-07-31 | Completed | ||
| Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma[NCT00006025] | Phase 1 | 0 participants | Interventional | 2001-01-05 | Completed | ||
| Evaluating the Expression Levels of microRNA-10b in Patients With Gliomas[NCT01849952] | 200 participants (Anticipated) | Observational | 2020-02-28 | Recruiting | |||
| A Phase II Study of Temozolomide (SCH 52365, Temodal(R)) for the Treatment of Recurrent Malignant Glioma[NCT00004113] | Phase 2 | 0 participants | Interventional | 1999-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"ORR was measured by the percentage of participants whose best overall response (BOR) is confirmed Complete Response (CR) or Partial Response (PR) divided by response evaluable participants. The best overall response (BOR) is determined once all the data for the participant is known. BOR is defined as the best response designation, as determined by investigators, recorded between the date of randomization and the date of objectively documented progression per RANO criteria, the date of subsequent therapy, or date of surgical resection, whichever occurs first.~Confidence interval based on the Clopper and Pearson method. For the comparison of the odds ratio of Nivolumab over Bevacizumab, the Cochran-Mantel-Haenszel (CMH) method of weighting was utilized." (NCT02017717)
Timeframe: Time from randomization to the date of the first documented tumor progression or death due to any cause (up to approximately 31 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Cohort 2: Arm N3 | 7.8 |
| Cohort 2: Arm B | 23.1 |
OS(12) is measured as the percentage of participants alive at 12 months per Kaplan-Meier curve of OS. Z test with variance estimation based on Greenwood formula using log(-log) transformation. (NCT02017717)
Timeframe: From randomization to 12 months following randomization
| Intervention | Percentage of Participants (Number) |
|---|---|
| Cohort 2: Arm N3 | 41.8 |
| Cohort 2: Arm B | 42.4 |
"OS was measured in months from the time of randomization to the event date (death) due to any cause. A participant who has not died will be censored at the last known alive date.~Based on Kaplan-Meier Estimates. Hazard ratio from Cox proportional hazard model stratified by presence of measurable lesions at baseline per IVRS. P-value from log-rank test stratified by presence of measurable lesions at baseline per IVRS." (NCT02017717)
Timeframe: Time between the date of randomization and the date of death due to any cause (up to 17Jun2019, approximately 5 years)
| Intervention | Months (Median) |
|---|---|
| Cohort 2: Arm N3 | 9.77 |
| Cohort 2: Arm B | 10.05 |
"OS was measured in months from the time of randomization (Part B) or time of treatment (Part A) to the event date (death) due to any cause. A participant who has not died will be censored at the last known alive date.~Based on Kaplan-Meier Estimates." (NCT02017717)
Timeframe: Time between the date of randomization and the date of death due to any cause (up to 17Jun2019, approximately 5 years)
| Intervention | Months (Median) |
|---|---|
| Part A Cohort 1c: Arm N3+RT+TMZ | 22.08 |
| Part A Cohort 1d: Arm N3+RT | 14.41 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 15.95 |
| Part B Cohort 1d: Arm N3+RT | 13.96 |
PFS was measured in months from the time of randomization to the date of the first documented tumor progression or death due to any cause. Based on Kaplan-Meier Estimates. Hazard ratio from Cox proportional hazard model stratified by presence of measurable lesions at baseline per IVRS. (NCT02017717)
Timeframe: Time from randomization to the date of the first documented tumor progression or death due to any cause (up to 17Jun2019, approximately 5 years)
| Intervention | Months (Median) |
|---|---|
| Cohort 2: Arm N3 | 1.51 |
| Cohort 2: Arm B | 3.61 |
The percentage of participants who experienced an adverse event by worst grade in each treatment arm. Toxicities were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. MedDRA Version: 24.1 (NCT02017717)
Timeframe: From first dose to 30 days post last dose (up to approximately 34 months).
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| Cohort 1: Arm N1+I3 | 0 | 10.0 | 70.0 | 20.0 | 0 |
| Cohort 1: Arm N3 | 20.0 | 30.0 | 40.0 | 10.0 | 0 |
| Cohort 1b: Arm N3+I1 | 5.0 | 25.0 | 50.0 | 20.0 | 0 |
| Part A Cohort 1c: Arm N3+RT+TMZ | 6.5 | 12.9 | 58.1 | 22.6 | 0 |
| Part A Cohort 1d: Arm N3+RT | 13.3 | 26.7 | 33.3 | 20.0 | 3.3 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 3.6 | 28.6 | 50.0 | 10.7 | 3.6 |
| Part B Cohort 1d: Arm N3+RT | 17.9 | 25.0 | 35.7 | 21.4 | 0 |
The percentage of participants who experienced a drug-related adverse event leading to drug discontinuation by worst grade (grade 5 being the worst) prior to complete four-dose treatment. Toxicities were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. MedDRA Version: 24.1 (NCT02017717)
Timeframe: Includes events reported between first dose and 30 days after last dose of study therapy (up to 3 doses, up to approximately 2 months)
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| Cohort 1: Arm N1+I3 | 0 | 0 | 16.7 | 33.3 | 0 |
| Cohort 1: Arm N3 | 0 | 0 | 0 | 0 | 0 |
| Cohort 1b: Arm N3+I1 | 0 | 0 | 0 | 0 | 0 |
| Part A Cohort 1c: Arm N3+RT+TMZ | 0 | 0 | 66.7 | 0 | 0 |
| Part A Cohort 1d: Arm N3+RT | 0 | 0 | 0 | 0 | 0 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 0 | 0 | 0 | 0 | 0 |
| Part B Cohort 1d: Arm N3+RT | 0 | 0 | 50.0 | 0 | 0 |
The percentage of participants who experienced a serious adverse event by worst grade in each treatment arm. Toxicities were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. MedDRA Version: 24.1 (NCT02017717)
Timeframe: From first dose to 30 days post last dose (up to approximately 34 months).
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| Cohort 1: Arm N1+I3 | 0 | 0 | 60.0 | 20.0 | 0 |
| Cohort 1: Arm N3 | 0 | 10.0 | 40.0 | 0 | 0 |
| Cohort 1b: Arm N3+I1 | 0 | 5.0 | 35.0 | 15.0 | 0 |
| Part A Cohort 1c: Arm N3+RT+TMZ | 3.2 | 0 | 45.2 | 16.1 | 0 |
| Part A Cohort 1d: Arm N3+RT | 0 | 16.7 | 16.7 | 16.7 | 3.3 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 0 | 3.6 | 35.7 | 3.6 | 3.6 |
| Part B Cohort 1d: Arm N3+RT | 0 | 10.7 | 32.1 | 14.3 | 0 |
"The percentage of participants who experienced a laboratory abnormality of the liver in each treatment arm.~MedDRA Version: 24.1~Aspartate aminotransferase (AST) Alanine aminotransferase (ALT) Upper Limit of Normal (ULN) Denominator corresponds to participants with at least on one treatment measurement of the corresponding laboratory parameter. Includes laboratory results reported after the first dose and within 30 days of last dose of study therapy." (NCT02017717)
Timeframe: From first dose to 30 days post last dose (up to approximately 34 months).
| Intervention | Percentage of participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ALT OR AST > 3*ULN | ALT OR AST > 5*ULN | ALT OR AST > 10*ULN | ALT OR AST > 20*ULN | TOTAL BILIRUBIN (Tbili) > 2*ULN | ALP > 1.5*ULN | ALT or AST > 3xULN w/ Tbili > 1.5*ULN within 1 day | ALT or AST > 3*ULN w/ Tbili > 1.5*ULN within 30 days | ALT or AST > 3xULN w/ Tbili > 2*ULN within 1 day | ALT or AST > 3*ULN w/ Tbili > 2*ULN within 30 days | |
| Cohort 1: Arm N1+I3 | 30.0 | 20.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 |
| Cohort 1: Arm N3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cohort 1b: Arm N3+I1 | 15.8 | 10.5 | 5.3 | 5.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Part A Cohort 1c: Arm N3+RT+TMZ | 22.6 | 12.9 | 6.5 | 3.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Part A Cohort 1d: Arm N3+RT | 10.0 | 3.3 | 3.3 | 3.3 | 0.0 | 3.3 | 0.0 | 0.0 | 0.0 | 0.0 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 18.5 | 11.1 | 3.7 | 0.0 | 7.4 | 0.0 | 3.7 | 3.7 | 3.7 | 3.7 |
| Part B Cohort 1d: Arm N3+RT | 14.8 | 3.7 | 3.7 | 3.7 | 0.0 | 3.7 | 0.0 | 0.0 | 0.0 | 0.0 |
"The percentage of participants who experienced a laboratory abnormality of the thyroid in each treatment arm.~MedDRA Version: 24.1~Free T3 (FT3) Free T4 (FT4) Lower Limit of Normal (LLN)~(A) Within a 2-week window after the abnormal TSH test date. (B) Includes participants with TSH abnormality and with no FT3/FT4 test values in the 2-week window or with non-abnormal value(s) from only one of the two tests and no value from the other test." (NCT02017717)
Timeframe: From first dose to 30 days post last dose (up to approximately 34 months).
| Intervention | Percentage of participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TSH > ULN | TSH > ULN, WITH TSH <= ULN AT BASELINE | TSH > ULN, WITH AT LEAST ONE FT3/FT4 TEST < LLN | TSH > ULN, WITH ALL OTHER FT3/FT4 TEST >= LLN | TSH > ULN, WITH FT3/FT4 TEST MISSING | TSH < LLN | TSH < LLN, WITH TSH >= LLN AT BASELINE | TSH | TSH < LLN, WITH ALL OTHER FT3/FT4 TEST <= ULN | TSH < LLN, WITH FT3/FT4 TEST MISSING | |
| Cohort 1: Arm N1+I3 | 20.0 | 20.0 | 20.0 | 0.0 | 0.0 | 60.0 | 60.0 | 30.0 | 20.0 | 10.0 |
| Cohort 1: Arm N3 | 50.0 | 30.0 | 30.0 | 10.0 | 10.0 | 30.0 | 30.0 | 10.0 | 20.0 | 0.0 |
| Cohort 1b: Arm N3+I1 | 10.5 | 10.5 | 10.5 | 0.0 | 0.0 | 31.6 | 31.6 | 15.8 | 10.5 | 5.3 |
| Part A Cohort 1c: Arm N3+RT+TMZ | 23.3 | 20.0 | 13.3 | 6.7 | 3.3 | 43.3 | 33.3 | 10.0 | 30.0 | 3.3 |
| Part A Cohort 1d: Arm N3+RT | 16.7 | 16.7 | 13.3 | 0.0 | 3.3 | 40.0 | 40.0 | 13.3 | 16.7 | 10.0 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 11.1 | 11.1 | 7.4 | 3.7 | 0.0 | 22.2 | 18.5 | 11.1 | 11.1 | 0.0 |
| Part B Cohort 1d: Arm N3+RT | 7.4 | 7.4 | 0.0 | 7.4 | 0.0 | 33.3 | 18.5 | 0.0 | 29.6 | 3.7 |
EORTC QLQ-CIPN20 sensory subscale score was calculated following the standard scoring algorithm, transformed to a 0 (low quality of life) to 100 (best quality of life) scale. A positive change from baseline indicates improvement. (NCT01506609)
Timeframe: Baseline, Week 18
| Intervention | score on a scale (Mean) |
|---|---|
| Group 2 Placebo + Carboplatin/Paclitaxel | 13.94 |
| Group 2 Veliparib + Carboplatin/Paclitaxel | 11.24 |
"CBR: percentage of participants who were progression-free at 18 weeks, defined as complete response (CR), partial response (PR), stable disease (SD) or non-CR/non-disease progression (PD) per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1.~CR: The disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 0 mm. PR: >= 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters (SOD). PD: >= 20% increase in the SOD of target lesions, taking as reference the smallest SOD recorded since the treatment started (baseline or after) or the appearance of >=1 new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD since the treatment started (baseline or after)." (NCT01506609)
Timeframe: Week 18
| Intervention | percentage of participants (Number) |
|---|---|
| Group 2 Placebo + Carboplatin/Paclitaxel | 87.0 |
| Group 2 Veliparib + Carboplatin/Paclitaxel | 90.7 |
| Group 2 Veliparib + TMZ | 73.0 |
The objective response rate, defined as percentage of participants with a confirmed CR or PR based on RECIST 1.1 criteria. CR: The disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 0 mm. PR: >= 30% decrease in the sum of diameters of target lesions, taking as reference the baseline SODs. (NCT01506609)
Timeframe: Radiographic evaluation every 9 weeks, clinical evaluation every cycle (data cutoff date: 04 March 2016); maximum duration of follow up for ORR was 34 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Group 2 Placebo + Carboplatin/Paclitaxel | 61.3 |
| Group 2 Veliparib + Carboplatin/Paclitaxel | 77.8 |
| Group 2 Veliparib + TMZ | 28.6 |
Time to death for a given participant was defined as the number of months from the day the participant is randomized to the date of the participant's death. All events of death were included, regardless of whether the event occurs while the participant was still taking study drug, or after the participant discontinued study drug. If a participant had not died, then the data will be censored at the date when the participant was last known to be alive. (NCT01506609)
Timeframe: From Cycle 1 Day 1 until participant's death or 3 years post discontinuation (data cutoff date: 04 March 2016); maximum duration of follow up for OS was 72 months.
| Intervention | months (Median) |
|---|---|
| Group 2 Placebo + Carboplatin/Paclitaxel | 25.4 |
| Group 2 Veliparib + Carboplatin/Paclitaxel | 28.3 |
| Group 2 Veliparib + TMZ | 19.1 |
PFS is defined as the number of months from the date the participant was randomized to the date of radiographic progression as determined by the central imaging center, or to the date of all cause deaths within 63 days of last tumor assessment if disease progression was not reached. (NCT01506609)
Timeframe: Radiographic evaluation every 9 weeks, clinical evaluation every cycle (data cutoff date: 04 March 2016); maximum duration of follow up for PFS was 34 months.
| Intervention | months (Median) |
|---|---|
| Group 2 Placebo + Carboplatin/Paclitaxel | 12.3 |
| Group 2 Veliparib + Carboplatin/Paclitaxel | 14.1 |
| Group 2 Veliparib + TMZ | 7.4 |
The MDASI-BT assesses the severity of multiple brain tumor-related symptoms and the impact of these symptoms on daily functioning in the last 24 hours. It consists of 22 symptom items and 6 interference items, each rated from 0 to 10. MDASI-BT symptom severity score is defined as average over 13 core symptom items and 9 brain tumor symptom items, with a total score of 0 to 10, with higher score indicating worse symptoms/interference. Changes in symptom severity score were classified into 3 categories: improved (≤ -1), stable (> -1 and < 1), and deteriorated (≥ 1). Deterioration is defined as satisfying the deterioration criteria (i.e., increase in symptom severity score by ≥ 1 unit) without further improvement (i.e., failing to satisfy deterioration criteria) within 8 weeks or occurrence of death. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 11.0 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 6.1 |
The MDASI-BT assesses the severity of multiple brain tumor-related symptoms and the impact of these symptoms on daily functioning in the last 24 hours. It consists of 22 symptom items and 6 interference items, each rated from 0 to 10. MDASI-BT symptom interference score is defined as an average of 6 interference items, with a total score of 0 to 10, where higher scores indicate worse interference. Changes in symptom interference score were classified into 3 categories: improved (≤ -1), stable (> -1 and < 1), and deteriorated (≥ 1). Deterioration is defined as satisfying the deterioration criteria (i.e., increase in symptom interference score by ≥ 1 unit) without further improvement (i.e., failing to satisfy deterioration criteria) within 8 weeks or occurrence of death. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 9.7 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 6.1 |
The HVLT-R consists of 3 parts. Free call has a range of 0 to 36, delayed recall has a range from 0 to 12, and delayed recognition has a range of -12 to 12. Higher scores indicating better function in all 3 parts. When scoring the HVLT-R, the 3 learning trials are combined to calculate a total recall score (range -12 to 60). Deterioration is defined as satisfying the deterioration criteria (i.e., decrease in HVLT-R total recall score by 5 units) without further improvement within 8 weeks or occurrence of death. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 13.2 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 10.7 |
Time to OS is defined as the number of days from the date of randomization to the date of death due to any cause. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 18.2 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 19.8 |
Time to OS is defined as the number of days from the date of randomization to the date of death due to any cause. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | NA |
| Depatuxizumab Mafodotin, Radiation and TMZ | 25.4 |
"Time to OS is defined as the number of days from the date of randomization to the date of death due to any cause.~Unmethylated MGMT promoter is associated with a worse prognosis in GBM" (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 16.2 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 16.1 |
Time to OS is defined as the number of days from the date of randomization to the date of death due to any cause. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 18.7 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 18.9 |
PFS will be defined as the number of days from the date of randomization to the date of earliest disease progression based on Response Assessment in Neuro-Oncology (RANO) criteria or to the date of death, if disease progression does not occur. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 5.9 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 8.3 |
PFS will be defined as the number of days from the date of randomization to the date of earliest disease progression based on Response Assessment in Neuro-Oncology (RANO) criteria (see Wen et al. J Clin Oncol. 2010 Apr 10;28(11):1963-72) or to the date of death, if disease progression does not occur. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 6.3 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 8.0 |
The objective response rate (ORR) included best overall responses - complete response (CR) and partial response (PR) - assessed by the independent review committee per response assessment in neurooncology criteria (RANO) criteria from the date of randomization until disease progression or death, whichever came first. All objective responses (CR and PR) must be have been confirmed by repeat MRI 4 weeks after the first time when CR or PR is identified. Any subject who did not meet CR or PR including those who did not have post-baseline radiological assessments was considered a nonresponder. (NCT02343406)
Timeframe: Every 8 weeks at each assessment of disease, up to 28 months
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-414/Temozolomide | 14.3 |
| ABT-414_adult | 7.7 |
| Control (Temozolomide/Lomustine) | 4.4 |
AUC is a measure of how long and how much drug is present in the body after dosing. The AUC of depatuxizumab mafodotin (ABT-414) in the pediatric population was measured following treatment to confirm that this was comparable to adults, and that the dosing levels are appropriate for a pediatric population. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2,3,5,8,15; Cycle 2 Day 1; Cycle 3 Day 1; Cycle 5 Day 1; Day 1 of every two cycles starting with Cycle 5; and 35 days after the last dose
| Intervention | µg*h/mL (Mean) |
|---|---|
| ABT-414_ Pediatric | 3170 |
AUC is a measure of how long and how much drug or drug metabolite is present in the body after dosing. The AUC of Cys-mcMMAF, a toxic metabolite of depatuxizumab mafodotin, in the pediatric population was measured following treatment to confirm that this was comparable to adults, and that the dosing levels are appropriate for a pediatric population. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2, 3, 5, 8
| Intervention | ng*h/mL (Mean) |
|---|---|
| ABT-414_ Pediatric | 14.1 |
Half-life is the calculated time it takes for half of the drug to leave the body. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2,3,5,8,15; Cycle 2 Day 1; Cycle 3 Day 1; Cycle 5 Day 1; Day 1 of every two cycles starting with Cycle 5; and 35 days after the last dose
| Intervention | days (Mean) |
|---|---|
| ABT-414_ Pediatric | 9.0 |
Half-life is the calculated time it takes for half of the drug or drug metabolite to leave the body. CysmcMMAF is a toxic metabolite of depatuxizumab mafodotin. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2, 3, 5, 8
| Intervention | days (Mean) |
|---|---|
| ABT-414_ Pediatric | 11.2 |
Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose. Cys-mcMMAF is a toxic metabolite of depatuxizumab mafodotin. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2, 3, 5, 8
| Intervention | ng/mL (Mean) |
|---|---|
| ABT-414_ Pediatric | 0.272 |
Cmax is the peak concentration that a drug achieves in a specified compartment after the drug has been administrated and before administration of a second dose. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2,3,5,8,15; Cycle 2 Day 1; Cycle 3 Day 1; Cycle 5 Day 1; Day 1 of every two cycles starting with Cycle 5; and 35 days after the last dose
| Intervention | µg/mL (Mean) |
|---|---|
| ABT-414_ Pediatric | 31.4 |
The severity of each adverse event was rated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE Version 4.0) (NCT02343406)
Timeframe: From participant's first visit until 49 days after the participant's last dose of study drug, up to 63 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-414_ Pediatric | 100 |
Overall Survival (OS) was defined as time from randomization to death due to any cause, regardless of whether the event occurred on or off study drug (depatuxizumab mafodotin/temozolomide/lomustine). (NCT02343406)
Timeframe: From the date of randomization up to the date of participant's death; participants who completed treatment were to be assessed every 12 weeks, up to 28 months.
| Intervention | months (Number) | ||
|---|---|---|---|
| 25th quartile | 50th quartile | 75th quartile | |
| ABT-414_adult | 4.6 | 7.9 | 15.5 |
| ABT-414/Temozolomide | 5.7 | 9.6 | 16.9 |
| Control (Temozolomide/Lomustine) | 4.9 | 8.2 | 12.6 |
Overall Survival (OS) was defined as time from randomization to death due to any cause, regardless of whether the event occurred on or off study drug (depatuxizumab mafodotin/temozolomide/lomustine) for all randomized participants that had the Epidermal Growth Factor Receptor (EGFRvIII) mutation. (NCT02343406)
Timeframe: From the date of randomization up to the date of participant's death; participants who completed treatment were to be assessed every 12 weeks, up to 28 months
| Intervention | months (Number) | ||
|---|---|---|---|
| 25th quartile | 50th quartile | 75th quartile | |
| ABT-414_adult | 5.0 | 8.4 | 13.9 |
| ABT-414/Temozolomide | 6.3 | 9.4 | 14.4 |
| Control (Temozolomide/Lomustine) | 4.7 | 7.5 | 12.4 |
Progression-free survival was assessed per response assessment in neuro-oncology criteria (RANO) criteria and assessed by an independent review committee and was defined as the length of time during and after the treatment of a disease, that the participant lived with the disease but did not get worse. (NCT02343406)
Timeframe: Measured every 8 weeks from date of randomization until the date of first objective progression or subject's death, whichever occurred first, up to 2 years
| Intervention | months (Number) | ||
|---|---|---|---|
| 25th quartile | 50th quartile | 75th quartile | |
| ABT-414_adult | 1.5 | 1.9 | 3.5 |
| ABT-414/Temozolomide | 1.8 | 2.7 | 4.9 |
| Control (Temozolomide/Lomustine) | 1.6 | 1.9 | 4.2 |
Duration of overall survival for patients that are alive (NCT03034135)
Timeframe: 14 months
| Intervention | months (Median) |
|---|---|
| DSF-Cu | 7.1 |
Duration of progression free survival according to RANO criteria (NCT03034135)
Timeframe: 12 months
| Intervention | months (Median) |
|---|---|
| DSF-Cu | 1.7 |
Number of Participants with Grade 3 and 4 serious adverse events (NCT03034135)
Timeframe: 14 months
| Intervention | Participants (Count of Participants) |
|---|---|
| DSF-Cu | 2 |
Percentage of patients that are free from progressive disease per RANO criteria (NCT03034135)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| DSF-Cu | 14 |
ORR will be defined as the percentage of patients with complete response (CR) or partial response (PR) according to the RANO criteria. (NCT03034135)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Complete response | Partial Response | |
| DSF-Cu | 0 | 0 |
Percentage of patients that are alive (NCT03034135)
Timeframe: 6 months and 12 months
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 6 months | 12 months | |
| DSF-Cu | 61 | 35 |
Percentage of participants surviving six months from the start of study treatment without progression of disease. PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Macdonald criteria, or to death due to any cause. (NCT00597493)
Timeframe: 6 months
| Intervention | percentage of patients (Number) |
|---|---|
| Sorafenib + Temozolomide | 9.4 |
Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. AUC-24 refers to area under the plasma concentration-time curve from 0 to 24 hours. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAEDs) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months
| Intervention | ug*H/L (Geometric Mean) |
|---|---|
| EIAEDs-Day 1 | 45309.7 |
| EIAEDs-Day 28 | 47148.2 |
| Non-EIAEDs-Day 1 | 45238.7 |
| Non-EIAEDs-Day 28 | 128820.8 |
Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. C-max refers to maximum plasma concentration. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAED) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months
| Intervention | ug/L (Geometric Mean) |
|---|---|
| EIAEDs-Day 1 | 3397.3 |
| EIAEDs-Day 28 | 3813.9 |
| Non-EIAEDs-Day 1 | 3155.1 |
| Non-EIAEDs-Day 28 | 8118.8 |
Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. T-max refers to time to maximum concentration. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAED) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months
| Intervention | hours (Median) |
|---|---|
| EIAEDs-Day 1 | 8.2 |
| EIAEDs-Day 28 | 2.1 |
| Non-EIAEDs-Day 1 | 24.0 |
| Non-EIAEDs-Day 28 | 4.2 |
Number of participants experiencing a toxicity of at least grade 3 that was deemed possibly, probably, or definitely related to the treatment. (NCT00597493)
Timeframe: 16 months
| Intervention | participants (Number) |
|---|---|
| Sorafenib + Temozolomide | 19 |
Percentage of participants surviving six months from the start of study treatment without progression of disease. PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Macdonald criteria, or to death due to any cause. [Optional: Macdonald criteria are standard criteria in neuro-oncology. Tumor assessment was made according to the adapted MacDonald criteria based on the combined evaluation of: 1) assessment of the MRI scan for measurable, evaluable, and new lesions (made by the independent external expert too), 2) overall assessment of neurological performance (made by the investigator), 3) concomitant steroid use (as reported by the investigator).] (NCT00501891)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab and Metronomic Temozolomide | 18.8 |
The number of participants with complete or partial response as determined by a modification of the Macdonald criteria. Complete response was defined as complete disappearance on MR/CT of all enhancing tumor and mass effect, off all corticosteroids (or receiving only adrenal replacement doses), accompanied by a stable or improving neurologic examination, and maintained for at least 4 weeks. Partial Response was defined as greater than or equal to 50% reduction in tumor size on MR/CT by bi-dimensional measurement, on a stable or decreasing dose of corticosteroids, accompanied by a stable or improving neurologic examination, and maintained for at least 4 weeks. (NCT00501891)
Timeframe: 27 months
| Intervention | Number of participants (Number) |
|---|---|
| Bevacizumab and Metronomic Temozolomide | 9 |
Number of participants experiencing a Central Nervous System (CNS) hemorrhage or systemic hemorrhage (NCT00501891)
Timeframe: 27 months
| Intervention | participants (Number) | |
|---|---|---|
| CNS Hemorrhage | Systemic Hemorrhage | |
| Bevacizumab and Metronomic Temozolomide | 0 | 0 |
Number of participants experiencing a grade ≥4 hematologic or grade ≥3 non-hematologic toxicity (NCT00501891)
Timeframe: 27 months
| Intervention | participants (Number) | |
|---|---|---|
| Grade ≥ 4 hematologic toxicities | Grade ≥ 3 non-hematologic toxicities | |
| Bevacizumab and Metromonic Temozolomide | 0 | 14 |
Progression free survival is defined by any of the following: ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions (compared with baseline if no decrease) on stable or increasing doses of corticosteroids; a significant increase in T2/FLAIR non-enhancing lesions on stable or increasing dose of corticosteroids compared with baseline scan or best response after initial of therapy, not due to comorbid events; the appearance of any new lesions; clear progression of non-measurable lesions; or definite clinical deterioration not attributable to another causes apart from the tumor, or to decrease in corticosteroid dose. (NCT02082119)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| High Grade Glioma | 82 |
All patients will have their tumor measurements recorded at baseline and at the time of each MRI scan. Lesions must be measured in two dimensions. The dose of gadolinium must be held constant from scan to scan. Macdonald criteria will be used for assessment of tumor response. (NCT00498927)
Timeframe: 2 years
| Intervention | months (Median) |
|---|---|
| Temozolomide | 7 |
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00498927)
Timeframe: at 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Temozolomide | 19 |
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
All patients will have their tumor measurements recorded at baseline and at the time of each MRI scan. Lesions must be measured in two dimensions. (NCT00026494)
Timeframe: 2 years
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Stable Disease (SD) | Progression of Disease (POD) | Partial Response (PR) | Minor Response (MR) | Complete Response (CR) | |
| 15mg/m2 - Vinorelbine | 3 | 2 | 0 | 0 | 0 |
| 20mg/m2 - Vinorelbine | 2 | 1 | 1 | 0 | 0 |
| 25mg/m2 - Vinorelbine | 4 | 11 | 0 | 1 | 0 |
| 30mg/m2 - Vinorelbine | 3 | 12 | 0 | 0 | 1 |
66 reviews available for temozolomide and Local Neoplasm Recurrence
| Article | Year |
|---|---|
The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials.
Topics: Adult; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Progression-F | 2022 |
Impact of angiogenic inhibition in the treatment of newly diagnosed and recurrent glioblastoma: a meta-analysis based on randomized controlled trials.
Topics: Adult; Angiogenesis Inhibitors; Bevacizumab; Glioblastoma; Humans; Neoplasm Recurrence, Local; Rando | 2022 |
Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis.
Topics: Aged; Antineoplastic Agents, Alkylating; Bayes Theorem; Brain Neoplasms; Dacarbazine; Glioblastoma; | 2022 |
Updates in the Management of Recurrent Glioblastoma Multiforme.
Topics: Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2023 |
Immune-checkpoint inhibitors for glioblastoma: what have we learned?
Topics: Brain Neoplasms; Clinical Trials, Phase III as Topic; Glioblastoma; Humans; Immune Checkpoint Inhibi | 2022 |
Irinotecan dose schedule for the treatment of Ewing sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Humans; Irinotecan; Neopl | 2023 |
Utility of the Cerebral Organoid Glioma 'GLICO' Model for Screening Applications.
Topics: Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Organoids; Temozolomide | 2022 |
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Lomustine; Ne | 2023 |
Is Autophagy Inhibition in Combination with Temozolomide a Therapeutically Viable Strategy?
Topics: Autophagy; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2023 |
Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Carcinoma | 2020 |
Management of glioblastoma: State of the art and future directions.
Topics: Antineoplastic Agents; Bevacizumab; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Glioblastom | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Radiation-Associated Glioblastoma after Prophylactic Cranial Irradiation in a Patient of ALL: Review of Literature and Report of a Rare Case.
Topics: Brain Neoplasms; Child, Preschool; Cranial Irradiation; Glioblastoma; Humans; Male; Neoplasm Recurre | 2020 |
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2021 |
Progress and prospect in tumor treating fields treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Th | 2021 |
Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches.
Topics: Capecitabine; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Everolimus; Humans; Neo | 2021 |
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Dis | 2017 |
Salinomycin's potential to eliminate glioblastoma stem cells and treat glioblastoma multiforme (Review).
Topics: Brain; Dacarbazine; Glioblastoma; Humans; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Pyrans; | 2017 |
The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.
Topics: Animals; Brain Neoplasms; Cause of Death; Chemoradiotherapy; Combined Modality Therapy; Disease Mana | 2018 |
Regression of Recurrent High-Grade Glioma with Temozolomide, Dexamethasone, and Levetiracetam: Case Report and Review of the Literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Corpus Ca | 2017 |
Treatment of Glioblastoma.
Topics: Aftercare; Age Factors; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Bra | 2017 |
Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2017 |
Remarkable efficacy of temozolomide for relapsed spinal myxopapillary ependymoma with multiple recurrence and cerebrospinal dissemination: a case report and literature review.
Topics: Adult; Antineoplastic Agents, Alkylating; Cauda Equina; Chemotherapy, Adjuvant; Combined Modality Th | 2018 |
Temozolomide-associated hypermutation in gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Progression; DNA Methylation; DNA Repair | 2018 |
Alternating Electric Fields Therapy for Malignant Gliomas: From Bench Observation to Clinical Reality.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Electric | 2018 |
Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Middle Aged; Neoplasm Recurrence, Loca | 2018 |
Anti-angiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brai | 2018 |
Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; Diagnosis, Differentia | 2019 |
How and when to use temozolomide to treat aggressive pituitary tumours.
Topics: Antineoplastic Agents, Alkylating; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prognosi | 2019 |
Pseudoprogression after glioma therapy: a comprehensive review.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2013 |
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Auranofin; Brain Neoplasms | 2013 |
Enhancing radiation therapy for patients with glioblastoma.
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Neopla | 2013 |
Temozolomide for high grade glioma.
Topics: Age Factors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; | 2013 |
Epigenetic pathways and glioblastoma treatment.
Topics: Adult; Animals; Brain Neoplasms; Dacarbazine; Drug Discovery; Epigenesis, Genetic; Gene Regulatory N | 2013 |
Extracranial glioblastoma with synchronous metastases in the lung, pulmonary lymph nodes, vertebrae, cervical muscles and epidural space in a young patient - case report and review of literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Biopsy; Chemoradiotherapy, Adjuvant; Dacarbazine; Epidural | 2013 |
Current evidence of temozolomide and bevacizumab in treatment of gliomas.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineop | 2015 |
Antiangiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brai | 2014 |
Treatment considerations for MGMT-unmethylated glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification M | 2015 |
Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.
Topics: Adenoma; Administration, Oral; Antineoplastic Agents, Alkylating; Cell Transformation, Neoplastic; C | 2014 |
The role of temozolomide in the treatment of aggressive pituitary tumors.
Topics: Adenoma; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; Disease Progression; DN | 2015 |
Intracranial fibrosarcoma treated with adjuvant radiation and temozolomide: Report of a case and review of all published cases.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2016 |
The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Neoplasm Recurrence | 2015 |
A case of papillary tumor of the pineal region with a long clinical history: molecular characterization and therapeutic consideration with review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Combined Modali | 2016 |
Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials | 2017 |
Temozolomide for high grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Neoplasm Recu | 2008 |
New advances that enable identification of glioblastoma recurrence.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Diffusion Magnetic Resonance Imaging; Glioblastoma; | 2009 |
[Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2009 |
[Drug therapy of patients with recurrent glioblastoma: is there any evidence?].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Age | 2011 |
Bevacizumab as a treatment option for radiation-induced cerebral necrosis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.
Topics: Algorithms; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chem | 2011 |
Glioblastoma multiforme: enhancing survival and quality of life.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Neoplas | 2011 |
Recent therapeutic advances and insights of recurrent glioblastoma multiforme.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agent | 2013 |
Imaging characteristics of an unusual, high-grade angiocentric glioma: a case report and review of the literature.
Topics: Adolescent; Brain Neoplasms; Combined Modality Therapy; Cranial Nerve Diseases; Dacarbazine; Diagnos | 2012 |
The use of temozolomide in recurrent malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; H | 2002 |
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic | 2003 |
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neop | 2004 |
Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.
Topics: Acute Disease; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosomes, | 2005 |
New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Methy | 2006 |
[Pattern of care of high-grade gliomas].
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Anticonvulsants; Antineoplastic Agents, Alkylatin | 2006 |
Anaplastic astrocytoma in adults.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical T | 2007 |
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dac | 2008 |
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Apoptosis; Brain Edema; Brain Neoplasms; Chemother | 2008 |
Atypical teratoid/rhabdoid tumors in adult patients: case report and review of the literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2001 |
Temozolomide for treating brain metastases.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemothera | 2001 |
A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Dacarbazi | 2002 |
Current and future developments in the use of temozolomide for the treatment of brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Res | 2001 |
161 trials available for temozolomide and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial.
Topics: Antineoplastic Agents, Alkylating; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Hu | 2022 |
A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neo | 2023 |
Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Humans; Irinotecan; Neopl | 2023 |
A phase I clinical trial of sonodynamic therapy combined with temozolomide in the treatment of recurrent glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studi | 2023 |
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Female; Humans; | 2023 |
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Bevacizumab; Brain Neopl | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Dose-Resp | 2021 |
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Dose-Resp | 2021 |
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Dose-Resp | 2021 |
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Dose-Resp | 2021 |
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cal | 2017 |
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2017 |
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2017 |
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2017 |
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2017 |
Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chem | 2017 |
VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; D | 2018 |
Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2017 |
Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomark | 2018 |
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Breas | 2018 |
Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dacarbaz | 2018 |
Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neo | 2018 |
The effect of an adenosine A
Topics: Adenosine A2 Receptor Agonists; Administration, Intravenous; Administration, Oral; Adult; Aged; Anti | 2018 |
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Growth | 2018 |
High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; | 2018 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combi | 2018 |
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Colorectal Neoplasms; | 2019 |
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Colorectal Neoplasms; | 2019 |
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Colorectal Neoplasms; | 2019 |
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Colorectal Neoplasms; | 2019 |
A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplasti | 2019 |
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Diagnostic Imaging; Gl | 2019 |
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Diagnostic Imaging; Gl | 2019 |
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Diagnostic Imaging; Gl | 2019 |
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Diagnostic Imaging; Gl | 2019 |
Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience.
Topics: Aged; Brain Neoplasms; Factor Analysis, Statistical; Female; Glioblastoma; Humans; Magnetic Resonanc | 2019 |
Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation.
Topics: Adolescent; Adult; Aged; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Female; Glioma; Humans; Ma | 2019 |
Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Chemoradiotherapy; C | 2013 |
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tu | 2013 |
[Multicenter randomized controlled study of temozolomide versus semustine in the treatment of recurrent malignant glioma].
Topics: Adult; Astrocytoma; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm R | 2013 |
Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; A | 2013 |
Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Be | 2013 |
Phase I study of temozolomide combined with oral etoposide in children with malignant glial tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; C | 2013 |
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2013 |
Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response | 2013 |
Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dacarbaz | 2014 |
Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Presc | 2014 |
A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2014 |
Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradio | 2014 |
Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Cerebellar Neoplasms; Child; Child, Preschool; | 2014 |
Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dos | 2014 |
Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cancer Vaccines; Combined Mo | 2015 |
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-F | 2015 |
Radiotherapy and temozolomide for anaplastic astrocytic gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Chemoradiotherapy; Cohort Studies; Daca | 2015 |
A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazi | 2015 |
Frequency of O⁶-methylguanine-DNA methyltransferase promoter methylation in cytological samples from small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Biopsy, Fine-Needle; Dacarbazine; DNA Methylation; Glioma; Guanine; | 2015 |
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dacarbaz | 2016 |
Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2015 |
The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping.
Topics: Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Tensor Imaging; Female | 2015 |
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neopl | 2016 |
The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazin | 2016 |
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Aurora Kina | 2016 |
A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas.
Topics: Adult; Antineoplastic Agents; Bortezomib; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2016 |
Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bioma | 2016 |
Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Brain Neoplasms; Dacarba | 2017 |
Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents; China; Cisplatin; Dacarbazine; Disease Progression; Female; Glio | 2017 |
Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm | 2008 |
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Astrocytoma; Brain Neoplasms; Chromosome | 2009 |
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Neoplasms; | 2008 |
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Resi | 2009 |
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; ErbB Recep | 2009 |
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; G | 2009 |
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbaz | 2009 |
Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazin | 2009 |
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Brai | 2010 |
Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2009 |
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | 2010 |
Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Child; C | 2010 |
Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2010 |
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Combined Modality T | 2010 |
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bra | 2011 |
Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Histor | 2010 |
Phase I study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplas | 2010 |
Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dacarbazine; Hu | 2010 |
A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Confidence Intervals; Dacarbazine; Disease-Free | 2011 |
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2011 |
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2012 |
Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
Bevacizumab and daily temozolomide for recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas.
Topics: Antineoplastic Agents, Alkylating; Asthenia; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Fe | 2012 |
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2012 |
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradi | 2012 |
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradi | 2012 |
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradi | 2012 |
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradi | 2012 |
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell | 2013 |
Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1).
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; | 2013 |
Chemosensitized radiosurgery for recurrent brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Male; | 2012 |
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dos | 2013 |
A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2013 |
"One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2013 |
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2003 |
Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2003 |
Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazin | 2003 |
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2003 |
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2003 |
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2003 |
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2003 |
A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease Progres | 2003 |
Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazin | 2004 |
Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Human | 2004 |
Temozolomide in the treatment of recurrent malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Dacarba | 2004 |
Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasm | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Con | 2004 |
Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cyclophosph | 2004 |
Temozolomide for treatment-resistant recurrent meningioma.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dexamethasone; Disease P | 2004 |
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Pr | 2004 |
First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cispl | 2004 |
Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2004 |
A phase II evaluation of Temozolomide in patients with recurrent epithelial ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine | 2004 |
Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Dacarbazine; Fe | 2004 |
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmusti | 2004 |
Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease P | 2004 |
Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost of Illness; Cost-Benefit Analy | 2005 |
Temozolomide in resistant or relapsed pediatric solid tumors.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Disease- | 2006 |
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbaz | 2005 |
Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplati | 2005 |
Phase II trial of temozolomide in children with recurrent high-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Child; Child, Preschool | 2006 |
Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma.
Topics: Adult; Anaplasia; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cyclophosphamide; | 2006 |
Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administrat | 2005 |
Role of temozolomide in spinal cord low grade astrocytomas: results in two paediatric patients.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Astrocytoma; Child; Dacarbazine; Disease Progression; | 2006 |
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacar | 2006 |
Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytochrome P-450 E | 2006 |
New approach in delivering chemotherapy: locoregional treatment for recurrent glioblastoma (rGBM).
Topics: Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Combined Modality | 2003 |
Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Austria; Brain Neoplasms; Dacarbazine; F | 2006 |
MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: preliminary results in 16 patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2006 |
Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study.
Topics: Administration, Oral; Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemothera | 2006 |
Temozolomide chemotherapy in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; | 2006 |
Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Dose-R | 2006 |
Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Ch | 2006 |
A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2006 |
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Constipation; Dacarbazine; | 2006 |
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2007 |
[Temozolomide in the treatment of recurrent malignant glioma].
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; D | 2006 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2007 |
Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cam | 2006 |
Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2008 |
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Met | 2007 |
Efficacy of temozolomide or dacarbazine in combination with an anthracycline for rescue chemotherapy in dogs with lymphoma.
Topics: Animals; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dog Diseases; | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; DNA Modi | 2007 |
A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2008 |
Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; | 2008 |
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Campt | 2007 |
Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas.
Topics: Administration, Intranasal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Blood-Brain Ba | 2008 |
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabin | 2007 |
Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Camptothecin; Dacarbazine; F | 2008 |
Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarba | 2008 |
Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Combined Modality Ther | 2008 |
CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; | 2008 |
The Charing Cross Hospital experience with temozolomide in patients with gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 1996 |
Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Dose-Res | 1998 |
Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; H | 1999 |
Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Evaluation Studies as Topic; | 2000 |
Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease P | 2000 |
Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; D | 2001 |
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2001 |
Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Humans; M | 2001 |
A phase II trial of temozolomide for patients with recurrent or progressive brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dac | 2001 |
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2002 |
Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2002 |
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Stu | 2002 |
360 other studies available for temozolomide and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Dr | 2021 |
Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2021 |
Effectiveness of bortezomib and temozolomide for eradication of recurrent human glioblastoma cells, resistant to radiation.
Topics: Antineoplastic Agents, Alkylating; Bortezomib; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neop | 2021 |
Oxyphyllanene B overcomes temozolomide resistance in glioblastoma: Structure-activity relationship and mitochondria-associated ER membrane dysfunction.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mitochondria; Neoplasm Recurrence | 2022 |
Pituitary carcinoma as a rare cause of liver metastases successfully treated with temozolomide.
Topics: Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Pituitary Neoplasms; Temozolomide | 2022 |
Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Carbonic Anhydrases; Cell Line, Tumor | 2021 |
WNT signaling modulates chemoresistance to temozolomide in p53-mutant glioblastoma multiforme.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2022 |
Intensive Multimodal Therapy Combined With Long-term Temozolomide and Etoposide Treatment for Recurrent Osteosarcoma to the Liver and Stomach.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Combined Modality Therapy; Et | 2022 |
Allopregnanolone suppresses glioblastoma survival through decreasing DPYSL3 and S100A11 expression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Ne | 2022 |
Recurrent oligodendroglioma with changed 1p/19q status.
Topics: Brain Neoplasms; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosome | 2022 |
Acquired temozolomide resistance in MGMT
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; D | 2022 |
HSP90-CDC37 functions as a chaperone for the oncogenic FGFR3-TACC3 fusion.
Topics: Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Chaperonins; Glioblastoma; Glioma; HSP90 Heat | 2022 |
Tumor treating fields therapy is feasible and safe in a 3-year-old patient with diffuse midline glioma H3K27M - a case report.
Topics: Adult; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Electric Stimulation The | 2022 |
Combining HDAC and MEK Inhibitors with Radiation against Glioblastoma-Derived Spheres.
Topics: Cell Line, Tumor; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Mitogen-Activated Protein Ki | 2022 |
Contrast enhancing pattern on pre-treatment MRI predicts response to anti-angiogenic treatment in recurrent glioblastoma: comparison of bevacizumab and temozolomide treatment.
Topics: Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, | 2022 |
Inhibition of TRPM7 with carvacrol suppresses glioblastoma functions in vivo.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cymenes; Glioblastoma; Humans; Mice; | 2022 |
Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Humans; Irinotecan; Neopl | 2022 |
PSMG3-AS1 enhances glioma resistance to temozolomide via stabilizing c-Myc in the nucleus.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resis | 2022 |
Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review.
Topics: Brain Neoplasms; Child; Humans; Meningeal Neoplasms; Meningioma; Neoplasm Recurrence, Local; Retrosp | 2022 |
PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisotopes; Chemotherapy, Adjuvant; Di | 2022 |
Aggressive giant prolactinoma: a case report.
Topics: Adolescent; Adult; Cabergoline; Female; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Pro | 2022 |
Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; DNA Methylation; DNA Modification M | 2022 |
The role of Shikonin in improving 5-aminolevulinic acid-based photodynamic therapy and chemotherapy on glioblastoma stem cells.
Topics: Aminolevulinic Acid; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Naphthoquinones; Neopl | 2022 |
Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence.
Topics: Brain Neoplasms; Carmustine; Cell Line, Tumor; Glioma; Humans; Hydrogels; Neoplasm Recurrence, Local | 2022 |
Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration of Human U251 Glioma Cells.
Topics: Antimicrobial Cationic Peptides; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cath | 2022 |
Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics.
Topics: Artesunate; Cellular Senescence; Curcumin; Glioblastoma; Humans; Lomustine; Neoplasm Recurrence, Loc | 2022 |
Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local | 2022 |
Current therapeutic options for glioblastoma and future perspectives.
Topics: Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Glioblas | 2022 |
MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repa | 2022 |
Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Glioblastoma; Glioma; | 2022 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Subclonal evolution and expansion of spatially distinct THY1-positive cells is associated with recurrence in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Male; Middle Aged; Neoplas | 2022 |
Observation of the delineation of the target volume of radiotherapy in adult-type diffuse gliomas after temozolomide-based chemoradiotherapy: analysis of recurrence patterns and predictive factors.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; | 2023 |
Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2023 |
Prognostic Factors of Gliosarcoma in the Real World: A Retrospective Cohort Study.
Topics: Brain Neoplasms; Glioblastoma; Gliosarcoma; Humans; Ki-67 Antigen; Neoplasm Recurrence, Local; Progn | 2023 |
Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Circulating Tumor DNA; Hum | 2023 |
RADIOSURGICAL TREATMENT OF RECURRENT GLIOBLASTOMA AND PROGNOSTIC FACTORS AFFECTING TREATMENT OUTCOMES.
Topics: Adult; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Prognosis; Radiosurgery; R | 2022 |
Metronomic Temozolomide in Heavily Pretreated Patients With Recurrent Isocitrate Dehydrogenase Wild-type Glioblastoma: A Large Real-Life Mono-Institutional Study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modific | 2023 |
E3 ligase MAEA-mediated ubiquitination and degradation of PHD3 promotes glioblastoma progression.
Topics: Brain Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; Cytoskeletal Proteins; Drug Resistance, | 2023 |
Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
Nanocomposite formulation for a sustained release of free drug and drug-loaded responsive nanoparticles: an approach for a local therapy of glioblastoma multiforme.
Topics: Adult; Brain Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Glioblastoma; Humans; Hydroge | 2023 |
SRSF4 Confers Temozolomide Resistance of Glioma via Accelerating Double Strand Break Repair.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Repair; Drug Resistance, N | 2023 |
High-dose carboplatin-irinotecan-temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Irinotecan; Neoplasm Recurrence | 2023 |
Moderately Hypofractionated Radio(chemo)therapy With Simultaneous Integrated Boost for Recurrent, Previously Irradiated, High-grade Glioma.
Topics: Combined Modality Therapy; Glioma; Humans; Neoplasm Recurrence, Local; Prognosis; Temozolomide | 2023 |
Development and Validation of a Targeted Treatment for Brain Tumors Using a Multi-Drug Loaded, Relapse-Resistant Polymeric Theranostic.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neoplasm Recurre | 2023 |
Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Lymphoproliferative disorder during temozolomide therapy; a representative case of a formidable complication and management challenges.
Topics: Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Immunologic Deficiency Syndromes; Lymph | 2023 |
Toward a theranostic device for gliomas.
Topics: Cell Line, Tumor; Glioblastoma; Glioma; Humans; Microbubbles; Neoplasm Recurrence, Local; Oligopepti | 2023 |
Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Immune Checkpoint Inhibitors; I | 2023 |
Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Middle Age | 2023 |
[Aggressive pituitary adenoma and pituitary carcinoma].
Topics: Adenoma; Bevacizumab; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Temozolomide | 2023 |
The Assessment of Clinical Outcomes and Prognostic Factors in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Neoplas | 2023 |
Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion.
Topics: Antineoplastic Agents; Cell Death; Glioblastoma; Humans; Neoplasm Recurrence, Local; Neoplastic Proc | 2023 |
Invadopodia associated Thrombospondin-1 contributes to a post-therapy pro-invasive response in glioblastoma cells.
Topics: Brain; Glioblastoma; Humans; Neoplasm Recurrence, Local; Podosomes; Temozolomide | 2023 |
Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences.
Topics: Adult; Astrocytoma; Child; Glioma; Humans; Mutation; Neoplasm Recurrence, Local; Temozolomide | 2023 |
LncRNA-associated competing endogenous RNA network analysis uncovered key lncRNAs involved in temozolomide resistance and tumor recurrence of glioblastoma.
Topics: Carrier Proteins; Cell Line, Tumor; Glioblastoma; Humans; MicroRNAs; Neoplasm Recurrence, Local; RNA | 2023 |
Identifying predictors of glioma evolution from longitudinal sequencing.
Topics: Adult; Brain Neoplasms; Glioma; Humans; Mutation; Neoplasm Recurrence, Local; Precision Medicine; Te | 2023 |
The effect of chemotherapies on the crosstalk interaction between CD8 cytotoxic T-cells and MHC-I peptides in the microenvironment of WHO grade 4 astrocytoma.
Topics: Astrocytoma; Brain Neoplasms; CD8-Positive T-Lymphocytes; Glioblastoma; Histocompatibility Antigens | 2023 |
Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Enhanced Sensitivity to ALDH1A3-Dependent Ferroptosis in TMZ-Resistant Glioblastoma Cells.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Ferroptosis; Glioblastoma; Humans; Neop | 2023 |
A local combination therapy to inhibit GBM recurrence.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Drug Carriers; Drug Delivery Systems; Glioblastoma; | 2019 |
Cerebral blood volume and apparent diffusion coefficient - Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bevacizumab; Brain N | 2019 |
Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Capillary | 2020 |
Prognostic impact of glioblastoma stem cell markers OLIG2 and CCND2.
Topics: Adult; Aged; Brain; Brain Neoplasms; Cell Nucleus; Chemoradiotherapy, Adjuvant; Cyclin D2; Female; G | 2020 |
Temozolomide plus PARP Inhibition in Small-Cell Lung Cancer: Could Patient-Derived Xenografts Accelerate Discovery of Biomarker Candidates?
Topics: Animals; Biomarkers; Cell Line, Tumor; Heterografts; Humans; Lung Neoplasms; Neoplasm Recurrence, Lo | 2019 |
BMP signaling mediates glioma stem cell quiescence and confers treatment resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Brain Neo | 2019 |
Craniotomy for recurrent glioblastoma: Is it justified? A comparative cohort study with outcomes over 10 years.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immu | 2020 |
Molecular Evolution of
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; C | 2020 |
Feasibility study of finalizing the extended adjuvant temozolomide based on methionine positron emission tomography (Met-PET) findings in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisot | 2019 |
Impact of treatment decision algorithms on treatment costs in recurrent glioblastoma: a health economic study.
Topics: Adult; Algorithms; Bevacizumab; Chronic Disease; Clinical Decision-Making; Female; Glioblastoma; Hea | 2019 |
Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; BRCA1 Protein; DNA Mismatch Repai | 2020 |
Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.
Topics: Antineoplastic Agents; Child; Child, Preschool; Female; Glioblastoma; Humans; Neoplasm Recurrence, L | 2020 |
Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions.
Topics: 5-Methylcytosine; Brain Neoplasms; Cell Line, Tumor; DNA Methylation; DNA Modification Methylases; D | 2020 |
MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2020 |
Metastatic VIPoma, Cosecreting Insulin, With Complete Response to Lanreotide, Capecitabine, and Temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Insulin; Middle Aged; | 2020 |
Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Female; Follow-Up Studies; H | 2021 |
The clinical, radiological, and immunohistochemical characteristics and outcomes of primary intracranial gliosarcoma: a retrospective single-centre study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gliosarcoma; H | 2021 |
Spinal metastasis of glioblastoma multiforme before gliosarcomatous transformation: a case report.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Craniotomy; Fatal Outcome; Female; Gliobl | 2020 |
LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2020 |
Temozolomide and etoposide combination for the treatment of relapsed osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2020 |
A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults.
Topics: Adult; Brain Neoplasms; Glioblastoma; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Neoplasm R | 2020 |
Influence of glioblastoma contact with the subventricular zone on survival and recurrence patterns.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Confidence Intervals; Female; | 2021 |
MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas.
Topics: Adolescent; Adult; Aged; Animals; Brain Neoplasms; Cell Line, Tumor; DNA Adducts; DNA Methylation; D | 2020 |
Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Diarrhea; Disease Prog | 2021 |
Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Humans; Isocitrate Dehydrogenase; | 2020 |
The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status.
Topics: Adult; Brain Neoplasms; Chitinase-3-Like Protein 1; DNA Methylation; DNA Modification Methylases; DN | 2020 |
Anti-PD-1, anti-VEGF, and temozolomide therapy in a patient with recurrent glioblastoma: a case report.
Topics: Adult; Angiogenesis Inhibitors; Bevacizumab; Brain Neoplasms; Female; Glioblastoma; Humans; Neoplasm | 2020 |
Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Brazil; Chemoradiotherapy; Chemotherapy, Adjuvan | 2020 |
Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology.
Topics: Animals; Brain Neoplasms; Glioblastoma; Glioma; Heterografts; Humans; Mice; Neoplasm Recurrence, Loc | 2020 |
Spatiotemporal combination of thermosensitive polypeptide fused interferon and temozolomide for post-surgical glioblastoma immunochemotherapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Mice; Neoplasm | 2021 |
Clinical characterization of glioblastoma patients living longer than 2 years: A retrospective analysis of two Italian institutions.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblas | 2021 |
Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Drug Resista | 2020 |
Drug repositioning of antiretroviral ritonavir for combinatorial therapy in glioblastoma.
Topics: Adult; Anti-Retroviral Agents; Antineoplastic Agents; Autophagy; Cell Line; Drug Repositioning; Drug | 2020 |
Hepatitis B virus reactivation during temozolomide administration for malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA, Viral; Glioma; Hepatitis B; Hepatitis B Ant | 2021 |
Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Disease-Free Su | 2021 |
Post-treatment hypermutation in a recurrent diffuse glioma with H3.3 p.G34 Mutation.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Drug Re | 2021 |
Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study.
Topics: Adolescent; Brain Neoplasms; Child; Ependymoma; Humans; Neoplasm Recurrence, Local; Radiotherapy, Ad | 2021 |
Regorafenib in glioblastoma recurrence: A case report.
Topics: Brain Neoplasms; Chemoradiotherapy, Adjuvant; Glioblastoma; Humans; Magnetic Resonance Imaging; Male | 2021 |
Final Results of the Prospective Biomarker Trial PETra: [
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2021 |
Timing of Chemoradiation in Newly Diagnosed Glioblastoma: Comparative Analysis Between County and Managed Care Health Care Models.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modalit | 2021 |
Differentiation of recurrent glioblastoma from radiation necrosis using diffusion radiomics with machine learning model development and external validation.
Topics: Adult; Aged; Brain; Chemoradiotherapy, Adjuvant; Diffusion Magnetic Resonance Imaging; Female; Gliob | 2021 |
Metastatic Myxofibrosarcoma with Durable Response to Temozolomide Followed by Atezolizumab: A Case Report.
Topics: Adult; Antibodies, Monoclonal, Humanized; Fibrosarcoma; Humans; Male; Neoplasm Recurrence, Local; Te | 2021 |
Adjuvant therapeutic potential of moderate hypothermia for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Glioblastoma; Humans; Hy | 2021 |
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
Topics: Brain; Brain Neoplasms; Glioma; Humans; Mutation; Neoplasm Recurrence, Local; Temozolomide | 2021 |
Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas.
Topics: Adult; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Diagnosis, Differential; Female; Glioma; | 2021 |
Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Ner | 2021 |
Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study.
Topics: Biomarkers, Tumor; Glioblastoma; Humans; Mutation; Neoplasm Recurrence, Local; Prospective Studies; | 2022 |
Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM.
Topics: AC133 Antigen; Adenosine; Adult; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle Check | 2021 |
[Glioblastoma].
Topics: Brain Neoplasms; Glioblastoma; Humans; Japan; Neoplasm Recurrence, Local; Temozolomide | 2021 |
Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Female; Humans; Irinotecan; M | 2022 |
17β-estradiol induces temozolomide resistance through NRF2-mediated redox homeostasis in glioblastoma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Glioblastoma; Ho | 2021 |
Oncological and functional outcomes of supratotal resection of IDH1 wild-type glioblastoma based on
Topics: Adult; Aged; Brain Neoplasms; Carbon Radioisotopes; Contrast Media; Craniotomy; Female; Glioblastoma | 2021 |
Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2021 |
Molecular characteristics of single patient-derived glioma stem-like cells from primary and recurrent glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation; | 2022 |
Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
Topics: ACTH-Secreting Pituitary Adenoma; Adult; Antineoplastic Agents, Alkylating; Carcinoma; Chemoradiothe | 2017 |
Recurrence Pattern Analysis of Primary Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2017 |
Long-term benefit of intra-arterial bevacizumab for recurrent glioblastoma.
Topics: Adult; Bevacizumab; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Male; N | 2017 |
MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.
Topics: Acetylation; Brain Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gene Exp | 2018 |
MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Dac | 2017 |
Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cohort Studies; Dacarbazine; Drug Resistance, | 2017 |
The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Anim | 2017 |
MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzym | 2017 |
PomGnT1 enhances temozolomide resistance by activating epithelial-mesenchymal transition signaling in glioblastoma.
Topics: Animals; Apoptosis; beta Catenin; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance | 2017 |
miR‑146b‑5p suppresses glioblastoma cell resistance to temozolomide through targeting TRAF6.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease-Free Survival; Drug R | 2017 |
Epidermal Growth Factor Receptor Expression Predicts Time and Patterns of Recurrence in Patients with Glioblastoma After Radiotherapy and Temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2018 |
Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; | 2017 |
Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bromocriptine; Cabergoline; Combined | 2017 |
Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness.
Topics: Benzimidazoles; Breast Neoplasms; Carboplatin; Humans; Neoplasm Recurrence, Local; Paclitaxel; Temoz | 2018 |
Role of Radiosensitizers in Radiation Treatment of Gliomas.
Topics: Dacarbazine; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; | 2018 |
Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; B | 2018 |
Improvement of health related quality of life in patients with recurrent glioma treated with bevacizumab plus daily temozolomide as the salvage therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; An | 2018 |
Temozolomide rechallenge in recurrent glioblastoma: when is it useful?
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Magn | 2018 |
[Clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent brain glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Da | 2018 |
Long-term follow-up results of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastoma multiforme patients. The importance of MRI information in survival: Single-center experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain; Central Nervous System Neoplasms; Chemoradiothera | 2018 |
The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Move | 2018 |
USE OF PERFUSION MRI FOR DETERMINATION OF IRRADIATION VOLUMES IN RADIOTHERAPY OF PATIENTS WITH BRAIN GLIOMA.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Contrast Media; Diffusion Magnetic Resona | 2018 |
Tumor-treating fields: time for demystification.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Electric Stimulation | 2018 |
Efficacy of bevacizumab and temozolomide therapy in locally advanced, recurrent, and metastatic malignant solitary fibrous tumour: A population-based analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Hemangiopericytoma | 2019 |
Stereotactic Brachytherapy with Iodine-125 Seeds Plus Temozolomide Induced Complete and Durable Remission in a Patient with Recurrent Primary Central Nervous System Lymphoma.
Topics: Antineoplastic Agents, Alkylating; Brachytherapy; Central Nervous System Neoplasms; Combined Modalit | 2018 |
Caffeine Sensitizes U87-MG Human Glioblastoma Cells to Temozolomide through Mitotic Catastrophe by Impeding G2 Arrest.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Caffeine; Cell Line, Tumor; Central Nervous System Sti | 2018 |
Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2019 |
Bevacizumab therapy for recurrent gliomas: another disappointment?
Topics: Bevacizumab; Brain Neoplasms; Glioma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2018 |
Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dose-Response Relationship, Drug; Female; | 2018 |
Diagnostic utility of restriction spectrum imaging (RSI) in glioblastoma patients after concurrent radiation-temozolomide treatment: A pilot study.
Topics: Adult; Aged; Biopsy; Brain Neoplasms; Chemoradiotherapy; Diffusion Magnetic Resonance Imaging; Femal | 2018 |
Feasibility and robustness of dynamic
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carbon; Female; Glioma; Heavy Ion Radiotherapy; Humans | 2018 |
Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2019 |
The clinical conundrum of managing relapsed small cell lung cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplas | 2019 |
Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell Movement; Cel | 2019 |
MiR-7-5p suppresses stemness and enhances temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1.
Topics: 3' Untranslated Regions; Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regul | 2019 |
Combined Applications of Repurposed Drugs and Their Detrimental Effects on Glioblastoma Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cel | 2019 |
Conventionally fractionated stereotactic radiotherapy (CFRT) in combination with dose-dense temozolomide (TMZ) in relapsed malignant glioma: A case report.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Female; Gliobl | 2019 |
Increased Expression of GRP78 Correlates with Adverse Outcome in Recurrent Glioblastoma Multiforme Patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherap | 2020 |
Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2018 |
Glioblastoma Recurrence and the Role of O
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; DNA Meth | 2019 |
Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma.
Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Plasticity; Drug Resistance, Neopla | 2019 |
Synergistic effect of arsenic trioxide, vismodegib and temozolomide on glioblastoma.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Casp | 2019 |
Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation.
Topics: Adult; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; DNA Mutational Analysis; Female; Fol | 2020 |
Bevacizumab Use in Refractory Adult Pilocytic Astrocytoma: A Single-Center Case Series.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Astrocytoma; Bevaciz | 2019 |
Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Combined Modality Therapy; D | 2019 |
Codelivery of paclitaxel and temozolomide through a photopolymerizable hydrogel prevents glioblastoma recurrence after surgical resection.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Combinations; Drug Delivery | 2019 |
Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Prol | 2013 |
Molecular analysis of a recurrent glioblastoma treated with bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevaci | 2014 |
Durable response of intracranial cellular hemangioma to bevacizumab and temozolomide.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2013 |
Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemot | 2013 |
Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2013 |
Solitary brain metastasis as first manifestation of small-cell parotid gland carcinoma with high sensitivity to temozolomide therapy on basis of tumor O6-methylguanine-DNA-methyltransferase expression.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Small Cell; Dacarbazine; Female; Huma | 2013 |
Chemoirradiation for glioblastoma multiforme: the national cancer institute experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2013 |
Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.
Topics: Amidohydrolases; Animals; Antifungal Agents; Aspartic Acid; Astrocytes; Brain; Brain Neoplasms; Cell | 2014 |
Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevac | 2014 |
Chemotherapy-induced secondary pneumothorax.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizuma | 2014 |
Factors associated with a higher rate of distant failure after primary treatment for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Modificati | 2014 |
Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; | 2013 |
Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Comb | 2014 |
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; DNA Helicases; DNA Mutationa | 2014 |
Extraneural metastases of anaplastic oligodendroglioma.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Neoplasms; Dacarbazine; Humans; Lymphatic M | 2014 |
Hyperdiploid tumor cells increase phenotypic heterogeneity within Glioblastoma tumors.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Proliferation; Daca | 2014 |
Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2014 |
Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2014 |
Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Dacarbazine; | 2013 |
Patterns of care and survival of glioblastoma patients: a comparative study between 2004 and 2008 in Lyon, France.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab | 2014 |
Antitumor effect of fibrin glue containing temozolomide against malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; | 2014 |
Inadvertent high-dose therapy with temozolomide in a child with recurrent pontine glioma followed by a rapid clinical response but deteriorated after substitution with low-dose therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Child; Dacarbazine; Dose-Response Relations | 2014 |
A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; D | 2014 |
The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradi | 2014 |
Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Fem | 2014 |
3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Aspartic Acid; Biomarkers, Tumor; Brain Neoplasms; C | 2014 |
Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease- | 2015 |
Temozolomide after radiotherapy in recurrent "low grade" diffuse brainstem glioma in adults.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Stem; Brain Stem Neoplasms; Combined Modality | 2014 |
Low-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: single-center experience with 201 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brachytherapy; Brain | 2014 |
Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Chemoradiotherapy; Coho | 2014 |
Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration | 2014 |
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Artesunate; Auran | 2014 |
Glioblastoma recurrence patterns after radiation therapy with regard to the subventricular zone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chil | 2014 |
KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis.
Topics: Animals; Apoptosis; Arsenites; Dacarbazine; DNA Damage; Drug Synergism; Glioblastoma; Humans; Mice; | 2014 |
Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.
Topics: Aniline Compounds; Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Protein | 2015 |
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Transformation, Neoplastic; Dacarbazine; Glioma; Humans | 2014 |
B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Drug Synergism; Human | 2014 |
Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Dacarbazi | 2015 |
Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence.
Topics: Aged; Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Dacarbazine; Disease Progression; Fema | 2015 |
Outcome of salvage treatment for recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2015 |
Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Magnetic Resonance Imaging; | 2016 |
Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkyla | 2015 |
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Huma | 2015 |
The evolving genomic landscape of recurrent gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Helicases; Genomics; Glioma; Hu | 2015 |
Volumetric modulated arc therapy for hippocampal-sparing radiotherapy in transformed low-grade glioma: A treatment planning case report.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Damage, Chronic; Cell Dedifferentiation; Combi | 2015 |
Epithelial-to-mesenchymal transition in paired human primary and recurrent glioblastomas.
Topics: Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Epithelial-Mesenchymal Transition | 2015 |
Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Benzylamines; Brain Neoplasms; Chemokine | 2015 |
Photodynamic therapy in the treatment of brain tumours. A feasibility study.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dihematoporphyrin | 2015 |
Prognostic impact of molecular phenotype in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases | 2015 |
Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Alkaloids; Antineoplastic Agents, Alkylating; Brain Neoplasms; Contr | 2015 |
Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Ependymoma; Fema | 2016 |
Spatiotemporal Evolution of the Primary Glioblastoma Genome.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Isoci | 2015 |
Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
Topics: Afatinib; Brain Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Co | 2015 |
Clinical, Radiographic, and Pathologic Findings in Patients Undergoing Reoperation Following Radiation Therapy and Temozolomide for Newly Diagnosed Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2017 |
Temozolomide for recurrent meningiomas: a case-report with unexpected clinical and radiological response.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Meningeal | 2016 |
Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
Topics: Adenocarcinoma; Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Follow | 2016 |
Multiple resections and survival of recurrent glioblastoma patients in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; | 2016 |
Current trends in the management of glioblastoma in a French University Hospital and associated direct costs.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Cost | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Beva | 2015 |
Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brai | 2016 |
BIRC3 is a novel driver of therapeutic resistance in Glioblastoma.
Topics: Animals; Baculoviral IAP Repeat-Containing 3 Protein; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2016 |
SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Dacarbazine; Dr | 2016 |
CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Class Ia Phosphatidylinositol 3-Kinase; Dacarbaz | 2016 |
Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA M | 2016 |
Clonal evolution of glioblastoma under therapy.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Proliferation; Clonal Ev | 2016 |
Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; C | 2016 |
Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2016 |
Recurrent Glioblastoma: Combination of High Cerebral Blood Flow with MGMT Promoter Methylation Is Associated with Benefit from Low-Dose Temozolomide Rechallenge at First Recurrence.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Volume; Brain Neoplasms; Cerebrova | 2017 |
Cyclin D1 Co-localizes with Beclin-1 in Glioblastoma Recurrences: A Clue to a Therapy-induced, Autophagy-mediated Degradative Mechanism?
Topics: Adult; Apoptosis; Autophagy; Beclin-1; Cell Line, Tumor; Cyclin D1; Dacarbazine; Drug Resistance, Ne | 2016 |
Changes in PlGF and MET-HGF expressions in paired initial and recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2016 |
Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Case-Control Studies; | 2016 |
Stem cell markers in glioma progression and recurrence.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Differentiation; Dacarbazine; Disease Pro | 2016 |
MRI and 11C-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazi | 2016 |
Refractory pituitary adenoma: a novel classification for pituitary tumors.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Cell Proliferation; Dacarbazine; Di | 2016 |
Case 38-2016. A 52-Year-Old Woman with Recurrent Oligodendroglioma.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Dia | 2016 |
Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line; Dacarbazine; Delayed-Action Preparations | 2017 |
Role of
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA | 2017 |
Temozolomide for recurrent low-grade spinal cord gliomas in adults.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Drug Administration Sc | 2008 |
A novel tool to analyze MRI recurrence patterns in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblas | 2008 |
Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2008 |
Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2008 |
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dac | 2009 |
ACNU-based chemotherapy for recurrent glioma in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2009 |
Methylation status of MGMT gene promoter in meningiomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Methylation; DNA Modification Methy | 2008 |
Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Ataxia; Brain Neoplasms; Chemotherapy, Adjuvant; Con | 2009 |
Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2009 |
Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status.
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modificat | 2009 |
Rechallenge with temozolomide in patients with recurrent gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cohort Studies; Dacarbazine; | 2009 |
MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Pro | 2008 |
Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain; Brain Neoplasms; Dacarbazi | 2009 |
Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Carboplatin; Cisplatin; Dacarbazine; Disease-Free Survival | 2009 |
Perioperative high-dose-rate brachytherapy in the treatment of recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brachytherapy; Brain Neoplasms; Chemoth | 2009 |
Recurrent glioblastoma of childhood treated with bevacizumab: case report and molecular features.
Topics: Adolescent; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anti | 2010 |
Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Dacarbazi | 2010 |
Esthesioneuroblastoma (Olfactory Neuroblastoma) with Ectopic ACTH Syndrome: a multidisciplinary case presentation from the Joan Karnell cancer center of Pennsylvania Hospital.
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Antifungal Agents; An | 2010 |
Temozolomide and MGMT forever?
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Modifica | 2010 |
Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2010 |
Bevacizumab is active as a single agent against recurrent malignant gliomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Cell Line, Tum | 2010 |
Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Combi | 2011 |
Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Cell Adhesion; Cell C | 2010 |
Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. Clinical article.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modal | 2011 |
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Celecoxi | 2011 |
Long-term outcomes in children with glioblastoma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Child | 2010 |
Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Colorado; | 2011 |
Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence.
Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Com | 2010 |
Brain metastasis of undifferentiated sarcoma and response to temozolomide treatment. Case report.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2010 |
Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2011 |
Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2010 |
Irradiation and bevacizumab in high-grade glioma retreatment settings.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Angiogenesis Inhibitors; Antibodies, Monoclonal, Huma | 2012 |
Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
Radiographic patterns of relapse in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Mod | 2011 |
Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Case of atypical teratoid/rhabdoid tumor in an adult, with long survival.
Topics: Adult; Biomarkers, Tumor; Brain Neoplasms; Chromosomal Proteins, Non-Histone; Combined Modality Ther | 2011 |
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Adult; Aged; Antineoplastic Agents; | 2011 |
Complete remission of recurrent and refractory uterine epithelioid leiomyosarcoma using weekly administration of bevacizumab and temozolomide.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating | 2011 |
Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2011 |
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2012 |
Primary gliosarcoma--clinical experience from a regional cancer centre in north India.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Care Facilities; Combined Modality | 2011 |
Glioblastoma: patterns of recurrence and efficacy of salvage treatments.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; F | 2011 |
In regard McDonald et al., to Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma (Int J Radiat Oncol Biol Phys 2011;79:130-136).
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2011 |
Temozolomide in relapsed pediatric brain tumors: 14 cases from a single center.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2012 |
Communicating hydrocephalus following surgery and adjuvant radiochemotherapy for glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebrospinal Fluid Shunts; Chemoradiother | 2011 |
O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarb | 2012 |
Rechallenge with temozolomide in recurrent glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Gliom | 2011 |
Combination therapy with rituximab and temozolomide for recurrent and refractory primary central nervous system lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Central Nervous System Neoplasm | 2011 |
Avastin: more questions than answers. . .
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2012 |
Prolonged administration of temozolomide in adult patients with anaplastic glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma; Dacarbazine; Disease Pro | 2011 |
Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2012 |
[Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2012 |
Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2012 |
Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab | 2012 |
Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment.
Topics: Adult; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Cranial Irradiation; Dacarbazine | 2012 |
A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Logistic Models; Male; Middle Age | 2012 |
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Daca | 2012 |
A single centre study of the treatment of relapsed primary central nervous system lymphoma (PCNSL) with single agent temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Disea | 2012 |
Efficacy of temozolomide in a central nervous system relapse of neuroblastoma with O 6 -methylguanine methyltransferase (MGMT) promoter methylation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Child, Preschool; Com | 2013 |
Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2013 |
Sarcomatous evolution of oligodendroglioma ("oligosarcoma"): confirmatory report of an uncommon pattern of malignant progression in oligodendroglial tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, | 2012 |
Malignant glioma with angiocentric features.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazi | 2013 |
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.
Topics: AC133 Antigen; Adult; Aged; Aged, 80 and over; Antigens, CD; Biomarkers, Tumor; Brain Neoplasms; Dac | 2012 |
Impact of temozolomide on gonadal function in patients with primary malignant brain tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; F | 2013 |
[Irinotecan plus temozolomide in refractory or relapsed pediatric solid tumors].
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Com | 2013 |
Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-F | 2014 |
The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Ad | 2013 |
Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2013 |
Breast metastasis of anaplastic oligodendroglioma: a case report.
Topics: Antineoplastic Agents, Alkylating; Aphasia; Brain Neoplasms; Breast Neoplasms, Male; Chemoradiothera | 2012 |
Temozolomide as second-line chemotherapy for relapsed gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans | 2002 |
[Treatment of anaplastic astrocytomas and glioblastomas in children by the use of temozolomide (TMZ)].
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Bra | 2002 |
Interobserver variability in the radiological assessment of response to chemotherapy in glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2003 |
Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Central Nervous Syst | 2003 |
Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplas | 2003 |
Treatment of glioblastoma multiforme in the elderly in functionally non-critical areas. Clinical remarks on 22 patients.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Neoplasm | 2003 |
Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2004 |
Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cost-Ben | 2004 |
Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Belgium; Brain Neoplasms; Dacarba | 2004 |
Successful treatment of a chemoresistant tumor with temozolomide in an adult patient: report of a recurrent intracranial mesenchymal chondrosarcoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Neoplasms; Chondrosarcoma, Mesenchym | 2005 |
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2005 |
Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2005 |
Response to temozolomide in second-line treatment of recurrent nonsmall cell lung carcinoma: case report.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Dacarbazine | 2005 |
Relapse of primary CNS lymphoma after more than 10 years in complete remission.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Mo | 2005 |
How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Lymphopenia; Neoplasm Recurren | 2005 |
[Temozolomide in patients with a glioblastoma multiforme: new developments].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastom | 2005 |
[Favourable result for temozolomide in recurrent high-grade glioma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; F | 2005 |
Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, P | 2006 |
[Spinal and cerebral leptomeningeal seeding from a melanocytoma of the cerebello-pontine angle].
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Arachnoid; Cerebellar Diseases; Cere | 2005 |
Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Topics: Adult; Aged; alpha-Methyltyrosine; Analysis of Variance; Antineoplastic Agents, Alkylating; Astrocyt | 2005 |
Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Sur | 2005 |
A case report of a recurrent intracranial ependymoma treated with temozolomide in remission 10 years after completing chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Ependymoma; Female; Humans; | 2006 |
[Management of malignant gliomas diagnosed during pregnancy].
Topics: Abortion, Therapeutic; Adrenal Cortex Hormones; Adult; Algorithms; Anesthesia, General; Antineoplast | 2006 |
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA-Binding Proteins; Female; | 2006 |
Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Combined Modalit | 2006 |
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2006 |
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2006 |
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2006 |
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2006 |
Local recurrence and distant metastasis of supratentorial primitive neuro-ectodermal tumor in an adult patient successfully treated with intensive induction chemotherapy and maintenance temozolomide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Cyclophosphamide; Daca | 2007 |
Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; British Columbia | 2006 |
Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain | 2008 |
Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2007 |
Ganglioglioma occurring with glioblastoma multiforme: separate lesions or the same lesion?
Topics: Antineoplastic Agents, Alkylating; Astrocytes; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adj | 2007 |
Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; D | 2006 |
Salvage therapy for primary central nervous system lymphoma with (90)Y-Ibritumomab and Temozolomide.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality | 2007 |
Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Carcinoma, Squamous Cell; Cerebellar Neoplasms; Dacarbazine | 2007 |
Fatal outcome related to carmustine implants in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Chemothera | 2007 |
Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chromosomal Instability; Dacar | 2007 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, H | 2007 |
Complete response to temozolomide treatment in an elderly patient with recurrent primary central nervous system lymphoma--case report.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; | 2007 |
Metastatic medulloblastoma in an adult; treatment with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Cerebellar Neoplasms; Dacarbazine; Female; Humans; Magneti | 2007 |
Temozolomide treatment of an adult with a relapsing medulloblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Cerebellar Neoplasms; Dacarbazine; Humans; Magnetic Resona | 2007 |
Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Asian People; Brai | 2007 |
Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2007 |
Astroblastoma with rhabdoid features and favorable long-term outcome: report of a case with a 12-year follow-up.
Topics: Antibodies, Antinuclear; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2008 |
Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?
Topics: Adult; Aged; Aging; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combi | 2008 |
A rare case of melanoma recurring as subcutaneous metastatic melanoma with overlying ecchymoses.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Ecchymosis; Female; Human | 2008 |
Adjuvant temozolomide: how long and how much?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Drug Admini | 2008 |
Temozolomide chemotherapy in recurrent oligodendroglioma.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Humans; Middle Aged; Neoplasm Recurrence | 2001 |
[Treatment of recidive malignant gliomas with temozolomide].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Male; Middle Ag | 2002 |